var images_info;if (!images_info) images_info =[]; images_info["105"]={"105000":{"type":"graphic_picture","displayName":"Tuberous xanthoma histopathology","title":"Tuberous xanthoma","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Tuberous xanthoma</div><div class=\"cntnt\"><img style=\"width:712px; height:532px;\" src=\"images/DERM/105000_Tbr_xnthm_hstpthlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Foam cells and associated fibrosis within the dermis.</div><div id=\"graphicVersion\">Graphic 105000 Version 1.0</div></div></div>"},"105001":{"type":"graphic_picture","displayName":"Verruciform xanthoma histopathology","title":"Verruciform xanthoma","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Verruciform xanthoma</div><div class=\"cntnt\"><img style=\"width:716px; height:536px;\" src=\"images/DERM/105001_Vrrcfrm_xnthm_hstpthlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Low-power view demonstrates a papillomatous epidermis with columns of pink parakeratosis.</div><div id=\"graphicVersion\">Graphic 105001 Version 1.0</div></div></div>"},"105002":{"type":"graphic_picture","displayName":"Verruciform xanthoma histopathology 2","title":"Verruciform xanthoma","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Verruciform xanthoma</div><div class=\"cntnt\"><img style=\"width:712px; height:534px;\" src=\"images/DERM/105002_Vrrcfrm_xnthm_hstpthlgy_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High-power view&nbsp;demonstrates foam cells within the papillary dermis.&nbsp;The overlying epidermis has parakeratosis, including columns between the epidermal projections with associated neutrophils.</div><div id=\"graphicVersion\">Graphic 105002 Version 1.0</div></div></div>"},"105003":{"type":"graphic_table","displayName":"Physiologic monitoring during polysomnography","title":"Physiologic monitoring during polysomnography","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Physiologic monitoring&nbsp;during polysomnography</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Electroencephalography (EEG)</td> </tr> <tr> <td>Chin electromyography (EMG)</td> </tr> <tr> <td>Electrooculography (EOG)</td> </tr> <tr> <td>Measures of airflow</td> </tr> <tr> <td>Measures of respiratory effort</td> </tr> <tr> <td>Pulse oximetry</td> </tr> <tr> <td>Electrocardiography (ECG)</td> </tr> <tr> <td>Limb electromyography</td> </tr> <tr> <td>Snore volume</td> </tr> <tr> <td>Body position monitor</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 105003 Version 1.0</div></div></div>"},"105006":{"type":"graphic_diagnosticimage","displayName":"Intracranial plaque and arterial wall imaging by MRI","title":"Intracranial plaque and arterial wall imaging by high-resolution MRI","html":"<div class=\"graphic\"><div style=\"width: 737px\" class=\"figure\"><div class=\"ttl\">Intracranial plaque and arterial wall imaging by high-resolution MRI</div><div class=\"cntnt\"><img style=\"width:717px; height:713px;\" src=\"images/NEURO/105006_Intrcrnl_plq_art_wll_img_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intracranial plaque and arterial wall imaging by high-resolution MRI. An intracranial atherosclerosis lesion located at proximal basilar artery with severe luminal stenosis was identified on time-of-flight magnetic resonance angiography (arrow, A). High-resolution MRI revealed an eccentric atherosclerotic plaque along the anterolateral and posterolateral walls of basilar artery (arrowhead, B through D).</div><div class=\"graphic_reference\">From: Leng X, Wong KS, Liebeskind DS. Evaluating intracranial atherosclerosis rather than intracranial stenosis. Stroke 2014; 45:645. DOI: <a href=\"http://stroke.ahajournals.org/content/45/2/645.extract\" spellcheck=\"true\" target=\"_blank\">10.1161/STROKEAHA.113.002491</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American Heart Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105006 Version 1.0</div></div></div>"},"105007":{"type":"graphic_diagnosticimage","displayName":"Mechanisms of stroke in intracranial atherosclerotic disease","title":"Mechanisms of stroke in patients with intracranial atherosclerotic disease","html":"<div class=\"graphic\"><div style=\"width: 790px\" class=\"figure\"><div class=\"ttl\">Mechanisms of stroke in patients with intracranial atherosclerotic disease</div><div class=\"cntnt\"><img style=\"width:770px; height:567px;\" src=\"images/NEURO/105007_Mchn_strk_intrcrn_athrsclr_dss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mechanisms of stroke in patients with ICAD.<br />(A) Thrombotic occlusion is a rare phenotype of ICAD. MRA shows in situ thrombotic occlusion at the site of stenotic plaque. DWI shows territorial infarcts by severe hemodynamic compromise and embolic infarcts on the cortex. High-resolution MRI can show vulnerable plaque on intracranial vessels. <br />(B) Artery-to-artery embolism is one of common phenotypes of ICAD. Artery-to-artery embolism is usually associated with a severe degree of intracranial stenosis, and transcranial Doppler ultrasonography can detect symptomatic or asymptomatic embolism during microembolic signal monitoring. DWI shows small, scattered, cortical embolic infarcts. <br />(C) Hemodynamic impairment is another phenotype of ICAD. This phenotype is usually associated with a severe stenosis and a marked hemodynamic compromise, as seen on a PWI. DWI typically shows borderzone-type infarcts, and infarct growth is common with clinical deterioration. <br />(D) Branch occlusive disease is a common phenotype of ICAD. This phenotype is often misclassified as small arterial disease due to a mild degree of stenosis on MRA, small deep infarcts on DWI, and relatively small perfusion defects. High-resolution MRI can reveal plaque without stenosis near the orifices of penetrating arteries.</div><div class=\"graphic_footnotes\">ICAD: intracranial atherosclerotic disease; DWI: diffusion-weighted imaging; PWI: perfusion-weighted imaging; TOF MRA: time-of-flight magnetic resonance angiography.</div><div class=\"graphic_reference\">Reproduced with permission from: Bang OY. Intracranial atherosclerosis: current understanding and perspectives. J Stroke 2014; 16:27. Copyright &copy; 2014 Korean Stroke Academy.</div><div id=\"graphicVersion\">Graphic 105007 Version 1.0</div></div></div>"},"105008":{"type":"graphic_algorithm","displayName":"Selection of initial therapy for PMF","title":"Algorithm for the initial management of primary myelofibrosis","html":"<div class=\"graphic\"><div style=\"width: 670px\" class=\"figure\"><div class=\"ttl\">Algorithm for the initial management of primary myelofibrosis</div><div class=\"cntnt\"><img style=\"width:650px; height:590px;\" src=\"images/HEME/105008_Slctn_intl_thrpy_PMF.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PMF: primary myelofibrosis; DIPSS: Dynamic International Prognostic Scoring System; HCT: hematopoietic cell transplantation.<br />* DIPSS Plus score is calculated based on age, leukocyte count, hemoglobin, percentage circulating blasts, constitutional symptoms, karyotype, platelet count, and need for transfusions.<br />&para; High-risk mutation profile is present if the abnormal clone contains both high-risk mutations (ASXL1, IDH1/2, or EZH2) and does not have a favorable mutation (CALR). If these tests are not performed locally, they are available from commercial laboratories (eg, Quest diagnostics), although the cost and coverage by insurance carriers is uncertain. If these results are not available, the clinician can proceed through the algorithm as if a high-risk mutation profile is not present, recognizing that a small percentage of patients that might benefit from HCT will be missed.<br />&Delta; Symptomatic splenomegaly, anemia, or constitutional symptoms.<br /><span class=\"lozenge\">&loz;</span> Low-risk mutation profile is present if the abnormal clone contains no high-risk mutations and has a favorable mutation.</div><div id=\"graphicVersion\">Graphic 105008 Version 1.0</div></div></div>"},"105009":{"type":"graphic_table","displayName":"DIPSS and DIPSS Plus for PMF","title":"Dynamic International Prognostic Scoring System (DIPSS) and DIPSS Plus for primary myelofibrosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dynamic International Prognostic Scoring System (DIPSS) and DIPSS Plus for primary myelofibrosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">DIPSS score</td> </tr> <tr> <td class=\"indent1\"><strong>The DIPSS score assigns points for the following five variables:</strong></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Age &#62;65 years: 1 point </li> <li>Leukocyte count &#62;25,000/microL (&#62;25 x 10<sup>9</sup>/L): 1 point </li> <li>Hemoglobin &#60;10 g/dL (&#60;100 g/L): 2 points </li> <li>Circulating blast cells &#8805;1%: 1 point </li> <li>Constitutional symptoms*: 1 point </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>The resulting score is interpreted as follows:</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>0 points &ndash; low risk </li> <li>1 to 2 points &ndash; intermediate-1 risk </li> <li>3 to 4 points &ndash; intermediate-2 risk </li> <li>5 to 6 points &ndash; high risk </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">DIPSS Plus score</td> </tr> <tr> <td class=\"indent1\"><strong>The DIPSS Plus score assigns points for the following variables:</strong></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>DIPSS low risk: 0 points </li> <li>DIPSS intermediate-1 risk: 1 point </li> <li>DIPSS intermediate-2 risk: 2 points </li> <li>DIPSS high risk: 3 points </li> <li>Unfavorable karyotype<sup>&#182;</sup>: 1 point </li> <li>Platelet count &#60;100,000/microL (&#60;100 x 10<sup>9</sup>/L): 1 point </li> <li>Anemia requiring transfusion: 1 point </li> </ul> </td> </tr> <tr> <td class=\"indent1\"><strong>The resulting score is interpreted as follows:</strong></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>0 points &ndash; low risk </li> <li>1 point &ndash; intermediate-1 risk </li> <li>2 to 3 points &ndash; intermediate-2 risk </li> <li>4 to 6 points &ndash; high risk </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PMF: primary myelofibrosis; DIPSS: Dynamic International Prognostic Scoring System.<br />* Constitutional symptoms include: Weight loss &gt;10% of the baseline value in the year preceding PMF diagnosis, and/or unexplained fever or excessive sweats persisting for more than one month.<br />&para; Unfavorable karyotype includes: Complex karyotype or one or two abnormalities that include +8, &ndash;7/7q&ndash;, i(17q), &ndash;5/5q&ndash;, 12p&ndash;, inv(3), or 11q23.</div><div class=\"graphic_reference\">Source: Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29:392.</div><div id=\"graphicVersion\">Graphic 105009 Version 1.0</div></div></div>"},"105010":{"type":"graphic_table","displayName":"First trimester fetal size smaller than expected","title":"First trimester fetal size smaller than expected","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">First trimester fetal size smaller than expected</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gestational age range based on LMP</td> <td class=\"subtitle1\">Biometric parameter(s) for ultrasound dating</td> <td class=\"subtitle1\">Discrepancy between ultrasound dating and LMP dating that supports redating</td> </tr> <tr> <td>&#8804;13<sup>6/7</sup> weeks of gestation</td> <td rowspan=\"3\">CRL</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>&#8804;8<sup>6/7</sup> weeks of gestation</li> </ul> </td> <td> <ul> <li>More than five days</li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>9<sup>0/7</sup> to 13<sup>6/7</sup> weeks of gestation</li> </ul> </td> <td> <ul> <li>More than seven days</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LMP: last menstrual period; CRL: crown rump length.</div><div class=\"graphic_reference\">Modified from: Committee on Obstetric Practice, American Institute of Ultrasound in Medicine, Society for Maternal-Fetal Medicine. Method for estimating due date. Obstet Gynecol 2014; 124:863.</div><div id=\"graphicVersion\">Graphic 105010 Version 1.0</div></div></div>"},"105011":{"type":"graphic_picture","displayName":"Atherosclerotic lesions Circle of Willis","title":"Atherosclerotic lesions in the Circle of Willis of a 90-year-old subject","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Atherosclerotic lesions in the Circle of Willis of a 90-year-old subject</div><div class=\"cntnt\"><img style=\"width:580px; height:528px;\" src=\"images/NEURO/105011_Athrsclrtc_lsn_crcl_wll.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Circle of Willis of a 90-year-old subject. Macroscopically, atherosclerotic lesions can be identified by the white vessels, whereas nondiseased arteries appear largely transparent. This case shows prominent atherosclerosis mainly in the internal carotid artery, vertebral artery, basilar artery, left middle cerebral artery, and posterior cerebral artery.</div><div class=\"graphic_reference\">From: Ritz K, Denswil NP, Stam OC, et al. Cause and mechanisms of intracranial atherosclerosis. Circulation 2014; 130:1407. DOI: <a href=\"http://circ.ahajournals.org/content/130/16/1407.extract\" spellcheck=\"true\" target=\"_blank\">10.1161/CIRCULATIONAHA.114.011147</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American Heart Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105011 Version 1.0</div></div></div>"},"105028":{"type":"graphic_table","displayName":"Qualities of clicks associated with valve disorders","title":"Qualities of clicks associated with valve disorders","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Qualities of clicks associated with valve disorders</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Valve</td> <td class=\"subtitle1\">Location</td> <td class=\"subtitle1\">Timing in systole</td> <td class=\"subtitle1\">Nature</td> </tr> <tr> <td>Mitral</td> <td>Apex</td> <td>Mid to late</td> <td>Constant</td> </tr> <tr> <td>Aortic</td> <td>Apex</td> <td>Early</td> <td>Constant</td> </tr> <tr> <td>Pulmonary</td> <td>LUSB</td> <td>Early</td> <td>Variable</td> </tr> <tr> <td>Tricuspid</td> <td>LLSB</td> <td>Mid to late</td> <td>Constant</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LUSB: left upper sternal border; LLSB: left lower sternal border.</div><div class=\"graphic_reference\">Reproduced from: Geggel RL, Fyler DC. History, growth, nutrition, physical examination, and routine laboratory tests. In: Nadas' Pediatric Cardiology, 2nd ed, Keane JF, Lock JE, Fyler DC (Eds), Saunders, Philadelphia 2006. p.129. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105028 Version 1.0</div></div></div>"},"105030":{"type":"graphic_table","displayName":"Grading of the intensity of heart murmurs","title":"Grading of the intensity of heart murmurs","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Grading of the intensity of heart murmurs</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10\"></colgroup><colgroup width=\"90%\"></colgroup> <tbody> <tr> <td><strong>Grade 1:</strong></td> <td>Faintest sound that can be detected; often detected by cardiologists but not by general physicians</td> </tr> <tr> <td><strong>Grade 2:</strong></td> <td>Soft murmur that is readily detectable</td> </tr> <tr> <td><strong>Grade 3:</strong></td> <td>Louder than grade 2 but not associated with a palpable thrill</td> </tr> <tr> <td><strong>Grade 4:</strong></td> <td>Easily detected murmur associated with a palpable thrill*</td> </tr> <tr> <td><strong>Grade 5:</strong></td> <td>Very loud murmur audible with the stethoscope placed lightly on the chest</td> </tr> <tr> <td><strong>Grade 6:</strong></td> <td>Extremely loud murmur audible with the stethoscope off the chest</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* A grade 4 murmur requires the presence of a precordial thrill. A thrill located only in the suprasternal notch or neck and not on the precordium does not fulfill this criterion.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Marino BS, Goldblatt A. Heart sounds and murmurs. In: Lilly LS, ed. Pathophysiology of heart disease. Philadelphia: Lea &amp; Febiger; 1992. p.18.</li>&#xD;&#xA;    <li>Freeman AR, Levine SA. The clinical significance of the systolic murmur. A study of 1,000 consecutive \"non-cardiac\" cases. Ann Intern Med 6:1371, 1933.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 105030 Version 1.0</div></div></div>"},"105032":{"type":"graphic_table","displayName":"Causes of murmurs in children","title":"Causes of systolic, diastolic, and continuous murmurs in infants and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of systolic, diastolic, and continuous murmurs in infants and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Systolic murmurs:</td> </tr> <tr> <td class=\"indent1\">Stenotic semilunar valves: valvar PS or AS</td> </tr> <tr> <td class=\"indent1\">Stenotic intracardiac lesions: subvalvar PS or AS, double chamber right ventricle</td> </tr> <tr> <td class=\"indent1\">Stenotic intravascular lesions: supravalvar PS or AS, COA, PPS</td> </tr> <tr> <td class=\"indent1\">Regurgitant AV valves: MR, TR</td> </tr> <tr> <td class=\"indent1\">Increased flow across normal semilunar valves: tachycardia, anemia, \"relative pulmonary stenosis\" associated with right ventricular volume overload (eg, ASD)</td> </tr> <tr> <td class=\"indent1\">Left-to-right shunt across VSD</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Normal cardiac anatomy (innocent murmur)</td> </tr> <tr> <td class=\"subtitle1_single\">Diastolic murmurs:</td> </tr> <tr> <td class=\"indent1\">Regurgitant flow across semilunar valves: PR or AR</td> </tr> <tr> <td class=\"indent1\">Turbulent flow across AV valves: MS or TS</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Increased flow across normal AV valves (\"relative AV valve stenosis\"): ASDs, VSDs, or PDAs with high degree of left-to-right shunting [Qp:Qs &#62;2]; severe MR or TR with increased flow across the affected valve in diastole</td> </tr> <tr> <td class=\"subtitle1_single\">Continuous murmurs:</td> </tr> <tr> <td class=\"indent1\">Connection between systemic and pulmonary circulation: PDA, surgically created systemic-pulmonary artery shunts, aortopulmonary collateral artery, aortopulmonary window, anomalous left coronary artery arising from the main pulmonary artery</td> </tr> <tr> <td class=\"indent1\">Connection between systemic artery and systemic vein: AVM</td> </tr> <tr> <td class=\"indent1\">Connection between systemic artery and cardiac chambers: coronary arteriovenous fistula, ruptured sinus of Valsalva aneurysm</td> </tr> <tr> <td class=\"indent1\">Disturbed flow in arteries: collateral flow associated with severe coarctation of the aorta</td> </tr> <tr> <td class=\"indent1\">Disturbed flow in veins: venous hum</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PS: pulmonary stenosis; AS: aortic stenosis; COA: coarctation of the aorta; PPS: peripheral pulmonary stenosis; AV: atrioventricular; MR: mitral regurgitation; TR: tricuspid regurgitation; ASD: atrial septal defect; VSD: ventricular septal defect; PR: pulmonary regurgitation; AR: aortic regurgitation; MS: mitral stenosis; TS: tricuspid stenosis; PDA: patent ductus arteriosus; Qp:Qs: ratio of pulmonary to systemic blood flow; AVM: arteriovenous malformation.</div><div class=\"graphic_reference\">Adapted from: Geggel RL. The cardiac examination. In: Comprehensive Pediatric Hospital Medicine, Zaoutis LB, Chiang VW (Eds), Philadelphia: Mosby, 2007. p.513.</div><div id=\"graphicVersion\">Graphic 105032 Version 1.0</div></div></div>"},"105035":{"type":"graphic_table","displayName":"Cardiac pathology vs. innocent murmurs in children","title":"Cardiac evaluation in infants and children: Features that distinguish heart disease from innocent murmurs and criteria for referral","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cardiac evaluation in infants and children: Features that distinguish heart disease from innocent murmurs and criteria for referral</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Features associated with cardiac disease</td> <td class=\"subtitle1\">Features associated innocent murmurs</td> <td class=\"subtitle1\">Criteria for referral</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Features in the history</strong></td> <td> <ul> <li>Parent or sibling with CHD* </li> <li>Abnormal prenatal ultrasound, fetal echocardiogram, or prenatal maternal condition associated with increased risk of CHD* </li> <li>Underlying genetic disorder associated with increased risk of CHD* </li> <li>Age &#60;1yr<sup>&#182;</sup> </li> <li>Symptoms suggestive of heart disease (eg, respiratory difficulties, cyanosis, poor growth, poor feeding [in infants], diaphoresis, chest pain, syncopal episodes)<sup>&#916;</sup> </li> </ul> </td> <td> <ul> <li>Negative family history </li> <li>Normal prenatal ultrasound </li> <li>Nonsyndromic </li> <li>Age &#62;2 </li> <li>Asymptomatic </li> </ul> </td> <td> <ul> <li>Abnormal fetal echocardiogram </li> <li>Underlying genetic disorder associated with increased risk of CHD* </li> <li>Symptoms suggestive of heart disease<sup>&#916;</sup> </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Physical examination findings:</td> </tr> <tr> <td class=\"indent1\">Murmurs</td> <td> <ul> <li>Grade &#8805;3 intensity </li> <li>Holosystolic timing </li> <li>Maximum intensity at the left upper sternal border<sup>&#9674;</sup> </li> <li>Harsh or blowing quality </li> <li>Increased intensity with upright position<sup>&#167;</sup> </li> <li>Diastolic murmur </li> </ul> </td> <td> <ul> <li>Grade &#8804;2 intensity </li> <li>Short systolic duration (ie, not holosystolic and not diastolic) </li> <li>Minimal radiation </li> <li>Musical or vibratory quality </li> <li>Softer intensity when the patient is sitting compared with when the patient is supine<sup>&#167;</sup> </li> </ul> </td> <td> <ul> <li>Grade &#8805;3 intensity </li> <li>Holosystolic timing </li> <li>Maximum intensity at the left upper sternal border<sup>&#9674;</sup> </li> <li>Harsh or blowing quality </li> <li>Increased intensity with upright position<sup>&#167;</sup> </li> <li>Diastolic murmur </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Other heart sounds</td> <td> <ul> <li>Abnormal S2 (eg, fixed or wide splitting, single S2, loud P2) </li> <li>Gallop rhythm (S3 or S4) </li> <li>Systolic click </li> <li>Friction rub </li> </ul> </td> <td> <ul> <li>Quiet precordium </li> <li>Normal S2 with normal physiologic splitting </li> <li>No gallop, click, or rub </li> </ul> </td> <td> <ul> <li>Abnormal S2 (eg, fixed or wide splitting, single S2, loud P2) </li> <li>Gallop rhythm (S3 or S4) </li> <li>Systolic click </li> <li>Friction rub </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Other findings</td> <td> <ul> <li>Abnormal vital signs (eg, tachycardia, bradycardia, &#62;10 mmHg SBP gradient between the right arm and leg) </li> <li>Abnormal pulses (eg, weak or absent femoral pulses, generalized decreased pulses, bounding pulses) </li> <li>Hepatomegaly </li> <li>Extracardiac congenital anomalies (particularly skeletal abnormalities) </li> </ul> </td> <td> <ul> <li>Normal vital signs </li> <li>Normal pulses </li> <li>No other findings </li> </ul> </td> <td> <ul> <li>&#62;10 mmHg SBP gradient between the right arm and leg) </li> <li>Abnormal pulses (eg, weak or absent femoral pulses, generalized decreased pulses, bounding pulses) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Diagnostic test findings<sup>&#167;</sup>:</td> <td> <ul> <li>Abnormal pulse oximetry<sup>&#165;</sup> </li> <li>Abnormal chest radiograph<sup>&#135;</sup> (eg, cardiomegaly, increased pulmonary vascular markings, pulmonary edema) </li> <li>Abnormal ECG<sup>&#135;</sup> (eg, LVH, RVH, abnormal axis, ischemic changes, arrhythmia, delta wave, prolonged QTc)</li> </ul> </td> <td> <ul> <li>Normal pulse oximetry<sup>&#165;</sup> </li> <li>Normal chest radiograph<sup>&#135;</sup> </li> <li>Normal ECG<sup>&#135;</sup> </li> </ul> </td> <td> <ul> <li>Abnormal newborn pulse oximetry screen<sup>&#165;</sup> </li> <li>Cardiomegaly or pulmonary edema (without a noncardiac explanation) on chest radiograph<sup>&#135;</sup> </li> <li>Abnormal ECG<sup>&#135;</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CHD: congenital heart disease; S2: second heart sound; P2: pulmonary valve closure sound; S3: third heart sound; S4: fourth heart sound; SBP: systolic blood pressure; ECG: electrocardiogram; LVH: left ventricular hypertrophy; RVH: right ventricular hypertrophy; QTc: corrected QT interval; PPS: peripheral pulmonary stenosis.<br />* For a summary of maternal, prenatal, familial, and genetic factors associated with increased risk of CHD, refer to the UpToDate tables \"Factors associated with an increased risk of congenital heart disease\" and \"Selected genetic disorders associated with cardiovascular malformations\".<br />¶ CHD is more likely to be diagnosed in infants &lt;1 year; however, innocent murmurs also commonly occur at this age, particularly the peripheral pulmonary stenosis (PPS) murmur which is caused by turbulence across the underdeveloped branch pulmonary arteries. The PPS murmur is characterized by a grade 1 to 2, medium to high-pitched midsystolic ejection murmur heard best at the upper left sternal border, radiating to the axilla and back. It disappears typically by age 6 to 12 months.<br />Δ For further discussion of symptoms associated with pediatric cardiac disease, refer to the UpToDate topic on suspected heart disease in infants children.<br /><FONT class=lozenge>◊</FONT> Innocent murmurs also commonly occur at this location. Other features of the examination (eg, the quality of S2 and systolic clicks) help distinguish the basis of the murmur. (Refer to UpToDate algorithm \"Synthesizing cardiac exam findings in infants and children with murmurs: Systolic ejection murmur at the left upper sternal border\").<br />§ Most innocent murmurs (with the exception of cervical venous hum) typically become softer in the upright position.<br />¥&nbsp;For details of pulse oximetry screening in newborns to identify critical heart disease, refer to the UpToDate topic on newborn screening for critical heart disease and the UpToDate algorithm \"Protocol for newborn pulse oximetry screening for critical congenital heart disease\".<br />‡&nbsp;Chest radiograph is generally warranted only if there are respiratory symptoms and/or cyanosis. Chest radiograph and/or ECG are not required in the evaluation of a child whose history and physical examination findings are consistent with an innocent murmur. For a summary of characteristic ECG and chest radiograph findings in specific CHD lesions, refer to UpToDate table \"Typical physical examination, chest radiography, and electrocardiography findings in some forms of cyanotic heart disease\".</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Frank JE, Jacobe KM. Evaluation and management of heart murmurs in children. Am Fam Physician 2011; 84:793.</li>&#xD;&#xA;    <li>Kang G, Xiao J, Wang Y, et al. Prevalence and clinical significance of cardiac murmurs in schoolchildren. Arch Dis Child 2015.</li>&#xD;&#xA;    <li>McCrindle BW, Shaffer KM, Kan JS, et al. Cardinal clinical signs in the differentiation of heart murmurs in children. Arch Pediatr Adolesc Med 1996; 150:169.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 105035 Version 4.0</div></div></div>"},"105050":{"type":"graphic_algorithm","displayName":"Diagnosis of hypertension in adults","title":"Diagnosis of hypertension in adults","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Diagnosis of hypertension in adults</div><div class=\"cntnt\"><img style=\"width:452px; height:975px;\" src=\"images/NEPH/105050_Apprchdgnshprtnsadlt.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ABPM: ambulatory blood pressure monitoring; AOBPM: automated oscillometric blood pressure monitoring.<br />&#x9;* Home blood pressure must be performed adequately in order for the measurements to be used for diagnosis and management. To be adequate: The accuracy of the home device should be verified in the clinician's office; the patient should measure their blood pressure while seated (with feet flat on the floor), with arm supported (such as on a table), and after several minutes of rest; the blood pressure should be measured at different times per day and over a series of multiple days. A common strategy is to have the patient measure his or her blood pressure twice daily (once in the morning and once in the evening) for seven days. Readings from the first day are discarded, and the remaining 12 measurements are averaged. Home blood pressure should not be used for diagnosis and management if it cannot be performed adequately. Adequate home blood pressure should be possible in most cases. Inexpensive devices to measure blood pressure at home are available over the counter. Alternatively, such devices can be borrowed (eg, provided by the clinic). Only rarely are such devices unavailable or unaffordable.<br />&#x9;&#182; ABPM is performed by having the patient wear, typically for 24 hours, an electronic blood pressure device that automatically measures the blood pressure, usually every half-hour during the day and hourly at night. We use the mean daytime value to determine the presence of hypertension. ABPM is possible if it is available in the clinic or via an external vendor and if it can be paid for by the patient's insurance or by the patient.<br />&#x9;&#916; Blood pressure measured in the office may vary according to the manner in which it is obtained. If blood pressure in the office is to be used for the diagnosis of hypertension (rather than using out-of-office blood pressures),we suggest performing unattended AOBPM(using a device that can average multiple readings while the patient sits alone in a room). Unattended AOBPM may provide a measurement that is 5 to 10 mmHg less than a manual measurement (ie, with a stethoscope). Office blood pressure must be performed with proper technique (eg, patient given time to rest, seated with feet flat on the floor, use of multiple measurements, appropriate-sized cuff placed on bare arm, etc). Office blood pressure measured with improper technique <strong>should not</strong> be used for diagnosis and management of hypertension. Refer to UpToDate topics on measurement of blood pressure for details of proper technique.</div><div id=\"graphicVersion\">Graphic 105050 Version 5.0</div></div></div>"},"105062":{"type":"graphic_picture","displayName":"US transducer position for talar dome transverse view","title":"US transducer position for talar dome transverse view","html":"<div class=\"graphic\"><div style=\"width: 802px\" class=\"figure\"><div class=\"ttl\">US transducer position for talar dome transverse view</div><div class=\"cntnt\"><img style=\"width:782px; height:262px;\" src=\"images/SM/105062_US_trnsdcr_pst_tlr_dm_trnsvr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the position of the ultrasound transducer for obtaining&nbsp;images of the&nbsp;talar dome in the transverse plane.</div><div class=\"graphic_footnotes\">Rectangle: transducer position</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105062 Version 1.0</div></div></div>"},"105063":{"type":"graphic_diagnosticimage","displayName":"US tibialis anterior insertion long axis view","title":"US tibialis anterior insertion long axis view","html":"<div class=\"graphic\"><div style=\"width: 807px\" class=\"figure\"><div class=\"ttl\">US tibialis anterior insertion long axis view</div><div class=\"cntnt\"><img style=\"width:787px; height:361px;\" src=\"images/SM/105063_US_tbl_antr_insrt_lng_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the insertion of the tibialis anterior tendon in its long axis.</div><div class=\"graphic_footnotes\">1st MT: first metatarsal head. Arrows: tibialis anterior tendon.<br />Left of the screen: proximal; right of the screen: distal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105063 Version 2.0</div></div></div>"},"105064":{"type":"graphic_diagnosticimage","displayName":"US fibularis tertius tendon insertion long axis view","title":"US fibularis tertius tendon insertion long axis view","html":"<div class=\"graphic\"><div style=\"width: 808px\" class=\"figure\"><div class=\"ttl\">US fibularis tertius tendon insertion long axis view</div><div class=\"cntnt\"><img style=\"width:788px; height:274px;\" src=\"images/SM/105064_US_fbl_trts_tnd_insrt_lng_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image&nbsp;shows the&nbsp;fibularis tertius tendon insertion in&nbsp;long axis.</div><div class=\"graphic_footnotes\">Arrows: fibularis tertius tendon; 5th MT: fifth metatarsal head.<br />Left of the screen: proximal; right of the screen: distal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105064 Version 1.0</div></div></div>"},"105065":{"type":"graphic_diagnosticimage","displayName":"US deep fibular nerve crossing dorsalis pedis artery","title":"US deep fibular nerve crossing superficial to dorsalis pedis artery","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US deep fibular nerve crossing&nbsp;superficial to&nbsp;dorsalis pedis artery</div><div class=\"cntnt\"><img style=\"width:364px; height:692px;\" src=\"images/SM/105065_US_dp_fbl_nrv_crss_drsl_pds_art.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This series of ultrasound images shows the&nbsp;deep fibular nerve in short-axis as it travels&nbsp;distally, moving&nbsp;from the lateral side of the dorsal pedis artery to the medial side by coursing superficially over the artery.&nbsp;Image A is proximal, image B is&nbsp;intermediate, and image C is distal.</div><div class=\"graphic_footnotes\">Dotted ellipse: deep fibular nerve; A: dorsalis pedis artery. <br />Left of the screen: lateral; right of the screen: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105065 Version 1.0</div></div></div>"},"105066":{"type":"graphic_diagnosticimage","displayName":"Hemodynamic tracings in a patient with mitral stenosis","title":"Hemodynamic tracings in a patient with mitral stenosis","html":"<div class=\"graphic\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Hemodynamic tracings in a patient with mitral stenosis</div><div class=\"cntnt\"><img style=\"width:480px; height:360px;\" src=\"images/CARD/105066_Hmdynmc_trcngs_mtrl_stensis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The LV and PCW (left side) tracings show a large mitral valve gradient of approximately 20 mmHg (pressure scale is 0 to 50 mmHg). On the right panel, LV and directly measured LA pressures (via transseptal approach) show higher fidelity pressure wave forms and marked reduction in the mitral pressure gradient (6 mmHg). Note the \"c\" notch and \"v\" wave are distinct compared with the wave forms on the PCW.</div><div class=\"graphic_footnotes\">LV: left ventricle; PCW: pulmonary capillary wedge; LA: left atrium.</div><div id=\"graphicVersion\">Graphic 105066 Version 1.0</div></div></div>"},"105067":{"type":"graphic_algorithm","displayName":"Induction of spermatogenesis","title":"Induction of spermatogenesis","html":"<div class=\"graphic\"><div style=\"width: 590px\" class=\"figure\"><div class=\"ttl\">Induction of spermatogenesis</div><div class=\"cntnt\"><img style=\"width:570px; height:1058px;\" src=\"images/ENDO/105067_Indctn_sprmtgns.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ART: assisted reproductive technology; hCG: human chorionic gonadotropin; hMG: human menopausal gonadotropin; SA: semen analysis.</div><div id=\"graphicVersion\">Graphic 105067 Version 3.0</div></div></div>"},"105069":{"type":"graphic_picture","displayName":"Urticaria pigmentosa in an infant","title":"Urticaria pigmentosa in an infant","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Urticaria pigmentosa in an infant</div><div class=\"cntnt\"><img style=\"width:420px; height:574px;\" src=\"images/ALLRG/105069_Urtcr_pgmnts_infnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This infant has multiple lesions of urticaria pigmentosa (UP). Lesions of UP are characterized by small, yellow-tan to reddish-brown macules or slightly raised papules.&nbsp;Pruritus associated with UP may be exacerbated by changes in temperature, exertion, local friction, or certain medications. UP lesions, as well as other lesions rich in mast cells, may demonstrate Darier's sign, which is the development of a localized&nbsp;whealing and erythema within about five minutes following rubbing, scratching, or stroking of the lesion.</div><div class=\"graphic_reference\">From: American Journal of Clinical Dermatology, Diagnosis and treatment of cutaneous mastocytosis in children: Practical recommendations, Vol. 12, 2011, p. 259, Castells M, Metcalfe DD, Escribano L, © Adis Data Information BV 2011. With permission of Springer.</div><div id=\"graphicVersion\">Graphic 105069 Version 2.0</div></div></div>"},"105070":{"type":"graphic_picture","displayName":"Patient position to begin lateral ankle US examination","title":"Patient position to begin lateral ankle US examination","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">Patient position to begin lateral ankle US examination</div><div class=\"cntnt\"><img style=\"width:783px; height:436px;\" src=\"images/SM/105070_Ptnt_pst_bgn_lat_ankl_US_exm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows proper patient positioning for performing an ultrasound examination of the lateral ankle .</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105070 Version 1.0</div></div></div>"},"105071":{"type":"graphic_picture","displayName":"US transducer position for AITFL in long axis","title":"US transducer position for AITFL in long axis","html":"<div class=\"graphic\"><div style=\"width: 806px\" class=\"figure\"><div class=\"ttl\">US transducer position for AITFL in long axis</div><div class=\"cntnt\"><img style=\"width:786px; height:489px;\" src=\"images/SM/105071_US_trnsdcr_pst_AITFL_lng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the position of the ultrasound transducer for obtaining an image the anterior-inferior tibiofibular ligament (AITFL)&nbsp;in its&nbsp;long axis.</div><div class=\"graphic_footnotes\">Rectangle: transducer position</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105071 Version 1.0</div></div></div>"},"105072":{"type":"graphic_picture","displayName":"US transducer position for CFL in long axis","title":"US transducer position for CFL in long axis","html":"<div class=\"graphic\"><div style=\"width: 806px\" class=\"figure\"><div class=\"ttl\">US transducer position for CFL in long axis</div><div class=\"cntnt\"><img style=\"width:786px; height:437px;\" src=\"images/SM/105072_US_trnsdcr_pst_CFL_lng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the position of the ultrasound transducer&nbsp;for obtaining&nbsp;images of&nbsp;the calcaneofibular ligament in its long axis.</div><div class=\"graphic_footnotes\">Rectangle: transducer position</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105072 Version 1.0</div></div></div>"},"105073":{"type":"graphic_picture","displayName":"US transducer position for fibular tendons in short axis","title":"US transducer position for fibular tendons in short axis","html":"<div class=\"graphic\"><div style=\"width: 805px\" class=\"figure\"><div class=\"ttl\">US transducer position for fibular tendons in short axis</div><div class=\"cntnt\"><img style=\"width:785px; height:439px;\" src=\"images/SM/105073_US_trnsdcr_pst_fblr_tnd_shrt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the position of the ultrasound transducer for obtaining images of&nbsp;the fibular tendons in their short axis.</div><div class=\"graphic_footnotes\">Rectangle: transducer position</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105073 Version 1.0</div></div></div>"},"105074":{"type":"graphic_picture","displayName":"US transducer position to trace fibular tendons caudally","title":"US transducer position to trace fibular tendons caudally","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">US transducer position to trace fibular tendons caudally</div><div class=\"cntnt\"><img style=\"width:784px; height:439px;\" src=\"images/SM/105074_US_trnsdcr_pst_trc_fbl_tnd_cdl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the succession of ultrasound transducer positions&nbsp;for obtaining&nbsp;images of&nbsp;the fibularis tendons in short-axis, moving&nbsp;from proximal (rectangle 1) to distal (rectangle 4), before they diverge from one another.</div><div class=\"graphic_footnotes\">Rectangle: transducer positions</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105074 Version 1.0</div></div></div>"},"105075":{"type":"graphic_picture","displayName":"US transducer position for fibularis brevis insertion long axis","title":"US transducer position for fibularis brevis insertion long axis","html":"<div class=\"graphic\"><div style=\"width: 807px\" class=\"figure\"><div class=\"ttl\">US transducer position for fibularis brevis insertion long axis</div><div class=\"cntnt\"><img style=\"width:787px; height:490px;\" src=\"images/SM/105075_US_trnsdcr_pst_fbl_brvs_insrt_lng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the position of the ultrasound transducer&nbsp;for obtaining a long-axis&nbsp;view of the fibularis brevis tendon at its insertion.</div><div class=\"graphic_footnotes\">Rectangle: transducer position</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105075 Version 1.0</div></div></div>"},"105076":{"type":"graphic_picture","displayName":"US transducer position sural nerve short axis","title":"US transducer position sural nerve short axis","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">US transducer position sural nerve short axis</div><div class=\"cntnt\"><img style=\"width:784px; height:451px;\" src=\"images/SM/105076_US_trnsdcr_pst_srl_nrv_shrt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the position of the ultrasound transducer&nbsp;for obtaining&nbsp;images of&nbsp;the sural nerve in its short-axis.</div><div class=\"graphic_footnotes\">Rectangle: transducer position</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105076 Version 1.0</div></div></div>"},"105077":{"type":"graphic_figure","displayName":"Pectoral chest region anatomy","title":"Pectoral chest region anatomy","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Pectoral chest region anatomy</div><div class=\"cntnt\"><img style=\"width:541px; height:508px;\" src=\"images/ANEST/105077_Pectoral_chest_region_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;lateral and medial pectoral nerves&nbsp;arise from the cords of the brachial plexus and innervate the pectoral major and minor muscles. The lateral pectoral nerve&nbsp; courses along the undersurface of the pectoralis major muscle, in the fascial plane between the pectoralis major and minor muscles. The medial pectoral nerve&nbsp;also runs between the pectoralis major and minor muscles.<br />The intercostobrachial nerve, the lateral cutaneous branches of the thoracic intercostal nerves, the long thoracic nerve, and the thoracodorsal nerve run in variable anatomic courses, piercing the fascial plane between the serratus anterior muscle, ribs, and pectoralis minor muscle. These nerves innervate deep structures in the anterior, posterior, and lateral breast; the chest wall; axillary structures; and the upper abdomen. </div><div class=\"graphic_footnotes\">m.: muscle; a.: artery; n.: nerve.</div><div class=\"graphic_reference\">Modified from: Hoffman GW, Elliot LF.&nbsp;The anatomy of the pectoral nerves and its significance to the general and plastic surgeon.&nbsp;Ann Surg 1987; 205:504.</div><div id=\"graphicVersion\">Graphic 105077 Version 1.0</div></div></div>"},"105078":{"type":"graphic_picture","displayName":"Patient position for medial ankle US examination","title":"Patient position for medial ankle US examination","html":"<div class=\"graphic\"><div style=\"width: 802px\" class=\"figure\"><div class=\"ttl\">Patient position for medial ankle US examination</div><div class=\"cntnt\"><img style=\"width:782px; height:456px;\" src=\"images/SM/105078_Ptnt_pstn_med_ankl_US_exm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the proper patient position for performing an ultrasound examination of the&nbsp;medial ankle.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105078 Version 1.0</div></div></div>"},"105083":{"type":"graphic_picture","displayName":"US transducer position medial ankle tendons over ST short axis","title":"US transducer position medial ankle tendons over ST short axis","html":"<div class=\"graphic\"><div style=\"width: 806px\" class=\"figure\"><div class=\"ttl\">US transducer position medial ankle tendons over ST short axis</div><div class=\"cntnt\"><img style=\"width:786px; height:452px;\" src=\"images/SM/105083_US_trnsdc_pst_med_ankl_tndn_ST.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the position of the ultrasound transducer for obtaining an image of the tibialis posterior, flexor digitorum longus, and flexor hallucis longus tendons in short-axis as they travel over the sustentaculum tali (ST).</div><div class=\"graphic_footnotes\">Rectangle: transducer position</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105083 Version 1.0</div></div></div>"},"105085":{"type":"graphic_diagnosticimage","displayName":"Thoracic interfascial plane blocks","title":"Pecs I, Pecs II and Serratus plane blocks","html":"<div class=\"graphic\"><div style=\"width: 647px\" class=\"figure\"><div class=\"ttl\">Pecs I, Pecs II and Serratus plane blocks</div><div class=\"cntnt\"><img style=\"width:627px; height:429px;\" src=\"images/ANEST/105085_Ssp_mchncl_vlv_obstr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graphic shows the ultrasound probe position and ultrasound images for the thoracic interfascial plane blocks, the&nbsp;Pecs I block (A), Pecs II block (B), and serratus plane block (C), and the relevant dermatomes of the chest wall. For details of the thoracic interfascial plane blocks, refer to the UpToDate&nbsp;topic on nerve blocks of the scalp, neck, and trunk.</div><div class=\"graphic_footnotes\">PMm: pectoralis major muscle; Pmm: pectoralis minor muscle; Sm: serratus muscle; R4: fourth rib; TMm: teres major muscle; LDm: latissimus dorsi muscle; R5: fifth rib.</div><div class=\"graphic_reference\">From: Blanco R, Parras T, McDonnell JG, et al. Serratus plane block: A novel ultrasound-guided thoracic wall nerve block. Anaesthesia 2013; 68:1107. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/anae.12344/abstract\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/anae.12344/abstract</a>. Copyright &copy; 2013 The Association of Anaesthetists of Great Britain and Ireland. Reproduced with permission of John Wiley &amp; Sons, Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared, or emailed. Please contact Wiley's Permissions Department either via email: <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<a href=\"http://www.onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">www.onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 105085 Version 3.0</div></div></div>"},"105086":{"type":"graphic_picture","displayName":"US transducer position for tibialis posterior long axis","title":"US transducer position for tibialis posterior long axis","html":"<div class=\"graphic\"><div style=\"width: 805px\" class=\"figure\"><div class=\"ttl\">US transducer position for tibialis posterior long axis</div><div class=\"cntnt\"><img style=\"width:785px; height:459px;\" src=\"images/SM/105086_US_trnsdcr_pst_tbl_pstr_lng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the position of the ultrasound transducer&nbsp;for obtaining&nbsp;long-axis images of&nbsp;the tibialis posterior tendon at its insertion.</div><div class=\"graphic_footnotes\">Rectangle: transducer position</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105086 Version 1.0</div></div></div>"},"105087":{"type":"graphic_picture","displayName":"Intercostal block positioning with probe","title":"Positioning and ultrasound probe placement for intercostal block","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Positioning and ultrasound probe placement for intercostal block</div><div class=\"cntnt\"><img style=\"width:371px; height:276px;\" src=\"images/ANEST/105087_Intrcstls_pstn_prb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photo shows patient positioning and the probe placement for ultrasound-guided intercostal block. For details of block technique, refer to the UpToDate topic on nerve blocks of the scalp, neck, and trunk.</div><div class=\"graphic_reference\">From: Ben-Ari A, Moreno M, Chelly JE, et al. Ultrasound-guided paravertebral block using an intercostal approach. Anesth Analg 2009; 109:1691. DOI: <A spellcheck=true href=\"http://journals.lww.com/anesthesia-analgesia/pages/articleviewer.aspx?year=2009&amp;issue=11000&amp;article=00057&amp;type=abstract\" target=_blank>10.1213/ANE.0b013e3181b72d50</A>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright © 2009 International Anesthesia Research Society. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105087 Version 1.0</div></div></div>"},"105088":{"type":"graphic_diagnosticimage","displayName":"Intercostal nerve block ultrasound","title":"Intercostal nerve block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 491px\" class=\"figure\"><div class=\"ttl\">Intercostal nerve block ultrasound</div><div class=\"cntnt\"><img style=\"width:471px; height:327px;\" src=\"images/ANEST/105088_TPVB_ultrasound_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For ultrasound-guided intercostal nerve block, the tip of the needle is placed between the internal intercostal muscle and the innermost intercostal muscle, as shown by the tip of the arrow in this image. LA should be visualized spreading the two muscles apart. </div><div class=\"graphic_footnotes\">R: rib; EX: external intercostal muscle; IN: internal intercostal muscle; INM: innermost intercostal muscle; PL: pleura; LA: local anesthetic.</div><div class=\"graphic_reference\">Copyright &copy; 2012 Jens B&oslash;rglum and Kenneth Jensen. Originally published in Abdominal Surgery, Derbel F (Ed), InTech 2012, under <a href=\"http://creativecommons.org/licenses/by/3.0/\" target=\"_blank\">CC BY 3.0 license</a>. Available from: <a href=\"http://www.intechopen.com/books/abdominal-surgery\" target=\"_blank\">DOI: 10.5772/3020</a> (Accessed on November 4, 2015).</div><div id=\"graphicVersion\">Graphic 105088 Version 2.0</div></div></div>"},"105089":{"type":"graphic_diagnosticimage","displayName":"Transversalis fascia plane block ultrasound","title":"Transversalis fascia plane block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 741px\" class=\"figure\"><div class=\"ttl\">Transversalis fascia plane block ultrasound</div><div class=\"cntnt\"><img style=\"width:721px; height:383px;\" src=\"images/ANEST/105089_Trnsvrsl_fsc_pln_blck_ultrsnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Composite ultrasound image of the IO and TA tapering off posteriorly into their common aponeurosis adjacent to the QL.<br />(B) The needle tip is positioned just under the aponeurosis of the TA. Injection in this location should result in visible LA spread in the TFP, as shown.</div><div class=\"graphic_footnotes\">EO: external oblique; IO: internal oblique; TA: transversus abdominis; QL: quadratus lumborum; LA: local anesthetic; TFP: transversalis fascia plane.</div><div class=\"graphic_reference\">Reproduced with permission. All rights reserved. Copyright &copy; 2008 Ultrasound for Regional Anesthesia, Toronto Western Hospital.</div><div id=\"graphicVersion\">Graphic 105089 Version 1.0</div></div></div>"},"105090":{"type":"graphic_picture","displayName":"US transducer position FDL over FHL (Knot of Henry)","title":"US transducer position FDL over FHL (Knot of Henry)","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">US transducer position FDL over FHL (Knot of Henry)</div><div class=\"cntnt\"><img style=\"width:784px; height:456px;\" src=\"images/SM/105090_US_trnsdc_pst_FDL_FHL_knt_hnry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the position of the ultrasound transducer&nbsp;for obtaining an&nbsp;image of the Knot of Henry, where the flexor digitorum longus tendon crosses over the&nbsp;flexor hallucis longus tendon.</div><div class=\"graphic_footnotes\">Rectangle: transducer position</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105090 Version 1.0</div></div></div>"},"105091":{"type":"graphic_diagnosticimage","displayName":"US FDL overlying FHL (Knot of Henry)","title":"US FDL overlying FHL (Knot of Henry)","html":"<div class=\"graphic\"><div style=\"width: 797px\" class=\"figure\"><div class=\"ttl\">US FDL overlying FHL (Knot of Henry)</div><div class=\"cntnt\"><img style=\"width:777px; height:747px;\" src=\"images/SM/105091_US_FDL_ovrly_FHL_knt_hnry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows a short axis view of the Knot of Henry where the flexor digitorum longus tendon crosses over and becomes superficial to the flexor hallucis longus tendon.</div><div class=\"graphic_footnotes\">Arrowheads: flexor digitorum longus tendon; *: flexor hallucis longus tendon; dotted ellipse: medial plantar nerve.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105091 Version 2.0</div></div></div>"},"105092":{"type":"graphic_picture","displayName":"US transducer position FHL insertion long axis","title":"US transducer position FHL insertion long axis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US transducer position FHL insertion long axis</div><div class=\"cntnt\"><img style=\"width:405px; height:783px;\" src=\"images/SM/105092_US_trnsdc_pst_FHL_insrt_lng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the position&nbsp;of the ultrasound transducer&nbsp;for obtaining&nbsp;images of the&nbsp;flexor hallucis longus tendon (long-axis) at its insertion.</div><div class=\"graphic_footnotes\">Rectangle: transducer location</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105092 Version 1.0</div></div></div>"},"105093":{"type":"graphic_algorithm","displayName":"Evaluation of suspected upper GI bleeding","title":"Evaluation of suspected upper gastrointestinal bleeding","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Evaluation of suspected upper gastrointestinal bleeding</div><div class=\"cntnt\"><img style=\"width:550px; height:1042px;\" src=\"images/GAST/105093_EvalsuspctdupprGIbledng.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">GI: gastrointestinal; CT: computed tomographic; CTA: computed tomographic angiography; MR: magnetic resonance.<br />* The presence of both hematemesis and melena suggests that brisk bleeding is present.<br />¶ Bleeding associated with signs such as hypotension, tachycardia, or orthostatic hypotension.<br />Δ Consider evaluation with a side-viewing duodenoscope if there are risk factors for hemobilia or hemosuccus pancreaticus; consider CTA (followed by push enteroscopy if the CTA is negative) in patients at risk for an aortoenteric fistula. Conventional angiography is typically performed if the patient remains hemodynamically unstable despite attempts at resuscitation.<br /><FONT class=lozenge>◊</FONT> ​Patients who present with hematemesis do not need to undergo colonoscopy, since hematemesis suggests the bleeding is proximal to the ligament of Treitz. They should proceed directly to an evaluation for small bowel bleeding.<br />§ If the patient becomes hemodynamically unstable following initial resuscitation, conventional angiography can be performed. Patients who present with hematemesis do not need to undergo colonoscopy and can skip this step in the evaluation because hematemesis suggests the bleeding is proximal to the ligament of Treitz.<br />¥ If the initial endoscopic evaluation was inadequate (eg, fair or poor visualization, failure to reach the cecum), repeat examination should be considered before initiating an evaluation for small bowel bleeding. Refer to UpToDate topic review on suspected small bowel bleeding for details.<br />‡ If not already done. If the patient remains hemodynamically stable and does not have evidence of aggressive bleeding (eg, ongoing hematochezia), perform a CTA or push enteroscopy (CTA is the initial test of choice if there is concern for an aortoenteric fistula). If the patient becomes hemodynamically unstable following initial resuscitation or has signs of aggressive bleeding, perform conventional angiography.<br />† If not already done, angiography or CTA may be obtained. If angiography or CTA has been performed and no source is identified, a Meckel's scan should be obtained in younger patients with overt bleeding, unless the only manifestation of bleeding was hematemesis. Surgical exploration is appropriate if no other studies have revealed a source and significant bleeding continues or if there is high suspicion for a small bowel neoplasm.<br />** If the deep small bowel enteroscopy was incomplete, a video capsule endoscopy study should be obtained, followed by CT enterography or MR enterography&nbsp;if the capsule endoscopy is negative.</div><div id=\"graphicVersion\">Graphic 105093 Version 2.0</div></div></div>"},"105094":{"type":"graphic_diagnosticimage","displayName":"US FHL insertion long axis","title":"US FHL insertion long axis view","html":"<div class=\"graphic\"><div style=\"width: 806px\" class=\"figure\"><div class=\"ttl\">US FHL insertion long axis view</div><div class=\"cntnt\"><img style=\"width:786px; height:393px;\" src=\"images/SM/105094_US_FHL_insrt_lng_axs_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the insertion of the flexor hallucis longus (FHL)&nbsp;tendon in a long-axis view.</div><div class=\"graphic_footnotes\">Arrows: FHL tendon; P1: proximal phalanx; P2: distal phalanx; *: interphalangeal joint sesamoid embedded within the joint capsule.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105094 Version 1.0</div></div></div>"},"105095":{"type":"graphic_picture","displayName":"US transducer positions to image tibial nerve caudally","title":"US transducer positions to image tibial nerve caudally","html":"<div class=\"graphic\"><div style=\"width: 807px\" class=\"figure\"><div class=\"ttl\">US transducer positions to image tibial nerve caudally</div><div class=\"cntnt\"><img style=\"width:787px; height:462px;\" src=\"images/SM/105095_US_trnsdcr_pstn_img_tbl_nrv_cdl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the successive positions of the ultrasound transducer&nbsp;that are used&nbsp;to image the tibial nerve in its short-axis as it travels caudally. Note that&nbsp;the branching&nbsp;of the medial plantar, lateral plantar, and calcaneal&nbsp;nerves off&nbsp;the tibial nerve&nbsp;is variable.</div><div class=\"graphic_footnotes\">Rectangles: transducer positions<br />Left of the screen: proximal; right of the screen: distal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105095 Version 1.0</div></div></div>"},"105096":{"type":"graphic_diagnosticimage","displayName":"US branches of tibial nerve","title":"US branches of tibial nerve","html":"<div class=\"graphic\"><div style=\"width: 807px\" class=\"figure\"><div class=\"ttl\">US branches of tibial nerve</div><div class=\"cntnt\"><img style=\"width:787px; height:503px;\" src=\"images/SM/105096_US_brnch_tbl_nrv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image&nbsp;shows the&nbsp;major branches of the tibial nerve in short-axis. Note that the location where the calcaneal, lateral plantar, and medial plantar nerve&nbsp;branches occur varies among individuals.</div><div class=\"graphic_footnotes\">Small arrowheads: calcaneal branch of tibial nerve; large arrowheads: lateral plantar nerve; arrows: medial plantar nerve; A: tibial artery; V: tibial veins.<br />Left of screen: posterior; right of screen: anterior.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105096 Version 1.0</div></div></div>"},"105099":{"type":"graphic_picture","displayName":"US transducer position tibiocalcaneal part deltoid ligament long","title":"US transducer position tibiocalcaneal part of deltoid ligament long axis view","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">US transducer position tibiocalcaneal part of deltoid ligament long axis view</div><div class=\"cntnt\"><img style=\"width:783px; height:457px;\" src=\"images/SM/105099_US_trnsd_pst_tbclcnl_dltd_lgm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the position of the ultrasound transducer&nbsp;for obtaining&nbsp;images of&nbsp;the tibiocalcaneal component of the deltoid ligament in its long axis.</div><div class=\"graphic_footnotes\">Rectangle: transducer position</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105099 Version 1.0</div></div></div>"},"105100":{"type":"graphic_diagnosticimage","displayName":"US tibiocalcaneal component of deltoid ligament long axis","title":"US tibiocalcaneal component of deltoid ligament long axis","html":"<div class=\"graphic\"><div style=\"width: 806px\" class=\"figure\"><div class=\"ttl\">US tibiocalcaneal component of deltoid ligament long axis</div><div class=\"cntnt\"><img style=\"width:786px; height:298px;\" src=\"images/SM/105100_US_tbclcnl_cmpn_dltd_lgm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image&nbsp;shows the tibiocalcaneal component of the deltoid ligament (arrowheads) in its long axis.</div><div class=\"graphic_footnotes\">Left of screen: proximal; right of screen: distal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105100 Version 1.0</div></div></div>"},"105101":{"type":"graphic_picture","displayName":"US transducer position tibionavicular deltoid ligament long axis","title":"US transducer position for tibionavicular part of deltoid ligament long axis view","html":"<div class=\"graphic\"><div style=\"width: 800px\" class=\"figure\"><div class=\"ttl\">US transducer position for tibionavicular part of deltoid ligament long axis view</div><div class=\"cntnt\"><img style=\"width:780px; height:448px;\" src=\"images/SM/105101_US_trnsdc_pst_tbnvc_dltd_lgm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the ultrasound transducer position&nbsp;for obtaining&nbsp;images of&nbsp;the tibionavicular and anterior tibiotalar components of the deltoid ligament in their long axis.</div><div class=\"graphic_footnotes\">Rectangle: transducer position</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105101 Version 1.0</div></div></div>"},"105102":{"type":"graphic_diagnosticimage","displayName":"US tibionavicular tibiotalar deltoid ligament long axis","title":"US tibionavicular and tibiotalar portions of deltoid ligament long axis view","html":"<div class=\"graphic\"><div style=\"width: 807px\" class=\"figure\"><div class=\"ttl\">US tibionavicular and tibiotalar portions of deltoid ligament long axis view</div><div class=\"cntnt\"><img style=\"width:787px; height:243px;\" src=\"images/SM/105102_US_tbnvclr_tbtl_dlt_lgm_lng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image&nbsp;shows&nbsp;the tibionavicular and anterior tibiotalar components of the deltoid ligament in their long axis. Note the presence of a tibiotalar joint effusion (*) and attenuation of the deep (tibiotalar) component of the deltoid ligament from prior injury.</div><div class=\"graphic_footnotes\">Arrows: tibionavicular component of deltoid ligament; arrowheads: anterior tibiotalar component of deltoid ligament; TIB: tibia; TAL: talus; NAV: navicular bone.<br />Left of screen: proximal; right of screen: distal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105102 Version 2.0</div></div></div>"},"105103":{"type":"graphic_picture","displayName":"US transducer position for posterior tibiotalar deltoid ligament","title":"US transducer position for posterior tibiotalar deltoid ligament","html":"<div class=\"graphic\"><div style=\"width: 805px\" class=\"figure\"><div class=\"ttl\">US transducer position for posterior tibiotalar deltoid ligament</div><div class=\"cntnt\"><img style=\"width:785px; height:460px;\" src=\"images/SM/105103_US_trnsd_pst_pst_tbt_dltd_lg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the position of the ultrasound transducer&nbsp;for obtaining long-axis&nbsp;images of&nbsp;the posterior tibiotalar component of the deltoid ligament.</div><div class=\"graphic_footnotes\">Rectangle: transducer position</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105103 Version 1.0</div></div></div>"},"105104":{"type":"graphic_diagnosticimage","displayName":"US posterior tibiotalar deltoid ligament long axis","title":"US posterior tibiotalar portion of deltoid ligament long axis view","html":"<div class=\"graphic\"><div style=\"width: 806px\" class=\"figure\"><div class=\"ttl\">US posterior tibiotalar portion of deltoid ligament long axis view</div><div class=\"cntnt\"><img style=\"width:786px; height:431px;\" src=\"images/SM/105104_US_pst_tbtlr_dltd_lgm_lng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image&nbsp;shows the posterior tibiotalar component of the deltoid ligament in its long axis.</div><div class=\"graphic_footnotes\">Arrowheads: posterior tibiotalar component of the deltoid ligament; PT: tibialis posterior tendon (short-axis).<br />Left of screen: proximal; right of screen: distal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105104 Version 1.0</div></div></div>"},"105105":{"type":"graphic_diagnosticimage","displayName":"US Achilles tendon formation","title":"US Achilles tendon formation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US Achilles tendon formation</div><div class=\"cntnt\"><img style=\"width:314px; height:728px;\" src=\"images/SM/105105_US_achlls_tndn_frmt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These ultrasound images&nbsp;depict the formation of the Achilles tendon&nbsp;and show the changes in the relative positions of the gastrocnemius&nbsp;and soleus portions of the tendon as the transducer is moved distal towards its insertion on the calcaneous.</div><div class=\"graphic_footnotes\">Gastroc: gastrocnemius component of Achilles tendon; Sol: soleus component of gastrocnemius tendon.<br />Left of screen: medial; right of screen: lateral.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105105 Version 3.0</div></div></div>"},"105106":{"type":"graphic_diagnosticimage","displayName":"US plantaris tendon short axis","title":"US plantaris tendon in short axis","html":"<div class=\"graphic\"><div style=\"width: 805px\" class=\"figure\"><div class=\"ttl\">US plantaris tendon in short axis</div><div class=\"cntnt\"><img style=\"width:785px; height:649px;\" src=\"images/SM/105106_US_pln_fsc_orgn_plntr_tnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image&nbsp;shows the plantaris tendon in short-axis.</div><div class=\"graphic_footnotes\">Dotted ellipse: plantaris tendon; arrows: Achilles tendon.<br />Left of screen: lateral; right of screen: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105106 Version 2.0</div></div></div>"},"105107":{"type":"graphic_diagnosticimage","displayName":"US plantar heel pad of foot","title":"US plantar heel pad of foot","html":"<div class=\"graphic\"><div style=\"width: 620px\" class=\"figure\"><div class=\"ttl\">US plantar heel pad of foot</div><div class=\"cntnt\"><img style=\"width:600px; height:721px;\" src=\"images/SM/105107_US_plntr_hl_pad_ft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These ultrasound images show the plantar fascia origin (arrows)&nbsp;and heel pad. Image A is a short-axis image, while image B provides a long-axis view.</div><div class=\"graphic_footnotes\">FDB: Flexor digitorum brevis<br />(Image A) Left of the screen: medial; right of the screen: lateral.<br />(Image B) Left of screen: proximal; right of screen: distal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105107 Version 2.0</div></div></div>"},"105115":{"type":"graphic_figure","displayName":"LDL-C levels and genetics in FH","title":"LDL cholesterol levels and genetic mutations in familial hypercholesterolemia","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">LDL cholesterol levels and genetic mutations in familial hypercholesterolemia</div><div class=\"cntnt\"><img style=\"width:762px; height:338px;\" src=\"images/PEDS/105115_LDL_chlstrl_lvls_gntc_famil.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">LDL-C units are mg/dL; divide by 38.67 to convert to mmol/L.</div><div class=\"graphic_footnotes\">LDL-C: low density lipoprotein cholesterol; FH: familial hypercholesterolemia; LDLR: LDL receptor gene; APOB: apolipoprotein B gene; PCSK9: proprotein convertase subtilisin kexin 9.</div><div class=\"graphic_reference\">Adapted from: Cuchel M, Bruckert E, Ginsberg HN, et al. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. Eur Heart J 2014; 35:2146.</div><div id=\"graphicVersion\">Graphic 105115 Version 2.0</div></div></div>"},"105116":{"type":"graphic_figure","displayName":"OS by R-ISS in MM","title":"Overall survival by Revised International Staging System (R-ISS) in multiple myeloma","html":"<div class=\"graphic\"><div style=\"width: 563px\" class=\"figure\"><div class=\"ttl\">Overall survival by Revised International Staging System (R-ISS) in multiple myeloma</div><div class=\"cntnt\"><img style=\"width:543px; height:513px;\" src=\"images/HEME/105116_OS_by_R_ISS_MM.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Overall survival&nbsp;in patients with multiple myeloma stratified by R-ISS. Median OS was not reached for patients included in R-ISS stage I, whereas it was 83 months for R-ISS stage II and 43 months for R-ISS stage III. R-ISS I was defined by ISS stage I (B2M &lt;3.5 mg/L and serum albumin ≥3.5 g/dL) and normal LDH and no del(17p), t(4;14) or t(14;16) by FISH. R-ISS II was defined as those not meeting criteria for R-ISS I or III. R-ISS III was defined by ISS stage III (B2M ≥5.5 mg/L) plus LDH above normal limits and/or detection of one of the following by FISH: del(17p), t(4;14) or t(14;16).</div><div class=\"graphic_footnotes\">OS: Overall survival; R-ISS: Revised International Staging System; ISS: International Staging System; LDH: lactate dehydrogenase.</div><div class=\"graphic_reference\">From: Palumbo A, Avet-Loiseau H, Oliva S, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol 2015; 33(26):2863-9. Reprinted with permission. Copyright &copy; 2015 American Society of Clinical Oncology. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105116 Version 2.0</div></div></div>"},"105117":{"type":"graphic_figure","displayName":"Scalp block insertion sites","title":"Scalp block insertion sites","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Scalp block insertion sites</div><div class=\"cntnt\"><img style=\"width:532px; height:535px;\" src=\"images/ANEST/105117_Scalp_block_insertion_sites.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The numbered dots in this graphic show the needle insertion sites for injection of local anesthetic for the six nerve blocks that comprise the scalp block, as follows:<br />(1) Supraorbital and supratrochlear nerve blocks<br />(2) Zygomaticotemporal nerve block<br />(3) Auriculotemporal nerve block<br />(4)&nbsp;Lesser occipital nerve<br />(5)&nbsp;Greater occipital nerve<br />For details of block technique, refer to UpToDate topic&nbsp;on nerve blocks of the scalp, neck, and trunk, section on scalp block.</div><div class=\"graphic_footnotes\">n.: nerve.</div><div class=\"graphic_reference\">Modified from: Guilfoyle MR, Helmy A, Duane D, et al.&nbsp; Regional scalp block for postcraniotomy analgesia: A systematic review and meta-analysis.&nbsp;Anesth Analg 2013; 116:1093.</div><div id=\"graphicVersion\">Graphic 105117 Version 2.0</div></div></div>"},"105118":{"type":"graphic_figure","displayName":"Rectus sheath block anatomy","title":"Rectus sheath block anatomy","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Rectus sheath block anatomy</div><div class=\"cntnt\"><img style=\"width:533px; height:282px;\" src=\"images/ANEST/105118_Rectus_sheath_block_anatomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">m.: muscle; a.: artery.</div><div id=\"graphicVersion\">Graphic 105118 Version 3.0</div></div></div>"},"105119":{"type":"graphic_figure","displayName":"Rectus sheath block coverage and US probe placement","title":"Rectus sheath coverage and ultrasound probe placement","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rectus sheath coverage and ultrasound probe placement</div><div class=\"cntnt\"><img style=\"width:417px; height:538px;\" src=\"images/ANEST/105119_Rectus_sheath_abdomen.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For rectus sheath block, the ultrasound probe is placed above the umbilicus, at the edge of the rectus abdominus muscle, as shown by the rectangle in this graphic. The sensory block includes an oval periumbilical area when the block is performed bilaterally.</div><div id=\"graphicVersion\">Graphic 105119 Version 5.0</div></div></div>"},"105120":{"type":"graphic_figure","displayName":"Cervix transformation zone histo","title":"Cervical transformation zone histology","html":"<div class=\"graphic\"><div style=\"width: 762px\" class=\"figure\"><div class=\"ttl\">Cervical transformation zone histology</div><div class=\"cntnt\"><img style=\"width:742px; height:446px;\" src=\"images/OBGYN/105120_Cervix_trnsfrmtn_zone_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The active T-zone has immature metaplasia at the squamocolumnar junction as the squamous cells migrate over the villi. When they form glycogen, they become mature and are resistant to human papillomavirus infection.</div><div class=\"graphic_reference\">Reproduced with permission from Kenneth Hatch, MD, University of Arizona, Department of Obstetrics and Gynecology. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 105120 Version 1.0</div></div></div>"},"105121":{"type":"graphic_figure","displayName":"Paravertebral space","title":"Paravertebral space anatomy","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Paravertebral space anatomy</div><div class=\"cntnt\"><img style=\"width:534px; height:379px;\" src=\"images/ANEST/105121_Paravertebral_space.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The paravertebral space (shaded green) and the related anatomic structures are shown in this graphic. For details of anatomy and technique for thoracic paravertebral block, refer to the UpToDate topic on nerve blocks of the scalp, neck, and trunk.</div><div class=\"graphic_footnotes\">m.: muscle; n.: nerve.</div><div id=\"graphicVersion\">Graphic 105121 Version 2.0</div></div></div>"},"105122":{"type":"graphic_picture","displayName":"Cervix transformation zone colpo","title":"Cervical transformation zone at colposcopy","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Cervical transformation zone at colposcopy</div><div class=\"cntnt\"><img style=\"width:720px; height:484px;\" src=\"images/OBGYN/105122_Cervix_trnsfrmtn_zone_colpo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A cervical transformation zone with mature metaplasia and active immature metaplasia.</div><div class=\"graphic_reference\">Reproduced with permission from Kenneth Hatch, MD, University of Arizona, Department of Obstetrics and Gynecology. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 105122 Version 1.0</div></div></div>"},"105123":{"type":"graphic_table","displayName":"Key points for hemodynamic management in adults with CHD","title":"Key points for hemodynamic management in adult patients with congenital heart disease having noncardiac surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key points for hemodynamic management in adult patients with congenital heart disease having noncardiac surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Lesions</td> <td class=\"subtitle1\">Hemodynamic goals</td> <td class=\"subtitle1\">Avoid</td> <td class=\"subtitle1\">Intervention if needed</td> <td class=\"subtitle1\">Physiologic concepts</td> </tr> <tr class=\"divider_bottom\"> <td>Right-to-left shunting</td> <td>Maintain or increase SVR</td> <td> <p>Avoid systemic vasodilation</p> Avoid increases in PVR</td> <td> <p>Administer a vasoconstrictor (vasopressin is preferred over phenylephrine because vasopressin increases SVR without increasing PVR).</p> Avoid or treat hypoxia or hypercarbia.</td> <td>Peripheral vasodilation decreases LVEDP and LAP, leading to an increase in right-to-left shunting and a decrease in SpO<sub>2</sub> and cyanosis. An increase in PVR will increase right-sided pressures and also increase right-to-left shunting. Because vasopressin increases SVR without increasing PVR, it is preferable to use vasopressin rather than phenylephrine to increase SVR.</td> </tr> <tr class=\"divider_bottom\"> <td>Left-to-right shunting</td> <td>Maintain or decrease SVR</td> <td>Avoid decreases in PVR</td> <td>Avoid hyperoxia and hypocarbia (reduce FiO<sub>2</sub> and minute ventilation).</td> <td>Increases in SVR increase left-sided pressure, leading to an increase in left-to-right shunting. Similarly, a decrease in PVR also increases left-to-right shunting. General anesthesia with mechanical ventilation tends to decrease SVR but may also decrease PVR, so the net effect is difficult to predict. Generally, hyperventilation and hyperoxia should be avoided since these conditions lower PaCO<sub>2</sub> and may lower PVR. Systemic hypotension may best be treated with phenylephrine because it will increase both SVR and PVR.</td> </tr> <tr class=\"divider_bottom\"> <td>Fontan physiology (cavopulmonary palliation)</td> <td> <p>Decrease PVR</p> <p>Maintain preload</p> Maintain contractility</td> <td> <p>Avoid increases in PVR</p> <p>Avoid hypovolemia</p> Avoid myocardial depressants</td> <td> <p>Avoid or treat hypoxia, hypercarbia.</p> <p>Maintain appropriate analgesia with sedation or anesthesia.</p> <p>Maintain adequate preload with fluid replacement.</p> Initiate inotropic support if necessary.</td> <td>Pulmonary blood flow depends on both adequate RAP (as there is no pumping chamber) and low PVR. Treatment is aimed at both maintaining right-sided filling pressure (hypervolemia) and decreasing PVR (avoiding hypoxia or hypoventilation). Myocardial depression may reduce LV performance and lead to an increase in LAP, thus decreasing the transpulmonary pressure gradient and causing a marked increase in right-sided pressure, resulting in right-sided heart failure.</td> </tr> <tr class=\"divider_bottom\"> <td>Pulmonary hypertension</td> <td> <p>Decrease PVR</p> Maintain preload</td> <td> <p>Avoid increases in PVR</p> Avoid hypovolemia</td> <td> <p>Continue preoperative medications that minimize PVR.</p> <p>Avoid or treat hypoxia or hypercarbia.</p> Consider inhalational pulmonary vasodilators (eg, nitric oxide or epoprostenol) for refractory increases in PVR.</td> <td>Often, little can be done to reduce chronically elevated PVR; therefore, measures should be directed at avoiding further increases. Anesthetics lower PVR, particularly inhalational or volatile agents (exceptions are N<sub>2</sub>O and ketamine). This is especially true if administration of anesthetic agents is combined with mechanical ventilation with modest hyperventilation and increased FiO<sub>2</sub> (both lower PVR).</td> </tr> <tr class=\"divider_bottom\"> <td>Obstructive lesion</td> <td> <p>Maintain sinus rhythm and normal HR</p> <p>Maintain preload</p> Maintain SVR</td> <td> <p>Avoid tachycardia/SVT</p> <p>Avoid severe bradycardia</p> <p>Avoid junctional rhythm</p> <p>Avoid hypovolemia</p> Avoid vasodilation</td> <td> <p>Control HR.</p> <p>Perform cardioversion for hemodynamically unstable SVT.</p> <p>Maintain intravascular volume status with fluid replacement.</p> Administer a vasoconstrictor.</td> <td> <p>Stroke volume across obstructive lesions is diminished due to elevated pressure gradients. A drop in SVR leads to hypotension as stroke volume is relatively fixed and cannot adequately increase to compensate.</p> <p>With atrioventricular (mitral or tricuspid) valve stenosis, a slower heart rate allows a longer diastolic period and promotes flow across the stenotic lesion. Maintaining sinus rhythm allows atrial contraction to contribute to ventricular filling.</p> <p>With aortic or pulmonic stenosis, a slower heart rate reduces myocardial work and allows time for ventricular filling and ejection across the stenotic valve.</p> With valvular stenosis, both tachycardia and hypotension can contribute to myocardial ischemia by increasing oxygen demand and decreasing oxygen supply.</td> </tr> <tr class=\"divider_bottom\"> <td>Regurgitant lesion</td> <td> <p>Normal to fast HR</p> Decrease SVR</td> <td> <p>Avoid bradycardia</p> Avoid hypertension</td> <td> <p>Treat bradycardia with glycopyrrolate, atropine, or ephedrine.</p> <p>Treat hypertension with vasodilators.</p> Maintain appropriate analgesia with sedation or anesthesia.</td> <td> <p>With regurgitant lesions, the objectives are to maintain forward flow and to diminish backward or retrograde flow.</p> <p>With atrioventricular (mitral or tricuspid) regurgitation, the objective is to lower impedance to ejection of blood from the LV or RV. Thus, vasodilatation tends to favor forward flow.</p> With aortic or pulmonic regurgitation, bradycardia prolongs diastole and promotes more regurgitation. Thus, maintaining a high normal HR is generally preferred.</td> </tr> <tr> <td>Heart transplant</td> <td> <p>Maintain contractility</p> <p>Maintain SVR</p> <p>Maintain HR</p> Lower PVR</td> <td>Avoid myocardial depressants</td> <td> <p>Treat hypotension or bradycardia with direct-acting agents.</p> <p>Hypotension due to vasodilation is treated with phenylephrine or vasopressin (vasopressin is preferred over phenylephrine to minimize effects on PVR).</p> <p>Poor contractility is treated with epinephrine or norepinephrine.</p> Bradycardia is treated with epinephrine or isoproterenol.</td> <td> <p>Transplant recipients often have early and/or late ventricular dysfunction due to causes including allograft ischemic injury, rejection, and cardiac allograft vasculopathy.</p> Current cardiac function should be assessed and managed as needed.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SVR: systemic vascular resistance; PVR: pulmonary vascular resistance; LVEDP: left ventricular end diastolic pressure; LAP: left atrial pressure; RAP: right atrial pressure; SPO<sub>2</sub>: oxygen saturation; FiO<sub>2</sub>: fraction of inspired oxygen; PaCO<sub>2</sub>: partial pressure of carbon dioxide; N<sub>2</sub>O: nitrous oxide; HR: heart rate; SVT: supraventricular tachyarrhythmia; LV: left ventricle; RV: right ventricle.</div><div class=\"graphic_reference\">Additional information provided by Dr. Martin Abel, MD, Mayo Clinic.</div><div id=\"graphicVersion\">Graphic 105123 Version 6.0</div></div></div>"},"105126":{"type":"graphic_table","displayName":"Dietary recommendations for salt intake CKD 3-4","title":"Dietary recommendations for salt intake in patients with CKD 3 to 4","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dietary recommendations for salt intake in patients with CKD 3 to 4</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">KDIGO <span style=\"white-space: nowrap;\">2012<sup>[1]</sup></span></td> <td class=\"subtitle1\">NKF KDOQI 2000<br /> (CKD class 1 through <span style=\"white-space: nowrap;\">4)<sup>[2]</sup></span></td> <td class=\"subtitle1\">US Department of Agriculture and Human Services: DGA <span style=\"white-space: nowrap;\">2010<sup>[3]</sup></span></td> <td class=\"subtitle1\">JNC-7 <span style=\"white-space: nowrap;\">2003<sup>[4]</sup></span></td> <td class=\"subtitle1\">European Society of Hypertension <span style=\"white-space: nowrap;\">2007<sup>[5]</sup></span></td> <td class=\"subtitle1\">&nbsp;US Institutes of Medicine<sup>[6]</sup></td> </tr> <tr> <td>&#60;2 Na g/day (5 g/day of NaCl)</td> <td>Na &#60;2.4 g/day (6 g/day of NaCl)</td> <td> <ul> <li>&#60;2.3 g/day for those ages &#62;2 years </li> <li>&#60;1.5 g/day for high-risk groups (CKD, black race, HTN, diabetes, &#8805;51 years of age) </li> </ul> </td> <td>&#60;2.3 Na g/day (5.75 g/day of NaCl)</td> <td>&#60;2 g/day Na (5 g/day of NaCl)</td> <td>&nbsp;&#60;2.3 Na g/day (5.75 g/day of NaCl)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">KDIGO: Kidney Disease: Improving Global Outcomes; NKF: National Kidney Foundation; KDOQI: Kidney Disease Outcomes Quality Initiatives; CKD: chronic kidney disease; DGA: Dietary Guidelines for Americans; HTN: hypertension; JNC: Joint National Committee.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. <A href=\"http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO_BP_GL.pdf\" target=_blank>http://www.kdigo.org/clinical_practice_guidelines/pdf/KDIGO_BP_GL.pdf</A> (Accessed on November 4, 2015).</LI>&#xD;&#xA;<LI>NKF KDOQI Guidelines 2000. Clinical practice guidelines for nutrition in chronic renal failure. <A href=\"https://www.kidney.org/sites/default/files/docs/kdoqi2000nutritiongl.pdf\" target=_blank>https://www.kidney.org/sites/default/files/docs/kdoqi2000nutritiongl.pdf</A> (Accessed on November 4, 2015).</LI>&#xD;&#xA;<LI>US Department of Agriculture and US Department of Health and Human Services. Dietary guidelines for Americans. Chapter 3. <A href=\"http://health.gov/dietaryguidelines/dga2010/dietaryguidelines2010.pdf\" target=_blank>http://health.gov/dietaryguidelines/dga2010/dietaryguidelines2010.pdf</A> (Accessed on November 4, 2015).</LI>&#xD;&#xA;<LI>The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. <A href=\"http://www.nhlbi.nih.gov/files/docs/guidelines/jnc7full.pdf\" target=_blank>http://www.nhlbi.nih.gov/files/docs/guidelines/jnc7full.pdf</A> (Accessed on November 4, 2015).</LI>&#xD;&#xA;<LI>Mancia G, De Backer G, Dominiczak A, et al. 2007 guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105.</LI>&#xD;&#xA;<LI>Sodium intake in populations: Assessment of Evidence. US Institutes of Medicine. May 14, 2013. <A href=\"http://iom.nationalacademies.org/Reports/2013/Sodium-Intake-in-Populations-assessment-of-Evidence.aspx\">http://iom.nationalacademies.org/Reports/2013/Sodium-Intake-in-Populations-assessment-of-Evidence.aspx</A> (Accessed on December 16, 2015).</LI></OL></div><div id=\"graphicVersion\">Graphic 105126 Version 3.0</div></div></div>"},"105127":{"type":"graphic_table","displayName":"Nutritional recommendations for adults with CKD 3-4","title":"Nutritional recommendations for adults with chronic kidney disease stages 3 to 4","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Nutritional recommendations for adults with chronic kidney disease stages 3 to 4</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"85%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Protein</strong></td> <td>&#8804;0.8 g/kg/day<sup>[1]</sup>, increase plant source.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Salt</strong></td> <td>&#60;2.3 g/day (&#60;5 g/day of NaCl)<sup>[1]</sup>.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Potassium</strong></td> <td>Individualize to keep the&nbsp;serum potassium&nbsp;within a normal range.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Calcium</strong></td> <td>1.5 g/day from both dietary and medication sources.*</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Phosphorus</strong></td> <td>0.8 to 1 g/day or individualize to keep the value within a normal range.<br /> Increase vegetable source and avoid processed foods as much as possible.</td> </tr> <tr class=\"divider_bottom\"> <td><span style=\"white-space: nowrap;\"><strong>Carbohydrate/fat</strong><sup>[2]</sup></span></td> <td>30 to 35 kcal/kg/day; &#60;30% of total calories from fat and &#60;10% of total fat from saturated fat; DASH diet pattern highly recommended.</td> </tr> <tr> <td><strong>Fiber</strong><sup>[3]</sup></td> <td>25 to 38 g/day.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Some clinicians favor a lower calcium intake of 1 g/day.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3:5.</li>&#xD;&#xA;    <li>NKF KDOQI Guidelines 2000. Clinical practice guidelines for nutrition in chronic renal failure. <a href=\"https://www.kidney.org/sites/default/files/docs/kdoqi2000nutritiongl.pdf\" target=\"_blank\">https://www.kidney.org/sites/default/files/docs/kdoqi2000nutritiongl.pdf</a> (Accessed on November 4, 2015).</li>&#xD;&#xA;    <li><a href=\"http://health.gov/dietaryguidelines/2010/\" target=\"_blank\">http://health.gov/dietaryguidelines/2010/</a> (Accessed on November 4, 2015).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 105127 Version 1.0</div></div></div>"},"105131":{"type":"graphic_algorithm","displayName":"Approach to the diagnosis of Whipple's disease","title":"Approach to the diagnosis of Whipple's disease","html":"<div class=\"graphic\"><div style=\"width: 788px\" class=\"figure\"><div class=\"ttl\">Approach to the diagnosis of Whipple's disease</div><div class=\"cntnt\"><img style=\"width:768px; height:894px;\" src=\"images/ID/105131_Appoch_dgn_whppl_dss.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CNS: central nervous system; CSF: cerebrospinal fluid; HIV: human immunodeficiency virus; PAS: periodic acid-Schiff; PCR: polymerase chain reaction.<br />* Classic Whipple's disease is a multisystemic process that presents over time. Joint symptoms, typically migratory arthralgias of the large joints, generally precede other manifestations by many years. Later in the course of disease, intermittent diarrhea with colicky abdominal pain occur and ultimately progress to a severe wasting syndrome. Many other organ systems can also be affected, including the central nervous system.<br />¶ The first step in the evaluation of Whipple's disease is to assess for alternative, more common disorders that cause chronic diarrhea, arthralgias, or progressive CNS disease. The differential diagnosis is wide and depends on the presentation.<br />Δ Endoscopy with small bowel biopsy is a safe and simple diagnostic test that we perform whenever the possibility of Whipple's disease is being considered, even in patients with predominantly extraintestinal features. We typically obtain seven to ten biopsies from different parts of the duodenum and, if possible, sample the stomach and proximal jejunum.<br /><FONT class=lozenge>◊</FONT> CSF PCR, if not already performed, is checked on all patients diagnosed with Whipple's disease to evaluate for CNS involvement.</div><div id=\"graphicVersion\">Graphic 105131 Version 1.0</div></div></div>"},"105132":{"type":"graphic_picture","displayName":"Breast reduction inferior pedicle flap 1","title":"Breast reduction inferior pedicle flap 1","html":"<div class=\"graphic\"><div style=\"width: 750px\" class=\"figure\"><div class=\"ttl\">Breast reduction inferior pedicle flap 1</div><div class=\"cntnt\"><img style=\"width:730px; height:242px;\" src=\"images/SURG/105132_Brst_rdct_infr_pdcl_flp_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Preoperative (A) and postoperative (B) photos after inferior pedicle breast reduction. Resection weights are 420 grams from right side and 436 grams from left side.</div><div id=\"graphicVersion\">Graphic 105132 Version 1.0</div></div></div>"},"105134":{"type":"graphic_table","displayName":"Manifestations of acute rheumatic fever","title":"Manifestations of acute rheumatic fever","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Manifestations of acute rheumatic fever</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"80%\"></colgroup><colgroup width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Percent</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Major manifestations</td> </tr> <tr> <td class=\"indent1\">Carditis and valvulitis (eg, pancarditis) that is clinical or subclinical</td> <td class=\"centered\">50 to 70%</td> </tr> <tr> <td class=\"indent1\">Arthritis (usually migratory polyarthritis predominantly involving the large joints)</td> <td class=\"centered\">35 to 66%</td> </tr> <tr> <td class=\"indent1\">Central nervous system involvement (eg, Sydenham chorea)</td> <td class=\"centered\">10 to 30%</td> </tr> <tr> <td class=\"indent1\">Subcutaneous nodules</td> <td class=\"centered\">0 to 10%</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Erythema marginatum</td> <td class=\"centered\">&#60;6%</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Minor manifestations</td> </tr> <tr> <td class=\"indent1\">Arthralgia</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Fever</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Elevated acute phase reactants (ESR, CRP)</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Prolonged PR interval on electrocardiogram</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ESR: erythrocyte sedimentation rate; CRP: C-reactive protein.</div><div class=\"graphic_reference\">Data from: Gewitz MH, Baltimore RS, Tani LH, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: A scientific statement from the American Heart Association. Circulation 2015; 131:1806.</div><div id=\"graphicVersion\">Graphic 105134 Version 3.0</div></div></div>"},"105175":{"type":"graphic_picture","displayName":"Management of diabetic foot abscess","title":"Management of diabetic foot abscess","html":"<div class=\"graphic\"><div style=\"width: 758px\" class=\"figure\"><div class=\"ttl\">Management of diabetic foot abscess</div><div class=\"cntnt\"><img style=\"width:738px; height:539px;\" src=\"images/SURG/105175_Chrnc_wnd_trtmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pictures show the management of a&nbsp;30-year-old&nbsp;patient with a diabetic foot infection. The patient presented with a five-day history of ankle swelling, fever, and chills. At the time of incision and drainage, a large deep abscess was found within the ankle joint.<br />Following debridement, the skin and soft tissue defect involved the anterior and lateral lower leg (A). The extensor tendons were exposed (B), and following interim care with wound dressings, a free flap was used to cover the anterior ankle defect (preferred to prevent later joint contracture), and a split-thickness skin graft was placed on the lateral wound (C). Four weeks postoperatively, the wounds were healed&nbsp;and the patient was able to ambulate without difficulty&nbsp;(D).<br />&nbsp;<br /></div><div id=\"graphicVersion\">Graphic 105175 Version 1.0</div></div></div>"},"105177":{"type":"graphic_picture","displayName":"Midline dehiscence healed with negative pressure wound therapy","title":"Midline dehiscence healed with negative pressure wound therapy","html":"<div class=\"graphic\"><div style=\"width: 600px\" class=\"figure\"><div class=\"ttl\">Midline dehiscence healed with negative pressure wound therapy</div><div class=\"cntnt\"><img style=\"width:580px; height:764px;\" src=\"images/SURG/105177_Midline_ab_wound_dehiscence.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These pictures&nbsp;are of a 60-year-old woman with a previously infected abdominal wall wound and failed hernia repair. The wound was located in the midline portion of a large pannus. It was debrided but not repaired due to medical comorbidities.&nbsp;After medical optimization, a negative pressure wound therapy device was placed with a sponge placed over the hernia sac. The area healed in by secondary intention over a period of 12 weeks. </div><div id=\"graphicVersion\">Graphic 105177 Version 2.0</div></div></div>"},"105178":{"type":"graphic_picture","displayName":"Definitive wound coverage following diabetic plantar infection","title":"Definitive wound coverage following diabetic plantar infection","html":"<div class=\"graphic\"><div style=\"width: 805px\" class=\"figure\"><div class=\"ttl\">Definitive wound coverage following diabetic plantar infection</div><div class=\"cntnt\"><img style=\"width:785px; height:366px;\" src=\"images/SURG/105178_Dfn_wnd_cov_fllw_dbt_plntr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pictures in the figure show the management of a diabetic patient with a chronic sinus draining from the plantar aspect of the foot that was present for over 9 months. Following debridement, the wound was dressed and treated with an interim matrix wound dressing to provide an appropriate wound bed for skin-grafting. The appearance of the foot following placement of a split-thickness skin graft (A), and healed appearance four weeks later (B) are shown.</div><div id=\"graphicVersion\">Graphic 105178 Version 1.0</div></div></div>"},"105179":{"type":"graphic_picture","displayName":"Healing of radiated-induced chronic leg wound","title":"Healing of radiated-induced chronic leg wound","html":"<div class=\"graphic\"><div style=\"width: 694px\" class=\"figure\"><div class=\"ttl\">Healing of radiated-induced chronic leg wound</div><div class=\"cntnt\"><img style=\"width:674px; height:722px;\" src=\"images/SURG/105179_Hl_rdt_chrnc_lg_wnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pictures show the management of a patient with a chronic wound following excision and radiation treatment for invasive squamous carcinoma of the left lower extremity five years before presentation. The anterior tibial tendon was exposed (A). Following 20 days of daily hyperbaric oxygen therapy, surgical debridement, and open wound dressings, the wound began to heal (B).<br /></div><div id=\"graphicVersion\">Graphic 105179 Version 1.0</div></div></div>"},"105180":{"type":"graphic_picture","displayName":"Chronic abdominal wound in child","title":"Chronic abdominal wound in child","html":"<div class=\"graphic\"><div style=\"width: 822px\" class=\"figure\"><div class=\"ttl\">Chronic abdominal wound in child</div><div class=\"cntnt\"><img style=\"width:802px; height:440px;\" src=\"images/SURG/105180_Chronic_ab_wound_child.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chronic sinus tracts within a midline abdominal scar (A). On closer inspection (B), residual suture material can be seen within the more cranially located&nbsp;sinus tract. Such wounds will not heal until the suture is removed.</div><div id=\"graphicVersion\">Graphic 105180 Version 2.0</div></div></div>"},"105181":{"type":"graphic_picture","displayName":"Management of infected orthopedic fibular plate","title":"Management of infected orthopedic fibular plate","html":"<div class=\"graphic\"><div style=\"width: 751px\" class=\"figure\"><div class=\"ttl\">Management of infected orthopedic fibular plate</div><div class=\"cntnt\"><img style=\"width:731px; height:549px;\" src=\"images/SURG/105181_Mng_infct_orth_fblr_plt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pictures show the management of a 53-year-old patient with a chronic draining sinus three years following open reduction and internal fixation for a fibular fracture (A). After debridement and removal of the previously placed fibular plate, a local flap based proximally off of peroneal perforators was rotated in to cover the exposed bone.&nbsp;A skin graft was placed to provide coverage of the residual exposed subcutaneous tissue (B). The appearance of the healed wounds is shown (C).</div><div id=\"graphicVersion\">Graphic 105181 Version 1.0</div></div></div>"},"105183":{"type":"graphic_picture","displayName":"Management of infected total knee arthroplasty","title":"Management of infected total knee arthroplasty","html":"<div class=\"graphic\"><div style=\"width: 749px\" class=\"figure\"><div class=\"ttl\">Management of infected total knee arthroplasty</div><div class=\"cntnt\"><img style=\"width:729px; height:727px;\" src=\"images/SURG/105183_Mng_infct-_kn_arthrpl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pictures show the management of a patient with an infected total knee arthroplasty. Four weeks after the procedure, the incision site evidenced drainage and was opened. Following debridement of necrotic tissue (A), a medial hemigastrocnemius rotation flap was performed to close the defect (B), over which a skin graft was placed to provide coverage of the muscle. The appearance of the healed wound is shown (C).</div><div id=\"graphicVersion\">Graphic 105183 Version 1.0</div></div></div>"},"105184":{"type":"graphic_picture","displayName":"Chronic draining sinus tract treatment","title":"Chronic draining sinus tract treatment","html":"<div class=\"graphic\"><div style=\"width: 692px\" class=\"figure\"><div class=\"ttl\">Chronic draining sinus tract treatment</div><div class=\"cntnt\"><img style=\"width:672px; height:637px;\" src=\"images/SURG/105184_Chrnc_drn_sns_trct_trt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pictures show the management of a patient with a chronic draining sinus related to repair of a prior calcaneal fracture one year previously. Incision, drainage, debridement, and removal of infected hardware resulted in an anterior leg wound and lateral foot defect (A). An arteriogram showed perfusion to the foot via only the anterior tibial artery (B). A free gracilis muscle flap was placed into the defect with the anterior tibial vessels used as recipient vessels (C). The appearance of the healed free muscle flap is shown (D).</div><div id=\"graphicVersion\">Graphic 105184 Version 2.0</div></div></div>"},"105185":{"type":"graphic_picture","displayName":"Chronic venous stasis ulcer healing","title":"Chronic venous stasis ulcer healing","html":"<div class=\"graphic\"><div style=\"width: 749px\" class=\"figure\"><div class=\"ttl\">Chronic venous stasis ulcer healing</div><div class=\"cntnt\"><img style=\"width:729px; height:276px;\" src=\"images/SURG/105185_Chrnc_vns_stss_ulcr_hl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pictures show the management of a patient with a laterally-located chronic venous stasis ulcer that was present for six months (A). Following local wound care and compression therapy, a xenograft and later skin grafting led to wound closure over a six-week period of time (B).</div><div id=\"graphicVersion\">Graphic 105185 Version 1.0</div></div></div>"},"105186":{"type":"graphic_picture","displayName":"Healing of tibial draining sinus with chronic osteomyelitis","title":"Healing of tibial draining sinus with chronic osteomyelitis","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Healing of tibial draining sinus with chronic osteomyelitis</div><div class=\"cntnt\"><img style=\"width:610px; height:763px;\" src=\"images/SURG/105186_Heal_tbl_drn_sns_chrn_ostmy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pictures in the figure show the management of a 30-year-old patient with chronic drainage following a prior traumatic injury (A). Chronic osteomyelitis was seen in a bony sequestrum on magnetic resonance imaging (B) and plain films (C). Following bone debridement and removal of the sequestrum, the bone was packed with an antibiotic spacer and a free muscle flap used to fill the space, over which a skin graft was used to provide coverage of the muscle. The early postoperative appearance of the free flap is shown (D).</div><div id=\"graphicVersion\">Graphic 105186 Version 2.0</div></div></div>"},"105190":{"type":"graphic_figure","displayName":"Nerves of the ankle","title":"Nerves of the ankle and ankle block injection sites","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Nerves of the ankle and ankle block injection sites</div><div class=\"cntnt\"><img style=\"width:539px; height:505px;\" src=\"images/ANEST/105190_Nerves_of_the_ankle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Injection sites for ankle block are numbered, as follows: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Deep peroneal and superficial peroneal nerve blocks</LI>&#xD;&#xA;<LI>Tibial nerve block</LI>&#xD;&#xA;<LI>Sural nerve block </LI>&#xD;&#xA;<LI>Saphenous nerve block</LI></OL>Details for injection are provided in the text.</div><div id=\"graphicVersion\">Graphic 105190 Version 2.0</div></div></div>"},"105211":{"type":"graphic_table","displayName":"The Amsterdam Preoperative Anxiety and Information Scale (APAIS)","title":"The Amsterdam Preoperative Anxiety and Information Scale (APAIS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The Amsterdam Preoperative Anxiety and Information Scale (APAIS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ol> <li>I am worried about the anesthetic </li> </ol> </td> </tr> <tr> <td> <ol start=\"2\"> <li>The anesthetic is on my mind continually </li> </ol> </td> </tr> <tr> <td> <ol start=\"3\"> <li>I would like to know as much as possible about the anesthetic </li> </ol> </td> </tr> <tr> <td> <ol start=\"4\"> <li>I am worried about the procedure </li> </ol> </td> </tr> <tr> <td> <ol start=\"5\"> <li>The procedure is on my mind continually </li> </ol> </td> </tr> <tr> <td> <ol start=\"6\"> <li>I would like to know as much as possible about the procedure </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The measure of agreement with these statements should be graded on a 5-point Likert scale from 1 \"not at all\" to 5 \"extremely.\"</div><div class=\"graphic_reference\">From: Moerman N, van Dam FS, Muller MJ, Oosting H. The Amsterdam Preoperative Anxiety and Information Scale (APAIS). Anesth Analg 1996; 82:445. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 1996 International Anesthesia Research Society. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105211 Version 1.0</div></div></div>"},"105214":{"type":"graphic_picture","displayName":"Kevorkian cervical biopsy forceps","title":"Kevorkian cervical biopsy forceps","html":"<div class=\"graphic\"><div style=\"width: 636px\" class=\"figure\"><div class=\"ttl\">Kevorkian cervical biopsy forceps</div><div class=\"cntnt\"><img style=\"width:616px; height:233px;\" src=\"images/OBGYN/105214_Kevorkian_cerv_biop_forceps.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Abu-Rustum NR, Ungar L, Alektiar K, Chi DS. Cancer of the cervix. In: TeLinde's Operative Gynecology, 11th ed, Jones HW, Rock JA (eds), Lippincott Williams &amp; Wilkins, 2015. Copyright &copy; 2015 Lippincott Williams &amp; Wilkins (<a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>). Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105214 Version 1.0</div></div></div>"},"105216":{"type":"graphic_table","displayName":"daEPOCH for non-Hodgkin lymphoma","title":"Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (daEPOCH) for non-Hodgkin lymphoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (daEPOCH) for non-Hodgkin lymphoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 21 days.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Starting dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Etoposide</strong></td> <td>50 mg/m<sup>2</sup> per day IV</td> <td rowspan=\"3\">Dilute a 24-hour supply of etoposide, doxorubicin, and vincristine in 500 mL NS and administer as continuous infusion over 24 hours per day through central venous line. Solution must be protected from light to maintain stability.</td> <td rowspan=\"3\">Days 1 to 4 (96 hours)</td> </tr> <tr> <td><strong>Doxorubicin</strong></td> <td>10 mg/m<sup>2</sup> per day IV</td> </tr> <tr> <td><strong>Vincristine</strong></td> <td>0.4 mg/m<sup>2</sup> per day IV (dose not capped)</td> </tr> <tr> <td><strong>Cyclophosphamide</strong></td> <td>750 mg/m<sup>2</sup> IV</td> <td>Dilute with 250 mL NS or D5W and administer over 30 minutes.</td> <td>Day 5</td> </tr> <tr> <td><strong>Prednisone</strong></td> <td>60 mg/m<sup>2</sup> orally twice daily</td> <td>Administer first dose 30 minutes prior to chemotherapy on day 1.</td> <td>Days 1 to 5</td> </tr> <tr> <td><strong>Granulocyte colony-stimulating factor</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> <td>Start day 6</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong><span style=\"color: black;\"><span style=\"color: black;\">&nbsp;MODERATE</span>.</span> Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Vesicant/irritant properties:</strong> Doxorubicin and vincristine are vesicants; avoid extravasation. Etoposide is an irritant. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-antineoplastic vesicants\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with hematopoietic growth factors is an essential component of this regimen. Regular or pegylated granulocyte colony-stimulating factor may be used according to center policy. In addition, due to the risk of developing Pneumocystis jiroveci pneumonia and other opportunistic infections, consider the use of antimicrobial prophylaxis<sup>[1]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> Adjustment of initial cyclophosphamide, doxorubicin, etoposide, and vincristine doses may be needed for preexisting liver dysfunction<sup>[2-5]</sup>. In addition, dose adjustment of etoposide and cyclophosphamide may be required for renal dysfunction. Refer to UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Cardiac screening:</strong> Doxorubicin is associated with cardiomyopathy, the incidence of which is related to cumulative dose. Assess baseline LVEF prior to initiation of therapy. Dose alterations should be considered for LVEF &#60;50 percent, and doxorubicin therapy is contraindicated in patients with LVEF &#60;30 percent at initiation, those with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmia, or previous therapy with high cumulative doses of doxorubicin or any other anthracyclines. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Central nervous system (CNS) prophylaxis:</strong> The need for CNS prophylaxis is determined based upon the aggressiveness of the tumor reflected in the histology, organ involvement, and presence or absence of high risk features. Refer to UpToDate topic on \"Secondary involvement of the CNS by non-Hodgkin lymphoma\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>HIV screening:</strong> Patients should be screened for HIV prior to starting therapy. Consider reducing the initial dose of cyclophosphamide to 187 mg/m<sup>2</sup> if CD4 &#60;100/microL at <span style=\"white-space: nowrap;\">diagnosis.<sup>[6]</sup></span></td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Neurotoxicity:</strong> Vincristine may cause constipation, and in severe cases, paralytic ileus. A routine prophylactic regimen against constipation is recommended in all patients receiving vincristine. Refer to UpToDate topic on \"Overview of neurologic complications of non-platinum cancer chemotherapy\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count twice weekly during treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess basic metabolic panel (creatinine and electrolytes) and liver function prior to each subsequent treatment cycle.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor cumulative doxorubicin dose. Reassess LVEF periodically during daEPOCH-R therapy, as clinically indicated. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <p>&#8226; <strong>Myelosuppression:</strong> Each new cycle should be delayed until ANC is &#62;1000/microL and platelet count is &#62;100,000/microL. Doses of etoposide, doxorubicin, and cyclophosphamide are adjusted based upon the nadir ANC and platelet counts<sup>[1]</sup>:</p> <p class=\"indent1\">- If nadir ANC &#8805;500 cells/microL, increase doses by 20 percent over preceding cycle.</p> <p class=\"indent1\">- If ANC &#60;500 cells/microL on one or two measurements, doses remain the same as preceding cycle.</p> <p class=\"indent1\">- If ANC &#60;500 on &#8805;3 measurements or platelets &#60;25,000/microL on one measurement, doses reduced by 20 percent from preceding cycle. Doxorubicin and etoposide doses are not reduced below starting dose.</p> </td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Neuropathy:</strong> Dose adjustment of vincristine may be necessary if the severity of neuropathy persists or worsens. No specific guidelines are available for dose adjustments.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Hepatic dysfunction:</strong> Dose adjustments of vincristine may be necessary in the setting of liver toxicity. Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease for more information\".</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, dose should be recalculated for all drugs.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; LVEF: left ventricular ejection fraction; CBC: complete blood count; ANC: absolute neutrophil count.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Wilson WH, et al. Blood 2002; 99:2685.</li>&#xD;&#xA;    <li>Cyclophosphamide injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed December 18, 2012).</li>&#xD;&#xA;    <li>Doxorubicin hydrochloride injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed December 18, 2012).</li>&#xD;&#xA;    <li>Vincristine sulfate injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed December 18, 2012).</li>&#xD;&#xA;    <li>Etoposide injection. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed December 18, 2012).</li>&#xD;&#xA;    <li>Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood 2010; 115:3008.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 105216 Version 2.0</div></div></div>"},"105217":{"type":"graphic_figure","displayName":"CO2 absorption during laparoscopy","title":"CO<SUB>2</SUB> absorption during laparoscopy","html":"<div class=\"graphic\"><div style=\"width: 617px\" class=\"figure\"><div class=\"ttl\">CO<SUB>2</SUB> absorption&nbsp;during laparoscopy</div><div class=\"cntnt\"><img style=\"width:597px; height:355px;\" src=\"images/ANEST/105217_CO2absrptlprscpy.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mean CO<SUB>2</SUB> elimination versus time in patients with transperitoneal and retroperitoneal laparoscopic approaches.</div><div class=\"graphic_footnotes\">CO<sub>2</sub>: carbon dioxide; VCO<sub>2</sub>: mean CO<sub>2</sub> elimination.</div><div class=\"graphic_reference\">Reproduced from: Kadam PG, Marda M, Shah VR. Carbon Dioxide Absorption During Laparoscopic Donor Nephrectomy: A Comparison Between Retroperitoneal and Transperitoneal Approaches. Transplant Proc 2008; 40:1119. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105217 Version 2.0</div></div></div>"},"105218":{"type":"graphic_waveform","displayName":"CPAP titration in a child","title":"Problems occurring during CPAP titration in a child","html":"<div class=\"graphic\"><div style=\"width: 904px\" class=\"figure\"><div class=\"ttl\">Problems occurring during CPAP titration in a child</div><div class=\"cntnt\"><img style=\"width:884px; height:433px;\" src=\"images/SLEEP/105218_CPAP_titration_cihld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Polysomnographic tracing from a 30-second fragment of a continuous positive airway pressure (CPAP) titration in a six-year-old child wearing a nasal mask. The CPAP pressure has been progressively increased from 6 to 15 cm H<SUB>2</SUB>O pressure, but the child continues to show signs of airway obstruction, with snoring (SNORE tracing, green) and an air leak at 73 L/minute (CLeak tracing, vertical line at 73.7), and paradoxical breathing (ABD tracing deviates in opposite direction from CHEST tracing during obstructive event). Thus, the CPAP is not effective, likely because of poorly fitting mask or nasal obstruction and/or open-mouth breathing. Note that there is no activity in the tracings for end-tidal CO<SUB>2</SUB> (EtCO2) and waveform (ETCO2WAV), indicating either a severe nasal obstruction or nonfunctional sensor. The transcutaneous C<SUB></SUB>O<SUB>2</SUB> sensor (TcCO2) demonstrates normal systemic CO<SUB>2 </SUB>levels. This child had a nasal tumor obstructing airflow. CPAP was ineffective.</div><div class=\"graphic_reference\">Courtesy of Ann Halbower, MD.</div><div id=\"graphicVersion\">Graphic 105218 Version 3.0</div></div></div>"},"105220":{"type":"graphic_waveform","displayName":"Continuous partial obstruction","title":"Continuous partial obstruction during NREM sleep","html":"<div class=\"graphic\"><div style=\"width: 841px\" class=\"figure\"><div class=\"ttl\">Continuous partial obstruction during NREM sleep</div><div class=\"cntnt\"><img style=\"width:821px; height:465px;\" src=\"images/SLEEP/105220_Contin_part_obstruct.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>This polysomnogram demonstrates continuous partial obstruction, occurring during non-rapid eye movement (NREM) sleep. Continuous partial obstruction is common in children and is clinically significant, but is not reflected in the polysomnographic scores for apnea and hypopnea. Therefore, this form of sleep-disordered breathing tends to be underestimated by polysomnography. Symptoms suggesting partial obstruction include head hyperextension and open-mouth breathing. </LI>&#xD;&#xA;<LI>In this tracing, signs of continuous partial obstruction include snoring (SNORE tracing, in blue), paradoxical breathing (chest and abdominal movements are in this case slightly out of phase), airflow limitation shown on the nasal pressure manometer (Nasal PR tracing is flow-limited on inspiration). </LI></UL></div><div class=\"graphic_reference\">Courtesy of Ann Halbower, MD.</div><div id=\"graphicVersion\">Graphic 105220 Version 2.0</div></div></div>"},"105221":{"type":"graphic_waveform","displayName":"Partial resolution of obstruction during CPAP titration","title":"Partial resolution of airflow obstruction during CPAP titration","html":"<div class=\"graphic\"><div style=\"width: 903px\" class=\"figure\"><div class=\"ttl\">Partial resolution of airflow obstruction during CPAP titration</div><div class=\"cntnt\"><img style=\"width:883px; height:449px;\" src=\"images/SLEEP/105221_Prtl_arflw_obstrct_dr_CPAP_ttr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Polysomnogram for continuous positive airway pressure (CPAP) titration in an obese child during rapid eye movement (REM) sleep. In this 30-second epoch, the CPAP has been titrated to a pressure that eliminates complete apneas. However, partial obstruction continues, indicated by tachypnea (respiratory rate 26), and paradoxical respiratory movements (CHEST and ABD tracings are not synchronous). Higher CPAP pressures may be attempted to overcome the partial obstruction.</div><div class=\"graphic_reference\">Courtesy of Ann Halbower, MD</div><div id=\"graphicVersion\">Graphic 105221 Version 2.0</div></div></div>"},"105234":{"type":"graphic_figure","displayName":"Radiation thyroid cancer at high doses","title":"Radiation thyroid cancer at high doses","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Radiation thyroid cancer at high doses</div><div class=\"cntnt\"><img style=\"width:505px; height:386px;\" src=\"images/ENDO/105234_Rdt_thrd_cncr_hgh_ds.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dose-response pattern for thyroid cancer following radiotherapy for childhood cancer. The graph is based on a pooled analysis including two cohort and two nested case-control studies including 16,757 patients.</div><div class=\"graphic_reference\">Reproduced with permission from: Veiga LH, Lubin JH, Anderson H, et al. A pooled analysis of thyroid cancer incidence following radiotherapy for childhood cancer. Radiation Res 2012; 178: 365. Copyright © 2012 Radiation Research Society.</div><div id=\"graphicVersion\">Graphic 105234 Version 2.0</div></div></div>"},"105235":{"type":"graphic_diagnosticimage","displayName":"Ultrasound image of bladder endometriosis","title":"Transabdominal ultrasound image of bladder endometriosis","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Transabdominal ultrasound image of bladder endometriosis</div><div class=\"cntnt\"><img style=\"width:715px; height:536px;\" src=\"images/OBGYN/105235_Ultrsnd_img_blddr_endmtrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transabdominal sagittal pelvic ultrasonography showing a heterogeneous endometriotic nodule protruding from the posterior wall of the bladder into the vesical lumen.</div><div class=\"graphic_reference\">Reproduced with permission from: Berlanda N, Vercellini P, Carmignani L, et al. Ureteral and vesical endometriosis: Two different clinical entities sharing the same pathogenesis. Obstet Gynecol Surv 2009; 64:830. DOI: <a href=\"http://journals.lww.com/obgynsurvey/Abstract/2009/12000/Ureteral_and_Vesical_Endometriosis__Two_Different.23.aspx\" spellcheck=\"true\" target=\"_blank\">10.1097/OGX.0b013e3181c4bc3a</a>. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105235 Version 1.0</div></div></div>"},"105244":{"type":"graphic_figure","displayName":"Ambulatory (Holter) ECG monitor","title":"Ambulatory (Holter) electrocardiography (ECG) monitor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Ambulatory (Holter) electrocardiography (ECG) monitor</div><div class=\"cntnt\"><img style=\"width:322px; height:494px;\" src=\"images/CARD/105244_Holter_monitor.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ambulatory (Holter) monitor is a lightweight continuous electrocardiographic (ECG) monitoring system that uses three surface electrodes to continuously record all cardiac electrical activity, typically for 24 to 48 hours. Once the monitoring period is over, the patient returns the device, and all of the acquired data are analyzed (usually by a trained technician) and a summary report is&nbsp;generated for clinician review.</div><div id=\"graphicVersion\">Graphic 105244 Version 1.0</div></div></div>"},"105245":{"type":"graphic_figure","displayName":"Iron regulation","title":"Regulation of iron balance","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Regulation of iron balance</div><div class=\"cntnt\"><img style=\"width:541px; height:620px;\" src=\"images/HEME/105245_Iron_regulation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The main cells implicated in systemic iron regulation are enterocytes, which absorb non-heme iron from the diet through DMT1; hepatocytes, which produce hepcidin according to the iron concentration; and macrophages, which release iron during the breakdown of hemoglobin from senescent red blood cells. Ferroportin exports iron from all of these cells into the circulation with the cooperation of a ferroxidase (hephaestin in enterocytes and ceruloplasmin [CP] in macrophages and hepatocytes) that oxidizes Fe<sup>2+</sup> to Fe<sup>3+</sup>.<br />(A) In iron deficiency there is increased iron absorption and recycling. Absorption of iron by enterocytes is facilitated by duodenal cytochrome b (DYCTB), an iron reductase. Hepcidin synthesis is suppressed. Ferroportin is free to export iron from macrophages and enterocytes, after which iron is bound to transferrin.<br />(B) In iron overload there is reduced iron absorption and recycling. Hepcidin production is high; its synthesis is stimulated by BMP6, which is induced by increased liver iron. Hepcidin released into the circulation binds ferroportin, and the complex is internalized and degraded, in turn blocking iron export into the circulation.</div><div class=\"graphic_footnotes\">DMT1: divalent metal transporter; DCYTB: duodenal cytochrome B; CP: ceruloplasmin; BMP6: bone morphogenetic protein 6; <em>HAMP</em>: hepcidin antimicrobial peptide (gene encoding hepcidin).</div><div class=\"graphic_reference\">Courtesy of Clara Camaschella, MD.</div><div id=\"graphicVersion\">Graphic 105245 Version 2.0</div></div></div>"},"105246":{"type":"graphic_figure","displayName":"Breast cancer burden by age at diagnosis ","title":"Breast cancer burden by age at diagnosis for the period 2007 to 2011","html":"<div class=\"graphic\"><div style=\"width: 816px\" class=\"figure\"><div class=\"ttl\">Breast cancer burden by age at diagnosis for the period 2007 to 2011</div><div class=\"cntnt\"><img style=\"width:796px; height:317px;\" src=\"images/PC/105246_Breast_cancer_brdn_age_diag.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Age distribution of invasive female breast cancer cases (n = 292,369). Source: Surveillance, Epidemiology, and End Results (SEER) 18 registries.<br />(B) Distribution of breast cancer deaths by age at diagnosis (n = 16,789), with patients followed up for 20 years after diagnosis. Source: SEER 9 registries.<br />(C) Distribution of person-years of life lost (PYLL) due to breast cancer by age at diagnosis (total = 326,560), with patients followed up for 20 years after diagnosis. Source: SEER 9 registries. The PYLL is based on the 2011 US Female Life Table<sup>[1]</sup>.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kochanek KD, Murphy SL, Xu J. Deaths: Final Data for 2011. Natl Vital Stat Rep 2015; 63:1.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from: Oeffinger KC, Fontham ET, Etzioni R, et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society. JAMA 2015; 314:1599. Copyright &copy; 2015 American Medical Association. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105246 Version 4.0</div></div></div>"},"105264":{"type":"graphic_figure","displayName":"Elbow carrying angle","title":"Carrying angle of the elbow","html":"<div class=\"graphic\"><div style=\"width: 505px\" class=\"figure\"><div class=\"ttl\">Carrying angle of the elbow</div><div class=\"cntnt\"><img style=\"width:485px; height:551px;\" src=\"images/SM/105264_Elbow_carrying_angle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The normal elbow carrying angle in males is approximately 5<SUP>0</SUP> and is typically between 10<SUP>0</SUP> and 15<SUP>0</SUP>&nbsp; in females. </div><div id=\"graphicVersion\">Graphic 105264 Version 1.0</div></div></div>"},"105265":{"type":"graphic_figure","displayName":"Elbow examination of epicondyles and olecranon","title":"Elbow examination of epicondyles and olecranon","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Elbow examination of epicondyles and olecranon</div><div class=\"cntnt\"><img style=\"width:521px; height:536px;\" src=\"images/SM/105265_Elbow_examination_of_epicondyles_and-olecranon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A. With the elbow flexed, the medial and lateral epicondyle form a symmetric triangle with the olecranon. B. When the elbow is extended, these structures form a straight line. </div><div id=\"graphicVersion\">Graphic 105265 Version 2.0</div></div></div>"},"105266":{"type":"graphic_figure","displayName":"Palpation of the distal biceps muscle and tendon","title":"Palpation of the distal biceps muscle and tendon","html":"<div class=\"graphic\"><div style=\"width: 483px\" class=\"figure\"><div class=\"ttl\">Palpation of the distal biceps muscle and tendon</div><div class=\"cntnt\"><img style=\"width:463px; height:578px;\" src=\"images/SM/105266_Palpation_of_the_distal_biceps_muscle_and_tendon.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The biceps becomes more prominent if the patient flexes the supinated arm with a closed fist against resistance. </div><div id=\"graphicVersion\">Graphic 105266 Version 1.0</div></div></div>"},"105267":{"type":"graphic_figure","displayName":"Palpation of the posterior elbow and triceps muscle","title":"Palpation of the posterior elbow and triceps muscle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Palpation of the posterior elbow and triceps muscle</div><div class=\"cntnt\"><img style=\"width:435px; height:667px;\" src=\"images/SM/105267_Palpation_of_the_posterior_elbow_and_triceps_muscle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Key structures to palpate include the olecranon process, olecranon bursa, and the insertion of the triceps brachii muscle and tendon.</div><div id=\"graphicVersion\">Graphic 105267 Version 1.0</div></div></div>"},"105268":{"type":"graphic_figure","displayName":"Skeleton of the proximal lower limb - Anterior view","title":"Skeleton of the proximal lower limb: Anterior view","html":"<div class=\"graphic\"><div style=\"width: 582px\" class=\"figure\"><div class=\"ttl\">Skeleton of the proximal lower limb: Anterior view</div><div class=\"cntnt\"><img style=\"width:562px; height:746px;\" src=\"images/SM/105268_Skeltn_prxml_lwr_limb_Anter.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105268 Version 1.0</div></div></div>"},"105269":{"type":"graphic_figure","displayName":"Skeleton of the proximal lower limb - Posterior view","title":"Skeleton of the proximal lower limb: Posterior view","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Skeleton of the proximal lower limb: Posterior view</div><div class=\"cntnt\"><img style=\"width:516px; height:746px;\" src=\"images/SM/105269_Skeletn_prxml_lwr_limb_Post.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105269 Version 1.0</div></div></div>"},"105270":{"type":"graphic_figure","displayName":"Muscle attachments of the proximal lower limb - Anterior view","title":"Muscle attachments of the proximal lower limb: Anterior view","html":"<div class=\"graphic\"><div style=\"width: 661px\" class=\"figure\"><div class=\"ttl\">Muscle attachments of the proximal lower limb: Anterior view</div><div class=\"cntnt\"><img style=\"width:641px; height:797px;\" src=\"images/SM/105270_Muscle_proxml_lwr_limb_Antr.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105270 Version 1.0</div></div></div>"},"105271":{"type":"graphic_figure","displayName":"Palpation of the radial head ","title":"Palpation of the radial head of the elbow","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">Palpation of the radial head of the elbow</div><div class=\"cntnt\"><img style=\"width:512px; height:335px;\" src=\"images/SM/105271_Palpation_of_the_radial_head_of_the_elbow.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The thumb is placed on the lateral aspect of the elbow just distal to the lateral epicondyle. Supination and pronation of the forearm rotate the radial head under the thumb. </div><div id=\"graphicVersion\">Graphic 105271 Version 1.0</div></div></div>"},"105272":{"type":"graphic_figure","displayName":"Muscle attachments of the proximal lower limb - Posterior view","title":"Muscle attachments of the proximal lower limb: Posterior view","html":"<div class=\"graphic\"><div style=\"width: 657px\" class=\"figure\"><div class=\"ttl\">Muscle attachments of the proximal lower limb: Posterior view</div><div class=\"cntnt\"><img style=\"width:637px; height:783px;\" src=\"images/SM/105272_Muscle_proxml_lwr_limb_Post.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Tank PW, Gest TR. Atlas of Anatomy, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright © 2009 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105272 Version 1.0</div></div></div>"},"105273":{"type":"graphic_figure","displayName":"Testing for elbow ligament stability","title":"Testing for elbow ligament stability","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Testing for elbow ligament stability</div><div class=\"cntnt\"><img style=\"width:510px; height:492px;\" src=\"images/SM/105273_Testing_for_elbow_ligament_stability.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the elbow slightly flexed to 15 degrees and hands placed as shown above, the examiner tests ligamentous stability of the: A. Medial (ulnar) collateral ligament and B. Lateral (radial) collateral ligament.</div><div id=\"graphicVersion\">Graphic 105273 Version 2.0</div></div></div>"},"105274":{"type":"graphic_figure","displayName":"Vastus lateralis","title":"Vastus lateralis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vastus lateralis</div><div class=\"cntnt\"><img style=\"width:372px; height:756px;\" src=\"images/SM/105274_Vastus_lateralis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105274 Version 1.0</div></div></div>"},"105275":{"type":"graphic_figure","displayName":"Vastus medialis","title":"Vastus medialis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vastus medialis</div><div class=\"cntnt\"><img style=\"width:372px; height:756px;\" src=\"images/SM/105275_Vastus_medialis.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105275 Version 1.0</div></div></div>"},"105276":{"type":"graphic_figure","displayName":"Vastus intermedius","title":"Vastus intermedius","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Vastus intermedius</div><div class=\"cntnt\"><img style=\"width:372px; height:756px;\" src=\"images/SM/105276_Vastus_intermedius.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: Cael C. Functional Anatomy: Musculoskeletal Anatomy, Kinesiology, and Palpation for Manual Therapists, Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright © 2010 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105276 Version 1.0</div></div></div>"},"105278":{"type":"graphic_table","displayName":"Management airflow obstruction in GVHD after HSCT","title":"General guidelines for monitoring and management of new airflow obstruction after hematopoietic stem cell transplantation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">General guidelines for monitoring and management of new airflow obstruction after hematopoietic stem cell transplantation</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Guidelines</td> </tr> <tr> <td class=\"indent1\">A. Significant new airflow obstruction with a % predicted FEV<sub>1</sub> &#8805;70% <ol> <li>Initiate inhaled glucocorticoid therapy. Add inhaled long-acting beta agonist, if patient symptomatic. Treatment should continue until either % FEV<sub>1</sub> becomes &#60;70% (see B below) or until GVHD resolves (ie, resolution of all reversible manifestations of GVHD without exacerbation for&nbsp;at least 6 months after discontinuation of all systemic immunosuppressive treatment) </li> <li>Other immunosuppressive treatment as indicated to control GVHD in other organs <ul> <li>Treatment should continue until either % FEV<sub>1</sub> becomes &#60;70% (see B below), or until GVHD resolves (ie, resolution of all reversible manifestation of GVHD without exacerbation&nbsp;for at least 12 months after discontinuation of all systemic treatments) </li> </ul> </li> <li>Monitor PFTs or spirometry monthly for at least 3 months <ul> <li>If % FEV<sub>1</sub> stabilizes, obtain PFTs or spirometry every 3 months for 1 year, then continue at 6 month intervals for 1 year and at 6 to 12 month intervals thereafter </li> <li>If % FEV<sub>1</sub> continues to decrease, go to B below </li> </ul> </li> </ol> </td> </tr> <tr> <td class=\"indent1\">B. Significant airflow obstruction with a % FEV<sub>1</sub> &#60;70% with/without significant airtrapping by high resolution chest CT <ol> <li>Consider bronchoscopy to rule out an undetected infectious etiology for airflow obstruction, even if no&nbsp;radiographic opacity&nbsp;is apparent </li> <li>After infection has been ruled out, evaluate the patient's eligibility for clinical trial for treatment of BOS and initiate (or increase) prednisone dose to 1 mg/kg per day <ul> <li>Start standard chronic GVHD taper at 2 weeks </li> <li>Consider continuing inhaled&nbsp;glucocorticoids throughout prednisone therapy </li> </ul> </li> <li>If % FEV<sub>1</sub> decreases further to &#60;70% during treatment, discuss changes of immunosuppressive treatment with transplant physician </li> <li>CMV monitoring in blood per standard practice </li> <li>Monitor PFTs or spirometry monthly for at least 3 months <ul> <li>If % FEV<sub>1</sub> stabilizes, continue PFTs or spirometry every 3 months for 1 year </li> <li>If % FEV<sub>1</sub> continues to decrease, go to C below </li> </ul> </li> </ol> </td> </tr> <tr> <td class=\"indent1\">C. Glucocorticoid-resistant airflow obstruction defined as progressive decline of FEV<sub>1</sub> by &#8805;10% despite treatment with 1 mg/kg per day&nbsp;of prednisone (or similar glucocorticoids) <ol> <li>May consider increasing the dose of prednisone to 2 mg/kg per day&nbsp;for a maximum of 2 weeks, followed by a taper to reach a dose of 1 mg/kg per day&nbsp;by 2 to 4 weeks </li> <li>Another treatment must be considered and discussed with the transplant team </li> <li>Monitor CMV in blood per standard practice </li> <li>Monitor PFTs monthly for at least 3 months <ul> <li>If % FEV<sub>1</sub> stabilizes, monitor PFTs every 3 months for 1 year </li> </ul> </li> </ol> </td> </tr> <tr> <td class=\"indent1\">D. Additional considerations <ol> <li>Consider changing prophylaxis for encapsulated bacterial infection to azithromycin 250 mg on Mondays-Wednesdays-Fridays <ul> <li>Assure patient is receiving adequate prophylaxis for <em>Pneumocystis</em>, varicella virus, and herpes simplex virus infections </li> <li>Fungal prophylaxis per standard practice </li> </ul> </li> <li>Monitor CMV in blood per standard practice </li> <li>May continue inhaled glucocorticoids throughout prednisone therapy </li> <li>Discontinuation of inhaled&nbsp;glucocorticoid treatment can be considered 12 months after treatment with prednisone has been discontinued </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Before considering treatment, all potential infectious etiologies of airflow obstruction must be investigated and treated if present. Investigations that should be considered (directed by clinical symptoms), include sinus CT scan, nasal washes, sinus aspiration, high-resolution chest CT scan, sputum culture, bronchoalveolar lavage, and lung biopsy.</div><div class=\"graphic_footnotes\">FEV<sub>1</sub>: forced expiratory volume in one second; GVHD: graft-versus-host disease; PFT: pulmonary function test; CT: computed tomography; CMV: cytomegalovirus.</div><div class=\"graphic_reference\">Reproduced with permission of the American Society of Hematology, from Flowers ME, Martin PJ. How we treat chronic graft-versus-host disease. Blood 2015; 125:606; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 105278 Version 3.0</div></div></div>"},"105280":{"type":"graphic_table","displayName":"Lab testing in ILD","title":"Laboratory testing in the evaluation of interstitial lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory testing in the evaluation of interstitial lung disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Laboratory tests to order in the majority of patients with interstitial lung disease</td> </tr> <tr> <td class=\"indent1\">Complete blood count and differential</td> </tr> <tr> <td class=\"indent1\">Urinalysis</td> </tr> <tr> <td class=\"indent1\">Alkaline phosphatase</td> </tr> <tr> <td class=\"indent1\">Alanine aminotransferase (ALT, SGPT) and aspartate aminotransferase (AST, SGOT)</td> </tr> <tr> <td class=\"indent1\">Blood urea nitrogen (BUN)</td> </tr> <tr> <td class=\"indent1\">Creatinine</td> </tr> <tr> <td class=\"indent1\">Tests for possible rheumatic disease</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Antinuclear antibody (ANA) </li> <li>Rheumatoid factor (RF) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory tests to order in selected patients with interstitial lung disease</td> </tr> <tr> <td class=\"indent1\">Additional possible tests for systemic rheumatic disease*</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Anti-cyclic citrullinated peptide (Anti-CCP) </li> <li>Creatine kinase (CK), aldolase </li> <li>Myositis-associated antibodies (eg, anti-tRNA synthetases Jo-1, PL-7, PL-12)</li> <li>Anti-neutrophil cytoplasmic antibody (ANCA) </li> <li>Anti-topoisomerase (Scl-70) antibody, anti-PM-1 (PM-Scl) antibody </li> <li>Anti-double stranded (ds) DNA antibodies </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Sicca features or positive anti-extractable nuclear antigen (ENA): Check anti-RO (SS-A), anti-La (SS-B), anti-ribonucleoprotein (RNP), serum protein electrophoresis, serum IgG4</td> </tr> <tr> <td class=\"indent1\">Sclerodactyly, prominent GERD: Check anti-centromere, anti-topoisomerase I (anti-Scl-70)</td> </tr> <tr> <td class=\"indent1\">Mechanics hands: Anti-tRNA synthetases (eg, Jo-1, PL-7, PL-12, and others)</td> </tr> <tr> <td class=\"indent1\">Amyopathic dermatomyositis: Anti-melanoma differentiation-associated gene 5 (MDA-5)</td> </tr> <tr> <td class=\"indent1\">Suspicion of heart failure or pulmonary hypertension: Brain natriuretic peptide (BNP) or N-terminal proBNP (NT-proBNP)</td> </tr> <tr> <td class=\"indent1\">Anemia and/or hemoptysis: Coagulation studies, anti-glomerular basement membrane (GBM) antibodies, antiphospholipid antibodies, serum IgA endomysial or tissue transglutaminase antibodies in patients who may have idiopathic pulmonary hemosiderosis</td> </tr> <tr> <td class=\"indent1\">Mediastinal lymphadenopathy: serum protein electrophoresis</td> </tr> <tr> <td class=\"indent1\">Beryllium exposure: Peripheral blood beryllium lymphocyte proliferation test</td> </tr> <tr> <td class=\"indent1\">Risk factors for HIV: HIV test </td> </tr> <tr> <td class=\"indent1\">Testing for hypersensitivity pneumonitis antibodies based on patient exposures</td> </tr> <tr> <td class=\"subtitle1_single\">Laboratory tests that are unlikely to be helpful in the diagnosis of interstitial lung disease</td> </tr> <tr> <td class=\"indent1\">Angiotensin converting enzyme (ACE)</td> </tr> <tr> <td class=\"indent1\">Erythrocyte sedimentation rate (ESR)<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">C-reactive protein (CRP)<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">GERD: gastroesophageal reflux disease; IgA: immunoglobulin A; IgG4: immunoglobulin G4.<br />* Additional tests are obtained when rheumatic disease is suspected based on clinical features, positive antinuclear antibody (ANA) test, positive rheumatoid factor (RF), or presence of pleural disease on chest imaging.<br />&para; These tests are nonspecific. Occasionally, patients will have elevated values for ESR or CRP that are twice normal in the setting of an idiopathic interstitial pneumonia (IIP). So, these tests may be obtained to assess for undifferentiated rheumatic disease in a patient with IIP.</div><div id=\"graphicVersion\">Graphic 105280 Version 3.0</div></div></div>"},"105282":{"type":"graphic_table","displayName":"Wilson disease scoring system","title":"Leipzig scoring system for Wilson disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Leipzig scoring system for Wilson disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Typical clinical symptoms and signs</td> <td class=\"subtitle1\" colspan=\"2\">Other tests</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">KF rings</td> <td class=\"subtitle2_left\" colspan=\"2\">Liver copper (in the absence of cholestasis)</td> </tr> <tr> <td class=\"indent1\">Present</td> <td class=\"centered\">2</td> <td class=\"indent1\">&#62;5x ULN (&#62;4 micromol/g)</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1 divider_bottom\">Absent</td> <td class=\"centered divider_bottom\">0</td> <td class=\"indent1\">0.8-4 micromol/g</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neurologic symptoms*</td> <td class=\"indent1\">Normal (&#60;0.8 micromol/g)</td> <td class=\"centered\">&ndash;1</td> </tr> <tr> <td class=\"indent1\">Severe</td> <td class=\"centered\">2</td> <td class=\"indent1 divider_bottom\">Rhodanine-positive granules<sup>&#182;</sup></td> <td class=\"centered divider_bottom\">1</td> </tr> <tr> <td class=\"indent1\">Mild</td> <td class=\"centered\">1</td> <td class=\"subtitle2_left\" colspan=\"2\">Urinary copper (in the absence of acute hepatitis)</td> </tr> <tr> <td class=\"indent1 divider_bottom\">Absent</td> <td class=\"centered divider_bottom\">0</td> <td class=\"indent1\">Normal</td> <td class=\"centered\">0</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Serum ceruloplasmin</td> <td class=\"indent1\">1-2x ULN</td> <td class=\"centered\">1</td> </tr> <tr> <td class=\"indent1\">Normal (&#62;0.2 g/L)</td> <td class=\"centered\">0</td> <td class=\"indent1\">&#62;2x ULN</td> <td class=\"centered\">2</td> </tr> <tr> <td class=\"indent1\">0.1-0.2 g/L</td> <td class=\"centered\">1</td> <td class=\"indent1 divider_bottom\">Normal, but &#62;5x ULN after D-penicillamine</td> <td class=\"centered divider_bottom\">2</td> </tr> <tr> <td class=\"indent1 divider_bottom\">&#60;0.1 g/L</td> <td class=\"centered divider_bottom\">2</td> <td class=\"subtitle2_left\" colspan=\"2\">Mutation analysis</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Coombs-negative hemolytic anemia</td> <td class=\"indent1\">On both chromosomes detected</td> <td class=\"centered\">4</td> </tr> <tr> <td class=\"indent1\">Present</td> <td class=\"centered\">1</td> <td class=\"indent1\">On one chromosome detected</td> <td class=\"centered\">1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Absent</td> <td class=\"centered\">0</td> <td class=\"indent1\">No mutations detected</td> <td class=\"centered\">0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1 highlight_gray_text\" colspan=\"4\">&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\">TOTAL SCORE</td> <td class=\"subtitle2_left\" colspan=\"3\">Evaluation:</td> </tr> <tr> <td class=\"indent1\">4 or more</td> <td class=\"indent1\" colspan=\"3\">Diagnosis established</td> </tr> <tr> <td class=\"indent1\">3</td> <td class=\"indent1\" colspan=\"3\">Diagnosis possible, more tests needed</td> </tr> <tr> <td class=\"indent1\">2 or less</td> <td class=\"indent1\" colspan=\"3\">Diagnosis very unlikely</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">KF: Kayser-Fleischer; ULN: upper limit of normal.<br />* Or typical abnormalities at brain magnetic resonance imaging.<br />&para; If no quantitative liver copper available.</div><div class=\"graphic_reference\">Reproduced from: European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 2012; 56:671. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105282 Version 1.0</div></div></div>"},"105284":{"type":"graphic_figure","displayName":"Location of lipoprotein glomerulopathy cases by genotype","title":"Location of lipoprotein glomerulopathy cases according to genotype","html":"<div class=\"graphic\"><div style=\"width: 829px\" class=\"figure\"><div class=\"ttl\">Location of lipoprotein glomerulopathy cases according to genotype</div><div class=\"cntnt\"><img style=\"width:809px; height:531px;\" src=\"images/NEPH/105284_Lct_lpprt_glmrlpthy_css_gnty.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Map of lipoprotein glomerulopathy. Cases are those assayed by DNA sequencing.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Kidney International. Saito T, Matsunaga A. Lipoprotein glomerulopathy may provide a key to unlock the puzzles of renal lipidosis. Kidney Int 2014; 85:243. Copyright &copy; 2014. <a href=\"http://www.nature.com/ki\" spellcheck=\"true\" target=\"_blank\">www.nature.com/ki</a>.</div><div id=\"graphicVersion\">Graphic 105284 Version 1.0</div></div></div>"},"105301":{"type":"graphic_table","displayName":"Major types of leg ulcers","title":"Comparison of the three major types of leg ulcers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of the three major types of leg ulcers</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Venous</td> <td class=\"subtitle1\">Arterial</td> <td class=\"subtitle1\">Neuropathic</td> </tr> <tr class=\"divider_bottom\"> <td><strong>History</strong></td> <td> <p>Prior deep venous thrombosis, stroke, miscarriages</p> <p>Obesity, multiple pregnancies</p> Pain upon prolonged standing</td> <td> <p>Cigarette smoking</p> <p>Diabetes</p> <p>Dyslipidemia</p> Intermittent claudication</td> <td> <p>Diabetes</p> Other causes of peripheral neuropathy</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Location</strong></td> <td> <p>Gaiter distribution</p> Malleolar regions (medial &#62; lateral)</td> <td> <p>Pressure sites</p> Distal points (toes)</td> <td>Pressure sites</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pain</strong></td> <td>Mild to moderate</td> <td>Severe</td> <td>Painless</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Morphology</strong></td> <td> <p>Irregular borders</p> Shallow</td> <td> <p>Necrotic eschar</p> Punched out</td> <td>Punched out</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Surrounding skin</strong></td> <td> <p>Pigmentation secondary to hemosiderin</p> Lipodermatosclerosis</td> <td>Shiny atrophic skin with hair loss</td> <td>Thick callus surrounding ulcer</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Other physical examination findings</strong></td> <td> <p>Varicosities</p> <p>Peripheral edema</p> Stasis dermatitis</td> <td> <p>Weak/absent peripheral pulses</p> <p>Prolonged capillary refilling time (&#62;3 to 4 seconds)</p> Pallor on leg elevation (45&#176; for 1 min)</td> <td>Peripheral neuropathy with decreased sensation</td> </tr> <tr> <td><strong>Relevant studies</strong></td> <td>Duplex ultrasonography</td> <td> <p>Ankle-brachial index</p> <p>Computed tomography angiography (CTA)</p> Magnetic resonance angiography (MRA)</td> <td>&nbsp;</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 105301 Version 1.0</div></div></div>"},"105315":{"type":"graphic_table","displayName":"Etiologies of leg ulcers","title":"Etiologies of leg ulcers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies of leg ulcers</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"2\"><span class=\"subtitle1_left\"></span>Common</td> </tr> <tr> <td>Venous</td> <td>&nbsp;</td> </tr> <tr> <td>Arterial</td> <td>&nbsp;</td> </tr> <tr> <td>Neuropathic</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"2\">Uncommon</td> </tr> <tr> <td>Physical</td> <td>Thermal burns, cold injury, radiation, trauma, factitial</td> </tr> <tr> <td>Bites</td> <td>Spider</td> </tr> <tr> <td>Infection</td> <td>Bacterial, fungal, spirochete, protozoal</td> </tr> <tr> <td>Vasculopathies</td> <td>Livedoid vasculopathy, Buerger's disease</td> </tr> <tr> <td>Hypercoagulable states (inherited and acquired)</td> <td>Factor V Leiden, antiphospholipid antibody syndrome, protein C and S deficiency, anti-thrombin III deficiency, prothrombin G20210A mutation, hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) polymorphism</td> </tr> <tr> <td>Vaso-occlusive disorders</td> <td>Calciphylaxis, cholesterol emboli, type I cryoglobulinemia, cryofibrinogenemia, oxalosis</td> </tr> <tr> <td>Vasculitis (small and medium-sized vessel)</td> <td>Henoch-Sch&#246;nlein purpura, rheumatoid vasculitis, mixed cryoglobulinemia, polyarteritis nodosa, granulomatosis with polyangiitis, lupus erythematosus</td> </tr> <tr> <td>Pyoderma gangrenosum</td> <td>&nbsp;</td> </tr> <tr> <td>Necrobiosis lipoidica</td> <td>&nbsp;</td> </tr> <tr> <td>Panniculitis</td> <td>Alpha-1-antitrypsin deficiency, pancreatic fat necrosis, erythema induratum (nodular vasculitis)</td> </tr> <tr> <td>Neoplastic conditions</td> <td>Squamous cell carcinoma, basal cell carcinoma, cutaneous T and B cell lymphoma, Kaposi's sarcoma</td> </tr> <tr> <td>Systemic sclerosis</td> <td>&nbsp;</td> </tr> <tr> <td>Hematologic disease</td> <td>Hemoglobinopathies, thrombocytosis</td> </tr> <tr> <td>Drugs</td> <td>Hydroxyurea, warfarin, heparin</td> </tr> <tr> <td>Metabolic</td> <td>Calcinosis cutis, gout, prolidase deficiency, leukocyte adhesion deficiency, Werner syndrome</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 105315 Version 1.0</div></div></div>"},"105316":{"type":"graphic_table","displayName":"CURB-65 score","title":"CURB-65 pneumonia severity score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">CURB-65 pneumonia severity score</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>C</strong>onfusion (based upon a specific mental test or new disorientation to person, place, or time)</td> </tr> <tr> <td><strong>U</strong>rea (blood urea nitrogen in the United States) &#62;7 mmol/L (20 mg/dL)</td> </tr> <tr> <td><strong>R</strong>espiratory rate &#8805;30 breaths/minute</td> </tr> <tr> <td><strong>B</strong>lood pressure (systolic &#60;90 mmHg or diastolic &#60;60 mmHg)</td> </tr> <tr> <td>Age &#8805;<strong>65</strong> years</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">1 point is assigned for each criterion that is met. UpToDate authors generally favor hospital admission for patients with a score of 1 or 2, although patients with a score of 1 due to being ≥65 years of age who do not have major comorbidities do not necessarily require admission. For patients with a score of 3 to 5, hospitalization is indicated, and the patient should be assessed for possible intensive care unit admission, especially if the score is 4 or 5.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58:377.</LI>&#xD;&#xA;<LI>Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 Suppl 3:iii1. </LI>&#xD;&#xA;<LI>Qureshi KN, Hodkinson HM. Evaluation of a ten-question mental test in the institutionalized elderly. Age Ageing 1974; 3:152.</LI></OL></div><div id=\"graphicVersion\">Graphic 105316 Version 2.0</div></div></div>"},"105317":{"type":"graphic_table","displayName":"Urodynamic test results in women with chronic urinary retention","title":"Urodynamic test results in women with chronic urinary retention","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Urodynamic test results in women with chronic urinary retention</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type of urinary retention</td> <td class=\"subtitle1\">Postvoid residual</td> <td class=\"subtitle1\">Urine flow rate</td> <td class=\"subtitle1\">Detrusor pressure</td> </tr> <tr> <td>Acontractile bladder</td> <td>Increased</td> <td>None to intermittent</td> <td>Absent</td> </tr> <tr> <td>Detrusor underactivity</td> <td>Increased</td> <td>Low to normal</td> <td>Decreased</td> </tr> <tr> <td>Bladder outlet obstruction</td> <td>Increased</td> <td>Low to normal</td> <td>Increased</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 105317 Version 1.0</div></div></div>"},"105318":{"type":"graphic_figure","displayName":"Rigid bronchoscopy coring","title":"Rigid bronchoscopy: Coring endobronchial tumor","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Rigid bronchoscopy: Coring endobronchial tumor</div><div class=\"cntnt\"><img style=\"width:419px; height:372px;\" src=\"images/PULM/105318_Rigid_bronchoscopy_coring.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Representative illustration of coring using a rigid bronchoscope. The barrel of the bronchoscope is shown in the trachea. A forceps has been placed through it to dissect visible obstructing tumor under direct visual guidance. The bronchoscope can also be used to push through the obstruction using a twisting or coring motion to open up the airway.</div><div id=\"graphicVersion\">Graphic 105318 Version 1.0</div></div></div>"},"105319":{"type":"graphic_diagnosticimage","displayName":"Superior sulcus tumor","title":"Superior sulcus tumor (Pancoast tumor)","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Superior sulcus tumor (Pancoast tumor)</div><div class=\"cntnt\"><img style=\"width:710px; height:484px;\" src=\"images/PULM/105319_Sprr_slcs_tmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Superior sulcus tumor presenting with a left apical mass that invades the mediastinum with encasement of the left subclavian artery, the left common carotid artery, the left wall of the esophagus, the anterior aspect of the vertebral body, the left second rib, and the second left intercostal space.</div><div id=\"graphicVersion\">Graphic 105319 Version 1.0</div></div></div>"},"105325":{"type":"graphic_diagnosticimage","displayName":"ECG repaired tetralogy Fallot and pulmonary valve regurgitation","title":"Electrocardiogram of repaired tetralogy of Fallot and severe pulmonary valve regurgitation","html":"<div class=\"graphic\"><div style=\"width: 980px\" class=\"figure\"><div class=\"ttl\">Electrocardiogram of repaired tetralogy of Fallot and severe pulmonary valve regurgitation</div><div class=\"cntnt\"><img style=\"width:960px; height:429px;\" src=\"images/CARD/105325_ECG_rpr_trgy_fllt_plmn_vlv_rgrg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Electrocardiogram from a patient with repaired tetralogy of Fallot and severe pulmonary valve regurgitation showing sinus rhythm, first degree atrioventricular block, and right bundle branch block (QRS duration 142 ms).</div><div id=\"graphicVersion\">Graphic 105325 Version 1.0</div></div></div>"},"105326":{"type":"graphic_picture","displayName":"Keratoconus ","title":"Keratoconus","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Keratoconus</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/PC/105326_Keratoconus_side_view.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cone-shaped protrusion of the cornea in a patient with keratoconus.</div><div class=\"graphic_reference\">Image created by Christopher J. Rapuano, MD. Reproduced with permission from VisualDx.</div><div id=\"graphicVersion\">Graphic 105326 Version 1.0</div></div></div>"},"105327":{"type":"graphic_diagnosticimage","displayName":"Radiograph repaired tetralogy of Fallot with severe PR","title":"Chest radiograph of repaired tetralogy of Fallot with severe pulmonary valve regurgitation","html":"<div class=\"graphic\"><div style=\"width: 884px\" class=\"figure\"><div class=\"ttl\">Chest radiograph of repaired tetralogy of Fallot with severe pulmonary valve regurgitation</div><div class=\"cntnt\"><img style=\"width:864px; height:438px;\" src=\"images/CARD/105327_Irn_dstrb_hrdt_hmchrmt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph from a patient with repaired tetralogy of Fallot with severe pulmonary valve regurgitation. The posterior-anterior film (A) demonstrates cardiomegaly due to right heart enlargement and enlargement of main pulmonary artery.&nbsp;Also noted is a right aortic arch. The lateral projection (B) shows obliteration of retrosternal space due to right ventricular enlargement. </div><div id=\"graphicVersion\">Graphic 105327 Version 1.0</div></div></div>"},"105328":{"type":"graphic_picture","displayName":"Corneal scarring in keratoconus","title":"Corneal scarring in keratoconus ","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Corneal scarring in keratoconus </div><div class=\"cntnt\"><img style=\"width:700px; height:524px;\" src=\"images/PC/105328_Keratoconus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cornea scarring in a patient with keratoconus. </div><div class=\"graphic_reference\">Image created by Christopher J. Rapuano, MD. Reproduced with permission from VisualDx.</div><div id=\"graphicVersion\">Graphic 105328 Version 1.0</div></div></div>"},"105329":{"type":"graphic_diagnosticimage","displayName":"Transthoracic 2D echocardiogram tetralogy of Fallot with PR","title":"Transthoracic two-dimensional echocardiogram of tetralogy of Fallot with severe pulmonary valve regurgitation","html":"<div class=\"graphic\"><div style=\"width: 891px\" class=\"figure\"><div class=\"ttl\">Transthoracic two-dimensional echocardiogram of tetralogy of Fallot with severe pulmonary valve regurgitation</div><div class=\"cntnt\"><img style=\"width:871px; height:340px;\" src=\"images/CARD/105329_Trnsthr_2D_echcrdg_ttrl_fllt_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transthoracic two-dimensional echocardiogram from a parasternal short axis view of the right ventricular outflow tract (A) in a patient with tetralogy of Fallot with severe pulmonary valve regurgitation. Color-Doppler shows laminar systolic antegrade pulmonary flow (B) and laminar diastolic retrograde flow (C)&nbsp;that occupies the entire outflow tract, consistent with severe pulmonary valve regurgitation.</div><div id=\"graphicVersion\">Graphic 105329 Version 1.0</div></div></div>"},"105330":{"type":"graphic_table","displayName":"Laboratory findings in antibody deficiencies","title":"Laboratory findings in antibody deficiencies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Laboratory findings in antibody deficiencies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"9\" width=\"9.5%\"></colgroup><colgroup width=\"14.5%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">Serum immunoglobulins</td> <td class=\"subtitle1\" colspan=\"2\">Specific antibodies</td> <td class=\"subtitle1\" colspan=\"3\">Flow cytometry</td> <td class=\"subtitle1\" rowspan=\"2\">Diagnosis</td> </tr> <tr> <td class=\"subtitle2\">IgG</td> <td class=\"subtitle2\">IgA</td> <td class=\"subtitle2\">IgM</td> <td class=\"subtitle2\">IgG subclass</td> <td class=\"subtitle2\">Protein</td> <td class=\"subtitle2\">Polysaccharide</td> <td class=\"subtitle2\">B cells</td> <td class=\"subtitle2\">Memory B cells</td> <td class=\"subtitle2\">Na&#239;ve B cells</td> </tr> <tr> <td class=\"centered\">NL</td> <td class=\"centered\">NL</td> <td class=\"centered\">NL</td> <td class=\"centered\">NL</td> <td class=\"centered\">NL</td> <td class=\"centered\">NL</td> <td class=\"centered\">NL</td> <td class=\"centered\">NL</td> <td class=\"centered\">NL</td> <td>Normal*</td> </tr> <tr> <td class=\"centered\">NL</td> <td class=\"centered\">NL</td> <td class=\"centered\">NL</td> <td class=\"centered\">NL</td> <td class=\"centered\">Usually NL</td> <td class=\"centered\">Low</td> <td class=\"centered\">NL</td> <td class=\"centered\">Usually NL, may be low</td> <td class=\"centered\">Usually NL, may be high</td> <td>SAD</td> </tr> <tr> <td class=\"centered\">NL</td> <td class=\"centered\">NL</td> <td class=\"centered\">NL</td> <td class=\"centered\">&#8805;1 low</td> <td class=\"centered\">Usually NL</td> <td class=\"centered\">Often low</td> <td class=\"centered\">NL</td> <td class=\"centered\">Usually NL, may be low</td> <td class=\"centered\">Usually NL, may be high</td> <td>IGGSD</td> </tr> <tr> <td class=\"centered\">NL</td> <td class=\"centered\">Absent</td> <td class=\"centered\">NL</td> <td class=\"centered\">NL</td> <td class=\"centered\">Usually NL</td> <td class=\"centered\">Usually NL</td> <td class=\"centered\">NL</td> <td class=\"centered\">Usually NL, may be low</td> <td class=\"centered\">Usually NL, may be high</td> <td>SIGAD</td> </tr> <tr> <td class=\"centered\">NL</td> <td class=\"centered\">Absent</td> <td class=\"centered\">NL</td> <td class=\"centered\">&#8805;1 low</td> <td class=\"centered\">Usually NL</td> <td class=\"centered\">Often low</td> <td class=\"centered\">NL</td> <td class=\"centered\">Usually NL, may be low</td> <td class=\"centered\">Usually NL, may be high</td> <td>IgA deficiency with IGGSD</td> </tr> <tr> <td class=\"centered\">Low</td> <td class=\"centered\">NL</td> <td class=\"centered\">NL</td> <td class=\"centered\">N/A</td> <td class=\"centered\">Usually NL</td> <td class=\"centered\">Usually NL</td> <td class=\"centered\">NL</td> <td class=\"centered\">Usually NL, may be low</td> <td class=\"centered\">Usually NL, may be high</td> <td>Possible secondary, unspecified, or transient hypogammaglobulinemia<sup>&#182;</sup></td> </tr> <tr> <td class=\"centered\">Low</td> <td class=\"centered\">NL or low</td> <td class=\"centered\">NL or low</td> <td class=\"centered\">N/A</td> <td class=\"centered\">Usually NL</td> <td class=\"centered\">Usually NL</td> <td class=\"centered\">NL or low</td> <td class=\"centered\">Usually NL, may be low</td> <td class=\"centered\">Usually NL, may be high</td> <td>Unspecified or transient hypogammaglobulinemia</td> </tr> <tr> <td class=\"centered\">Low</td> <td class=\"centered\">Low</td> <td class=\"centered\">NL or low</td> <td class=\"centered\">N/A</td> <td class=\"centered\">Usually IgM only</td> <td class=\"centered\">Usually IgM only</td> <td class=\"centered\">NL</td> <td class=\"centered\">Usually low</td> <td class=\"centered\">Usually high</td> <td>HIM</td> </tr> <tr> <td class=\"centered\">Low</td> <td class=\"centered\">Low</td> <td class=\"centered\">NL or low</td> <td class=\"centered\">N/A</td> <td class=\"centered\">Usually low</td> <td class=\"centered\">Usually low</td> <td class=\"centered\">NL or low</td> <td class=\"centered\">Usually low, may be NL</td> <td class=\"centered\">Usually high, may be NL</td> <td>CVID, possible transient hypogammaglobulinemia</td> </tr> <tr> <td class=\"centered\">Absent</td> <td class=\"centered\">Absent</td> <td class=\"centered\">Absent</td> <td class=\"centered\">N/A</td> <td class=\"centered\">Usually low</td> <td class=\"centered\">Usually low</td> <td class=\"centered\">Absent</td> <td class=\"centered\">Absent</td> <td class=\"centered\">Absent</td> <td>Agammaglobulinemia or severe CVID<sup>&#916;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The initial laboratory examination of humoral immunity consists of measuring levels of various immunoglobulin isotypes (IgG, IgA, IgM, and possibly IgG subclasses) in serum, as well as a measure of function or specific antibody production, which should include both protein and polysaccharide antigens.</div><div class=\"graphic_footnotes\">IgG: immunoglobulin G; IgA: immunoglobulin A; IgM: immunoglobulin M; NL: normal; SAD: specific antibody deficiency; IGGSD: IgG subclass deficiency; SIGAD: selective IgA deficiency; N/A: not applicable, the total IgG is low, and the relative amounts of IgG subclasses have no diagnostic or pathologic importance; HIM: hyper-IgM syndrome; CVID: common variable immunodeficiency; CID: combined immunodeficiency.<br />*Consider complement deficiency or phagocyte defect.<br />¶ In this circumstance, it is useful to measure serum total protein and/or albumin levels; if low, this is consistent with secondary hypogammaglobulinemia.<br />Δ Cellular immunity should be evaluated as indicated by other clinical features but is often worth considering when significant impairment of humoral immunity is observed because it could be a component of a CID.</div><div class=\"graphic_reference\">Original figure modified for this publication. Bonilla FA, Khan DA, Ballas ZK, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. J Allergy Clin Immunol 2015; 136:1186. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105330 Version 2.0</div></div></div>"},"105331":{"type":"graphic_diagnosticimage","displayName":"TTE continuous wave Doppler pulmonary valve","title":"Transthoracic echocardiogram showing continuous wave Doppler at the level of the pulmonary valve","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Transthoracic echocardiogram showing continuous wave Doppler at the level of the pulmonary valve</div><div class=\"cntnt\"><img style=\"width:715px; height:532px;\" src=\"images/CARD/105331_TTE_cntn_wv_dppl_plmn_vlv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transthoracic echocardiogram spectral display&nbsp;of continuous wave Doppler at the level of the pulmonary valve obtained in the parasternal short axis&nbsp;view showing severe pulmonic regurgitation. There is systolic antegrade pulmonary flow (arrow) with velocity of 1.8 meters per second and diastolic retrograde flow/pulmonary valve regurgitation (arrowhead). Note the rapid deceleration of the continuous wave Doppler signal to baseline, consistent with rapid equalization of pressures between pulmonary artery and right ventricle.</div><div id=\"graphicVersion\">Graphic 105331 Version 1.0</div></div></div>"},"105332":{"type":"graphic_diagnosticimage","displayName":"MRI RV enlargement repaired tetralogy of Fallot","title":"MRI of short axis stack showing severe right ventricular enlargement with severe pulmonary valve regurgitation related to repaired tetralogy of Fallot","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">MRI of short axis stack showing severe right ventricular enlargement with severe pulmonary valve regurgitation related to repaired tetralogy of Fallot</div><div class=\"cntnt\"><img style=\"width:550px; height:496px;\" src=\"images/CARD/105332_MRI_RV_enlrg_rpr_ttrlgy_fllt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cardiovascular magnetic resonance imaging, Steady State Free Procession (SSFP) sequence of a short axis series showing severe right ventricular enlargement (asterisk) in an adult with severe pulmonary valve regurgitation subsequent to tetralogy of Fallot repair. The indexed right ventricular end-diastolic and end-systolic volumes were 168 and 89 mL/m<sup>2</sup>, respectively. Right ventricular ejection fraction was 47 percent.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div id=\"graphicVersion\">Graphic 105332 Version 2.0</div></div></div>"},"105334":{"type":"graphic_figure","displayName":"Modified radical vulvectomy","title":"Modified radical vulvectomy","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Modified radical vulvectomy</div><div class=\"cntnt\"><img style=\"width:766px; height:575px;\" src=\"images/ONC/105334_Modified_radical_vulvectomy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Anterior hemivulvectomy.<br />(B) Right hemivulvectomy with clitoral sparing.<br />(C) Posterior hemivulvectomy.</div><div class=\"graphic_reference\">Reproduced with permission from: Hoffman MS, Stickles XB. Malignancies of the vulva. In: Te Linde's Operative Gynecology, 11th ed, Jones III HW, Rock JA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2015. Copyright © 2015 Wolters Kluwer. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105334 Version 1.0</div></div></div>"},"105336":{"type":"graphic_figure","displayName":"Inguinal-femoral lymphadenectomy","title":"Inguinal-femoral lymphadenectomy","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Inguinal-femoral lymphadenectomy</div><div class=\"cntnt\"><img style=\"width:766px; height:622px;\" src=\"images/ONC/105336_Inguinal-femoral_lymphdnctm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) En bloc removal.<br />(B) Radical vulvectomy with bilateral inguinal-femoral lymphadenectomy through three separate incisions.<br />(C) Unilateral lymphadenectomy for a well-lateralized lesion.<br />(D) Early lesion with omission of lymphadenectomy.</div><div class=\"graphic_reference\">Reproduced with permission from: Hoffman MS, Stickles XB. Malignancies of the vulva. In: Te Linde's Operative Gynecology, 11th ed, Jones III HW, Rock JA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2015. Copyright © 2015 Wolters Kluwer. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105336 Version 1.0</div></div></div>"},"105337":{"type":"graphic_figure","displayName":"Radical vulvectomy procedure","title":"Radical vulvectomy: Procedure","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radical vulvectomy: Procedure</div><div class=\"cntnt\"><img style=\"width:442px; height:961px;\" src=\"images/ONC/105337_Radical_vulvectomy_procedre.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Radical vulvectomy with bilateral inguinal lymphadenectomy done through three separate incisions.<br />(A) Bilateral inguinofemoral lymphadenectomy through separate incisions is completed. Separate incision for radical vulvectomy is marked.<br />(B) Labiocrural incisions are extended to deep fascia of the urogenital diaphragm.<br />(C) Dissection proceeds dorsally off of the pubic bone. The vascular base of the clitoris is clamped, followed by transection and ligation.<br />(D) Perineal body and posterior vulvar tissues are dissected away from the anus.<br />(E) The vascular vestibular tissue along the sides of the vaginal tube is clamped. Transection and suture ligation to follow.<br />(F) Radical vulvectomy resection is completed.<br />(G) Closure of the vulvar wound is completed.</div><div class=\"graphic_reference\">Reproduced with permission from: Hoffman MS, Stickles XB. Malignancies of the vulva. In: Te Linde's Operative Gynecology, 11th ed, Jones III HW, Rock JA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2015. Copyright © 2015 Wolters Kluwer. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105337 Version 1.0</div></div></div>"},"105340":{"type":"graphic_picture","displayName":"Iron distribution hereditary hemochromatosis","title":"Hepatic iron distribution in hereditary hemochromatosis","html":"<div class=\"graphic\"><div style=\"width: 803px\" class=\"figure\"><div class=\"ttl\">Hepatic iron distribution in hereditary hemochromatosis</div><div class=\"cntnt\"><img style=\"width:783px; height:585px;\" src=\"images/GAST/105340_Irn_dstrb_hrdt_hmchrmts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Early in the course of hereditary hemochromatosis, there is a decreasing gradient of parenchymal iron distribution from periportal to centrilobular areas. (Prussian blue stain.)</div><div id=\"graphicVersion\">Graphic 105340 Version 1.0</div></div></div>"},"105345":{"type":"graphic_picture","displayName":"Severe telogen effluvium","title":"Severe telogen effluvium","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Severe telogen effluvium</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/105345_Svr_tlgn_efflvm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reduced hair density in a patient with severe telogen effluvium.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105345 Version 1.0</div></div></div>"},"105347":{"type":"graphic_picture","displayName":"Atrichia with papular lesions","title":"Atrichia with papular lesions","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Atrichia with papular lesions</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/105347_Atrch_pplr_lsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Complete hair loss on the scalp and face in a child with atrichia with papular lesions.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105347 Version 1.0</div></div></div>"},"105358":{"type":"graphic_figure","displayName":"Classification of conjoined twins","title":"Classification of conjoined twins","html":"<div class=\"graphic\"><div style=\"width: 857px\" class=\"figure\"><div class=\"ttl\">Classification of conjoined twins</div><div class=\"cntnt\"><img style=\"width:837px; height:743px;\" src=\"images/OBGYN/105358_Classifictn_conjoined_twins.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Bold font indicates presence in 100% of cases.</div><div class=\"graphic_reference\">Reproduced with permission from: Baken L, Rousian M, Kompanje EJ, et al. Diagnostic techniques and criteria for first-trimester conjoined twin documentation: A review of the literature illustrated by three recent cases. Obstet Gynecol Surv 2013; 68:743. DOI:<a href=\"http://journals.lww.com/obgynsurvey/Abstract/2013/11000/Diagnostic_Techniques_and_Criteria_for.11.aspx?trendmd-shared=0\" target=\"_blank\">10.1097/OGX.00000000000000000</a>. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105358 Version 1.0</div></div></div>"},"105360":{"type":"graphic_figure","displayName":"Key components of the renin-angiotensin system","title":"Key components of the renin-angiotensin system","html":"<div class=\"graphic\"><div style=\"width: 576px\" class=\"figure\"><div class=\"ttl\">Key components of the renin-angiotensin system</div><div class=\"cntnt\"><img style=\"width:556px; height:310px;\" src=\"images/NEPH/105360_Key_components_of_the_renin_angiotensin_system.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PRR: prorenin receptor; MAP: mitogen-activated protein; ERK: extracellular signal-regulated kinase; ACE: angiotensin-converting enzyme; ARBs: angiotensin II receptor blockers; AT1: type 1 Ang II receptor; AT2: type 2 Ang II receptor; Ang #: angiotensin #; APA: aminopeptidase A; APN: aminopeptidase N; AT4: type 4 Ang II receptor; IRAP: insulin-regulated aminopeptidase; ACE2: angiotensin-converting enzyme 2.</div><div class=\"graphic_reference\">Adapted from:<br /><OL>&#xD;&#xA;<LI>Li Q, Verma A, Zhu P, et al. Gene therapy for diabetic retinopathy – Targeting the renin-angiotensin system. In: Gene Therapy - Tools and Potential Applications, Martin F (Ed), InTech, 2013. Available from: <A spellcheck=true href=\"http://www.intechopen.com/books/gene-therapy-tools-and-potential-applications/gene-therapy-for-diabetic-retinopathy-targeting-the-renin-angiotensin-system\" target=_blank>http://www.intechopen.com/books/gene-therapy-tools-and-potential-applications/gene-therapy-for-diabetic-retinopathy-targeting-the-renin-angiotensin-system</A> (Accessed on March 22, 2016).</LI>&#xD;&#xA;<LI>Zhou JL, Ferrao FM, Zheng Y, Li XC. New frontiers in the intrarenal renin-angiotensin system: A critical review of classical and new paradigms. Front Endocrinol (Lausanne) 2013; 4:166.</LI></OL></div><div id=\"graphicVersion\">Graphic 105360 Version 3.0</div></div></div>"},"105365":{"type":"graphic_table","displayName":"Causes of iron overload","title":"Causes of iron overload","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of iron overload</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Mechanism</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Increased intake</td> </tr> <tr> <td class=\"indent1\">Transfusional overload (eg, in inherited bone marrow failure syndromes,&nbsp;hemolytic anemias, myelodysplastic syndrome, aplastic anemia)</td> <td>Iatrogenic, used to treat severe anemia</td> </tr> <tr> <td class=\"indent1\">Iron-loaded diet (eg, \"African iron overload\")</td> <td>Dietary, from iron in barrels used to store homemade beer; may have genetic component</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Repeated hemin infusions (eg, to treat acute intermittent porphyria)</td> <td>Iatrogenic, used to treat acute porphyric attacks</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Increased absorption (with normal intake)</td> </tr> <tr> <td class=\"indent1\">Hereditary hemochromatosis due to <em>HFE</em> mutation (eg, C282Y/C282Y; C282Y/H63D)</td> <td>Incompletely understood effects on iron absorption</td> </tr> <tr> <td class=\"indent1\">Hereditary hemochromatosis due to rare mutations (eg, ferroportin, hemojuvelin, hepcidin, ceruloplasmin)</td> <td>Alterations in known regulators of intestinal iron absorption</td> </tr> <tr> <td class=\"indent1\">Thalassemia major or intermedia</td> <td>Ineffective erythropoiesis leading to suppression of hepcidin; transfusional iron overload may also contribute</td> </tr> <tr> <td class=\"indent1\">Sideroblastic anemia (inherited or acquired)</td> <td>Ineffective erythropoiesis leading to suppression of hepcidin</td> </tr> <tr> <td class=\"indent1\">Inherited anemias (eg, CDA, DBA)</td> <td>Ineffective erythropoiesis leading to suppression of hepcidin</td> </tr> <tr> <td class=\"indent1\">Gestational alloimmune liver disease (GALD)*</td> <td>Maternal alloantibody causing liver injury in utero</td> </tr> <tr> <td class=\"indent1\">Chronic liver disease, especially alcoholic liver disease, chronic hepatitis, and non-alcoholic fatty liver disease (NAFLD)</td> <td>Incompletely understood, possible&nbsp;reduced hepcidin production?</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate content on iron overload, iron balance, and specific disorders for further details.</div><div class=\"graphic_footnotes\"><em>HFE</em>: hereditary hemochromatosis gene; CDA: congenital dyserythropoietic anemia; DBA: Diamond-Blackfan anemia.<br />* Many cases of GALD were previously called neonatal hemochromatosis; however, the conditions are not synonymous.</div><div class=\"graphic_reference\">Courtesy of Stan Schrier, MD.</div><div id=\"graphicVersion\">Graphic 105365 Version 1.0</div></div></div>"},"105366":{"type":"graphic_table","displayName":"CVD risk factors in pediatric dyslipidemia management","title":"Risk factors for early cardiovascular disease in children, definitions used in pediatric dyslipidemia screening and management","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for early cardiovascular disease in children, definitions used in pediatric dyslipidemia screening and management</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Positive family history:</td> </tr> <tr> <td class=\"indent1\">Premature coronary artery disease (ie, heart attack, treated angina, interventions for coronary artery disease, stroke, or sudden cardiac death) in a first- or second-degree male relative &#60;55 years or female relative &#60;65 years*</td> </tr> <tr> <td class=\"indent1\">Known dyslipidemia (eg, familial hypercholesterolemia) or total cholesterol (TC) &#62;240 mg/dL (6.2 mmol/L) in either parent</td> </tr> <tr> <td class=\"subtitle1_single\">High-level risk factors:</td> </tr> <tr> <td class=\"indent1\">Hypertension that requires drug therapy (BP &#8805;99th percentile + 5 mmHg)</td> </tr> <tr> <td class=\"indent1\">Current cigarette smoker</td> </tr> <tr> <td class=\"indent1\">Obesity with BMI &#8805;97th percentile</td> </tr> <tr> <td class=\"indent1\">Presence of a high risk condition: <ul class=\"decimal_heading\"> <li>Diabetes (type 1 or type 2) </li> <li>Chronic kidney disease/end-stage renal disease/post-renal transplant </li> <li>Post-orthotopic heart transplant </li> <li>Kawasaki disease with current aneurysms </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Moderate-level risk factors:</td> </tr> <tr> <td class=\"indent1\">Hypertension (defined as systolic and/or diastolic BP &#8805;95th percentile measured on three or more separate occasions) that does not require drug therapy</td> </tr> <tr> <td class=\"indent1\">Obesity: <ul class=\"decimal_heading\"> <li>For children age 2 to 11 years: BMI &#8805;95th to &#60;97th percentile </li> <li>For adolescents &#8805;12 years: BMI &#8805;85th to &#60;97th percentile </li> </ul> </td> </tr> <tr> <td class=\"indent1\">HDL cholesterol &#60;40 mg/dL</td> </tr> <tr> <td class=\"indent1\">Presence of a moderate risk condition: <ul class=\"decimal_heading\"> <li>Kawasaki disease with regressed coronary aneurysms </li> <li>Chronic inflammatory disease (eg, systemic lupus erythematosus, juvenile idiopathic arthritis) </li> <li>HIV infection </li> <li>Nephrotic syndrome </li> <li>Adolescent depressive and bipolar disorders<sup>&#182;</sup> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">BMI: body mass index; BP: blood pressure; HDL: high-density lipoprotein; HIV: human immunodeficiency virus.<br />*&nbsp;First- and second-degree relatives include parents, sibling, aunts, uncles, and grandparents.<br />¶ Though not included in the 2011 National Heart, Lung, and Blood Institute (NHLBI) recommendations, a 2015 American Heart Association (AHA) statement advocates including major depressive disorder and bipolar disorder in adolescents as moderate risk conditions for premature cardiovascular disease (CVD).</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Goldstein BI, Carnethon MR, Matthews KA, et al. Major Depressive Disorder and Bipolar Disorder Predispose Youth to Accelerated Atherosclerosis and Early Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2015; 132:965.</LI></OL>Adapted from: Daniels SR, Benuck I, Christakis DA, et al. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Full report, 2011. National Heart Lung and Blood Institute. Available at: <A spellcheck=true href=\"http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=_blank>http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</A> (Accessed on November 13, 2015).</div><div id=\"graphicVersion\">Graphic 105366 Version 3.0</div></div></div>"},"105367":{"type":"graphic_algorithm","displayName":"Pediatric dyslipidemia algorithm","title":"Overview of initial evaluation and management of children undergoing lipid screening","html":"<div class=\"graphic\"><div style=\"width: 840px\" class=\"figure\"><div class=\"ttl\">Overview of initial evaluation and management of children undergoing lipid screening</div><div class=\"cntnt\"><img style=\"width:820px; height:846px;\" src=\"images/PEDS/105367_Pediatric_dyslipidemia_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">LDL-C and non-HDL-C units are mg/dL; divide by 38.67 to convert to mmol/L.</div><div class=\"graphic_footnotes\">HDL-C: high-density lipoprotein cholesterol; LDL-C: low density lipoprotein cholesterol; NHLBI: National Heart, Lung, and Blood Institute; CVD: cardiovascular disease; FH: familial hypercholesterolemia.<br />* Risk factors for premature CVD, as defined by the NHLBI expert panel are: positive family history of premature cardiovascular disease and/or known dyslipidemia; high-risk conditions (including type 1 and 2 diabetes mellitus, chronic kidney disease, heart transplant recipients, and Kawasaki disease with current coronary aneurysms); high-level comorbidities (including hypertension requiring drug therapy [ie, blood pressure &ge;99th percentile + 5 mmHg], current cigarette smoker, and body mass index [BMI] &ge;97th percentile); moderate-risk conditions (including Kawasaki disease with regressed coronary aneurysms, chronic inflammatory diseases [eg, systemic lupus erythematosus, juvenile idiopathic arthritis], human immunodeficiency virus [HIV] infection, nephrotic syndrome, and adolescent depressive and bipolar disorders); and moderate-level comorbidities (including hypertension not requiring drug therapy, BMI &ge;95th and &lt;97th percentile, and HDL-C &lt;40 mg/dL [1 mmol/L]).<br />&para; In children with underlying risk factors for CVD, lipid screening is generally performed at the time of diagnosis or identification of the risk factor (no earlier than age two years) and then every two years thereafter. In children without underlying risk factors for CVD, routine lipid screening is performed at age 9 to 11 years and again at age 17 to 21 years.<br />&Delta; Lifestyle modifications may include low saturated fat diet; increased intake of dietary fiber through fruits, vegetables, and whole grains; supplementation with plant stanols and sterols; increasing physical activity; and, in obese children, weight loss. Refer to the UpToDate topic on management of dyslipidemia in children for further details of nonpharmacologic management of hypercholesterolemia.<br /><span class=\"lozenge\">&loz;</span> Confirmatory testing consists of two fasting lipid profiles obtained two weeks to three months apart (ie, if the patient had a fasting lipid profile performed as the initial screen, a second fasting lipid profile is obtained two weeks to three months later; if the patient's initial screen was performed using non-HDL-C, two separate fasting lipid profiles should be performed). Average the two results.<br />&sect; Secondary causes of hypercholesterolemia include diabetes mellitus, nephrotic syndrome, hypothyroidism, pregnancy, hepatic disease, and certain medications (eg, glucocorticoids, antiretrovirals). Refer to the UpToDate topic on screening and diagnosis of dyslipidemia in children for further details.</div><div class=\"graphic_reference\">Adapted from: Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report. Pediatrics 2011; 128 Suppl 5:S213.</div><div id=\"graphicVersion\">Graphic 105367 Version 2.0</div></div></div>"},"105369":{"type":"graphic_table","displayName":"Response to therapy definitions based on initial therapy","title":"Response to therapy definitions based on initial therapy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Response to therapy definitions based on initial therapy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"3\">Initial therapy</td> </tr> <tr> <td class=\"subtitle2\">Total thyroidectomy and RAI ablation</td> <td class=\"subtitle2\">Total thyroidectomy without RAI ablation</td> <td class=\"subtitle2\">Lobectomy</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Excellent response</strong></td> <td> <p>Nonstimulated Tg level &#60;0.2 ng/mL*</p> <p>or</p> <p>stimulated Tg level &#60;1 ng/mL*</p> <p>and</p> <p>undetectable TgAb</p> <p>and</p> negative imaging</td> <td> <p>Nonstimulated Tg level &#60;0.2 ng/mL*</p> <p>or</p> <p>stimulated Tg level &#60;2 ng/mL*</p> <p>and</p> <p>undetectable TgAb</p> <p>and</p> negative imaging</td> <td> <p>Stable, nonstimulated Tg level &#60;30 ng/mL*</p> <p>and</p> <p>undetectable TgAb</p> <p>and</p> negative imaging</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Biochemical incomplete response</strong></td> <td> <p>Nonstimulated Tg level &#62;1 ng/mL*</p> <p>or</p> <p>stimulated Tg level &#62;10 ng/mL*</p> <p>or</p> <p>increasing TgAb levels</p> <p>and</p> negative imaging</td> <td> <p>Nonstimulated Tg level &#62;5 ng/mL*</p> <p>or</p> <p>stimulated Tg level &#62;10 ng/mL*</p> <p>or</p> <p>increasing Tg values over time with similar TSH levels</p> <p>or</p> <p>increasing TgAb levels</p> <p>and</p> negative imaging</td> <td> <p>Nonstimulated Tg level &#62;30 ng/mL*</p> <p>or</p> <p>increasing Tg level values over time with similar TSH levels</p> <p>or</p> <p>increasing TgAb levels</p> <p>and</p> negative imaging</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Structural incomplete response</strong></td> <td>Structural or functional evidence of disease regardless of Tg or TgAb</td> <td>Structural or functional evidence of disease regardless of Tg or TgAb</td> <td>Structural or functional evidence of disease regardless of Tg or TgAb</td> </tr> <tr> <td><strong>Indeterminate response</strong></td> <td> <p>Nonspecific findings on imaging studies</p> <p>or</p> <p>faint uptake in thyroid bed on RAI scanning</p> <p>or</p> <p>nonstimulated Tg level 0.2-1 ng/mL*</p> <p>or</p> <p>stimulated Tg level 1-10 ng/mL*</p> <p>or</p> TgAb levels stable or declining in the absence of structural or functional disease</td> <td> <p>Nonspecific findings on imaging studies</p> <p>or</p> <p>faint uptake in thyroid bed on RAI scanning</p> <p>or</p> <p>nonstimulated Tg level 0.2-5 ng/mL*</p> <p>or</p> <p>stimulated Tg level 2-10 ng/mL*</p> <p>or</p> TgAb levels stable or declining in the absence of structural or functional disease</td> <td> <p>Nonspecific findings on imaging studies</p> <p>or</p> TgAb levels stable or declining in the absence of structural or functional disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">RAI: radioactive iodine; Tg: thyroglobulin; TgAb: thyroglobulin antibody; TSH: thyroid-stimulating hormone.<br />* In the absence of interfering anti-TgAb.</div><div class=\"graphic_reference\">Reproduced from: Momesso DP, Tuttle RM. Update on differentiated thyroid cancer staging. Endocrinol Metab Clin North Am 2014; 43:401. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105369 Version 1.0</div></div></div>"},"105371":{"type":"graphic_picture","displayName":"Cutaneous protothecosis","title":"Cutaneous protothecosis","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Cutaneous protothecosis</div><div class=\"cntnt\"><img style=\"width:712px; height:532px;\" src=\"images/ID/105371_Ctns_prtthcss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A large erythematous plaque with extensive soft tissue involvement of the arm.</div><div class=\"graphic_reference\">Courtesy of Dr. Reynaldo Arosemena, Panama.</div><div id=\"graphicVersion\">Graphic 105371 Version 1.0</div></div></div>"},"105372":{"type":"graphic_picture","displayName":"Protothecosis skin biopsy","title":"<EM>Prototheca</EM>: Skin biopsy demonstrating sporangia with endospores","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\"><EM>Prototheca</EM>: Skin biopsy demonstrating sporangia with endospores</div><div class=\"cntnt\"><img style=\"width:715px; height:536px;\" src=\"images/ID/105372_Prtthcs_skn_bpsy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The biopsy demonstrates \"morula-like\" sporangia containing 4 to 5 endospores. 400x, periodic acid-Schiff staining.</div><div id=\"graphicVersion\">Graphic 105372 Version 1.0</div></div></div>"},"105378":{"type":"graphic_table","displayName":"Simpson-Angus Scale","title":"Simpson-Angus Scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Simpson-Angus Scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td>Patient name:</td> <td>Date:</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Simpson-Angus Extrapyramidal Side Effects Scale</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">The exam should be conducted in a room where the subject can walk a sufficient distance to allow him/her to get into a natural rhythm (eg, 15 paces). Each side of the body should be examined. If one side shows more pronounced pathology than the other, this score should be noted and this taken. Cogwheel rigidity may be palpated when the examination is carried out for items 3, 4, 5, and 6. It is not rated separately and is merely another way to detect rigidity. It would indicate that a minimum score of 1 would be mandatory.</td> </tr> <tr> <td> <ol> <li><strong>Gait:</strong> The patient is examined as he walks into the examining room, his gait, the swing of his arms, his general posture, all form the basis for an overall score for this item. This is rated as follows: </li> </ol> </td> <td> <ol start=\"6\"> <li><strong>Leg pendulousness:</strong> The patient sits on a table with his legs hanging down and swinging free. The ankle is grasped by the examiner and raised until the knee is partially extended. It is then allowed to fall. The resistance to falling and the lack of swinging form the basis for the score on this item: </li> </ol> </td> </tr> <tr> <td class=\"indent3\">0 &ndash; Normal</td> <td class=\"indent3\">0 &ndash; The legs swing freely</td> </tr> <tr> <td class=\"indent3\">1 &ndash; Diminution in swing while the patient is walking</td> <td class=\"indent3\">1 &ndash; Slight diminution in the swing of the legs</td> </tr> <tr> <td class=\"indent3\">2 &ndash; Marked diminution in swing with obvious rigidity in the arm</td> <td class=\"indent3\">2 &ndash; Moderate resistance to swing</td> </tr> <tr> <td class=\"indent3\">3 &ndash; Stiff gait with arms held rigidly before the abdomen</td> <td class=\"indent3\">3 &ndash; Marked resistance and damping of swing</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">4 &ndash; Stooped shuffling gait with propulsion and retropulsion</td> <td class=\"indent3\">4 &ndash; Complete absence of swing</td> </tr> <tr> <td> <ol start=\"2\"> <li><strong>Arm dropping:</strong> The patient and the examiner both raise their arms to shoulder height and let them fall to their sides. In a normal subject, a stout slap is heard as the arms hit the sides. In the patient with extreme Parkinson's syndrome, the arms fall very slowly: </li> </ol> </td> <td> <ol start=\"7\"> <li><strong>Head dropping:</strong> The patient lies on a well-padded examining table and his head is raised by the examiner's hand. The hand is then withdrawn and the head allowed to drop. In the normal subject the head will fall upon the table. The movement is delayed in extrapyramidal system disorder, and in extreme parkinsonism it is absent. The neck muscles are rigid and the head does not reach the examining table. Scoring is as follows: </li> </ol> </td> </tr> <tr> <td class=\"indent3\">0 &ndash; Normal, free fall with loud slap and rebound</td> <td class=\"indent3\">0 &ndash; The head falls completely with a good thump as it hits the table</td> </tr> <tr> <td class=\"indent3\">1 &ndash; Fall slowed slightly with less audible contact and little rebound</td> <td class=\"indent3\">1 &ndash; Slight slowing in fall, mainly noted by lack of slap as head meets the table</td> </tr> <tr> <td class=\"indent3\">2 &ndash; Fall slowed, no rebound</td> <td class=\"indent3\">2 &ndash; Moderate slowing in the fall quite noticeable to the eye</td> </tr> <tr> <td class=\"indent3\">3 &ndash; Marked slowing, no slap at all</td> <td class=\"indent3\">3 &ndash; Head falls stiffly and slowly</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">4 &ndash; Arms fall as though against resistance; as though through glue</td> <td class=\"indent3\">4 &ndash; Head does not reach the examining table</td> </tr> <tr> <td> <ol start=\"3\"> <li><strong>Shoulder shaking:</strong> The subject's arms are bent at a right angle at the elbow and are taken one at a time by the examiner who grasps one hand and also clasps the other around the patient's elbow. The subject's upper arm is pushed to and fro and the humerus is externally rotated. The degree of resistance from normal to extreme rigidity is scored as follows: </li> </ol> </td> <td> <ol start=\"8\"> <li><strong>Glabella tap:</strong> Subject is told to open eyes wide and not to blink. The glabella region is tapped at a steady, rapid speed. The number of times patient blinks in succession is noted: </li> </ol> </td> </tr> <tr> <td class=\"indent3\">0 &ndash; Normal</td> <td class=\"indent3\">0 &ndash; 0 to 5 blinks</td> </tr> <tr> <td class=\"indent3\">1 &ndash; Slight stiffness and resistance</td> <td class=\"indent3\">1 &ndash; 6 to 10 blinks</td> </tr> <tr> <td class=\"indent3\">2 &ndash; Moderate stiffness and resistance</td> <td class=\"indent3\">2 &ndash; 11 to 15 blinks</td> </tr> <tr> <td class=\"indent3\">3 &ndash; Marked rigidity with difficulty in passive movement</td> <td class=\"indent3\">3 &ndash; 16 to 20 blinks</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">4 &ndash; Extreme stiffness and rigidity with almost a frozen shoulder</td> <td class=\"indent3\">4 &ndash; 21 and more blinks</td> </tr> <tr> <td> <ol start=\"4\"> <li><strong>Elbow rigidity:</strong> The elbow joints are separately bent at right angles and passively extended and flexed, with the subject's biceps observed and simultaneously palpated. The resistance to this procedure is rated. (The presence of cogwheel rigidity is noted separately.) </li> </ol> </td> <td> <ol start=\"9\"> <li><strong>Tremor:</strong> Patient is observed walking into examining room and is then reexamined for this item: </li> </ol> </td> </tr> <tr> <td class=\"indent3\">0 &ndash; Normal</td> <td class=\"indent3\">0 &ndash; Normal</td> </tr> <tr> <td class=\"indent3\">1 &ndash; Slight stiffness and resistance</td> <td class=\"indent3\">1 &ndash; Mild finger tremor, obvious to sight and touch</td> </tr> <tr> <td class=\"indent3\">2 &ndash; Moderate stiffness and resistance</td> <td class=\"indent3\">2 &ndash; Tremor of hand or arm occurring spasmodically</td> </tr> <tr> <td class=\"indent3\">3 &ndash; Marked rigidity with difficulty in passive movement</td> <td class=\"indent3\">3 &ndash; Persistent tremor of one or more limbs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent3\">4 &ndash; Extreme stiffness and rigidity with almost a frozen elbow</td> <td class=\"indent3\">4 &ndash; Whole body tremor</td> </tr> <tr> <td> <ol start=\"5\"> <li><strong>Wrist rigidity or fixation of position:</strong> The wrist is held in one hand and the fingers held by the examiner's other hand, with the wrist moved to extension, flexion and ulnar and radial deviation: </li> </ol> </td> <td> <ol start=\"10\"> <li><strong>Salivation:</strong> Patient is observed while talking and then asked to open his mouth and elevate his tongue. The following ratings are given: </li> </ol> </td> </tr> <tr> <td class=\"indent3\">0 &ndash; Normal</td> <td class=\"indent3\">0 &ndash; Normal</td> </tr> <tr> <td class=\"indent3\">1 &ndash; Slight stiffness and resistance</td> <td class=\"indent3\">1 &ndash; Excess salivation to the extent that pooling takes place if the mouth is open and the tongue raised</td> </tr> <tr> <td class=\"indent3\">2 &ndash; Moderate stiffness and resistance</td> <td class=\"indent3\">2 &ndash; When excess salivation is present and might occasionally result in difficulty speaking</td> </tr> <tr> <td class=\"indent3\">3 &ndash; Marked rigidity with difficulty in passive movement</td> <td class=\"indent3\">3 &ndash; Speaking with difficulty because of excess salivation</td> </tr> <tr> <td class=\"indent3\">4 &ndash; Extreme stiffness and rigidity with almost frozen wrist</td> <td class=\"indent3\">4 &ndash; Frank drooling</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11.</div><div id=\"graphicVersion\">Graphic 105378 Version 1.0</div></div></div>"},"105380":{"type":"graphic_table","displayName":"RBC fragmentation","title":"Causes of red blood cell fragmentation","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of red blood cell fragmentation</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Mechanism(s)</td> </tr> <tr> <td class=\"subtitle2_left\">Primary TMAs*</td> <td class=\"subtitle2_left\">Intravascular RBC shearing and platelet microthrombi</td> </tr> <tr> <td class=\"indent1\">TTP</td> <td class=\"indent1\">Ultralarge VWF multimers and platelet microthrombi</td> </tr> <tr> <td class=\"indent1\">HUS</td> <td class=\"indent1\">Damaged endothelium and platelet microthrombi</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Complement-mediated TMA</td> <td class=\"indent1\">Damaged endothelium and platelet microthrombi</td> </tr> <tr> <td class=\"subtitle2_left\">Systemic conditions</td> <td class=\"subtitle2_left\">Intravascular RBC shearing and platelet/fibrin thrombi</td> </tr> <tr> <td class=\"indent1\">DIC</td> <td class=\"indent1\">Intravascular platelet/fibrin thrombi</td> </tr> <tr> <td class=\"indent1\">HELLP and preeclampsia</td> <td class=\"indent1\">Damaged endothelium and platelet microthrombi</td> </tr> <tr> <td class=\"indent1\">Malignancy</td> <td class=\"indent1\">Shearing within intravascular tumor deposits</td> </tr> <tr> <td class=\"indent1\">Malignant hypertension</td> <td class=\"indent1\">Damaged endothelium and platelet microthrombi</td> </tr> <tr> <td class=\"indent1\">Scleroderma renal crisis</td> <td class=\"indent1\">Damaged endothelium and platelet microthrombi</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">APS</td> <td class=\"indent1\">Intravascular thrombi</td> </tr> <tr> <td class=\"subtitle2_left\">Isolated intravascular sites of hemolysis</td> <td class=\"subtitle2_left\">Intravascular RBC shearing by turbulence and/or mechanical trauma in the isolated site</td> </tr> <tr> <td class=\"indent1\">Kasabach-Merritt syndrome</td> <td class=\"indent1\">Platelet trapping and&nbsp;localized intravascular&nbsp;coagulation within the angioma</td> </tr> <tr> <td class=\"indent1\">TIPS</td> <td class=\"indent1\">Shear stress&nbsp;and mechanical trauma in the shunt</td> </tr> <tr> <td class=\"indent1\">Malfunctioning cardiac valves or cardiac assist devices</td> <td class=\"indent1\">Shear stress&nbsp;and mechanical trauma across the valve or assist device</td> </tr> <tr> <td class=\"indent1\">March hemoglobinuria, extreme running, bongo drumming</td> <td class=\"indent1\">Repetitive trauma as blood passes through vessels in feet or hands</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate content on hemolytic anemias due to red blood cell fragmentation and on the individual disorders for further details.</div><div class=\"graphic_footnotes\">DIC: disseminated intravascular coagulation; HELLP: hemolysis, elevated liver function tests, and low platelets; APS: antiphospholipid syndrome; TIPS: transjugular intrahepatic portosystemic shunt; VWF: Von Willebrand factor; TMA: thrombotic microangiopathy; RBC: red blood cell.<br />* Primary TMAs include thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS), complement-mediated TMA, drug-induced TMA, coagulation-mediated TMA, and metabolism-mediated TMA.</div><div class=\"graphic_reference\">Courtesy of Stanley L. Schrier, MD</div><div id=\"graphicVersion\">Graphic 105380 Version 1.0</div></div></div>"},"105383":{"type":"graphic_table","displayName":"Basic rehab incomplete tension femoral neck stress fracture*","title":"Basic rehabilitation for uncomplicated incomplete tension side femoral neck stress fracture*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic rehabilitation for uncomplicated incomplete&nbsp;tension side femoral neck stress fracture*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Phase 1: Strict non-weight bearing:</td> </tr> <tr> <td class=\"indent1\">Patient is placed&nbsp;on strict bed rest for one to two weeks. This is followed by non-weight bearing on the injured extremity with ambulation using crutches for&nbsp;an additional four&nbsp;to eight weeks until patient is pain free, repeat plain radiographs are normal, and a hop test is negative.</td> </tr> <tr> <td class=\"subtitle1_single\">Phase 2: Walking:</td> </tr> <tr> <td class=\"indent1\">This continues for four weeks after completion of Phase 1. During this phase the patient is allowed to walk two miles up to two times per day. The patient may cross-train on a stationary bicycle, elliptical machine, or with pool running, but cross training must not exceed 45 minutes per day, and is not permitted if the patient develops any pain.</td> </tr> <tr> <td class=\"subtitle1_single\">Phase 3: Return to running:</td> </tr> <tr> <td class=\"indent1\"> <p><strong>Week 1:</strong> Patient may run up to 2 miles, but no more than four days per week</p> <p><strong>Week 2:</strong> Patient may run up to 2.5 miles up to five times per week</p> <p><strong>Week 3:</strong> Patient may run for 30 minutes up to six times per week</p> <strong>Week 4:</strong> Patient may run for 45 minutes up to six times per week</td> </tr> <tr> <td class=\"indent1\"> <p>If the return to running phase (phase 3)&nbsp;proceeds&nbsp;to completion&nbsp;without difficulty, the patient may resume full training. However, total mileage should not increase by more than 5 to 10 miles (8 to 15 km) over the mileage for week 4 above, and&nbsp;total running time should not increase by more than 30 minutes to one hour.</p> <p>Reevaluation is required if symptoms recur at any time.</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*This rehabilitation program is appropriate for patients with uncomplicated, incomplete, tension-side femoral neck fractures only. It is&nbsp;<STRONG>NOT</STRONG>&nbsp;appropriate for patients with fractures&nbsp;that&nbsp;extend&nbsp;beyond&nbsp;50 percent of the width of the femoral neck or that are complicated in any way. Patients with such fractures should be referred to an orthopedic surgeon.</div><div id=\"graphicVersion\">Graphic 105383 Version 3.0</div></div></div>"},"105384":{"type":"graphic_algorithm","displayName":"Approach to the management of patients with metastatic melanoma","title":"General approach to the management of patients with metastatic melanoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">General approach to the management of patients with metastatic melanoma</div><div class=\"cntnt\"><img style=\"width:324px; height:552px;\" src=\"images/ONC/105384_Mgmt_metastatc_melanm_edt1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm provides an overview of the management of patients with metastatic melanoma. For additional details, refer to other UpToDate content on the use of immune checkpoint inhibitors, molecularly targeted therapy, and surgery in patients with metastatic melanoma.</div><div class=\"graphic_footnotes\">PD: progressive disease.<br />* Including extent of metastatic disease, suitability for metastasectomy, performance status, and evaluation for the presence of a targetable driver mutation.<br />¶ Metastasectomy may have a role in eradicating residual disease for patients with a good response to initial systemic therapy.<br />Δ Nivolumab plus ipilimumab appears to have better efficacy (response rate and progression-free survival) than nivolumab alone. The increase in efficacy needs to be weighed against the potential increase in toxicity. In addition, more information is necessary to determine how the combination compares with single-agent anti-programmed cell death 1 (PD-1) followed by ipilimumab at PD or followed by BRAF/MEK inhibitors for patients with a V600 <EM>BRAF</EM> mutation.<br /><FONT class=lozenge>◊</FONT> High-dose interleukin-2 (IL-2) is an option for centers with appropriate expertise.<br />§ Whether these patients should receive immunotherapy or targeted therapy is unclear. Enrollment in a clinical trial (EA6134) comparing alternative sequences is preferred.</div><div id=\"graphicVersion\">Graphic 105384 Version 5.0</div></div></div>"},"105385":{"type":"graphic_table","displayName":"Basic rehab uncomplicated compression femoral neck fracture","title":"Basic rehabilitation program for uncomplicated incomplete compression side femoral neck stress fracture*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic rehabilitation program for uncomplicated incomplete compression side femoral neck stress fracture*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\"><strong>Phase 1: Rest phase</strong></td> </tr> <tr> <td class=\"indent1\"><strong>Weeks 1 to 2:</strong> Strict non-weight-bearing on affected lower extremity; patient to use crutches to ambulate.</td> </tr> <tr> <td class=\"indent1\"><strong>Weeks 3 to 4:</strong> Advance weight-bearing as tolerated, ensuring patient remains pain-free (if patient develops any pain with weight-bearing, extend the Rest Phase an additional 2 weeks [until pain-free with ambulation for 1 week]). Begin basic range-of-motion exercises.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Weekly plain radiographs should be obtained to monitor for fracture progression or non-union during the first 4 to 6 weeks, followed by bi-monthly radiographs, until the patient is 12 weeks out from presentation.</td> </tr> <tr> <td class=\"subtitle1_single\">Phase 2: Cross-training</td> </tr> <tr> <td class=\"indent1\"><strong>Weeks 5 to 6:</strong> Patient may gradually advance low-impact exercise, such as swimming, stationary cycling, and aqua-jogging. Begin proprioception exercises (eg, single-leg balance), light strength training, and continue range-of-motion exercises. Any exercise that causes pain should be stopped.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Weeks 7 to 8:</strong> Patient may gradually advance moderate-impact exercise, such as walking, elliptical machine, and stair-climber. Any exercise that causes pain should be stopped.</td> </tr> <tr> <td class=\"subtitle1_single\">Phase 3: Return to running</td> </tr> <tr> <td class=\"indent1\"><strong>Weeks 9:</strong> Patient begins running every other day. Start with quarter mile (0.4 km), and advance to 1 to 2 miles (1.6 to 3.2 km) per session by end of week. Begin lower extremity weight training. Limit total exercise (including cross-training and strength training) on affected lower extremity to 45 minutes per day. Patient must remain pain-free (or an additional 1 to 2 weeks is taken at the previous (pain-free) stage.</td> </tr> <tr> <td class=\"indent1\"><strong>Week 10:</strong> Continue running every other day. Begin with 15 to 20-minute running session, and gradually advance to 30-minute running session. Limit total exercise (including cross-training and strength training) on affected lower extremity to 60 minutes per day. Patient must remain pain-free or training regimen reverts to previous week.</td> </tr> <tr> <td class=\"indent1\"><strong>Week 11:</strong> Continue running every other day. Begin with 30-minute running session. For athletes/patients who are targeting high-mileage running, gradually advance to 40-minute running session. Limit total exercise (including cross-training and strength training) on affected lower extremity to 75 minutes per day. Running must be pain-free or training regimen reverts to previous week.</td> </tr> <tr> <td class=\"indent1\"><strong>Week 12:</strong> Continue running every other day. Begin with 40-minute running session; gradually advance to 50 minute session. Limit total exercise (including cross-training and strength training) on affected lower extremity to 80 minutes per day. Running must be pain free or training regimen reverts to previous week.</td> </tr> <tr> <td class=\"indent1\"><strong>Week 13:</strong> Continue running every other day. Begin week with 50-minute running session; may advance to one 60-minute session. Running must be pain free or training regimen reverts to previous week.</td> </tr> <tr> <td class=\"indent1\"><strong>Week 14:</strong> Patient runs 5 days this week, but limits sessions to 60 minutes or less. Total weekly running time should not exceed 180 minutes.</td> </tr> <tr> <td class=\"indent1\">If the return to running phase (Phase 3) proceeds to completion without return of symptoms, the patient may gradually resume full training. Total weekly mileage should not increase by more than 5 to 10 miles (8 to 15 km), and total weekly running time should not increase more than 1 hour.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*This rehabilitation program is appropriate for patients with uncomplicated, incomplete, compression-side femoral neck fractures only. It is <strong>NOT</strong> appropriate for patients with fractures that extend beyond 50% of the width of the femoral neck or that are complicated in any way. Patients with such fractures should be referred to an orthopedic surgeon.</div><div id=\"graphicVersion\">Graphic 105385 Version 4.0</div></div></div>"},"105386":{"type":"graphic_table","displayName":"Basic rehab uncomplicated femoral shaft stress fracture","title":"Basic rehabilitation program following uncomplicated femoral shaft stress fracture*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic rehabilitation program following uncomplicated femoral shaft stress fracture*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td><strong>Program typically begins after six weeks of rest following diagnosis of an uncomplicated, femoral shaft stress fracture. Patient may begin the basic phase of the program when he or she meets all the following criteria:</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Walks without pain </li> <li>Hop test is negative </li> <li>Can jog slowly without a limp </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>If the patient has biomechanical issues that require orthotics or other interventions, these should be addressed before resuming training.</td> </tr> <tr> <td class=\"subtitle1_single\">Phase 1: Rest</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Weeks 1 to 3:</strong> Patient should be non- or partial-weight bearing on the affected lower extremity (ie, use crutches). This phase may be bypassed in cases of femoral stress reaction (no radiographic fracture line) if the patient is completely pain-free with ambulation (ie, only develops pain with running).</td> </tr> <tr> <td class=\"subtitle1_single\">Phase 2: Cross-training</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Weeks 4 to 6:</strong> Resume full weight-bearing. May start swimming (and can transition to stationary bike) and general weight training, but no strength training of the affected extremity is permitted.</td> </tr> <tr> <td class=\"subtitle1_single\">Phase 3: Return to running</td> </tr> <tr> <td class=\"indent1\"><strong>Week 7:</strong> Patient begins jogging every other day. Patient jogs for 2 minutes and then walks for 1 minute, with a total duration not to exceed 21 minutes. Limited cross training with weights is permitted, and may include partial squats and lunges with moderate weight (approximately 40 to 60 lbs/20 to 30 kg for adults; no more than 30% of body weight). Knee flexion limited to 45 degrees with squats. Cross training using a stationary bicycle is permitted, but maximum time for aerobic exercise on any given day is 45 minutes.</td> </tr> <tr> <td class=\"indent1\"><strong>Week 8:</strong> Jogging 5 to 10 minutes followed by walking for 1 to 2 minutes, with a total duration not to exceed 30 minutes. This is performed every other day. Weight work and cross training are the same as week 7.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"><strong>Week 9:</strong> Jogging 10 to 15 minutes followed by walking for 4 to 5 minutes. This may be repeated once if the patient remains pain free (ie, maximum total jogging time of 30 minutes). This is performed up to four days during the week. Weight work and cross training are the same as week 7.</td> </tr> <tr> <td class=\"subtitle1_single\">Phase 4: Advance running<sup>​&#182;</sup></td> </tr> <tr> <td class=\"indent1\"><strong>Week 10:</strong> Jogging up to 30 minutes continuously, up to five days per week. Aerobic cross training allowed, but no more than 1 hour total of aerobic training daily. Weight work as above but may add 5 to 10 lbs/2 to 5 kg (approximately 5 to 10% of initial load) to the loads used. May add step up exercises to squats and lunges. Knee flexion for squats continues to be limited to 45 degrees.</td> </tr> <tr> <td class=\"indent1\"><strong>Week 11:</strong> Jogging up to 45 minutes continuously, up to five days per week. Cross training and weight work unchanged.</td> </tr> <tr> <td class=\"indent1\"><strong>Week 12:</strong> Jogging up to 45 minutes six days per week. Cross training and weight work unchanged.</td> </tr> <tr> <td class=\"indent1\"><strong>Week 13:</strong> If a patient completes the resumption phase through week 12 without complications, they may resume regular training on week 13. However, total mileage should not increase by more than 5 to 10 miles (8 to 15 km) over the mileage of week 12; total running time should not increase by more than 30 minutes to one hour.</td> </tr> <tr> <td class=\"indent1\">The hop test and fulcrum test are done at the end of each phase. If the patient is symptomatic, the patient should repeat that phase of rehabilitation.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* This rehabilitation program is appropriate for patients with uncomplicated, incomplete, femoral shaft stress fractures only. It is <strong>NOT</strong> appropriate for patients with fractures that extend beyond 50% of the width of the femoral shaft or that are complicated in any way. Patients with such fractures should be referred to an orthopedic surgeon.<br />&para; Elite runners, particularly those accustomed to training with high mileage, may be able to progress more quickly than the steps outlined here.</div><div id=\"graphicVersion\">Graphic 105386 Version 5.0</div></div></div>"},"105387":{"type":"graphic_algorithm","displayName":"LV ejection murmur algorithm","title":"Synthesizing cardiac examination findings in infants and children with murmurs: Systolic ejection murmur at the right upper sternal border","html":"<div class=\"graphic\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Synthesizing cardiac examination findings in infants and children with murmurs: Systolic ejection murmur at the right upper sternal border</div><div class=\"cntnt\"><img style=\"width:688px; height:664px;\" src=\"images/PEDS/105387_LV_ejection_murmur_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AS: aortic stenosis; S3: third heart sound; S4: fourth heart sound.</div><div id=\"graphicVersion\">Graphic 105387 Version 2.0</div></div></div>"},"105388":{"type":"graphic_figure","displayName":"Varicella cases before and after vaccine","title":"Varicella (chickenpox): Number* of reported cases – Illinois, Michigan, Texas, and West Virginia<SUP>[1]</SUP>, 1991-2013","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Varicella (chickenpox): Number* of reported cases – Illinois, Michigan, Texas, and West Virginia<SUP>[1]</SUP>, 1991-2013</div><div class=\"cntnt\"><img style=\"width:610px; height:390px;\" src=\"images/ID/105388_Vrcll_cases_bfre_after_vacc.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* In thousands.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Data from CDC. National Center for Immunization and Respiratory Diseases.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Adams D, Fullerton K, Jajosky R, et al. Summary of notifiable infectious diseases and conditions - United States, 2013. MMWR Morb Mortal Wkly Rep 2015; 62:1.</div><div id=\"graphicVersion\">Graphic 105388 Version 1.0</div></div></div>"},"105389":{"type":"graphic_algorithm","displayName":"RV ejection murmur algorithm","title":"Synthesizing cardiac examination findings in infants and children with murmurs: Systolic ejection murmur at the left upper sternal border","html":"<div class=\"graphic\"><div style=\"width: 780px\" class=\"figure\"><div class=\"ttl\">Synthesizing cardiac examination findings in infants and children with murmurs: Systolic ejection murmur at the left upper sternal border</div><div class=\"cntnt\"><img style=\"width:760px; height:816px;\" src=\"images/PEDS/105389_RV_ejection_murmur_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">PS: pulmonic stenosis; TOF: tetralogy of Fallot; ASD: atrial septal defect; AVM: arteriovenous malformation; PAPVC: partial anomalous pulmonary venous connection; TAPVC: total anomalous pulmonary venous connection; PPS: peripheral pulmonary stenosis; S2: second heart sound; RV: right ventricle; S3: third heart sound; S4: fourth heart sound; PDA: patent ductus arteriosus.<br />* Other causes of murmurs heard in this location include aortic or pulmonary regurgitation, PDA, cervical venous hum, and coronary artery fistula; however, the timing of the murmurs in these lesions distinguishes them from the lesions reviewed in this algorithm. Aortic and pulmonary regurgitation produce diastolic murmurs; PDA, cervical venous hum, and coronary artery fistula produce continuous murmurs.</div><div id=\"graphicVersion\">Graphic 105389 Version 3.0</div></div></div>"},"105390":{"type":"graphic_figure","displayName":"Extraperitoneal laparoscopic LND","title":"Extraperitoneal laparoscopic pelvic and paraaortic lymphadenectomy: Placement of ports","html":"<div class=\"graphic\"><div style=\"width: 596px\" class=\"figure\"><div class=\"ttl\">Extraperitoneal laparoscopic pelvic and paraaortic lymphadenectomy: Placement of ports</div><div class=\"cntnt\"><img style=\"width:576px; height:391px;\" src=\"images/ONC/105390_Extrprtnl_lprscpc_LND.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic illustrating port placement in the left flank. The lowermost port (10 mm) is located two fingerbreadths medial to, and three to six fingerbreadths superior to, the left anterior superior iliac spine. The remaining trocars are triangulated one finger's length from the initial incision. The second, more posterior trocar is 10 mm. The third, most cephalad 5 mm trocar is located just inferior to the costal margin.</div><div class=\"graphic_reference\">Reproduced from: Dowdy SC, Aletti G, Cilby WA, et al. Extra-peritoneal laparoscopic para-aortic lymphadenectomy - A prospective cohort study of 293 patients with endometrial cancer. Gynecol Oncol 2008; 111:418. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105390 Version 1.0</div></div></div>"},"105391":{"type":"graphic_algorithm","displayName":"VSD murmur algorithm","title":"Synthesizing cardiac examination findings in infants and children with murmurs: Holosystolic murmur at the left lower sternal border","html":"<div class=\"graphic\"><div style=\"width: 806px\" class=\"figure\"><div class=\"ttl\">Synthesizing cardiac examination findings in infants and children with murmurs: Holosystolic murmur at the left lower sternal border</div><div class=\"cntnt\"><img style=\"width:786px; height:526px;\" src=\"images/PEDS/105391_VSD_murmur_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">VSD: ventricular septal defect; LV: left ventricle; RV: right ventricle; S2: second heart sound; S3: third heart sound.<br />* Note that the intensity of the murmur is less helpful in characterizing VSDs than it is in characterizing many other lesions. Loud VSD murmurs (eg, grade 4) can be heard with large defects (due to large amount of left to right flow across the defect) and with small restrictive lesions (due to the large systolic pressure gradient between ventricles).<br />&#182; Innocent Still's murmur and tricuspid regurgitation can also be heard in this location and can be distinguished from VSD murmurs by the quality and timing of the murmur (VSD murmurs are harsh and holosystolic [although small muscular defects may produce early systolic murmurs]; Still's murmur has a vibratory or musical quality and occurs in early systole; the murmur of tricuspid regurgitation has a blowing quality and increases in intensity during inspiration). Other murmurs that may be heard in this location include semilunar valve regurgitation or tricuspid stenosis; however, these produce diastolic murmurs.<br />&#916; Small muscular defects may produce an early systolic murmur rather than a holosystolic murmur.</div><div id=\"graphicVersion\">Graphic 105391 Version 1.0</div></div></div>"},"105392":{"type":"graphic_figure","displayName":"Types of femoral neck stress fractures","title":"Types of femoral neck stress fractures","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Types of femoral neck stress fractures</div><div class=\"cntnt\"><img style=\"width:540px; height:277px;\" src=\"images/SM/105392_Typesoffemoralneckstressfractures.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The major types of femoral neck stress fractures are shown above. Tension-side fractures typically require surgery and immediate orthopedic consultation should be obtained.</div><div id=\"graphicVersion\">Graphic 105392 Version 2.0</div></div></div>"},"105393":{"type":"graphic_figure","displayName":"Retroperitoneal space","title":"Retroperitoneal space","html":"<div class=\"graphic\"><div style=\"width: 546px\" class=\"figure\"><div class=\"ttl\">Retroperitoneal space</div><div class=\"cntnt\"><img style=\"width:526px; height:574px;\" src=\"images/ONC/105393_Retroperitoneal_space.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Retroperitoneal dissection of paraaortic lymph nodes involved with metastatic ovarian cancer.</div><div class=\"graphic_reference\">Reproduced with permission from: Ramirez PT, Gershenson DM. Ovarian cancer. In: Te Linde's Operative Gynecology, 11th ed, Jones III HW, Rock JA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2015. Copyright © 2015 Wolters Kluwer. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105393 Version 1.0</div></div></div>"},"105394":{"type":"graphic_picture","displayName":"Retroperitoneal dissection","title":"Retroperitoneal dissection","html":"<div class=\"graphic\"><div style=\"width: 630px\" class=\"figure\"><div class=\"ttl\">Retroperitoneal dissection</div><div class=\"cntnt\"><img style=\"width:610px; height:425px;\" src=\"images/ONC/105394_Retroperitoneal_dissection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pelvic lymphadenectomy.</div><div class=\"graphic_reference\">Reproduced with permission from: Hoffman MS, Stickles XB. Malignancies of the vulva. In: Te Linde's Operative Gynecology, 11th ed, Jones III HW, Rock JA (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2015. Copyright © 2015 Wolters Kluwer. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105394 Version 1.0</div></div></div>"},"105395":{"type":"graphic_diagnosticimage","displayName":"Fetal lung mass and pleural effusion","title":"Left lower lobe high lung mass with moderate left pleural effusion","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Left lower lobe high lung mass with moderate left pleural effusion</div><div class=\"cntnt\"><img style=\"width:504px; height:336px;\" src=\"images/OBGYN/105395_Ftl_lng_mss_plrl_effs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Coronal and (B) sagittal T2w magnetic resonance images (MRI) at 23 weeks of gestation demonstrate a left lower lobe high lung mass with moderate left pleural effusion. Systemic vessel not well visualized by MRI.</div><div id=\"graphicVersion\">Graphic 105395 Version 1.0</div></div></div>"},"105396":{"type":"graphic_diagnosticimage","displayName":"Enlarging pleural effusion at 28 weeks of gestation","title":"Enlarging pleural effusion at 28 weeks of gestation","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Enlarging pleural effusion at 28 weeks of gestation</div><div class=\"cntnt\"><img style=\"width:400px; height:424px;\" src=\"images/OBGYN/105396_Enlrg_plrl_effsn_28_wk_gstt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial ultrasound at 28 weeks of gestation demonstrates an enlarging pleural effusion. The amniotic fluid volume is also increased.</div><div id=\"graphicVersion\">Graphic 105396 Version 1.0</div></div></div>"},"105397":{"type":"graphic_table","displayName":"Melanoma risk factors","title":"Risk factors for melanoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for melanoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"45%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Risk<br /> (given as relative risk [RR] with 95% CI unless indicated otherwise)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>Genotype</strong></td> <td>Xeroderma pigmentosum</td> <td>Approximately one in every five patients will develop melanoma<sup>[1]</sup></td> </tr> <tr> <td> <p>CDKN2A</p> Suspected in: <ul class=\"decimal_heading\"> <li>families with multiple melanomas or pancreatic cancer </li> </ul> </td> <td> <p>35- to 70-fold<sup>[2]</sup></p> 67% lifetime risk</td> </tr> <tr> <td>CDK4 (very rare)</td> <td>Significantly elevated<sup>[3]</sup></td> </tr> <tr> <td>BRCA2 &ndash; Familial breast and ovarian cancer</td> <td>2.58 (1.28-5.17)<sup>[4]</sup></td> </tr> <tr> <td> <p>MC1R</p> Suspected in: <ul class=\"decimal_heading\"> <li>Caucasians with red hair, freckling phenotype in family </li> </ul> </td> <td>2-3.5<sup>[2]</sup></td> </tr> <tr class=\"divider_bottom\"> <td> <p>OCA2</p> Suspected in: <ul class=\"decimal_heading\"> <li>Patients with a family history of albinism </li> </ul> </td> <td>Slightly increased risk, independent of phenotype</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Personal history of skin cancer</strong></td> <td>Melanoma</td> <td>1 to 8% of melanoma patients will be diagnosed with another melanoma<sup>[5]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Nonmelanoma skin cancer (including actinic damage)</td> <td>4.28 (2.80-6.55)<sup>[6]</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\"><strong>Family history</strong></td> <td>Any</td> <td>1.74 (1.41-2.14)<sup>[6]</sup></td> </tr> <tr> <td>Parent</td> <td> <p>2.40 (2.10-2.72)<sup>[7]</sup></p> <p>3.2 (2.6-3.9) for North American males<sup>[8]</sup>*</p> 4.4 (3.5-5.2) for North American females</td> </tr> <tr> <td>Sibling</td> <td> <p>2.98 (2.54-3.47)<sup>[7]</sup></p> <p>3.2 (2.6-3.9) for North American males<sup>[8]</sup></p> 4.4 (3.5-5.2) for North American females<sup>[8]</sup></td> </tr> <tr> <td>Two first-degree relatives</td> <td>8.92 (4.25-15.31)<sup>[7]</sup></td> </tr> <tr class=\"divider_bottom\"> <td>Parent with multiple primary melanomas</td> <td>61.78 (5.82-227.19)<sup>[7]</sup></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>Atypical nevi<sup>[9]</sup></strong></td> <td>0</td> <td>1.00</td> </tr> <tr> <td>1</td> <td>1.45 (1.31-1.60)</td> </tr> <tr> <td>2</td> <td>2.10 (1.71-2.54)</td> </tr> <tr> <td>3</td> <td>3.03 (2.23-4.06)</td> </tr> <tr> <td>4</td> <td>4.39 (2.91-6.47)</td> </tr> <tr class=\"divider_bottom\"> <td>5</td> <td>6.36 (3.80-10.33)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\"><strong>Common nevi<sup>[9]</sup></strong></td> <td>0 to 15</td> <td>1.00</td> </tr> <tr> <td>16 to 40</td> <td>1.47 (1.36-1.59)</td> </tr> <tr> <td>41 to 60</td> <td>2.24 (1.90-2.64)</td> </tr> <tr> <td>61 to 80</td> <td>3.26 (2.55-4.15)</td> </tr> <tr> <td>81 to 100</td> <td>4.74 (3.44-6.53)</td> </tr> <tr class=\"divider_bottom\"> <td>101 to 120</td> <td>6.89 (4.63-10.25)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Phenotypic traits<sup>[6]</sup></td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"3\">Hair color</td> <td>Red versus dark</td> <td>3.64 (2.56-5.37)</td> </tr> <tr> <td>Blond&nbsp;versus dark</td> <td>1.96 (1.41-2.74)</td> </tr> <tr class=\"divider_bottom\"> <td>Light brown&nbsp;versus dark</td> <td>1.62 (1.11-2.34)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Freckles</td> <td>High&nbsp;versus low density</td> <td>2.10 (1.80-2.45)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Eye color</td> <td>Light (green, hazel, blue)&nbsp;versus dark</td> <td>Approximately 1.5</td> </tr> <tr> <td rowspan=\"4\"><strong>Sun exposure</strong></td> <td>Intermittent</td> <td>2.35 (1.78-3.09)<sup>[6]</sup></td> </tr> <tr> <td>Chronic</td> <td>0.98 (0.85-1.12)</td> </tr> <tr> <td>Sunburn history</td> <td>2.02 (1.73-2.34)</td> </tr> <tr> <td>Tanning salon</td> <td>Ever&nbsp;versus never, 1.15 (1.00-1.31)<sup>[10]</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Estimates are for cases of familial melanoma.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Kraemer KH, Lee MM, Andrews AD, Lambert WC. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. The xeroderma pigmentosum paradigm. Arch Dermatol 1994; 130:1018.</li>&#xD;&#xA;    <li>High WA, Robinson WA. Genetic mutations involved in melanoma: a summary of our current understanding. Adv Dermatol 2007; 23:61.</li>&#xD;&#xA;    <li>Goldstein AM, Struewing JP, Chidambaram A, et al. Genotype-phenotype relationships in U.S. melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000; 92:1006.</li>&#xD;&#xA;    <li>Easton D, The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91:1310.</li>&#xD;&#xA;    <li>Stam-Posthuma JJ, van Duinen C, Scheffer E, et al. Multiple primary melanomas. J Am Acad Dermatol 2001; 44:22.</li>&#xD;&#xA;    <li>Gandini S, Sera F, Cattaruzza MS, et al. Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005; 41:2040.</li>&#xD;&#xA;    <li>Hemminki K, Zhang H, Czene K. Familial and attributable risks in cutaneous melanoma: effects of proband and age. J Invest Dermatol 2003; 120:217.</li>&#xD;&#xA;    <li>Begg CB, Hummer A, Mujumdar U, et al. Familial aggregation of melanoma risks in a large population-based sample of melanoma cases. Cancer Causes Control 2004; 15:957.</li>&#xD;&#xA;    <li>Swerdlow AJ, English J, MacKie RM, et al. Benign melanocytic naevi as a risk factor for malignant melanoma. Br Med J (Clin Res Ed) 1986; 292:1555.</li>&#xD;&#xA;    <li>The International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: a systematic review. Int J Cancer 2007; 120:1116.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Psaty EL, Scope A, Halpern AC, Marghoob AA. Defining the patient at high risk for melanoma. Int J Dermatol 2010; 49:362. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1365-4632.2010.04381.x/abstract\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/j.1365-4632.2010.04381.x/abstract</a>. Copyright &copy; 2010 The International Society of Dermatology. Reproduced with permission of John Wiley &amp; Sons, Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared, or emailed. Please contact Wiley's Permissions Department either via email: <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true\" trget=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<a href=\"http://www.onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">www.onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 105397 Version 1.0</div></div></div>"},"105398":{"type":"graphic_diagnosticimage","displayName":"Systemic feeding vessel to fetal lung mass","title":"Systemic feeding vessel to fetal lung mass","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Systemic feeding vessel to fetal lung mass</div><div class=\"cntnt\"><img style=\"width:392px; height:413px;\" src=\"images/OBGYN/105398_Systmc_fd_vssl_ftl_lng_mss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal ultrasound image demonstrates a systemic feeding vessel to fetal lung mass. Thoracoamniotic shunt was placed at 29 weeks of gestation. Following delivery at 33 weeks of gestation due to premature labor, the mass was resected due to respiratory distress.</div><div class=\"graphic_footnotes\">LT: left.</div><div id=\"graphicVersion\">Graphic 105398 Version 2.0</div></div></div>"},"105400":{"type":"graphic_picture","displayName":"Pediculosis capitis excoriations","title":"Pediculosis capitis","html":"<div class=\"graphic\"><div style=\"width: 494px\" class=\"figure\"><div class=\"ttl\">Pediculosis capitis</div><div class=\"cntnt\"><img style=\"width:474px; height:712px;\" src=\"images/DERM/105400_Pdclsscptsexcrtn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple excoriations and crusts on the posterior neck in a patient with pediculosis capitis.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright © 2015 Scott Camazine, MD, PhD. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105400 Version 3.0</div></div></div>"},"105402":{"type":"graphic_figure","displayName":"Phases of damage control","title":"Phases of damage control","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Phases of damage control</div><div class=\"cntnt\"><img style=\"width:292px; height:318px;\" src=\"images/SURG/105402_Phases_damage_control.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">DC: damage control.<br />* May require multiple, separate operative interventions.<br />&para; Only needed in cases where definitive soft tissue/fascial closure cannot be obtained during DC-III.</div><div class=\"graphic_reference\">Adapted from: Johnson JW, Gracias VH, Schwab CW, et al. Evolution in damage control for exsanguinating penetrating abdominal injury. J Trauma 2001; 51:261.</div><div id=\"graphicVersion\">Graphic 105402 Version 1.0</div></div></div>"},"105403":{"type":"graphic_picture","displayName":"Severe solid organ injury ","title":"Severe solid organ injury ","html":"<div class=\"graphic\"><div style=\"width: 631px\" class=\"figure\"><div class=\"ttl\">Severe solid organ injury </div><div class=\"cntnt\"><img style=\"width:611px; height:366px;\" src=\"images/SURG/105403_Grd_4_rnl_splnc_lcrtn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pictures show severe solid organ injury: a grade IV renal laceration (A), and a grade IV splenic laceration (B). For hemodynamically unstable patients with multiple severe injuries, damage control surgery supports rapid removal of severely injured, nonessential organs rather than prolonged attempts at salvage that would otherwise contribute to further physiologic deterioration.</div><div id=\"graphicVersion\">Graphic 105403 Version 1.0</div></div></div>"},"105404":{"type":"graphic_picture","displayName":"Vascular damage control with temporary shunts","title":"Vascular damage control with temporary shunts in the proximal radial and ulnar artery","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Vascular damage control with temporary shunts in the proximal radial and ulnar artery</div><div class=\"cntnt\"><img style=\"width:640px; height:480px;\" src=\"images/SURG/105404_Vscl_dmg_cntrl_tmp_shnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The picture shows vascular shunts placed into the proximal right radial and ulnar arteries just distal to the bifurcation of the brachial artery. The shunts allow ongoing perfusion to the distal upper extremity until definitive repair of the vascular injury can be performed.</div><div id=\"graphicVersion\">Graphic 105404 Version 1.0</div></div></div>"},"105405":{"type":"graphic_picture","displayName":"Damage control closure of the abdominal wall","title":"Damage control closure of the abdominal wall","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Damage control closure of the abdominal wall</div><div class=\"cntnt\"><img style=\"width:514px; height:403px;\" src=\"images/SURG/105405_Dmg_cntrl_clsr_abdmnl_wll.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Temporary closure of the abdominal wall uses a dressing that allows for rapid re-entry, while providing an avenue for efflux of abdominal fluid and protecting the viscera.</div><div id=\"graphicVersion\">Graphic 105405 Version 1.0</div></div></div>"},"105406":{"type":"graphic_picture","displayName":"Orthopedic damage control","title":"Orthopedic damage control","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Orthopedic damage control</div><div class=\"cntnt\"><img style=\"width:715px; height:427px;\" src=\"images/SURG/105406_Orthpdc_dmg_cntrl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Following open extremity fracture, damage control surgery may include placement of an external fixation device to provide rapid bony stabilization. Definitive extremity reconstruction is performed at a later time once other life-threatening injuries have been managed.</div><div id=\"graphicVersion\">Graphic 105406 Version 1.0</div></div></div>"},"105408":{"type":"graphic_picture","displayName":"Confluent and reticulated papillomatosis on back","title":"Confluent and reticulated papillomatosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Confluent and reticulated papillomatosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/105408_Cnflnt_rtclt_ppllmts_bck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented, reticulated plaques with fine scale on the back.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105408 Version 1.0</div></div></div>"},"105409":{"type":"graphic_picture","displayName":"Confluent and reticulated papillomatosis on face","title":"Confluent and reticulated papillomatosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Confluent and reticulated papillomatosis</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/105409_Cnflnt_rtcl_ppllmts_fc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented, reticulated plaques on the face.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105409 Version 1.0</div></div></div>"},"105410":{"type":"graphic_picture","displayName":"Confluent and reticulated papillomatosis in groin area","title":"Confluent and reticulated papillomatosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Confluent and reticulated papillomatosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/105410_Cnflnt_rtcl_ppllmts_grn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented, reticulated plaques on the pubic area and proximal thighs.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105410 Version 1.0</div></div></div>"},"105411":{"type":"graphic_picture","displayName":"Confluent and reticulated papillomatosis on flexural skin","title":"Confluent and reticulated papillomatosis","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Confluent and reticulated papillomatosis</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/105411_Cnflnt_rtclt_ppllmts_flxrl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Hyperpigmented, reticulated plaques in the antecubital folds and axillary area.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105411 Version 1.0</div></div></div>"},"105412":{"type":"graphic_figure","displayName":"Molecular pathways in head and neck squamous carcinoma","title":"Molecular pathways in head and neck squamous carcinoma","html":"<div class=\"graphic\"><div style=\"width: 890px\" class=\"figure\"><div class=\"ttl\">Molecular pathways in head and neck squamous carcinoma</div><div class=\"cntnt\"><img style=\"width:870px; height:636px;\" src=\"images/ONC/105412_Molecular_pathwys_head_neck.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Deregulation of signaling pathways and transcription factors for n = 279 samples. The frequency (%) of genetic alterations for HPV(&ndash;) and HPV(+) tumors are shown separately within sub-panels and highlighted.</div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Nature. Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517:576. Copyright &copy; 2015. <a href=\"http://www.nature.com/nature\" target=\"_blank\">www.nature.com/nature</a>.</div><div id=\"graphicVersion\">Graphic 105412 Version 1.0</div></div></div>"},"105413":{"type":"graphic_picture","displayName":"Circumferential urethral prolapse","title":"Circumferential urethral prolapse","html":"<div class=\"graphic\"><div style=\"width: 664px\" class=\"figure\"><div class=\"ttl\">Circumferential urethral prolapse</div><div class=\"cntnt\"><img style=\"width:644px; height:717px;\" src=\"images/EM/105413_Circumfrntlurthrlprolapse.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This young girl developed urethral prolapse, manifesting with the characteristic doughnut sign, demonstrated here as a swollen round tissue with a central dimple that is smooth and friable.</div><div class=\"graphic_reference\">Reproduced with permission from: Fleisher GR. Genitourinary emergencies. In: Atlas of Pediatric Emergency Medicine, Fleisher GR, Ludwig S, Baskin MN (Eds), Lippincott Williams &amp; Wilkins 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 105413 Version 3.0</div></div></div>"},"105414":{"type":"graphic_picture","displayName":"Sarcoma botryoides of the distal urethra","title":"Sarcoma botryoides of the distal urethra","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Sarcoma botryoides of the distal urethra</div><div class=\"cntnt\"><img style=\"width:468px; height:478px;\" src=\"images/EM/105414_Sarcmbotryoidesdstlurthr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The botryoid variant of embryonal&nbsp;RMS (sarcoma botryoides) takes its name from the \"grape-like\" gross appearance of the tumor. The botryoid variant typically arises within the wall of the bladder or vagina and is seen almost exclusively in infants. </div><div class=\"graphic_footnotes\">RMS: rhabdomyosarcoma.</div><div class=\"graphic_reference\">Reproduced with permission from: Emans SJ. Vulvovaginal problems in the prepubertal child. In: Emans, Laufer, and Goldstein's Pediatric and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright © 2011 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105414 Version 2.0</div></div></div>"},"105415":{"type":"graphic_table","displayName":"Normal values WBC and ANC child","title":"Normal values for white blood count and absolute neutrophil count in neonates and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal values for white blood count and absolute neutrophil count in neonates and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Age</td> <td class=\"subtitle1\">WBC (cells/microL)</td> <td class=\"subtitle1\">ANC (cells/microL)</td> <td class=\"subtitle1\">Percent neutrophils (approximate)</td> </tr> <tr class=\"divider_bottom\"> <td>Fetus &#62;30 weeks</td> <td>7710<br /> (range 2720 to 12,700)</td> <td>&nbsp;</td> <td>23% of nucleated cells including nucleated RBCs</td> </tr> <tr class=\"divider_bottom\"> <td>Birth</td> <td>18,100<br /> (range 9000 to 30,000)</td> <td>11,000<br /> (range 6000 to 26,000)</td> <td>61% of WBCs</td> </tr> <tr class=\"divider_bottom\"> <td>24 hours</td> <td>18,900<br /> (range 9000 to 34,000)</td> <td>11,500<br /> (range 5000 to 21,000)</td> <td>61% of WBCs</td> </tr> <tr class=\"divider_bottom\"> <td>1 week</td> <td>12,200<br /> (range 5000 to 21,000)</td> <td>5500<br /> (range 1500 to 10,000)</td> <td>45% of WBCs</td> </tr> <tr class=\"divider_bottom\"> <td>1 month</td> <td>10,800<br /> (range 5000 to 19,500)</td> <td>3800<br /> (range 1000 to 9000)</td> <td>35% of WBCs</td> </tr> <tr class=\"divider_bottom\"> <td>1 year</td> <td>11,400<br /> (range 6000 to 17,500)</td> <td>3500<br /> (range 1500 to 8500)</td> <td>31% of WBCs</td> </tr> <tr> <td>10 years</td> <td>8100<br /> (range 4500 to 13,500)</td> <td>4400<br /> (range 1800 to 8000)</td> <td>54% of WBCs</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate content on neutropenia in children for information about causes of neutropenia and appropriate interventions, and an ANC calculator. Percent neutrophils depends on the percentages of other cells, and ANC should always be used when evaluating neutropenia; this value is presented only as a guide.</div><div class=\"graphic_footnotes\">WBC: white blood cell count; ANC: absolute neutrophil count; RBCs: red blood cells.</div><div class=\"graphic_reference\">Adapted from Orkin SH, Nathan DG, Ginsburg D, et al. Nathan and Oski's Hematology of Infancy and Childhood, 7th Edition, Saunders, Philadelphia 2009.</div><div id=\"graphicVersion\">Graphic 105415 Version 1.0</div></div></div>"},"105416":{"type":"graphic_picture","displayName":"US transducer position medial patellofemoral ligament long axis","title":"US transducer position to view medial patellofemoral ligament in long axis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US transducer position to view medial patellofemoral ligament in long axis</div><div class=\"cntnt\"><img style=\"width:428px; height:710px;\" src=\"images/SM/105416_US_trnsdcr_pst_mdl_ptllfm_lgm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows the position of the ultrasound transducer and patient&nbsp;for obtaining&nbsp;images of&nbsp;the medial patellofemoral ligament in its long axis.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105416 Version 1.0</div></div></div>"},"105417":{"type":"graphic_diagnosticimage","displayName":"US lateral patellar retinaculum","title":"US lateral patellar retinaculum","html":"<div class=\"graphic\"><div style=\"width: 808px\" class=\"figure\"><div class=\"ttl\">US lateral patellar retinaculum</div><div class=\"cntnt\"><img style=\"width:788px; height:306px;\" src=\"images/SM/105417_US_ltrl_ptllr_rtnclm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows the&nbsp;lateral patellar retinaculum in long-axis.</div><div class=\"graphic_footnotes\">Arrowheads: lateral patellar retinaculum; *: lateral recess of knee joint.<br />Left of the screen: lateral; right of the screen: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105417 Version 1.0</div></div></div>"},"105419":{"type":"graphic_algorithm","displayName":"Decision tree elderly patients with metastatic prostate ca","title":"A decision tree for treating elderly patients with metastatic prostate cancer","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">A decision tree for treating elderly patients with metastatic prostate cancer</div><div class=\"cntnt\"><img style=\"width:598px; height:364px;\" src=\"images/ONC/105419_Dcsn_tree_eldrly_prostat_ca.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CISR-G: Cumulative Illness Score Rating for Geriatrics; IADL: instrumental activities of daily living; ADL: activities of daily living.</div><div class=\"graphic_reference\">From: Droz JP, Balducci L, Bolla M, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010; 106:462. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2010.09334.x/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2010.09334.x/abstract</a>. Copyright &copy; 2009 BJU International. Reproduced with permission of John Wiley &amp; Sons, Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared, or emailed. Please contact Wiley's Permissions Department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<a href=\"http://www.onlinelibrary.wiley.com/\" target=\"_blank\">www.onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 105419 Version 1.0</div></div></div>"},"105420":{"type":"graphic_algorithm","displayName":"Decision tree localized prostate cancer elderly","title":"A decision tree for treating elderly patients with localized prostate cancer","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">A decision tree for treating elderly patients with localized prostate cancer</div><div class=\"cntnt\"><img style=\"width:598px; height:348px;\" src=\"images/ONC/105420_Dcsn_tree_lclzd_prostat_ca.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CISR-G: Cumulative Illness Score Rating for Geriatrics; IADL: instrumental activities of daily living; ADL: activities of daily living.</div><div class=\"graphic_reference\">From: Droz JP, Balducci L, Bolla M, et al. Management of prostate cancer in older men: recommendations of a working group of the International Society of Geriatric Oncology. BJU Int 2010; 106:462. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2010.09334.x/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.2010.09334.x/abstract</a>. Copyright &copy; 2009 BJU International. Reproduced with permission of John Wiley &amp; Sons, Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared, or emailed. Please contact Wiley's Permissions Department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<a href=\"http://www.onlinelibrary.wiley.com/\" target=\"_blank\">www.onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 105420 Version 1.0</div></div></div>"},"105421":{"type":"graphic_diagnosticimage","displayName":"Femoral neck stress fracture in a 31-year-old female runner","title":"Femoral neck stress fracture in a 31-year-old female marathon runner","html":"<div class=\"graphic\"><div style=\"width: 783px\" class=\"figure\"><div class=\"ttl\">Femoral neck stress fracture in a 31-year-old female marathon runner</div><div class=\"cntnt\"><img style=\"width:763px; height:559px;\" src=\"images/SM/105421_Femoral_neck_stress_fractre.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Femoral neck stress fracture in a 31-year-old female marathon runner.<br />(A) Anteroposterior radiograph shows subtle sclerosis at the site of an incomplete nondisplaced midcervical fracture of the femoral neck (arrow).<br />(B) T1-weighted MR image confirms the fracture line involving the femoral neck (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Cooley M, Azevedo D, Palmer W. Radiographic evaluation of the hip. In: The Adult Hip: Hip Arthroplasty Surgery, 3rd ed, Callaghan JJ, Rosenberg AG, Rubash HE, et al (Eds), Wolters Kluwer, Philadelphia 2016. Copyright © 2016 Wolters Kluwer. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105421 Version 1.0</div></div></div>"},"105423":{"type":"graphic_diagnosticimage","displayName":"MRI of right femoral neck stress fracture in 38-year-old woman","title":"MRI of a right femoral neck stress fracture in a 38-year-old woman with right hip pain","html":"<div class=\"graphic\"><div style=\"width: 622px\" class=\"figure\"><div class=\"ttl\">MRI of a right femoral neck stress fracture in a 38-year-old woman with right hip pain</div><div class=\"cntnt\"><img style=\"width:602px; height:427px;\" src=\"images/SM/105423_Rfmlnkstrsfctr38yowmn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right femoral neck stress fracture in a 38-year-old woman with right hip pain.<br />(A) Coronal T1-weighted image (FSE 450/9) shows a low signal intensity region in the medial femoral neck with a very low signal intensity area immediately adjacent to the medial cortex.<br />(B) Coronal fat-saturated T2-weighted image (FSE 4300/90) shows matching high signal intensity bone marrow edema surrounding the low signal intensity stress fracture. The stress fracture was occult on conventional radiographs.</div><div class=\"graphic_reference\">Reproduced with permission from: Murphy WA, Vogler III JB. Diffuse marrow diseases. In: MRI of the Musculoskeletal System, 6th ed, Berquist TH (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 105423 Version 1.0</div></div></div>"},"105424":{"type":"graphic_diagnosticimage","displayName":"MRI medial femoral (compressive) neck stress fracture","title":"MRI of medial femoral (compressive) neck stress fracture","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">MRI of medial femoral (compressive) neck stress fracture</div><div class=\"cntnt\"><img style=\"width:583px; height:347px;\" src=\"images/SM/105424_Medialfmrlcmpnkstsfrctr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the MRI images above, the coronal T1-weighted image (A) shows a large area of edema medially (arrow), while the fast spin-echo T2-weighted image (B) demonstrates edema and a low intensity fracture line (arrowhead).</div><div class=\"graphic_reference\">Reproduced with permission from: Berquist TH. Pelvis, hips, and thigh. In: MRI of the Musculoskeletal System, 6th ed, Berquist TH (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 105424 Version 1.0</div></div></div>"},"105425":{"type":"graphic_diagnosticimage","displayName":"Plain radiograph and bone scan stress fracture femoral neck","title":"Plain radiograph and bone scan of a stress fracture of the femoral neck","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Plain radiograph and bone scan of a stress fracture of the femoral neck</div><div class=\"cntnt\"><img style=\"width:766px; height:519px;\" src=\"images/SM/105425_Stress_fractre_Proxml_femur.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Stress fractures of the femoral neck are a frequent complication of osteoporosis and are also found in&nbsp;long distance&nbsp;runners.<br />(A) AP Hip. Note that the stress fracture can be appreciated by the radiopaque transverse band, which is present in the area of the femoral neck (arrow).<br />(B) Bone scan, hip. Observe the focal area of increased radionuclide uptake in the area of the stress fracture of the femoral neck (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Rowe LJ, Yochum TR, Maola CJ. Trauma. In: Yochum and Rowe's Essentials of Skeletal Radiology, 3rd ed, Yochum TR, Rowe LJ (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. Copyright © 2005 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105425 Version 2.0</div></div></div>"},"105426":{"type":"graphic_diagnosticimage","displayName":"Hamate fracture - Oblique view","title":"Hamate fracture: Oblique view","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Hamate fracture: Oblique view</div><div class=\"cntnt\"><img style=\"width:716px; height:592px;\" src=\"images/SM/105426_HamatefractureObliquevw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">On the pronated oblique view of the wrist shown above, a fracture of the hamate body is clearly evident (arrow).</div><div class=\"graphic_reference\">Reproduced with permission from: Upper limb III: Distal forearm, wrist, and hand. In: Orthopedic Imaging: A Practical Approach, 6th ed, Greenspan A, Beltran J (Eds), Wolters Kluwer Health, Philadelphia 2015. Copyright &copy; 2015 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 105426 Version 1.0</div></div></div>"},"105427":{"type":"graphic_diagnosticimage","displayName":"CT of hook of hamate fracture","title":"CT of a fracture of the hook of the hamate","html":"<div class=\"graphic\"><div style=\"width: 489px\" class=\"figure\"><div class=\"ttl\">CT of a fracture of the hook of the hamate</div><div class=\"cntnt\"><img style=\"width:469px; height:761px;\" src=\"images/SM/105427_CTfracturehookhamate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Axial CT image of the wrist shows a fracture of the hook of the hamate (arrow).<br />(B) Axial CT image of an intact hook is shown for comparison.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reproduced with permission from: Upper limb III: Distal forearm, wrist, and hand. In: Orthopedic Imaging: A Practical Approach, 6th ed, Greenspan A, Beltran J (Eds), Wolters Kluwer Health, Philadelphia 2015. Copyright &copy; 2015 Wolters Kluwer Health.</div><div id=\"graphicVersion\">Graphic 105427 Version 1.0</div></div></div>"},"105428":{"type":"graphic_diagnosticimage","displayName":"Clinical anatomy in region of hamate hook","title":"Clinical anatomy in the region of the hook of the hamate ","html":"<div class=\"graphic\"><div style=\"width: 666px\" class=\"figure\"><div class=\"ttl\">Clinical anatomy in the region of the hook&nbsp;of the hamate&nbsp;</div><div class=\"cntnt\"><img style=\"width:646px; height:732px;\" src=\"images/SM/105428_Excisionhamatehookfractr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The image above shows the bones, major ligaments, and ulnar nerve and artery in the vicinity of the hook of the hamate. The ulnar nerve and artery travel distally into the wrist, ulnar and superficial to the hamate hook.</div><div class=\"graphic_reference\">Reproduced with permission from: Means KR, Graham TJ. Surgical treatment of carpal bone fractures, excluding the scaphoid. In: Operative Techniques in Hand, Wrist, and Forearm Surgery, Hunt TR, Kozin SH, Wiesel SW (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 105428 Version 1.0</div></div></div>"},"105430":{"type":"graphic_diagnosticimage","displayName":"MRI and sagittal CT of occult hamate fracture","title":"MRI and sagittal CT of occult hamate fracture in a golfer with chronic wrist pain","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">MRI and sagittal CT of occult hamate fracture in a golfer with chronic wrist pain</div><div class=\"cntnt\"><img style=\"width:762px; height:610px;\" src=\"images/SM/105430_Oclthmtfrctglfchcwtpn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The MRI images above show an occult hamate fracture in a golfer with chronic wrist pain. There is marrow edema (arrows) on both the axial T1W image (A) and the axial T2W fat saturation image (B) in the hook of hamate. The sagittal CT image&nbsp;(C) confirms the diagnosis of a fracture (dashed arrow).</div><div class=\"graphic_footnotes\">H: hamate; MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Campbell RSD, Harris JH Jr. Wrist. In: Harris &amp; Harris' The Radiology of Emergency Medicine, 5th ed, Pope TL Jr, Harris JH Jr (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins.</div><div id=\"graphicVersion\">Graphic 105430 Version 1.0</div></div></div>"},"105431":{"type":"graphic_table","displayName":"Varicella vaccine contraindications and precautions","title":"Contraindications and precautions for varicella vaccine","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Contraindications and precautions for varicella vaccine</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Contraindications</td> </tr> <tr> <td class=\"indent1\">Severe allergic reaction (eg, anaphylaxis) after a previous dose of varicella vaccine or to a varicella vaccine component (eg, neomycin, gelatin)</td> </tr> <tr> <td class=\"indent1\">Pregnancy or possibility of pregnancy within 4 weeks</td> </tr> <tr> <td class=\"indent1\"><strong>Severe</strong> immunosuppression due to: <ul class=\"decimal_heading\"> <li>Solid tumors and hematologic malignancies (eg, blood dyscrasia, leukemia, lymphoma, malignant neoplasms affecting the bone marrow or lymphatic system) </li> <li>Current receipt of chemotherapy </li> <li>Immunosuppressive agents administered to patients who have undergone solid organ or hematopoietic stem cell transplant </li> <li>Biologic agents for autoimmune conditions (eg, IL-1 receptor antagonists [eg, anakinra], tumor necrosis factor-alpha inhibitors [eg, etanercept, infliximab, adalimumab], and anti-CD20 agents [eg, rituximab]) </li> <li>Congenital or acquired T-lymphocyte immunodeficiency* </li> <li>HIV infection (HIV-infected patients without severe immunosuppression may receive varicella vaccine)<sup>&#182;</sup> </li> <li>Long-term high-dose systemic glucocorticoids (ie, &#8805;2 weeks of prednisone &#8805;20 mg per day or prednisone &#8805;2 mg/kg per day [for children who weigh &#60;10 kg] or equivalent) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Untreated active tuberculosis</td> </tr> <tr> <td class=\"subtitle1_single\">Precautions<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Varicella vaccination should be deferred in patients at risk for congenital or hereditary immunodeficiency (ie, parent or sibling with hereditary immunodeficiency) until the immunocompetence of the potential vaccinee is clinically substantiated or verified with laboratory testing</td> </tr> <tr> <td class=\"indent1\">Salicylate therapy</td> </tr> <tr> <td class=\"indent1\">Personal history of seizures or seizures in sibling or parent (this a precaution for MMRV, but not for single-antigen varicella vaccine)</td> </tr> <tr> <td class=\"indent1\">Receipt of antibody-containing blood product within past 3 to 11 months<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent1\">Concomitant antiviral therapy with acyclovir, valacyclovir, or famciclovir (may interfere with varicella vaccine; antiviral therapy should be discontinued &#8805;24 hours before administration of varicella vaccine and avoided for 14 days after vaccination)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Moderate or severe illness with or without fever (ie, illness more severe than upper respiratory infection, otitis media, gastroenteritis)</td> </tr> <tr> <td class=\"subtitle1_single\">Conditions commonly misperceived as contraindications that are not contraindications to varicella vaccine</td> </tr> <tr> <td class=\"indent1\">HIV infection without severe immunosuppression<sup>&#182;</sup> (this is not a contraindication to varicella vaccine, but is a contraindication to MMRV, which contains &#8805;7-fold VZV than single-antigen varicella vaccine)</td> </tr> <tr> <td class=\"indent1\">B-lymphocyte (humoral) immunodeficiency (eg, agammaglobulinemia) or congenital complement deficiencies</td> </tr> <tr> <td class=\"indent1\">Breastfeeding</td> </tr> <tr> <td class=\"indent1\">Pregnant contact<sup>&#167;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Immunocompromised&nbsp;family member or household contact<sup>&#167;</sup></td> </tr> <tr> <td class=\"subtitle1_single\">Conditions commonly misperceived as contraindications that are not contraindications to ANY vaccine</td> </tr> <tr> <td class=\"indent1\">Mild acute illness with or without fever (eg, upper respiratory infection, otitis media, gastroenteritis)</td> </tr> <tr> <td class=\"indent1\">Mild-to-moderate local reaction (eg, swelling, redness, soreness) after previous dose</td> </tr> <tr> <td class=\"indent1\">Low-grade or moderate fever after previous dose</td> </tr> <tr> <td class=\"indent1\">Current antibiotic therapy</td> </tr> <tr> <td class=\"indent1\">Convalescent phase of illness</td> </tr> <tr> <td class=\"indent1\">Preterm birth (except for hepatitis B vaccine in infants who weigh &#60;2000 g and whose mother is hepatitis B surface antigen negative at the time of birth)</td> </tr> <tr> <td class=\"indent1\">Recent exposure to infectious disease</td> </tr> <tr> <td class=\"indent1\">History of penicillin allergy, other nonvaccine allergies, relatives with allergies, or receiving allergen extract immunotherapy</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; MMRV: measles, mumps, rubella, varicella combination vaccine.<br />* Refer to UpToDate topic on medical management of immunodeficiency for definitions of severe immunodeficiency in specific disorders.<br />¶ Refer to UpToDate topic on immunizations in HIV-infected patients for definition of severe immunosuppression in HIV infection.<br />Δ Precautions are conditions that may increase the risk of adverse reactions, diminish the immune response, or make it difficult to differentiate between a clinical manifestation of the condition and a vaccine adverse effect. When precautions are present, the risks and benefits of immunization (versus postponing the immunization) should be considered on a case-by-case basis.<br /><FONT class=lozenge>◊</FONT> The specific interval depends upon the product. Refer to UpToDate topic on vaccination for the prevention of primary varicella infection for details.<br />§ If vaccinee develops a presumed vaccine-related rash after vaccination, the vacinee should avoid direct contact with immunocompromised persons and susceptible pregnant women&nbsp;for the duration of the rash.</div><div class=\"graphic_reference\">Data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>American Academy of Pediatrics. Varicella-zoster virus infections. In: Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed, Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2015. p.846.</LI>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. Varicella. In: Epidemiology and Prevention of Vaccine-Preventable Diseases. The Pink Book: Course Textbook, 13th ed, Hamborsky J, Kroger A, Wolfe S, (Eds). Public Health Foundation, Washington, DC 2015. <A spellcheck=true href=\"http://www.cdc.gov/vaccines/pubs/pinkbook/index.html\" target=_blank>www.cdc.gov/vaccines/pubs/pinkbook/index.html</A> (Accessed on July 09, 2015).</LI>&#xD;&#xA;<LI>Kroger AT, Duchin J, Vázquez M. General best practice guidelines for immunization. Best practices guidance of the Advisory Committee on Immunization Practices (ACIP). Available at: <A spellcheck=true href=\"http://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html\" target=_blank>www.cdc.gov/vaccines/hcp/acip-recs/general-recs/index.html</A>&nbsp;(Accessed on April 28, 2017).</LI>&#xD;&#xA;<LI>Marin M, Güris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.</LI>&#xD;&#xA;<LI>Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 2014; 58:e44.</LI></OL></div><div id=\"graphicVersion\">Graphic 105431 Version 3.0</div></div></div>"},"105444":{"type":"graphic_table","displayName":"Sampling rates and filter settings for routine PSG","title":"Sampling rates and filter settings for routine polysomnography recordings","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sampling rates and filter settings for routine polysomnography recordings</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Desirable sampling rate (Hz)</td> <td class=\"subtitle1\">Minimal sampling rate (Hz)</td> <td class=\"subtitle1\">Low frequency filter (Hz)</td> <td class=\"subtitle1\">High frequency filter (Hz)</td> </tr> <tr> <td><strong>EEG</strong></td> <td class=\"centered\">500</td> <td class=\"centered\">200</td> <td class=\"centered\">0.3</td> <td class=\"centered\">35</td> </tr> <tr> <td><strong>EOG</strong></td> <td class=\"centered\">500</td> <td class=\"centered\">200</td> <td class=\"centered\">0.3</td> <td class=\"centered\">35</td> </tr> <tr> <td><strong>EMG</strong></td> <td class=\"centered\">500</td> <td class=\"centered\">200</td> <td class=\"centered\">10</td> <td class=\"centered\">100</td> </tr> <tr> <td><strong>ECG</strong></td> <td class=\"centered\">500</td> <td class=\"centered\">200</td> <td class=\"centered\">0.3</td> <td class=\"centered\">70</td> </tr> <tr> <td><strong>Airflow</strong></td> <td class=\"centered\">100</td> <td class=\"centered\">25</td> <td class=\"centered\">0.1</td> <td class=\"centered\">15</td> </tr> <tr> <td><strong>Oximetry, transcutaneous PCO<sub>2</sub></strong></td> <td class=\"centered\">25</td> <td class=\"centered\">10</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td><strong>Nasal pressure</strong></td> <td class=\"centered\">100</td> <td class=\"centered\">25</td> <td class=\"centered\">DC or &#8804;0.03</td> <td class=\"centered\">100</td> </tr> <tr> <td><strong>End-tidal PCO<sub>2</sub></strong></td> <td class=\"centered\">100</td> <td class=\"centered\">25</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td><strong>PAP device flow</strong></td> <td class=\"centered\">100</td> <td class=\"centered\">25</td> <td class=\"centered\">DC</td> <td class=\"centered\">DC</td> </tr> <tr> <td><strong>Esophageal pressure</strong></td> <td class=\"centered\">100</td> <td class=\"centered\">25</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td><strong>Body position</strong></td> <td class=\"centered\">1</td> <td class=\"centered\">1</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td><strong>Snoring</strong></td> <td class=\"centered\">500</td> <td class=\"centered\">200</td> <td class=\"centered\">10</td> <td class=\"centered\">100</td> </tr> <tr> <td><strong>Chest and abdominal belts</strong></td> <td class=\"centered\">100</td> <td class=\"centered\">25</td> <td class=\"centered\">0.1</td> <td class=\"centered\">15</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EEG: electroencephalography; EOG: electrooculography; EMG: surface electromyography; ECG: electrocardiography; DC: direct current; PCO<SUB>2</SUB>: partial pressure of carbon dioxide; PAP: positive airway pressure.</div><div class=\"graphic_reference\">Modified with permission from: Berry RB, Brooks R, Gamaldo CE, et al for the American Academy of Sleep Medicine. The AASM Manual for the Scoring of Sleep and Associated Events: Rules, Terminology and Technical Specifications, Version 2.2, American Academy of Sleep Medicine, Darien, IL 2015. p.12. Copyright &copy; 2015 American Academy of Sleep Medicine.</div><div id=\"graphicVersion\">Graphic 105444 Version 1.0</div></div></div>"},"105445":{"type":"graphic_diagnosticimage","displayName":"US medial collateral ligament with bursa long axis","title":"US medial (tibial) collateral ligament with bursa in long axis","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">US medial (tibial) collateral ligament with bursa in long axis</div><div class=\"cntnt\"><img style=\"width:715px; height:233px;\" src=\"images/SM/105445_US_mdl_cllt_lgm_brs_lng_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image&nbsp;above shows the&nbsp;medial collateral ligament in long-axis, along&nbsp;with Voshell's bursa, which is enlarged with fluid suggesting a bursitis.</div><div class=\"graphic_footnotes\">+: Voshell's bursa (bursitis); arrows: tibial collateral ligament; small arrowheads: meniscofemoral ligament; large arrowheads: meniscotibial ligament.<br />Left of the screen: proximal; right of the screen: distal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105445 Version 2.0</div></div></div>"},"105446":{"type":"graphic_diagnosticimage","displayName":"US pes anserine bursa long axis","title":"US pes anserine bursa in long axis","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">US pes anserine bursa in long axis</div><div class=\"cntnt\"><img style=\"width:716px; height:435px;\" src=\"images/SM/105446_US_ps_ansrn_brs_lng_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image&nbsp;above shows the&nbsp;pes anserine bursa, which is enlarged with fluid suggesting bursitis.</div><div class=\"graphic_footnotes\">*: pes anserine bursa (bursitis); arrows: pes anserine tendons; arrowheads: distal tibial collateral ligament (long-axis).<br />Left of the screen: proximal; right of the screen: distal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105446 Version 1.0</div></div></div>"},"105447":{"type":"graphic_diagnosticimage","displayName":"Right subcutaneous-pleural fistula","title":"Right subcutaneous-pleural fistula","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Right subcutaneous-pleural fistula</div><div class=\"cntnt\"><img style=\"width:473px; height:634px;\" src=\"images/PULM/105447_Rght_sbctns_plrl_fstl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Chest frontal radiograph in a patient who underwent a right lower lobe lobectomy complicated by a postoperative air leak. A large right basal hydropneumothorax with gas-liquid level is visible. An additional pocket of gas with a level is seen in the axillary soft tissues of the right hemithorax. These findings are suggestive of fistula development between the pleural space and the nearby subcutaneous tissue.<br />(B) Axial images from chest computed tomography performed in the same patient confirms the presence of a large right hydropneumothorax with a right-sided subcutaneous-pleural fistula due to a postoperative defect in the right side of the rib cage.</div><div id=\"graphicVersion\">Graphic 105447 Version 1.0</div></div></div>"},"105448":{"type":"graphic_diagnosticimage","displayName":"US popliteal (Baker's) cyst showing neck","title":"US popliteal (Baker's) cyst showing neck","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">US popliteal (Baker's) cyst showing neck</div><div class=\"cntnt\"><img style=\"width:714px; height:387px;\" src=\"images/SM/105448_US_ppltl_bkr_cst_shw_nck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above shows a popliteal (Baker's) cyst, including its neck, which arises between the semimembranosus and medial head of the gastrocnemius tendons</div><div class=\"graphic_footnotes\">+: neck of Baker's cyst; arrowheads: semimembranosus tendon; arrows: medial border of medial head of gastrocnemius tendon; MHG: medial head of gastrocnemius muscle; *: articular cartilage.<br />Left of the screen: lateral; right of the screen: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105448 Version 3.0</div></div></div>"},"105449":{"type":"graphic_picture","displayName":"US transducer position for proximal gastrocnemius","title":"US transducer position for viewing proximal gastrocnemius muscle","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US transducer position for viewing proximal gastrocnemius muscle</div><div class=\"cntnt\"><img style=\"width:344px; height:710px;\" src=\"images/SM/105449_US_rnsdcr_pst_prxm_gstrcnm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the position of the ultrasound transducer and patient&nbsp;for obtaining&nbsp;images of&nbsp;the proximal gastrocnemius muscle in its short-axis.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105449 Version 1.0</div></div></div>"},"105450":{"type":"graphic_diagnosticimage","displayName":"US proximal gastrocnemius extended view","title":"US proximal gastrocnemius extended field view","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">US proximal gastrocnemius extended field view</div><div class=\"cntnt\"><img style=\"width:716px; height:261px;\" src=\"images/SM/105450_US_prx_gstrcnms_extnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The ultrasound image above is an extended field view&nbsp;of the proximal&nbsp;gastrocnemius muscle, including both the medial and lateral heads,&nbsp;in the short-axis.</div><div class=\"graphic_footnotes\">FHL: flexor hallucis longus muscle.<br />Left of the screen: lateral; right of the screen: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105450 Version 2.0</div></div></div>"},"105451":{"type":"graphic_diagnosticimage","displayName":"US anterior cruciate ligament","title":"US anterior cruciate ligament","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">US anterior cruciate ligament</div><div class=\"cntnt\"><img style=\"width:712px; height:576px;\" src=\"images/SM/105451_US_antrr_crct_lgmnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Ultrasound provides only limited views of the anterior cruciate ligament. The image above shows the posterior view of the ligament in short axis.</div><div class=\"graphic_footnotes\">Arrowheads: anterior cruciate ligament; arrows: intercondylar notch; MFC: medial femoral condyle; LFC: lateral femoral condyle; A: popliteal artery; MHG: medial head of gastrocnemius muscle; *: articular cartilage.<br />Left of the screen: lateral; right of the screen: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 105451 Version 2.0</div></div></div>"},"105453":{"type":"graphic_movie","displayName":"Martius flap","title":"Martius flap","html":"<div class=\"graphic normal\"><div style=\"width: 500px\" class=\"figure\"><div class=\"ttl\">Martius flap</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/105453_Martiusflapvid.mp4\" style=\"width:480px;height:288px\"></div><img style=\"width:634px; height:350px;\" src=\"images/SURG/105453_Martiusflapimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video clip depicts a typical Martius flap repair of a rectovaginal fistula.</div><div class=\"graphic_reference\">From: Kniery KR, Johnson EK, Steele SR. Martius flap for repair of recurrent rectovaginal fistulas. Dis Colon Rectum 2015; 58:1210. DOI: <a href=\"http://journals.lww.com/dcrjournal/Citation/2015/12000/Martius_Flap_for_Repair_of_Recurrent_Rectovaginal.13.aspx\" target=\"_blank\">10.1097/DCR.0000000000000465</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2015 American Society of Colon and Rectal Surgeons. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105453 Version 1.0</div></div></div>"},"105455":{"type":"graphic_picture","displayName":"Alopecia areata 6","title":"Alopecia areata","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Alopecia areata</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/105455_Alopecia_areata_6.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Round patch of alopecia on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105455 Version 1.0</div></div></div>"},"105457":{"type":"graphic_table","displayName":"Dulguerov staging system for olfactory neuroblastoma","title":"Dulguerov staging system for olfactory neuroblastoma","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Dulguerov staging system for olfactory neuroblastoma</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"5%\"></colgroup><colgroup width=\"95%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">New staging</td> </tr> <tr> <td>T1:</td> <td>Tumor involving the nasal cavity and/or paranasal sinuses (excluding sphenoid), sparing the most superior ethmoidal cells</td> </tr> <tr> <td>T2:</td> <td>Tumor involving the nasal cavity and/or paranasal sinuses (including the sphenoid) with extension to or erosion of the cribrilorm plate</td> </tr> <tr> <td>T3:</td> <td>Tumor extending into the orbit or protruding into the anterior cranial fossa</td> </tr> <tr> <td>T4:</td> <td>Tumor involving the brain</td> </tr> <tr> <td>N0:</td> <td>No cervical lymph node involvement</td> </tr> <tr> <td>N1:</td> <td>Cervical lymph node metastasis present</td> </tr> <tr> <td>M0:</td> <td>No distant metastases</td> </tr> <tr> <td>M1:</td> <td>Distant metastases present</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Dulguerov P, Calcaterra T. Esthesioneuroblastoma: the UCLA experience 1970-1990. Laryngoscope 1992; 102:843.</div><div id=\"graphicVersion\">Graphic 105457 Version 1.0</div></div></div>"},"105459":{"type":"graphic_waveform","displayName":"Inappropriate HR counting and pacing system pseudomalfunction","title":"Inappropriate heart rate counting and pacing system pseudomalfunction","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Inappropriate heart rate counting and pacing system pseudomalfunction</div><div class=\"cntnt\"><img style=\"width:716px; height:275px;\" src=\"images/ANEST/105459_Inprt_HR_cnt_pac_sst_psdmlfn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI><FONT color=black>A patient with AV nodal disease and a Medtronic A2DR01 magnetic resonance conditional dual-chamber pacemaker set to MVP <FONT color=black>mode (mode designed to limit right ventricular pacing) </FONT>was being monitored in the ICU with an ECG monitor configured to display pacemaker artifacts. The top trace is ECG lead II (bipolar, white-to-red lead). The middle trace is lead V5, which is a unipolar lead. The bottom trace is from an invasive intra-arterial catheter. No EMI was present.</FONT></LI>&#xD;&#xA;<LI><FONT color=black>The strip recorded a bradycardia alarm at 35 bpm, despite effective atrial pacing at 70 bpm with an effective ventricular rate of 54 bpm. Using the arrhythmia/rhythm \"relearn\" function on the monitor may correct such miscounting. However, as pacing activity changes, miscounting can recur.</FONT></LI>&#xD;&#xA;<LI><FONT color=black>The blue down-arrows point to atrial pacing artifacts (AAI pacing) until a QRS complex was dropped (ie, two atrial pacing events without an intervening QRS complex). After the third atrial pace, the pacemaker in the MVP mode delivered a ventricular-paced beat&nbsp;(red up-arrow) on the S-T segment 60 msec after the atrial pace, generating an effective QRS complex. Note the two other dropped QRS complexes that were followed by this 60-msec AV ventricular pacing sequence. The MVP is typically programmed to deliver such a 60-msec ventricular pacing sequence when QRS complexes are dropped.</FONT></LI></UL></div><div class=\"graphic_footnotes\">HR: heart rate; AV: atrioventricular; MVP: managed ventricular pacing; ICU: intensive care unit; ECG: electrocardiography; EMI: electromagnetic interference; AAI: atrial chamber spacing, atrial chamber sensing, atrial chamber inhibited; bpm: beats/minute; msec: millisecond.</div><div id=\"graphicVersion\">Graphic 105459 Version 4.0</div></div></div>"},"105461":{"type":"graphic_waveform","displayName":"Ventricular oversensing monopolar ESU causes pacing inhibition","title":"Ventricular oversensing from monopolar electrosurgery (ESU) causes pacing inhibition","html":"<div class=\"graphic\"><div style=\"width: 734px\" class=\"figure\"><div class=\"ttl\">Ventricular oversensing from monopolar electrosurgery (ESU) causes pacing inhibition</div><div class=\"cntnt\"><img style=\"width:714px; height:237px;\" src=\"images/ANEST/105461_Vntrcovrs_mnplr_ESU_css_pc_inhb.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 61-year-old <FONT color=black>woman undergoing a T10 vertebrectomy&nbsp;wh</FONT>o was&nbsp;pacing-dependent due to third-degree AV block had a&nbsp;Medtronic Kappa 401 dual-chamber pacemaker in the left pectoral position. During surgery, a&nbsp;monopolar ESU was used, with&nbsp;the current dispersion pad placed on&nbsp;the thigh. Note the lack of ventricular pacing for five seconds due to&nbsp;EMI during monopolar ESU use, which caused ventricular oversensing (ie, energy entering the system&nbsp;via the ventricular lead caused cessation of all pacing output).<br />The two arrows represent native P-waves that were unconducted due to the patient's AV block. The circle shows an atrial pace without a following ventricular pace because of fluctuating noise, a common issue with monopolar ESU. The event occurring at <STRONG>*</STRONG> is a \"ventricular safety pace,\" which results from an electrical signal occurring on the ventricular channel&nbsp;shortly after&nbsp;an atrial pace&nbsp;(after 60 to 90 msec, depending upon manufacturer). This&nbsp;pacemaker emits a ventricular pace 110 msec after the atrial&nbsp;pace since it cannot determine whether the early event is a native ventricular event or noise.</div><div class=\"graphic_footnotes\">AV: atrioventricular; ESU: electrosurgery; EMI: electromagnetic interference; msec: millisecond.</div><div id=\"graphicVersion\">Graphic 105461 Version 2.0</div></div></div>"},"105462":{"type":"graphic_diagnosticimage","displayName":"Implantable loop recorder (ILR)","title":"Implantable loop recorder (ILR)","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Implantable loop recorder (ILR)</div><div class=\"cntnt\"><img style=\"width:712px; height:556px;\" src=\"images/ANEST/105462_Implntd_loop_rcrd_ILR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A Medtronic LINQ implantable loop recorder (ILR) is demonstrated on this chest film (arrow). Insert shows enlarged image. Usually, ILRs are implanted subcutaneously on the anterior chest wall. They have no leads to project into or onto the heart.</div><div id=\"graphicVersion\">Graphic 105462 Version 2.0</div></div></div>"},"105463":{"type":"graphic_table","displayName":"Comparison of perioperative CIED advisories","title":"Comparison of perioperative CIED advisories","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of perioperative CIED advisories</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" rowspan=\"2\">Preoperative recommendation</td> <td class=\"subtitle1\" rowspan=\"2\">Intraoperative magnet use</td> <td class=\"subtitle1\" rowspan=\"2\">ESU dispersive electrode placement</td> <td class=\"subtitle1\" rowspan=\"2\">Postoperative recommendation</td> <td class=\"subtitle1\" colspan=\"2\">Emergency procedures </td> </tr> <tr> <td class=\"subtitle2\">Pacemaker (PM)</td> <td class=\"subtitle2\"> <p>Implantable</p> <p>cardioverter-defibrillator</p> <p>(ICD)</p> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>ASA </strong></td> <td>\"Timely interrogation\" prior to elective surgery, suggestive of de-novo interrogation.</td> <td>Shuns magnet use in favor of reprogramming.</td> <td>Prevent presumed current path from crossing the chest/CIED system.</td> <td> <p>Interrogation recommended.</p> Footnotes added to 2011 revision suggesting that CIED re-interrogation not needed if no monopolar ESU used.</td> <td colspan=\"2\">(Silent)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"><strong>HRS</strong></td> <td class=\"divider_bottom\" rowspan=\"2\">PM interrogation within 12 months, ICD interrogation within&nbsp;six months, and CRT interrogation within&nbsp;three to six&nbsp;months. CIED physician must provide prescription for perioperative care.</td> <td class=\"divider_bottom\" rowspan=\"2\">Magnet use suggested to produce asynchronous pacing (where needed in PM patients) and disabling ICD high-energy therapy, provided that patient position does not interfere with magnet access or observation.</td> <td class=\"divider_bottom\" rowspan=\"2\">Prevent presumed current path from crossing the chest/CIED system.</td> <td class=\"divider_bottom\" rowspan=\"2\">For most cases involving EMI (especially those inferior to the umbilicus and where no preoperative reprogramming was performed), interrogation can take place within&nbsp;one month as an ambulatory procedure. For reprogrammed CIEDs, hemodynamically challenging cases, cardiothoracic surgery, RFA, and external cardioversion, interrogation prior to transfer from cardiac telemetry.</td> <td colspan=\"2\"> <p>Use 12-lead ECG to identify pacing need; presume dependence if 100% pacing.</p> Cardiac monitoring until postoperative interrogation.</td> </tr> <tr class=\"divider_bottom\"> <td>Use magnet to&nbsp;produce asynchronous pacing to prevent pacing inhibition.</td> <td>Use magnet to suspend ICD tachyarrhythmia therapy.</td> </tr> <tr class=\"divider_bottom\"> <td><strong>CAS-CCS</strong></td> <td>De-novo interrogation likely not needed, but CIED physician must provide prescription for perioperative care.</td> <td>Where reasonable, magnet use suggested for asynchronous pacing (where needed in PM patients) and disabling ICD high-energy therapy.</td> <td>No mention.</td> <td>Clear plan for postoperative care established prior to elective case.</td> <td colspan=\"2\"> <p>Use 12-lead ECG to identify pacing need; assume pacing dependence if 100% paced; careful monitoring to determine if magnet application to a PM (notICD) produces asynchronous pacing with an acceptable hemodynamic profile;&nbsp;asynchronous pacing might be indicated in a pacing-dependent patient (PM or ICD) if ESU interference&nbsp;is observed (a magnet does not produce asynchronous pacing in an ICD).</p> <p>If a reprogramming machine cannot be employed before or during surgery in such emergencies, EMI may be minimized by use of bipolar instead of monopolar ESU, with short, intermittent bursts at the lowest feasible energy levels.</p> </td> </tr> <tr> <td rowspan=\"2\"><strong>MHRA*</strong></td> <td rowspan=\"2\">Preoperative contact with the pacemaker/ICD follow-up clinic for evaluation and perioperative recommendations.</td> <td rowspan=\"2\">Caution advised since magnet behavior can be affected by programming.</td> <td rowspan=\"2\">\"Ensure that the return electrode is anatomically positioned so that the current pathway between the diathermy electrode and return electrode is as far away from the pacemaker/defibrillator (and leads) as possible.\"</td> <td rowspan=\"2\">Follow-up clinic to prescribe postoperative follow-up.</td> <td colspan=\"2\">Attempt to follow routine steps; postoperative interrogation as soon as possible.</td> </tr> <tr> <td>Magnet might create asynchronous pacing.</td> <td>Magnet might prevent inappropriate discharge.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">No recommendations have been published for the leadless intracardiac pacemaker or the subcutaneous ICD.</div><div class=\"graphic_footnotes\">CIED: cardiac implantable electronic device; ESU: electrosurgical unit (\"Bovie\"); PM: pacemaker; ICD: implanted cardioverter-defibrillator; ASA: American Society of Anesthesiologists Perioperative Advisory; HRS: Heart Rhythm Society; CRT: cardiac resynchronization therapy (any CIED that has right- and left-ventricular pacing capability); EMI: electromagnetic interference; RFA: radio frequency ablation; ECG: electrocardiogram; CAS-CCS: Canadian Anesthesiologists' Society/Canadian Cardiovascular Society Joint Position Statement; MHRA: [British] Medicines and Health Care products Regulatory Agency.<br />* MHRA recommendations appear relevant only if EMI will be present.</div><div class=\"graphic_reference\">Original figure modified for this publication. Rozner MA. Implantable cardiac pulse generators: Pacemakers and cardioverter-defibrillators. In: Miller's Anesthesia, 8th ed, Miller RD (Ed), Saunders, Philadelphia 2015. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105463 Version 3.0</div></div></div>"},"105464":{"type":"graphic_table","displayName":"Preoperative evaluation for patients with a CIED","title":"Preoperative evaluation for patients with a cardiac implantable electronic device (CIED)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Preoperative evaluation for patients with a cardiac implantable electronic device (CIED)</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">A: CIED information needed at time of preoperative evaluation</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Manufacturer </li> <li>CIED type (transvenous or intracardiac PM, transvenous or subcutaneous ICD) </li> <li>Remaining battery longevity </li> <li>Programmed values <ul> <li>Modes <ul> <li>Pacing (PM and ICD) </li> <li>High-energy (ICD) modes </li> </ul> </li> <li>Pacing basic rate </li> <li>Maximum (upper) tracking rate if dual-chamber tracking mode (VDD, DDD) </li> <li>For ICDs <ul> <li>First treatment (ATP or shock) </li> <li>If ATP, will ATP delay shock? </li> <li>HR&nbsp;for first treatment </li> <li>Does programming permit treatment delay (eg, therapy hold for presumed supraventricular tachycardia)? </li> </ul> </li> <li>Enhancements that might masquerade as pacing system malfunction (pseudo-malfunction)&nbsp; <ul> <li>Hysteresis rate (promotes intrinsic cardiac activity by allowing the intrinsic heart rate to fall below the LRL of the CIED before pacing is initiated [Note: The LRL determines the rate at which the CIED will pace the heart in the absence of intrinsic activity.]) </li> <li>Sleep rate (allows pacing at a rate lower than the programmed LRL of the CIED during presumed sleep hours) </li> <li>Rate drop response (high-rate pacing &ndash; typically 100 bpm for 1 to 10 minutes &ndash; instigated by a falling native HR to prevent neurocardiogenic syncope) </li> <li>RV&nbsp;pacing avoidance algorithms <ul> <li>Allowing prolonged AV delay (to 450 msec) <ul> <li>Biotronik \"Vp suppression mode\" </li> <li>St. Jude Medical&nbsp;\"ventricular intrinsic preference\" </li> </ul> </li> <li>Allowing dropped QRS events <ul> <li>Boston Scientific \"RYTHMIQ\" </li> <li>Medtronic \"managed ventricular pacing\" </li> <li>Sorin \"AAI-SafeR\" </li> </ul> </li> </ul> </li> </ul> </li> </ul> </li> <li>Magnet behavior (pacing mode, rate, and AV delay) and setting (on, off) <ul> <li>The following CIEDs have programmable magnet behavior: <ul> <li>Biotronik PMs (default is NO asynchronous pacing) </li> <li>Boston Scientific PMs and ICDs </li> <li>St Jude Medical PMs and ICDs </li> </ul> </li> </ul> </li> <li>Rate responsiveness <ul> <li>Maximum (upper) sensor rate </li> <li>Sensor type <ul> <li>Mechanical sensor </li> <li>Minute ventilation sensor (consider programming off) </li> </ul> </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">B: Patient information</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Indication for implant </li> <li>Underlying native cardiac rhythm and rate to determine pacing dependency </li> <li>Date of last comprehensive check, which includes pacing threshold determination(s) </li> <li>History of arrhythmias and pharmacologic as well as ICD treatment (if ICD) </li> <li>History of manufacturer alerts necessitating special care <ul> <li>Device alerts with possible need for temporary transvenous pacing backup </li> <li>Lead alerts </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">C: Procedure information</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Facility where procedure will occur </li> <li>Nature of procedure </li> <li>Anatomic site(s) of procedure </li> <li>Patient position during the procedure </li> <li>Need for radiofrequency energy device(s) <ul> <li>Monopolar ESU (commonly known as cautery or the \"Bovie\") </li> <li>Radiofrequency ablative instruments </li> <li>Lithotripsy </li> </ul> </li> <li>Anticipated high-risk event <ul> <li>Significant blood loss </li> <li>Need for cardioversion or defibrillation </li> <li>Difficult or no access to device </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For further explanation of terms, refer to UpToDate topics on modes of cardiac pacing and cardiac pacing nomenclature.</div><div class=\"graphic_footnotes\">CIED: cardiac&nbsp;implantable&nbsp;electronic&nbsp;device; PM: pacemaker; ICD: implantable cardioverter-defibrillator; VDD: ventricular chamber paced, atrial and ventricular chambers sensed, atrial and ventricular chambers triggered and inhibited; DDD: atrial and ventricular chambers paced, atrial and ventricular chambers sensed, atrial and ventricular chambers triggered and inhibited; ATP: antitachycardia pacing; LRL: lower rate limit; bpm: beats per minute; HR: heart rate: RV: right ventricular; msec: millisecond; AV: atrioventricular;&nbsp;Vp: ventricular pacing;&nbsp;AAI: atrial chamber pacing, atrial chamber sensing, atrial chamber inhibited; ESU: electrosurgery.</div><div class=\"graphic_reference\">Adapted from: Crossley GH, Poole JE, Rozner MA, et al. The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) Expert Consensus Statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management this document was developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Heart Rhythm 2011; 8:1114.</div><div id=\"graphicVersion\">Graphic 105464 Version 5.0</div></div></div>"},"105465":{"type":"graphic_table","displayName":"CIED reprogramming likely necessary","title":"Reprogramming of the cardiac implantable electronic device (CIED) likely to be necessary to:","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Reprogramming of the cardiac implantable electronic device (CIED) likely to be necessary to:</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Disable anti-tachyarrhythmia therapy (shock[s] and antitachycardia pacing) in an ICD when EMI is expected. </li> </ul> </td> </tr> <tr> <td> <ul> <li>Disable anti-tachyarrhythmia therapy where movement from shock might create a hazard&nbsp;(eg, intraocular surgery). </li> </ul> </td> </tr> <tr> <td> <ul> <li>&nbsp;Produce asynchronous pacing in a pacing-dependent patient when EMI is expected.</li> </ul> </td> </tr> <tr> <td> <ul id=\"_telerik_insertedList_id\"> <li>Increase the paced heart rate in a patient with sinus node incompetence to augment perioperative cardiac output and oxygen delivery.</li> </ul> </td> </tr> <tr> <td> <ul> <li>Disable a minute ventilation sensor to prevent inappropriate high-rate pacing or the presence of any monopolar radiofrequency instruments.</li> </ul> </td> </tr> <tr> <td> <ul> <li>Disable a&nbsp;mechanical rate sensor where surgery will likely produce mechanical stimulation near the pulse generator (eg, breast surgery).</li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\">Magnet use may be an&nbsp;acceptable alternative&nbsp;to reprogramming with a programming machine&nbsp;if:</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Response to magnet is known and effect is desirable</li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Patient is supine</li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Access to magnet is adequate</li> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <ul> <li>Magnet can be observed</li> </ul> </ul> </td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <ul> <li>Magnet can be easily removed in case of arrhythmia</li> </ul> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; ICD: implanted cardioverter-defibrillator; EMI: electromagnetic interference; AV: atrioventricular.</div><div class=\"graphic_reference\">Adapted from: Crossley GH, Poole JE, Rozner MA, et al. The Heart Rhythm Society (HRS)/American Society of Anesthesiologists (ASA) Expert Consensus Statement on the perioperative management of patients with implantable defibrillators, pacemakers and arrhythmia monitors: facilities and patient management this document was developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA), and the Society of Thoracic Surgeons (STS). Heart Rhythm 2011; 8:1114.</div><div id=\"graphicVersion\">Graphic 105465 Version 3.0</div></div></div>"},"105466":{"type":"graphic_algorithm","displayName":"Treatment options for CMS","title":"Treatment options for congenital myasthenic syndromes","html":"<div class=\"graphic\"><div style=\"width: 918px\" class=\"figure\"><div class=\"ttl\">Treatment options for congenital myasthenic syndromes</div><div class=\"cntnt\"><img style=\"width:898px; height:420px;\" src=\"images/NEURO/105466_Treatment_options_CMS.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">3,4-DAP: 3,4-diaminopyridine; AChR deficiency: acetylcholine receptor deficiency; CMS: congenital myasthenic syndrome.<br />* Refer to text and table \"Diagnostic clues to congenital myasthenic syndromes\" for details.</div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Rodr&iacute;guez Cruz PM, Palace J, Beeson D. Congenital myasthenic syndromes and the neuromuscular junction. Curr Opin Neurol 2014; 27:566.</li>&#xD;&#xA;    <li>Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol 2015; 14:420.</li>&#xD;&#xA;    <li>Rodr&iacute;guez Cruz PM, Palace J, Ramjattan H, et al. Salbutamol and ephedrine in the treatment of severe AChR deficiency syndromes. Neurology 2015; 85:1043.</li>&#xD;&#xA;    <li>Zhu H, Grajales-Reyes GE, Alicea-V&aacute;zquez V, et al. Fluoxetine is neuroprotective in slow-channel congenital myasthenic syndrome. Exp Neurol 2015; 270:88.</li>&#xD;&#xA;    <li>Tsao CY. Effective Treatment of Albuterol in DOK7 Congenital Myasthenic Syndrome in Children. Pediatr Neurol 2016; 54:85.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 105466 Version 1.0</div></div></div>"},"105468":{"type":"graphic_table","displayName":"Pacemaker response to magnet placement","title":"Pacemaker response to magnet placement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pacemaker response to magnet placement</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"15%\"></colgroup><colgroup width=\"55%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">Pacemaker company</td> <td class=\"subtitle1\">Magnet mode designation</td> <td class=\"subtitle1\">Explanation</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Biotronik</td> <td class=\"divider_bottom\" rowspan=\"2\">INOS</td> <td>ASYNCH (DEFAULT)</td> <td>Asynchronous VOO (even if dual-chamber device) pacing at 70 or 90 bpm, depending upon programming, if normal conditions. 80 bpm at ERI. There is no way to determine the magnet rate without the programmer or magnet application.</td> </tr> <tr class=\"divider_bottom\"> <td>SYNCH</td> <td>VVI (even if dual-chamber device) pacing at 70 or 90 bpm, depending upon programming, if normal conditions. 80 bpm at ERI. There is no way to determine the magnet rate without the programmer or magnet application. Also, if the patient's intrinsic ventricular rate is greater than 80 bpm, there will be no way to identify ERI.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">DROMOS</td> <td>ASYNCH</td> <td>Refer to \"AUTO,\" below.</td> </tr> <tr class=\"divider_bottom\"> <td>SYNCH</td> <td>Refer to \"SYNCH,\" below.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">All others</td> <td>AUTO (DEFAULT)</td> <td>If normal conditions, 10 asynchronous events at 90 bpm, then returns to original programmed mode, without rate responsiveness. Pacing is at lowest available rate (LRL, sleep rate, or hysteresis rate). If battery at ERI, 10 asynchronous events at 80 bpm in VOO mode, then either VDD (dual-chamber) or VVI (single-chamber) pacing at 11% lower than lowest available rate. For any dual-chamber mode (DDD, DDI, or VDD), the AVd shortens to 100 msec while the magnet is in place.</td> </tr> <tr> <td>ASYNCH</td> <td>Asynchronous pacing at 90 bpm if normal conditions. At ERI, 80 bpm (single-step change) in VOO mode regardless of original programming. For any dual-chamber mode (DDD, DDI, or VDD), the AVd shortens to 100 msec while the magnet is in place.</td> </tr> <tr class=\"divider_bottom\"> <td>SYNCH</td> <td>If normal conditions, pacing in original programmed mode, without rate responsiveness. Pacing is at lowest available rate (LRL, sleep rate, or hysteresis rate). If battery at ERI, then either VDD (dual chamber) or VVI (single chamber) pacing at 11% lower than lowest available rate. For any dual-chamber mode (DDD, DDI, or VDD), the AVd shortens to 100 msec while the magnet is in place.</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> &nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"> <p>Boston Scientific</p> (includes Guidant Medical CPI)</td> <td class=\"divider_bottom\" rowspan=\"3\">&nbsp;</td> <td>ASYNCH (DEFAULT)</td> <td>If normal conditions, asynchronous pacing with 100-msec AVd at 100 bpm. If ERI, 85 bpm (single-step change). The Insignia and Altrua models have an intermediate step (90 bpm) at ERN. Most models shorten the pulse width to 50% on the third paced ventricular event (TMT). For Triumph and Prelude models, see Medtronic pacemakers, below.</td> </tr> <tr> <td>OFF</td> <td>No change; magnet is ignored. OFF is also the magnet mode after a \"power on reset,\" or activation of \"safety core,\" which can occur secondary to EMI.</td> </tr> <tr class=\"divider_bottom\"> <td>EGM mode</td> <td>No change in pacing. Magnet application initiates data collection.</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <p>&nbsp;</p> <p>&nbsp;</p> <br /> &nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"> <p>Intermedics</p> (purchased by Guidant in&nbsp;1998, now Boston Scientific, but special programmer needed)</td> <td>&nbsp;</td> <td>Five&nbsp;asynchronous events at 90 bpm (regardless of battery voltage), then 60 additional asynchronous events at LRL if normal conditions, 90 bpm if ERI, and 80 bpm if EOL. The fifth paced event is emitted at 50% of the originally programmed pulse width (TMT). After the 65<sup>th</sup> asynchronous event, the magnet is ignored.</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> &nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Medtronic (refer to caution, below)</td> <td>Standard transvenous pacemaker</td> <td class=\"divider_bottom\" rowspan=\"2\">&nbsp;</td> <td>Asynchronous pacing at 85 bpm (programmed mode) if normal conditions 65 bpm SOO regardless of original programming if ERI (single-step change). Medtronic pacemakers (except Enrhythm P1501 and all \"Surescan\" models) pace the first three events at 600-msec intervals (rate = 100 bpm) with a short AVd. During the first&nbsp;three to seven&nbsp;asynchronous events, most Medtronic pacemakers emit one or more ventricular pulses at a reduced pulse width or voltage (TMT). Also, Medtronic pacemakers default to single-chamber pacing at 65 bpm, without rate responsiveness, upon reset or detection of ERI when no magnet is present. Important caveat:&nbsp;A Medtronic dual-chamber pacemaker in AAI mode will revert to VVI on ERI or reset, which might result in asystole and death with a dysfunctional ventricular lead but atrial pacing dependence.</td> </tr> <tr class=\"divider_bottom\"> <td>\"Micra\" leadless intra-cardiac pacemaker</td> <td>NO MAGNET RESPONSE</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\"> <p>Sorin</p> (was ELA Medical)</td> <td>&nbsp;</td> <td>Asynchronous pacing at 96 bpm gradually declining to 80 bpm at ERI. Sorin/ELA pacemakers take&nbsp;eight additional asynchronous pacing cycles (the final&nbsp;two cycles are at LRL with long AVd) upon magnet removal.</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"9\">St. Jude Medical</td> <td class=\"divider_bottom\" rowspan=\"4\">\"SJM\" x-ray logo; standard transvenous pacemaker</td> <td>Battery test (DEFAULT)</td> <td>Asynchronous pacing at 100 bpm (older models 98.6 bpm) gradually decreasing to 86.3 bpm at ERI.</td> </tr> <tr> <td>OFF</td> <td>No magnet response.</td> </tr> <tr> <td>Event snapshots</td> <td>No change in pacing. Magnet application causes pacemaker to collect data. Identity and Entity models lack this feature.</td> </tr> <tr class=\"divider_bottom\"> <td>Event snapshots + Battery test</td> <td>For a magnet placed&nbsp;on the device for two seconds, pacing mode and rate are unchanged, and the device stores an electrogram. If the magnet is placed for&nbsp;&#8805;5 seconds, the battery test mode (see above) is activated. Identity and Entity models lack this feature.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Pacesetter x-ray logo(&#969;); standard transvenous pacemaker</td> <td>Battery test (DEFAULT)</td> <td>Asynchronous pacing, and the rate depends upon specific model. In general, a pacing rate of less than 90 bpm should prompt further evaluation.</td> </tr> <tr> <td>OFF</td> <td>No magnet response.</td> </tr> <tr class=\"divider_bottom\"> <td>VARIO mode (present in some models)</td> <td>VARIO results in a series of 32 asynchronous pacing events. The rate of the first 16 paces reflects battery voltage, gradually declining from 100 bpm to 85 bpm at ERI. The next 15 paces are used to document ventricular pacing capture safety margin. The rate will be 119 bpm with gradually declining pacing voltage. The 16<sup>th</sup> pace of this group is at no output. The next pace restarts the 32-event sequence. The 32-event sequence repeats while the magnet remains in place.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">\"Nanostim\" leadless intra-cardiac pacemaker</td> <td>On (DEFAULT)</td> <td>Asynchronous pacing at 100 bpm for&nbsp;eight cycles, then 90 bpm if normal conditions;&nbsp;65 bpm if ERI.</td> </tr> <tr class=\"divider_bottom\"> <td>OFF</td> <td>No magnet response.</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> &nbsp;</td> </tr> <tr> <td rowspan=\"5\">Telectronics</td> <td class=\"divider_bottom\"> <p>Meta</p> 1202</td> <td class=\"divider_bottom\">&nbsp;</td> <td class=\"divider_bottom\">Asynchronous pacing at 99 bpm, gradually declining to &#60;93 bpm&nbsp;at ERI.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Meta</p> <p>1204</p> <p>1206</p> 1256</td> <td>&nbsp;</td> <td>Asynchronous pacing at 100 bpm, gradually declining to &#60;82.5 bpm at ERI.</td> </tr> <tr class=\"divider_bottom\"> <td> <p>Meta</p> <p>1230</p> <p>1250</p> 1254</td> <td>&nbsp;</td> <td>Asynchronous VOO pacing (regardless of original programming) at &#62;85 bpm, gradually declining to &#60;78 bpm at ERI.</td> </tr> <tr class=\"divider_bottom\"> <td>Tempo</td> <td>&nbsp;</td> <td>Asynchronous pacing at 100 bpm, gradually declining to 80 bpm at ERI.</td> </tr> <tr> <td>All others</td> <td>&nbsp;</td> <td>Contact St. Jude Medical.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The effect(s) of appropriately placing a magnet over a pacemaker are shown, assuming normal battery and lead function. Column 1 shows the pacemaker manufacturer. Where a manufacturer has multiple responses, Column 1 is subdivided. If the magnet response is programmable, then Column 2 shows the various magnet modes available. The first mode shown is the default. A device reset from EMI might produce some other mode (ie, magnet mode disabled). Column 3 shows the effect on pacing therapy for the magnet mode shown in Column 2. Unless otherwise specified, asynchronous pacing takes place, without rate responsiveness, in the chambers originally programmed. Thus, a dual-chamber program would result in DOO pacing; a single-chamber program would result in VOO (unless an atrial device, which would be AOO) pacing; and a biventricular, dual-chamber device would be DOOOV.<br />Caution for Medtronic transvenous pacemakers: All Medtronic transvenous pacemakers except Enrhythm P1501, EMDR series, Revo, Advisa, and Ensura suspend magnet detection for up to 60 minutes following removal of the programming head after an interrogation session, unless specific programming action (which requires multiple \"button\" depressions) is taken prior to removing the programming head.<br />Caution for all dual-chamber pacemakers: An electrical fault or exposure to strong EMI could cause a \"power on reset\" or \"safety core event\" (BSC - Boston-labeled devices), causing the pacemaker to switch to VVI pacing only, regardless of prior pacing programming. For a dual-chamber pacemaker with a bad RV lead and programmed to atrial pacing only (AAI, AOO) in a pacing-dependent patient, this event could result in patient injury or death.<br /><STRONG>For further explanation of terms, refer to UpToDate topics on modes of cardiac pacing and cardiac pacing nomenclature.</STRONG></div><div class=\"graphic_footnotes\"><STRONG>VOO</STRONG>: ventricular asynchronous pacing, no sensing; <STRONG>bpm</STRONG>: beats/minute; <STRONG>ERI</STRONG>: elective replacement indicator (the device should be replaced promptly; the US Food and Drug Administration [FDA] requires pacemakers to perform safely for at least three months from onset of ERI); <STRONG>VVI</STRONG>: ventricle paced, ventricle sensed, and pacemaker inhibited in response to a sensed beat; <STRONG>LRL</STRONG>: lower rate limit (the programmed lower rate, or set point, of the pacemaker); <STRONG>VDD</STRONG>: ventricle paced, atrium and ventricle sensed, and either inhibition or tracking of the pacemaker in response to a sensed beat; <STRONG>DDD</STRONG>: atrium and ventricle paced, atrium and ventricle sensed, with tracking of intrinsic atrial activity; <STRONG>DDI</STRONG>: atrium and ventricle paced, atrium and ventricle sensed, no tracking of intrinsic atrial activity; <STRONG>AVd</STRONG>: atrioventricular delay (for dual-chamber pacing, this is a programmed value; however, the AVd can be shortened during the first 3 to 15 events upon magnet placement; note that a short AVd can reduce stroke volume and produce untoward hemodynamics in some patients); <STRONG>ERN</STRONG>: elective replacement near (the device should be undergoing monthly checks [IFI]); <STRONG>TMT</STRONG>: threshold margin test (the emission of a single pacing pulse [except VARIO; see St. Jude Medical – Pacesetter Logo] at a lower amplitude or pulse width to demonstrate adequacy of pacing output relative to pacing threshold; typically, this is the third or fifth pacing pulse; failure to capture [pace] on this event suggests an inadequate safety margin for capture; properly programmed atrial-only pacemakers are unlikely to demonstrate this feature); <STRONG>EMI</STRONG>: electromagnetic interference; <STRONG innerHtml>EGM: </STRONG>electrogram;&nbsp;<STRONG>EOL</STRONG>: end of life (the device should be replaced immediately); <STRONG>SOO</STRONG>: single-chamber asynchronous pacing; <STRONG>AAI</STRONG>: atrium paced, atrium sensed, and pacemaker inhibited in response to sensed atrial beat;&nbsp;<STRONG>IFI</STRONG>: intensified follow-up interval (the device needs monthly battery checks); <STRONG>ERT</STRONG>: elective replacement time (same as ERI; for Boston Scientific pacemakers [Guidant, CPI labels also], at ERT, rate-responsive programming is cancelled; at three months post-ERT, only single-chamber operation continues); <STRONG>SSI</STRONG>: single-chamber, inhibited mode (if implanted for ventricular pacing, then SSI = VVI; for an atrial pacemaker, SSI = AAI.).</div><div class=\"graphic_reference\">Original figure modified for this publication. Rozner MA. Implantable cardiac pulse generators: Pacemakers and cardioverter-defibrillators. In: Miller's Anesthesia, 8th ed, Miller RD (Ed), Saunders, Philadelphia 2015. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105468 Version 3.0</div></div></div>"},"105469":{"type":"graphic_table","displayName":"ICD response to magnet placement","title":"ICD response to magnet placement","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">ICD response to magnet placement</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">ICD manufacturer</td> <td class=\"subtitle1\">Magnet mode designation</td> <td class=\"subtitle1\">Effect on tachy therapy</td> <td class=\"subtitle1\">Effect on brady therapy (regular pacing)</td> <td class=\"subtitle1\">Magnet mode confirmation</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">Biotronik</td> <td>&nbsp;</td> <td>Disables</td> <td>No effect</td> <td>None</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Boston Scientific (Guidant Medical, CPI)</td> <td class=\"divider_bottom\" rowspan=\"2\">Transvenous \"BSC\" - all \"BOS\" (except 119, 203) x-ray label</td> <td>ON (DEFAULT)</td> <td>Disables</td> <td>No effect</td> <td>Short beep every second, or constant tone*</td> </tr> <tr class=\"divider_bottom\"> <td>OFF</td> <td>No effect</td> <td>No effect</td> <td>None</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\"> <p>Transvenous</p> <p>\"GDT,\" \"CPI,\"</p> <p>\"BOS 119,\"</p> <p>\"BOS 203\"</p> x-ray label</td> <td>ON (DEFAULT)</td> <td>Disables</td> <td>No effect</td> <td>Short beep with each R wave, or constant tone*</td> </tr> <tr class=\"divider_bottom\"> <td>OFF</td> <td>No effect</td> <td>No effect</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td>Subcutaneous</td> <td>&nbsp;</td> <td>Disables</td> <td>No effect&nbsp;- The subcutaneous ICD has NO regular pacing. However, post-shock pacing (VVI, 50 bpm, 30 seconds, nonprogrammable) is terminated.</td> <td>Short beep with each R wave, whether ICD therapy is on or off, for the first 60 seconds of magnet application. Thereafter, no confirmation.</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Medtronic</td> <td>AT-500<sup>&#182;</sup></td> <td>&nbsp;</td> <td>Disables</td> <td>No effect</td> <td class=\"divider_bottom\" rowspan=\"2\">None<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td>All others</td> <td>&nbsp;</td> <td>Disables</td> <td>No effect</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\" colspan=\"2\">Pacesetter and St. Jude Medical</td> <td>NORMAL (DEFAULT)</td> <td>Disables</td> <td>No effect</td> <td class=\"divider_bottom\" rowspan=\"2\">None</td> </tr> <tr class=\"divider_bottom\"> <td>IGNORE</td> <td>No effect</td> <td>No effect</td> </tr> <tr> <td colspan=\"2\">Sorin (was ELA Medical)</td> <td>&nbsp;</td> <td>Disables</td> <td>The pacing rate, but not mode, changes to 96 (new device), declining to 80 bpm as battery voltage falls, indicating elective replacement time.</td> <td>Pacing rate change as noted</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The effect(s) of appropriately placing a magnet over an ICD are shown. Column 1 shows the manufacturer. Some manufacturers have multiple responses that can be determined by the x-ray identifier. If the magnet response is programmable, then Column 2 shows the various magnet modes available. The first mode shown is the default mode. A device reset from EMI might produce some other mode (ie, magnet mode disabled). Column 3 shows the effect on antitachycardia therapy (defibrillation, cardioversion, and antitachycardia pacing) for the magnet mode shown in Column 2. Only ICDs from Sorin Medical alter their antibradycardia pacing rate upon magnet placement (Column 4), and this pacing rate can be used to predict remaining battery life, provided that the patient's native heart rate is less than the magnet rate. Only ICDs from Boston Scientific/Guidant/CPI produce reliable audio feedback for confirmation of magnet placement (Column 5). For devices from Angeion, Pacesetter, and St. Jude Medical, a device interrogation is required to determine the magnet mode.<br /><STRONG>For further explanation of terms, refer to UpToDate topics on modes of cardiac pacing and cardiac pacing nomenclature.</STRONG></div><div class=\"graphic_footnotes\">ICD: implantable cardioverter-defibrillator; tachy: tachycardia; brady: bradycardia; VVI: single-chamber ventricular pacemaker; bpm: beats/minute.<br />* Any Boston Scientific/Guidant/CPI ICD that does not emit sound when a magnet is applied should undergo an immediate device interrogation. A stethoscope might be needed; for electronic stethoscopes, only the \"Diaphragm\" mode should be used since filtering in the \"Bell\" mode might not permit the sound to be transmitted to the earpiece.<br />For Boston Scientific/Guidant/CPI ICDs, if magnet mode is programmed to \"ON,\" appropriate magnet placement disables tachy detection and therapy, and tachy therapies remain disabled for as long as the magnet remains appropriately applied. When magnet mode is enabled in these devices, the ICD will emit either a constant tone or \"beep\" to identify appropriate magnet placement. If the device emits a constant tone, then tachy therapy is disabled whether or not a magnet is present, and tachy therapy will not be present even after the magnet is removed. If any of these ICDs emit a \"beep\" (ICDs with \"GDT\" or \"CPI\" x-ray codes emit each beep with any paced or sensed R wave; ICDs with \"BOS\" or \"BSC\" x-ray code emits a beep every second), then a properly working ICD will be enabled for tachy therapy upon magnet removal.<br />Note that the \"Change Tachy Mode with Magnet\" feature is present only in very few remaining \"GDT\" and \"CPI\" x-ray-labeled devices. When programmed \"ON,\" after 30 seconds of continuous magnet application, the tachy mode will toggle; ie, it will switch from enabled when the magnet is removed (beeping with magnet correctly applied) to permanently disabled (constant tone when magnet is correctly applied) or vice versa. This mode has been phased out for most BOS/GDT/CPI ICD families, and software in programmers since October, 2009 is designed to disable and eliminate this feature.<br />¶ The Medtronic AT-500 series atrial defibrillators provide antitachycardia pacing in the atrium ONLY, and usually after a delay often exceeding one minute from onset of atrial tachyarrhythmia. They do not have any shock coils on any lead and are very difficult to distinguish from a conventional two-chamber pacemaker. They have NO apparent magnet response. The X-RAY identifier on these devices includes the Medtronic \"M,\" but the first character is \"I.\" All other Medtronic cardiac generators have the Medtronic \"M\" with the first letter identifier \"P\".<br />Δ Some Medtronic ICDs will emit a tone for 15 to 30 seconds when a magnet is placed on the device. However, this tone is not continuous with magnet placement, and it will not be interrupted with immediate magnet removal. As a result, the tone cannot be used for confirmation of appropriate magnet placement.</div><div class=\"graphic_reference\">Original figure modified for this publication. Rozner MA. Implantable cardiac pulse generators: Pacemakers and cardioverter-defibrillators. In: Miller's Anesthesia, 8th ed, Miller RD (Ed), Saunders, Philadelphia 2015. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105469 Version 2.0</div></div></div>"},"105471":{"type":"graphic_table","displayName":"Fredrickson classification and associated xanthomas","title":"Fredrickson classification of lipid disorders and associated xanthomas<sup>[1,2]</sup>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fredrickson classification of lipid disorders and associated xanthomas<sup>[1,2]</sup></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Frederickson phenotype</td> <td class=\"subtitle1\">Lipoprotein abnormality</td> <td class=\"subtitle1\">Typical lipid levels</td> <td class=\"subtitle1\">Xanthomas Observed</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">I</td> <td>Chylomicrons</td> <td>Triglycerides (TG) &#62;99th percentile</td> <td>Eruptive</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">IIa</td> <td>LDL</td> <td>Total cholesterol (TC) &#62;90th percentile; depending upon type, may also see TG and/or apolipoprotein B &#8805;90th percentile</td> <td>Tendinous, tuberous, interdigital xanthomas</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">IIb</td> <td>LDL and VLDL</td> <td>Depending upon type, TC and/or TG &#8805;90th percentile and apolipoprotein B &#8805;90th percentile</td> <td>Tuberous</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">III</td> <td>Remnants of VLDL and chylomicrons</td> <td>TC and TG &#62;90th percentile</td> <td>Tuberoeruptive xanthomas (80% of patients); plane xanthomas of the palmar creases (xanthoma striatum palmare [2/3 of patients])</td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\">IV</td> <td>VLDL</td> <td>TC &#62;90th percentile; depending upon type, may also see TG &#62;90th percentile or low HDL</td> <td>Eruptive</td> </tr> <tr> <td class=\"centered\">V</td> <td>Chylomicrons and VLDL</td> <td>TG &#62;99th percentile</td> <td>Eruptive</td> </tr> </tbody></table></div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins--an integrated approach to mechanisms and disorders. N Engl J Med 1967; 276:148.</li>&#xD;&#xA;    <li>Fredrickson DS. An international classification of hyperlipidemias and hyperlipoproteinemias. Ann Intern Med 1971; 75:471.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 105471 Version 1.0</div></div></div>"},"105474":{"type":"graphic_table","displayName":"Topical drugs for pediculosis capitis","title":"Topical drugs for pediculosis capitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Topical drugs for pediculosis capitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Pediculicide*</td> <td class=\"subtitle1\">Mechanism of action</td> <td class=\"subtitle1\">Age group</td> <td class=\"subtitle1\">Regimen</td> <td class=\"subtitle1\">Precautions/side effects</td> </tr> <tr> <td>Pyrethrins and piperonyl butoxide</td> <td>Neurotoxin</td> <td>&#8805;2 years</td> <td>Leave on hair for 10 minutes, then rinse; repeat on day 9</td> <td>Skin irritation</td> </tr> <tr> <td>Permethrin (1%)</td> <td>Neurotoxin</td> <td>&#8805;2 months</td> <td>Leave on hair for 10 minutes, then rinse; repeat on day 9</td> <td>Skin irritation; pyrethrins may induce breathing difficulties in patients with ragweed allergy; avoid permethrin in patients with chrysanthemum allergy</td> </tr> <tr> <td>Malathion</td> <td>Neurotoxin</td> <td>&#8805;6 years; contraindicated in children under 2 years; safety has not been established in children 2 to 6 years</td> <td>Leave on hair for 8 to 12 hours, then wash with a non-medicated shampoo; a single application may be effective; repeat in 7 to 9 days if live lice are seen</td> <td>Malodorous, flammable, skin irritation, theoretical risk for respiratory depression if ingested</td> </tr> <tr> <td>Benzyl alcohol</td> <td>Asphyxiation</td> <td>&#8805;6 months</td> <td>Leave on hair for 10 minutes, then rinse; repeat after 7 days</td> <td>Skin and eye irritation, transient skin numbness</td> </tr> <tr> <td>Spinosad</td> <td>Neurotoxin</td> <td>&#8805;6 months</td> <td>Leave on hair for 10 minutes, then rinse; repeat in 7 days if live lice remain</td> <td>Skin irritation</td> </tr> <tr> <td>Ivermectin</td> <td>Neurotoxin</td> <td>&#8805;6 months</td> <td>Leave on hair for 10 minutes, then rinse</td> <td>Skin or eye irritation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* There is wide variation in the cost of topical pediculicides. In general, pyrethrins and permethrin are the least expensive agents. Current United States pricing information is available in the Lexicomp Drug Information content provided in UpToDate.</div><div id=\"graphicVersion\">Graphic 105474 Version 2.0</div></div></div>"},"105475":{"type":"graphic_movie","displayName":"Fulcrum test for femoral shaft stress fracture","title":"Fulcrum test for femoral shaft stress fracture","html":"<div class=\"graphic normal\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Fulcrum test for femoral shaft stress fracture</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SM/105475_Fulcrumfmrlshftstrssvid.mp4\" style=\"width:560px;height:336px\"></div><img style=\"width:565px; height:312px;\" src=\"images/SM/105475_Fulcrumfmrlshftstrssimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The fulcrum test is used to help identify stress fractures of the femoral shaft.</div><div class=\"graphic_reference\">Courtesy of Jonathan Jackson, MD.</div><div id=\"graphicVersion\">Graphic 105475 Version 1.0</div></div></div>"},"105476":{"type":"graphic_table","displayName":"Ten steps to successful breastfeeding","title":"Ten steps to successful breastfeeding","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ten steps to successful breastfeeding</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Ten steps to successful breastfeeding</td> <td class=\"subtitle1\">mPINC indicator</td> </tr> <tr> <td>1. Have a written breastfeeding policy that is routinely communicated to all health care staff</td> <td><strong>Model breastfeeding policy:</strong> Hospital has a written breastfeeding policy that includes 10 model policy elements*</td> </tr> <tr> <td>2. Train all health care staff in skills necessary to implement this policy</td> <td><strong>Staff competency assessment:</strong> Nurses/birth attendants are assessed for competency in basic breastfeeding management and support at least once per year</td> </tr> <tr> <td>3. Inform all pregnant women about the benefits and management of breastfeeding</td> <td><strong>Prenatal breastfeeding education:</strong> Breastfeeding education is included as a routine element of prenatal classes</td> </tr> <tr> <td>4. Help mothers initiate breastfeeding within one hour of birth</td> <td><strong>Early initiation of breastfeeding:</strong> &#8805;90% of healthy full-term breastfed infants initiate breastfeeding within one hour of uncomplicated vaginal birth</td> </tr> <tr> <td>5. Show mothers how to breastfeed, and how to maintain lactation, even if they should be separated from their infants</td> <td><strong>Teach breastfeeding techniques:</strong> &#8805;90% of mothers who are breastfeeding or intend to breastfeed are taught breastfeeding techniques (eg, positioning, how to express milk, etc.)</td> </tr> <tr> <td>6. Give breastfeeding newborn infants no food or drink other than breastmilk, unless medically indicated</td> <td><strong>Limited non-breast milk feeds of breastfed infants:</strong> &#60;10% of healthy full-term breastfed infants are given formula, glucose water, or water</td> </tr> <tr> <td>7. Practice rooming-in-allow mothers and infants to remain together 24 hours per day</td> <td><strong>Rooming-in:</strong> &#8805;90% of healthy full-term infants, regardless of feeding method, remain with their mother for at least 23 hours per day during the hospital stay</td> </tr> <tr> <td>8. Encourage breastfeeding on demand</td> <td><strong>Teach feeding cues:</strong> &#8805;90% of mothers are taught to recognize and respond to infant feeding cues instead of feeding on a set schedule</td> </tr> <tr> <td>9. Give no artificial teats or pacifiers to breastfeeding infants</td> <td><strong>Limited use of pacifiers:</strong> &#60;10% of healthy full-term breastfed infants are given pacifiers by maternity care staff</td> </tr> <tr> <td>10. Foster the establishment of breastfeeding support groups and refer mothers to these groups on discharge from the hospital or clinic</td> <td><strong>Post-discharge support:</strong> Hospital routinely provides three modes of post-discharge support to breastfeeding mothers: physical contact, active reaching out, and referrals<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The Ten Steps listed above were developed by the World Health Organization (WHO) and United Nations Children's Fund (UNICEF).<SUP>[1]</SUP> Implementation of these Ten Step in the United States is captured by the biennial Maternity Practices in Infant Nutrition and Care (mPINC) survey, conducted by the Centers for Disease Control.<SUP>[2]</SUP></div><div class=\"graphic_footnotes\">* Model policy elements are: &#xD;&#xA;<OL>&#xD;&#xA;<LI>In-service training</LI>&#xD;&#xA;<LI>Prenatal breastfeeding classes</LI>&#xD;&#xA;<LI>Asking about mothers' feeding plans</LI>&#xD;&#xA;<LI>Initiating breastfeeding within one hour of uncomplicated vaginal birth</LI>&#xD;&#xA;<LI>Initiating breastfeeding after recovery for uncomplicated Cesarean sections and/or showing mothers how to express milk and maintain lactation if separated from infant</LI>&#xD;&#xA;<LI>Giving only breast milk to breastfed infants</LI>&#xD;&#xA;<LI>Rooming-in 24 hour/day</LI>&#xD;&#xA;<LI>Breastfeeding on demand</LI>&#xD;&#xA;<LI>No pacifier use by breastfed infants</LI>&#xD;&#xA;<LI>Referral of mothers with breastfeeding problems and/or referral of mothers to appropriate breastfeeding resources at discharge.</LI></OL>¶ Physical contact is defined as home visit, hospital postpartum follow-up visit. Active reaching out is defined as a follow-up phone call to patient after discharge. Referrals is defined as a hospital phone number to call, hospital-based support group, other breastfeeding support group, lactation consultant/specialist, or outpatient clinic in the US Department of Agriculture Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) program.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Joint WHO/UNICEF Statement Protecting, Promoting and Supporting Breastfeeding: The Special Role of Maternity Services, (WHO, 1989). Available at: <a href=\"http://www.who.int/nutrition/publications/infantfeeding/9241561300/en/\" target=\"_blank\">http://www.who.int/nutrition/publications/infantfeeding/9241561300/en/</a></li>&#xD;&#xA;    <li>Centers for Disease Control and Prevention, Maternity practices in infant nutrition and care (mPINC) survey. Available at: <a href=\"http://www.cdc.gov/breastfeeding/data/mpinc/state_reports.html\" target=\"_blank\">http://www.cdc.gov/breastfeeding/data/mpinc/state_reports.html</a></li>&#xD;&#xA;</ol>&#xD;&#xA;Adapted from: Perrine CG, Galuska DA, Dohack JL, et al. Vital Signs: Improvements in Maternity Care Policies and Practices That Support Breastfeeding - United States, 2007-2013. MMWR Morb Mortal Wkly Rep 2015; 64:1112.</div><div id=\"graphicVersion\">Graphic 105476 Version 1.0</div></div></div>"},"105481":{"type":"graphic_picture","displayName":"Laser treatment of burn scars 1","title":"Laser treatment of hypertrophic burn scars","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Laser treatment of hypertrophic burn scars</div><div class=\"cntnt\"><img style=\"width:582px; height:327px;\" src=\"images/DERM/105481_Laser_treatmnt_burn_scars_1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 19-year-old woman sustained a deep partial-thickness grease burn to her chest, treated by sheet grafting. After developing hypertrophic scarring over her sternum, she underwent two pulsed dye laser sessions, followed by two fractional carbon dioxide laser sessions, with complete resolution of her hyperemia, itching, and paresthesias. Shown are preoperation and follow-up photos at 22 months.</div><div class=\"graphic_reference\">Originally published in: Hultman CS, Edkins RE, Wu C, et al. Prospective, before-after cohort study to assess the efficacy of laser therapy on hypertrophic burn scars. Ann Plast Surg 2013; 70:521. From: Hultman CS, Friedstat JS, Edkins RE, et al. Laser resurfacing and remodeling of hypertrophic burn scars: the results of a large, prospective, before-after cohort study, with long-term follow-up. Ann Surg 2014; 260:519. DOI: <a href=\"http://journals.lww.com/annalsofsurgery/Abstract/2014/09000/Laser_Resurfacing_and_Remodeling_of_Hypertrophic.13.aspx\" target=\"_blank\">10.1097/SLA.0000000000000893</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American Surgical Association and European Surgical Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105481 Version 1.0</div></div></div>"},"105482":{"type":"graphic_picture","displayName":"Laser treatment of burn scars 2","title":"Laser treatment of hypertrophic burn scars","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Laser treatment of hypertrophic burn scars</div><div class=\"cntnt\"><img style=\"width:583px; height:373px;\" src=\"images/DERM/105482_Laser_treatmnt_burn_scars_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This five-year-old girl sustained an intermediate partial-thickness scald injury to her scalp and posterior neck. She underwent excision and allograft placement but developed severe hypertrophic scarring of her neck and posterior scalp with chronic folliculitis and minimal alopecia. She had complete resolution of her symptoms after four pulsed dye laser sessions and no steroid injections. Shown are preoperation and follow-up photos at 34 months.</div><div class=\"graphic_reference\">Originally published in: Hultman CS, Edkins RE, Wu C, et al. Prospective, before-after cohort study to assess the efficacy of laser therapy on hypertrophic burn scars. Ann Plast Surg 2013; 70:521. From: Hultman CS, Friedstat JS, Edkins RE, et al. Laser resurfacing and remodeling of hypertrophic burn scars: the results of a large, prospective, before-after cohort study, with long-term follow-up. Ann Surg 2014; 260:519. DOI: <a href=\"http://journals.lww.com/annalsofsurgery/Abstract/2014/09000/Laser_Resurfacing_and_Remodeling_of_Hypertrophic.13.aspx\" target=\"_blank\">10.1097/SLA.0000000000000893</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American Surgical Association and European Surgical Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105482 Version 1.0</div></div></div>"},"105483":{"type":"graphic_picture","displayName":"Laser treatment of burn scars 3","title":"Laser treatment of hypertrophic burn scars","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Laser treatment of hypertrophic burn scars</div><div class=\"cntnt\"><img style=\"width:583px; height:369px;\" src=\"images/DERM/105483_Laser_treatmnt_burn_scars_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 25-year-old laborer sustained full-thickness burns from an electrical flash while working on a roof. Despite early excision and grafting, he developed severe hypertrophic scarring of his hands, resulting in both intrinsic and extrinsic tightness. He underwent two pulsed dye laser sessions, steroid injections, three fractional carbon dioxide laser sessions, and web space releases with small full-thickness skin grafts. Now, he demonstrates near-normal function and has returned to his original job with minimal restrictions. Shown are preoperation and follow-up photos at 37 months.</div><div class=\"graphic_reference\">Originally published in: Hultman CS, Edkins RE, Wu C, et al. Prospective, before-after cohort study to assess the efficacy of laser therapy on hypertrophic burn scars. Ann Plast Surg 2013; 70:521. From: Hultman CS, Friedstat JS, Edkins RE, et al. Laser resurfacing and remodeling of hypertrophic burn scars: the results of a large, prospective, before-after cohort study, with long-term follow-up. Ann Surg 2014; 260:519. DOI: <a href=\"http://journals.lww.com/annalsofsurgery/Abstract/2014/09000/Laser_Resurfacing_and_Remodeling_of_Hypertrophic.13.aspx\" target=\"_blank\">10.1097/SLA.0000000000000893</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American Surgical Association and European Surgical Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105483 Version 1.0</div></div></div>"},"105484":{"type":"graphic_picture","displayName":"Laser treatment of burn scars 4","title":"Laser treatment of hypertrophic burn scars","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Laser treatment of hypertrophic burn scars</div><div class=\"cntnt\"><img style=\"width:583px; height:254px;\" src=\"images/DERM/105484_Laser_treatmnt_burn_scars_4.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 32-year-old man sustained a 60% total body surface area burn with inhalation injury from an industrial explosion at a food processing plant. His perioral burns were allowed to heal by secondary intention, but he developed hypertrophic scarring with unrelenting pruritus, shortening of the upper lip, and chronic folliculitis of his lips, chin, and scalp. He underwent two alexandrite laser sessions, two fractional carbon dioxide laser sessions, and steroid injections, with near-complete resolution of his symptoms, relaxation of his perioral tightness, and lengthening of his upper lip. Shown are preoperation and follow-up photos at 36 months.</div><div class=\"graphic_reference\">Originally published in: Hultman CS, Edkins RE, Wu C, et al. Prospective, before-after cohort study to assess the efficacy of laser therapy on hypertrophic burn scars. Ann Plast Surg 2013; 70:521. From: Hultman CS, Friedstat JS, Edkins RE, et al. Laser resurfacing and remodeling of hypertrophic burn scars: the results of a large, prospective, before-after cohort study, with long-term follow-up. Ann Surg 2014; 260:519. DOI: <a href=\"http://journals.lww.com/annalsofsurgery/Abstract/2014/09000/Laser_Resurfacing_and_Remodeling_of_Hypertrophic.13.aspx\" target=\"_blank\">10.1097/SLA.0000000000000893</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American Surgical Association and European Surgical Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105484 Version 1.0</div></div></div>"},"105485":{"type":"graphic_picture","displayName":"Laser treatment of burn scars 5","title":"Laser treatment of hypertrophic burn scars","html":"<div class=\"graphic\"><div style=\"width: 604px\" class=\"figure\"><div class=\"ttl\">Laser treatment of hypertrophic burn scars</div><div class=\"cntnt\"><img style=\"width:584px; height:391px;\" src=\"images/DERM/105485_Laser_treatmnt_burn_scars_5.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 17-year-old young woman had a 50% total body surface area burn from a propane grill explosion and developed severe hypertrophic scarring on her chest, extremities, neck, and face, with distortion of her forehead and brow, upper and lower lips, and preauricular region. She underwent a series of tissue rearrangements, complemented by steroid injections, five pulsed dye laser sessions, and three fractional carbon dioxide laser sessions. Shown are preoperation and follow-up photos at 39 months.</div><div class=\"graphic_reference\">Originally published in: Hultman CS, Edkins RE, Wu C, et al. Prospective, before-after cohort study to assess the efficacy of laser therapy on hypertrophic burn scars. Ann Plast Surg 2013; 70:521. From: Hultman CS, Friedstat JS, Edkins RE, et al. Laser resurfacing and remodeling of hypertrophic burn scars: the results of a large, prospective, before-after cohort study, with long-term follow-up. Ann Surg 2014; 260:519. DOI: <a href=\"http://journals.lww.com/annalsofsurgery/Abstract/2014/09000/Laser_Resurfacing_and_Remodeling_of_Hypertrophic.13.aspx\" target=\"_blank\">10.1097/SLA.0000000000000893</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American Surgical Association and European Surgical Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105485 Version 1.0</div></div></div>"},"105487":{"type":"graphic_picture","displayName":"Laser treatment of burn scars 6","title":"Laser treatment of hypertrophic burn scars","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Laser treatment of hypertrophic burn scars</div><div class=\"cntnt\"><img style=\"width:582px; height:436px;\" src=\"images/DERM/105487_Laser_treatmnt_burn_scars_6.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 17-year-old young woman had a 50% TBSA burn from a propane grill explosion and developed severe hypertrophic scarring on her chest, extremities, neck, and face, with distortion of her forehead and brow, upper and lower lips, and preauricular region (oblique view). Shown are preoperation and follow-up photos at 39 months.</div><div class=\"graphic_footnotes\">TBSA: total percentage of body surface area.</div><div class=\"graphic_reference\">Originally published in: Hultman CS, Edkins RE, Wu C, et al. Prospective, before-after cohort study to assess the efficacy of laser therapy on hypertrophic burn scars. Ann Plast Surg 2013; 70:521. From: Hultman CS, Friedstat JS, Edkins RE, et al. Laser resurfacing and remodeling of hypertrophic burn scars: the results of a large, prospective, before-after cohort study, with long-term follow-up. Ann Surg 2014; 260:519. DOI: <a href=\"http://journals.lww.com/annalsofsurgery/Abstract/2014/09000/Laser_Resurfacing_and_Remodeling_of_Hypertrophic.13.aspx\" target=\"_blank\">10.1097/SLA.0000000000000893</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American Surgical Association and European Surgical Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105487 Version 1.0</div></div></div>"},"105488":{"type":"graphic_picture","displayName":"Laser treatment of burn scars 7","title":"Laser treatment of hypertrophic burn scars","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Laser treatment of hypertrophic burn scars</div><div class=\"cntnt\"><img style=\"width:583px; height:430px;\" src=\"images/DERM/105488_Laser_treatmnt_burn_scars_7.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This 17-year-old young woman had a 50% TBSA burn from a propane grill explosion and developed severe hypertrophic scarring on her chest, extremities, neck, and face, with distortion of her forehead and brow, upper and lower lips, and preauricular region (lateral view). Shown are preoperation and follow-up photos at 39 months.</div><div class=\"graphic_footnotes\">TBSA: total percentage of body surface area.</div><div class=\"graphic_reference\">Originally published in: Hultman CS, Edkins RE, Wu C, et al. Prospective, before-after cohort study to assess the efficacy of laser therapy on hypertrophic burn scars. Ann Plast Surg 2013; 70:521. From: Hultman CS, Friedstat JS, Edkins RE, et al. Laser resurfacing and remodeling of hypertrophic burn scars: the results of a large, prospective, before-after cohort study, with long-term follow-up. Ann Surg 2014; 260:519. DOI: <a href=\"http://journals.lww.com/annalsofsurgery/Abstract/2014/09000/Laser_Resurfacing_and_Remodeling_of_Hypertrophic.13.aspx\" target=\"_blank\">10.1097/SLA.0000000000000893</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American Surgical Association and European Surgical Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105488 Version 1.0</div></div></div>"},"105493":{"type":"graphic_figure","displayName":"Cervix colpo punctation histo","title":"Colposcopy of the cervix: Punctation histology","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Colposcopy of the cervix: Punctation histology</div><div class=\"cntnt\"><img style=\"width:762px; height:470px;\" src=\"images/OBGYN/105493_Cervix_colpo_punctatn_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Punctation occurs when the columnar villi blood vessels are recruited to feed the neoplastic tissue.</div><div class=\"graphic_reference\">Reproduced with permission from Kenneth Hatch, MD, University of Arizona, Department of Obstetrics and Gynecology. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 105493 Version 1.0</div></div></div>"},"105494":{"type":"graphic_figure","displayName":"Cervix colpo mosaicism histo","title":"Colposcopy of the cervix: Mosaicism histology","html":"<div class=\"graphic\"><div style=\"width: 805px\" class=\"figure\"><div class=\"ttl\">Colposcopy of the cervix: Mosaicism histology</div><div class=\"cntnt\"><img style=\"width:785px; height:460px;\" src=\"images/OBGYN/105494_Cervix_colpo_mosaicism_hist.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mosaic is formed when the neoplasia replaces glands and the vascular network forms a circle.</div><div class=\"graphic_footnotes\">CIN: cervical intraepithelial neoplasia.</div><div class=\"graphic_reference\">Reproduced with permission from Kenneth Hatch, MD, University of Arizona, Department of Obstetrics and Gynecology. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 105494 Version 1.0</div></div></div>"},"105495":{"type":"graphic_picture","displayName":"Cervix colpo CIN1","title":"Colposcopy of the cervix: Cervical intraepithelial neoplasia, low-grade","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Colposcopy of the cervix: Cervical intraepithelial neoplasia, low-grade</div><div class=\"cntnt\"><img style=\"width:720px; height:483px;\" src=\"images/OBGYN/105495_Cervix_colpo_CIN1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CIN 1 transformation zone completely seen.</div><div class=\"graphic_footnotes\">CIN: cervical intraepithelial neoplasia.</div><div class=\"graphic_reference\">Reproduced with permission from Kenneth Hatch, MD, University of Arizona, Department of Obstetrics and Gynecology. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 105495 Version 1.0</div></div></div>"},"105496":{"type":"graphic_picture","displayName":"Cervix colpo CIN2","title":"Colposcopy of the cervix: Cervical intraepithelial lesion, high-grade","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Colposcopy of the cervix: Cervical intraepithelial lesion, high-grade</div><div class=\"cntnt\"><img style=\"width:720px; height:462px;\" src=\"images/OBGYN/105496_Cervix_colpo_CIN2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CIN 2. The outer border is smooth and distinct.</div><div class=\"graphic_footnotes\">CIN: cervical intraepithelial neoplasia.</div><div class=\"graphic_reference\">Reproduced with permission from Kenneth Hatch, MD, University of Arizona, Department of Obstetrics and Gynecology. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 105496 Version 1.0</div></div></div>"},"105497":{"type":"graphic_picture","displayName":"Cervix colpo punct mosaic","title":"Colposcopy of the cervix: Punctation and mosaicism with swab technique to evert transformation zone","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Colposcopy of the cervix: Punctation and mosaicism with swab technique to evert transformation zone</div><div class=\"cntnt\"><img style=\"width:720px; height:505px;\" src=\"images/OBGYN/105497_Cervix_colpo_punct_mosaic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cotton swab is used to avert the anterior lip of the cervix to see the entire lesion. With complete visualization of the transformation zone, examination is adequate.</div><div class=\"graphic_reference\">Reproduced with permission from Kenneth Hatch, MD, University of Arizona, Department of Obstetrics and Gynecology. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 105497 Version 1.0</div></div></div>"},"105499":{"type":"graphic_picture","displayName":"Cervix colpo ridge mosaic","title":"Colposcopy of the cervix: Ridge sign and mosaicism","html":"<div class=\"graphic\"><div style=\"width: 820px\" class=\"figure\"><div class=\"ttl\">Colposcopy of the cervix: Ridge sign and mosaicism</div><div class=\"cntnt\"><img style=\"width:800px; height:541px;\" src=\"images/OBGYN/105499_Cervix_colpo_ridge_mosaic.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Large transformation zone before application of acetic acid.<br />(B) After application of acetic acid, showing ridge sign.<br />(C) After acetic acid has faded, showing mosaicism.</div><div class=\"graphic_reference\">Reproduced with permission from Kenneth Hatch, MD, University of Arizona, Department of Obstetrics and Gynecology. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 105499 Version 1.0</div></div></div>"},"105500":{"type":"graphic_picture","displayName":"Cervix colpo CIN3","title":"Colposcopy of the cervix: Cervical intraepithelial neoplasia, high-grade with abnormal vessels","html":"<div class=\"graphic\"><div style=\"width: 807px\" class=\"figure\"><div class=\"ttl\">Colposcopy of the cervix: Cervical intraepithelial neoplasia, high-grade with abnormal vessels</div><div class=\"cntnt\"><img style=\"width:787px; height:488px;\" src=\"images/OBGYN/105500_Cervix_colpo_CIN3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cervical intraepithelial neoplasia, grade 3.</div><div class=\"graphic_reference\">Reproduced with permission from Kenneth Hatch, MD, University of Arizona, Department of Obstetrics and Gynecology. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 105500 Version 1.0</div></div></div>"},"105501":{"type":"graphic_picture","displayName":"Cervix colpo vaginitis","title":"Colposcopy of the cervix: Vaginitis","html":"<div class=\"graphic\"><div style=\"width: 1035px\" class=\"figure\"><div class=\"ttl\">Colposcopy of the cervix: Vaginitis</div><div class=\"cntnt\"><img style=\"width:1015px; height:367px;\" src=\"images/OBGYN/105501_Cervix_colpo_vaginitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Low-power view of cervix in a patient with high-grade cervical intraepithelial neoplasia (CIN3) and trichomonas vaginitis.<br />(B) Cervical intraepithelial lesion, grade 3. Cuffed gland sign, sometimes seen in high-grade cervical neoplasia. Stippled appearance consistent with trichomonas vaginitis and cervicitis.</div><div class=\"graphic_reference\">Reproduced with permission from Kenneth Hatch, MD, University of Arizona, Department of Obstetrics and Gynecology. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 105501 Version 1.0</div></div></div>"},"105502":{"type":"graphic_picture","displayName":"Cervix colpo invasive ca","title":"Colposcopy of the cervix: Invasive cervical carcinoma","html":"<div class=\"graphic\"><div style=\"width: 1036px\" class=\"figure\"><div class=\"ttl\">Colposcopy of the cervix: Invasive cervical carcinoma</div><div class=\"cntnt\"><img style=\"width:1016px; height:346px;\" src=\"images/OBGYN/105502_Cervix_colpo_invasive_ca.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Invasive cervical cancer, abnormal branching blood vessels.<br />(B) Invasive cervical cancer, abnormal loop blood vessels.</div><div class=\"graphic_footnotes\">HPV: human papillomavirus.</div><div class=\"graphic_reference\">Reproduced with permission from Kenneth Hatch, MD, University of Arizona, Department of Obstetrics and Gynecology. Copyright &copy; 2016.</div><div id=\"graphicVersion\">Graphic 105502 Version 1.0</div></div></div>"},"105504":{"type":"graphic_table","displayName":"Endovascular LAA closure devices","title":"Endovascular left atrial appendage closure devices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Endovascular left atrial appendage closure devices</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Device name</td> <td class=\"subtitle1\">Company</td> <td class=\"subtitle1\">Design</td> <td class=\"subtitle1\">Device sizes (mm)</td> <td class=\"subtitle1\">Approval status</td> </tr> <tr> <td>WATCHMAN</td> <td>Boston Scientific</td> <td>Single-lobe occluder with nitinol frame, PET membrane, 10 hooks.</td> <td>21, 24, 27, 30, 33</td> <td> <p>CE Mark</p> FDA approval</td> </tr> <tr> <td>Amplatzer Cardiac Plug (ACP)</td> <td>St. Jude Medical</td> <td>Lobe &#38; disc (polyester mesh in both) nitinol mesh construct. Stabilizing wires.</td> <td>16, 18, 20, 22, 24, 26, 28, 30</td> <td>CE Mark</td> </tr> <tr> <td>Amulet</td> <td>St. Jude Medical</td> <td>Similar design as ACP, but wider lobe and disc, and more stabilizing wires.</td> <td>16, 18, 20, 22, 25, 28, 31, 34</td> <td>CE Mark</td> </tr> <tr> <td>WaveCrest</td> <td>Coherex Medical</td> <td>Single-lobe occluder. Nitinol frame, polyurethane foam, ePTFE membrane, retractable anchors.</td> <td>22, 27, 32</td> <td>CE Mark</td> </tr> <tr> <td>Occlutech LAA Occluder</td> <td>Occlutech</td> <td>Single-lobe occluder. Nitinol wire mesh, stabilizing loops, nanomaterial covering.</td> <td>15, 18, 21, 24, 27, 30, 33, 36, 39</td> <td>CE Mark</td> </tr> <tr> <td>Sideris Transcatheter Patch</td> <td>Custom Medical Devices</td> <td>Frameless detachable latex balloon covered with polyurethane.</td> <td>&nbsp;</td> <td>Not yet</td> </tr> <tr> <td>Lambre</td> <td>Lifetech</td> <td>Lobe and disc nitinol frame. PET membrane. Distal barbs anchors.</td> <td>16 to 36</td> <td>CE Mark</td> </tr> <tr> <td>pfm</td> <td>pfm Medical</td> <td>Dual disc nitinol frame (distal anchor, variable middle connector, proximal disc).</td> <td>&nbsp;</td> <td>Not yet</td> </tr> <tr> <td>Cardia</td> <td>Cardia</td> <td>Lobe and disc nitinol frame. Ivalon covering. Distal anchors.</td> <td>16, 20, 24, 28, 32</td> <td>Not yet</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PET: polyethylene terephthalate; ePTFE: polytetrafluoroethylene; LAA: left atrial appendage.</div><div id=\"graphicVersion\">Graphic 105504 Version 2.0</div></div></div>"},"105505":{"type":"graphic_table","displayName":"Epicardial percutaneous or surgical LAA closure devices","title":"Epicardial percutaneous or surgical left atrial appendage closure devices","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Epicardial percutaneous or surgical left atrial appendage closure devices</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Device name</td> <td class=\"subtitle1\">Company</td> <td class=\"subtitle1\">Design</td> <td class=\"subtitle1\">Device sizes (mm)</td> <td class=\"subtitle1\">Approval status</td> </tr> <tr> <td>LARIAT</td> <td>SentreHeart</td> <td>Endocardial and epicardial percutaneous access required. Magnetically-assisted snaring of LAA.</td> <td>LAA sizes up to 40 width, 20 height, 70 length</td> <td> <p>FDA approval</p> <p>CE Mark</p> (for tissue apposition)</td> </tr> <tr> <td>AtriClip</td> <td>AtriCure</td> <td>Surgical/thoracotomy approach. Parallel clip with polyester mesh.</td> <td>35, 40, 45, 50</td> <td> <p>FDA approval</p> CE Mark</td> </tr> <tr> <td>TigerPaw II</td> <td>Marquet</td> <td>Surgical approach. Compliant soft silicone fastener.</td> <td>Current class 1 recall, not commercially available</td> <td> <p>FDA approval</p> CE Mark</td> </tr> <tr> <td>AEGIS</td> <td>AEGIS Medical Innovations</td> <td>Epicardial subxiphoid percutneous approach. Electrode-guided navigation for LAA tissue capture.</td> <td>&nbsp;</td> <td>Not yet</td> </tr> <tr> <td>Cardioblate Closure System</td> <td>Medtronic</td> <td>Epicardial approach. Silicone band covered by polyester fabric.</td> <td>&nbsp;</td> <td>Not yet</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LAA: left atrial appendage.</div><div id=\"graphicVersion\">Graphic 105505 Version 1.0</div></div></div>"},"105509":{"type":"graphic_algorithm","displayName":"Laser treatment of hypertrophic scars","title":"Laser therapy for hypertrophic burn scars","html":"<div class=\"graphic\"><div style=\"width: 536px\" class=\"figure\"><div class=\"ttl\">Laser therapy for hypertrophic burn scars</div><div class=\"cntnt\"><img style=\"width:516px; height:258px;\" src=\"images/DERM/105509_Laser_tx_hypertrophic_scars.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Each laser treatment consists of two to four sessions each, spaced four to six weeks apart. Platforms are chosen based upon scar characteristics. The end points are determined by the patient and the provider. Contractures may require release and reconstruction. Hydroquinone and tretinoin can be used for improvement of color and texture. Consider fat grafting for refractory symptoms of pain and itching.</div><div class=\"graphic_footnotes\">OT: occupational therapy; PT: physical therapy; fCO<sub>2</sub>: fractional carbon dioxide.</div><div class=\"graphic_reference\">Yoshida &amp; Hultman, University of North Carolina, 2015.</div><div id=\"graphicVersion\">Graphic 105509 Version 1.0</div></div></div>"},"105512":{"type":"graphic_diagnosticimage","displayName":"Congenital bicuspid aortic valve w/ severe leaflet calcification","title":"Congenital bicuspid aortic valve with severe calcification of leaflets","html":"<div class=\"graphic\"><div style=\"width: 728px\" class=\"figure\"><div class=\"ttl\">Congenital bicuspid aortic valve&nbsp;with severe calcification of leaflets</div><div class=\"cntnt\"><img style=\"width:708px; height:574px;\" src=\"images/ANEST/105512_Cngn_bc_art_vlv_svr_lflt_clcf.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Short-axis, mid-esophageal view of congenital bicuspid aortic valve&nbsp;with severe leaflet calcification resulting in aortic stenosis.</div><div class=\"graphic_footnotes\">LA: left atrium; RA: right atrium; AV: aortic valve; PA: pulmonary&nbsp;artery.</div><div id=\"graphicVersion\">Graphic 105512 Version 2.0</div></div></div>"},"105514":{"type":"graphic_table","displayName":"Comparison of hemorrhoidectomy techniques","title":"Comparison of hemorrhoidectomy techniques","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of hemorrhoidectomy techniques</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Postoperative pain/complication rate</td> <td class=\"subtitle1\">Recurrence rate</td> </tr> <tr> <td><strong>Conventional with scalpel or monopolar cautery</strong></td> <td>*****</td> <td>*</td> </tr> <tr> <td><strong>Conventional with Ligasure or Harmonic scalpel</strong></td> <td>**</td> <td>*</td> </tr> <tr> <td><strong>Stapled hemorrhoidopexy</strong></td> <td>***</td> <td>****</td> </tr> <tr> <td><strong>Hemorrhoid artery ligation</strong></td> <td>*</td> <td>*****</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Postoperative pain/complication and recurrence rates are ranked from * (lowest) to ***** (highest).</div><div id=\"graphicVersion\">Graphic 105514 Version 1.0</div></div></div>"},"105517":{"type":"graphic_table","displayName":"Cardiovascular changes during laparoscopy","title":"Cardiovascular changes during laparoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Cardiovascular changes during laparoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parameters</td> <td class=\"subtitle1\">Change</td> <td class=\"subtitle1\">Causes</td> </tr> <tr class=\"divider_bottom\"> <td>Systemic vascular resistance and<br /> mean arterial pressure</td> <td>Increased</td> <td> <ul> <li>Hypercarbia </li> <li>Neuroendocrine response (ie, increased catecholamines, vasopressin, and cortisol) </li> <li>Mechanical factors (ie, direct compression of aorta) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Cardiac filling pressures </td> <td>Increased</td> <td> <ul> <li>Increased intrathoracic pressure secondary to pneumoperitoneum </li> <li>Increased sympathetic output due to neuroendocrine response and hypercarbia </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Cardiac filling volumes</td> <td>Variable; increased or no change</td> <td>Interaction among: <ul class=\"decimal_heading\"> <li>Increased intravascular volume resulting from compression of liver and spleen </li> <li>Reduced preload and venous return </li> <li>Positioning </li> <li>Patient's preexisting status </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Cardiac index</td> <td>Variable; decreased or no change</td> <td>Interaction among: <ul class=\"decimal_heading\"> <li>Increased afterload </li> <li>Decreased venous return </li> <li>Decreased cardiac filling </li> <li>Increased intravascular volume </li> <li>Positioning </li> <li>Patient's preexisting status </li> </ul> </td> </tr> <tr> <td rowspan=\"2\">Cardiac rhythm</td> <td>Bradyarrhythmias</td> <td>Peritoneal stretch - vagal</td> </tr> <tr> <td>Tachyarrhythmias</td> <td class=\"indent1\"> <ul> <li>Hypercarbia </li> <li>Hypoxia </li> <li>Capnothorax </li> <li>Pulmonary embolism </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: Joshi G, Cunningham A. Anesthesia for laparoscopic and robotic surgeries. In: Clinical Anesthesia, 7th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013.</div><div id=\"graphicVersion\">Graphic 105517 Version 2.0</div></div></div>"},"105518":{"type":"graphic_table","displayName":"Causes of hypoxemia during laparoscopic and robotic surgery","title":"Causes of hypoxemia during laparoscopic and robotic surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hypoxemia during laparoscopic and robotic surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Patient factors</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Preexisting cardiopulmonary dysfunction </li> <li>Morbid obesity </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Intraoperative ventilation</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Low FiO<sub>2</sub> </li> <li>Hypoventilation </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">V/Q mismatch</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Endobronchial intubation </li> <li>Atelectasis </li> <li>Capno (pneumo) thorax </li> <li>Pulmonary embolism </li> <li>Patient position (eg, lateral decubitus) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Reduced cardiac output</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Inferior vena cava compression </li> <li>Dysrhythmias </li> <li>Myocardial depression (eg, anesthetic drug effects) </li> <li>Hemorrhage </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Anemia</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Pre-existing anemia </li> <li>Hemorrhage </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FiO<SUB>2</SUB>: fraction of inspired oxygen; <SPAN style=\"COLOR: black\">V/Q</SPAN><SPAN style=\"COLOR: black\">:</SPAN> ventilation/perfusion.</div><div class=\"graphic_reference\">Adapted with permission from: Joshi G, Cunningham A. Anesthesia for laparoscopic and robotic surgeries. In: Clinical Anesthesia, 7th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright © 2013 Lippincott Williams &amp; Wilkins. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105518 Version 2.0</div></div></div>"},"105519":{"type":"graphic_table","displayName":"Causes of subcutaneous emphysema, capnothorax, capnomediastinu","title":"Causes of subcutaneous emphysema, capnothorax, and capnomediastinum during laparoscopy and robotic surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of subcutaneous emphysema, capnothorax, and capnomediastinum during laparoscopy and robotic surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td> <ul> <li>Inadvertent peritoneal breach </li> <li>Retroperitoneal insufflation </li> <li>Misdirected Veress needle or peritoneal port (eg, damage to falciform ligament, subcutaneous needle or port placement) </li> <li>Specific to capnothorax and capnomediastinum: <ul> <li>Gas tracked through fascial planes from neck and thorax into the mediastinum and pleural space </li> <li>Dissection around the diaphragm (eg, during Nissen fundoplication, gastric bypass surgery) </li> <li>Passage of gas through the pleuroperitoneal hiatus (ie, foramen of Bochdalek) </li> <li>Passage of gas through congenital defects (ie, foramen of Morgagni) </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted with permission from: Joshi G, Cunningham A. Anesthesia for laparoscopic and robotic surgeries. In: Clinical Anesthesia, 7th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 105519 Version 2.0</div></div></div>"},"105520":{"type":"graphic_table","displayName":"Differential diagnosis hemodynamic collapse in laparoscopy","title":"Differential diagnosis of hemodynamic collapse during laparoscopy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of hemodynamic collapse during laparoscopy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Decreased cardiac preload:</td> </tr> <tr> <td class=\"indent1\">Hemorrhage</td> </tr> <tr> <td class=\"indent1\">Positional blood pooling</td> </tr> <tr> <td class=\"indent1\">Gas embolism</td> </tr> <tr> <td class=\"indent1\">Excessive intraabdominal pressure</td> </tr> <tr> <td class=\"indent1\">Capnothorax</td> </tr> <tr> <td class=\"indent1\">Cardiac tamponade due to capnomediastinum or capnopericardium</td> </tr> <tr> <td class=\"subtitle1_single\">Decreased cardiac contractility:</td> </tr> <tr> <td class=\"indent1\">Anesthetic medication effect</td> </tr> <tr> <td class=\"indent1\">Myocardial ischemia or infarction</td> </tr> <tr> <td class=\"indent1\">Acidosis due to hypercarbia</td> </tr> <tr> <td class=\"subtitle1_single\">Decreased SVR:</td> </tr> <tr> <td class=\"indent1\">Anesthetic overdose</td> </tr> <tr> <td class=\"indent1\">Acidosis due to hypercarbia</td> </tr> <tr> <td class=\"indent1\">Anaphylaxis</td> </tr> <tr> <td class=\"indent1\">Sepsis</td> </tr> <tr> <td class=\"subtitle1_single\">Bradycardia:</td> </tr> <tr> <td class=\"indent1\">Vagal stimulation</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SVR: systemic vascular resistance.</div><div class=\"graphic_reference\">Adapted from: Joshi G, Cunningham A. Anesthesia for laparoscopic and robotic surgeries. In: Clinical Anesthesia, 7th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013.</div><div id=\"graphicVersion\">Graphic 105520 Version 2.0</div></div></div>"},"105521":{"type":"graphic_table","displayName":"Differential diagnosis hypercarbia laparoscopy & robotic surgery","title":"Differential diagnosis of hypercarbia during laparoscopic and robotic surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Differential diagnosis of hypercarbia during laparoscopic and robotic surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"100%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single\">Increased CO<sub>2</sub> absorption</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>CO<sub>2</sub> insufflation (extraperitoneal insufflation &#62; intraperitoneal insufflation) </li> <li>Subcutaneous emphysema </li> <li>CO<sub>2</sub> embolism </li> <li>Capnothorax, capnomediastinum, capnopericardium </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Decreased alveolar ventilation (ie, hypoventilation, V/Q mismatch)</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Endobronchial intubation </li> <li>Atelectasis </li> <li>Airway obstruction </li> <li>Reduced cardiac output </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Increased CO<sub>2</sub> production</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Obesity </li> <li>Malignant hyperthermia </li> <li>Fever </li> <li>Thyrotoxicosis </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">CO<sub>2</sub> rebreathing</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Defective CO<sub>2</sub> absorber </li> <li>Malfunctioning breathing circuit valves </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CO<SUB>2</SUB>: carbon dioxide; <SPAN style=\"COLOR: black\">V/Q</SPAN>: ventilation/perfusion.</div><div class=\"graphic_reference\">Adapted with permission from: Joshi G, Cunningham A. Anesthesia for laparoscopic and robotic surgeries. In: Clinical Anesthesia, 7th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 105521 Version 2.0</div></div></div>"},"105522":{"type":"graphic_table","displayName":"Pulmonary changes during laparoscopic and robotic surgery","title":"Pulmonary changes during laparoscopic and robotic surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pulmonary changes during laparoscopic and robotic surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Parameter</td> <td class=\"subtitle1\">Change</td> <td class=\"subtitle1\">Causes</td> </tr> <tr class=\"divider_bottom\"> <td>Lung volume (ie, functional residual capacity)</td> <td>Decrease</td> <td> <ul> <li>Elevation of diaphragm </li> <li>Increased&nbsp;intraabdominal pressure </li> <li>Positioning </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Lung compliance</td> <td>Decreased <ul class=\"decimal_heading\"> <li>Increased pleural pressure </li> <li>Increased airway pressure </li> </ul> </td> <td> <ul> <li>Elevation of diaphragm </li> <li>Increased intraabdominal pressure </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>PCO<sub>2</sub></td> <td>Increased, depending on ventilation</td> <td>CO<sub>2</sub> absorption</td> </tr> <tr class=\"divider_bottom\"> <td>PO<sub>2</sub></td> <td>Variable</td> <td>Interaction among: <ul class=\"decimal_heading\"> <li>Atelectasis </li> <li>Hypoxic pulmonary vasoconstriction </li> <li>Preoperative pulmonary status </li> </ul> </td> </tr> <tr> <td>Tracheal position</td> <td>Cephalad displacement, possible mainstem intubation</td> <td> <ul> <li>Increased&nbsp;intraabdominal pressure </li> <li>Trendelenburg position </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">PO<SUB>2</SUB>: partial pressure of oxygen; PCO<SUB>2</SUB>: partial pressure of carbon dioxide; CO<SUB>2</SUB>: carbon dioxide.</div><div class=\"graphic_reference\">Adapted from: Joshi G, Cunningham A. Anesthesia for laparoscopic and robotic surgeries. In: Clinical Anesthesia, 7th ed, Barash PG, Cullen BF, Stoelting RK, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013.</div><div id=\"graphicVersion\">Graphic 105522 Version 2.0</div></div></div>"},"105523":{"type":"graphic_waveform","displayName":"Localizing focal interictal epileptiform discharges","title":"Localizing focal interictal epileptiform discharges","html":"<div class=\"graphic\"><div style=\"width: 808px\" class=\"figure\"><div class=\"ttl\">Localizing focal interictal epileptiform discharges</div><div class=\"cntnt\"><img style=\"width:788px; height:739px;\" src=\"images/SLEEP/105523_Lclzng_fcl_intrctl_eplptfrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) EEG 10-second epoch, longitudinal bipolar montage. Focal spike and slow wave epileptiform discharge localized to T3 based on the phase reversal of the discharge (arrowhead).<br />(B) EEG 10-second epoch, Cz referential montage. The same focal spike and slow wave epileptiform discharge from panel A, localized to T3 based on the highest amplitude of the discharge (arrowhead).</div><div class=\"graphic_footnotes\">EEG: electroencephalography; ECG: electrocardiography.</div><div id=\"graphicVersion\">Graphic 105523 Version 1.0</div></div></div>"},"105524":{"type":"graphic_picture","displayName":"Psychogenic purpura","title":"Psychogenic purpura","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Psychogenic purpura</div><div class=\"cntnt\"><img style=\"width:392px; height:247px;\" src=\"images/HEME/105524_Pschgnc_prpr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The image shows a bruise on the left lateral thigh of a 48-year-old woman with a one-year history of spontaneous skin bruising associated with skin stinging, popping, and pulsating sensation. This lesion had appeared 16&nbsp;hours earlier. Petechiae and multiple ecchymoses seen in the image were nonpalpable but tender. Extensive workup for a bleeding disorder was negative. Skin biopsies of areas involved with bruises showed a mild perivascular granulocytic infiltrate around dermal capillaries but no frank vasculitis. There was a striking absence of erythrocyte extravasation.</div><div class=\"graphic_reference\">From: Moll S. Psychogenic purpura. Am J Hematol 1997; 55:146. <a href=\"http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1096-8652(199707)55:3%3C146::AID-AJH5%3E3.0.CO;2-S/abstract\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1002/(SICI)1096-8652(199707)55:3%3C146::AID-AJH5%3E3.0.CO;2-S/abstract</a>. Copyright &copy; 1997 Wiley Periodicals, Inc. Reproduced with permission of John Wiley &amp; Sons, Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared, or emailed. Please contact Wiley's Permissions Department either via email: <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true\">permissions@wiley.com</a> or use the RightsLink service by clicking on the Request Permission link accompanying this article on Wiley Online Library (<a href=\"http://www.onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">www.onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 105524 Version 1.0</div></div></div>"},"105528":{"type":"graphic_diagnosticimage","displayName":"Rectus sheath ultrasound","title":"Rectus sheath ultrasound","html":"<div class=\"graphic\"><div style=\"width: 784px\" class=\"figure\"><div class=\"ttl\">Rectus sheath ultrasound</div><div class=\"cntnt\"><img style=\"width:764px; height:331px;\" src=\"images/ANEST/105528_Rectus_sheath_ultrasound.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The first ultrasound image shows a needle with the needle-tip positioned below the rectus muscle. The second ultrasound image is one second later as LA is injected to lift the rectus muscle off the posterior rectus sheath.</div><div class=\"graphic_footnotes\">R: rectus muscle; I: injectate (local anesthetic); PRS: posterior rectus sheath (twin \"tram\"-lines); LA: local anesthetic.</div><div class=\"graphic_reference\">Reproduced with permission from: Webster K. Ultrasound Guided rectus sheath block &ndash; analgesia for abdominal surgery. Update in Anaesthesia 2010; 26:12, available at: <a href=\"http://www.wfsahq.org/resources/update-in-anaesthesia\" target=\"_blank\">www.wfsahq.org/resources/update-in-anaesthesia</a>. Copyright &copy; 2010 Update in Anaesthesia. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105528 Version 1.0</div></div></div>"},"105545":{"type":"graphic_table","displayName":"Clinical diagnosis CNS findings SCD","title":"Clinical distinction between stroke, cerebral malaria, and bacterial meningitis in patients with sickle cell disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical distinction between stroke, cerebral malaria, and bacterial meningitis in patients with sickle cell disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">History</td> <td class=\"subtitle1\">Presenting symptoms</td> <td class=\"subtitle1\">Examination</td> <td class=\"subtitle1\">Laboratory findings</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Acute stroke</strong></td> <td> <ul> <li>May have a history of prior strokes or cognitive deficits </li> </ul> </td> <td> <ul> <li>Sudden onset </li> <li>Focal abnormalities </li> </ul> </td> <td> <ul> <li>Focal neurologic findings </li> <li>May have fever </li> </ul> </td> <td> <ul> <li>No specific findings </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Cerebral malaria</strong></td> <td> <ul> <li>Young child (typically &#60;5 years) </li> </ul> </td> <td> <ul> <li>Gradual or sudden </li> <li>Generalized encephalopathy, coma or seizures </li> </ul> </td> <td> <ul> <li>Altered mental status </li> <li>Coma at least one hour after termination of a seizure or correction of hypoglycemia </li> </ul> </td> <td> <ul> <li>Hematuria </li> <li>Relative anemia </li> <li>Asexual forms of <em>Plasmodium falciparum</em> parasites on peripheral blood smear </li> </ul> </td> </tr> <tr> <td><strong>Meningitis (bacterial or tuberculous)</strong></td> <td> <ul> <li>Typically nonspecific </li> </ul> </td> <td> <ul> <li>Gradual or sudden </li> <li>May have fever, meningeal signs, seizures </li> </ul> </td> <td> <ul> <li>Fever </li> <li>Meningismus </li> </ul> </td> <td> <ul> <li>White blood cells in CSF </li> <li>Low CSF glucose (CSF glucose &#60;50 mg/dL or CSF/blood glucose ratio of &#60;0.5) </li> <li>High CSF protein </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">This table describes clinical features that can be used to distinguish acute stroke from other conditions in resource-poor settings where routine CNS imaging is not available. Refer to UpToDate content on SCD in sub-Saharan Africa for further details of the evaluation and management. If the diagnosis is uncertain, it may be appropriate to treat for more than one condition until further information&nbsp;is obtained&nbsp;from the clinical course, laboratory findings, or microbiology.</div><div class=\"graphic_footnotes\">CNS: central nervous system; SCD: sickle cell disease; CSF: cerebrospinal fluid.</div><div id=\"graphicVersion\">Graphic 105545 Version 2.0</div></div></div>"},"105554":{"type":"graphic_picture","displayName":"Endoscopy of portal hypertensive gastropathy","title":"Portal hypertensive gastropathy","html":"<div class=\"graphic\"><div style=\"width: 638px\" class=\"figure\"><div class=\"ttl\">Portal hypertensive gastropathy</div><div class=\"cntnt\"><img style=\"width:618px; height:683px;\" src=\"images/GAST/105554_Endscpy_prt_hprtn_gstrp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(Panels A and B) Representative images of mild portal hypertensive gastropathy (PHG). Panel A shows a forward-viewing image of the proximal stomach. Panel B shows a retroflex view of the cardia with the classic form of PHG, the typical \"mosaic-like pattern\" without significant stigmata of bleeding or erythema or edema.<br />(Panels C and D) Representative images of severe PHG. Red lesions of variable diameter are evident. There is often irregular mucosa. Cherry spots may be confluent or not. Slow oozing may also be seen as in panel D, an up-close view in the proximal stomach.</div><div class=\"graphic_reference\">Reproduced from: Urrunaga NH, Rockey DC. Portal Hypertensive Gastropathy and Colopathy. Clin Liver Dis 2014; 18:389. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105554 Version 1.0</div></div></div>"},"105564":{"type":"graphic_picture","displayName":"Habit tic deformity onychotillomania","title":"Habit tic deformity onychotillomania","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Habit tic deformity onychotillomania</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/105564_Habit_tic_deform_onychotill.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105564 Version 1.0</div></div></div>"},"105574":{"type":"graphic_picture","displayName":"Fox-Fordyce disease in axilla","title":"Fox-Fordyce disease","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Fox-Fordyce disease</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/105574_Fox_Frdyc_dss_axll.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple follicular papules in the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105574 Version 1.0</div></div></div>"},"105576":{"type":"graphic_picture","displayName":"Fox-Fordyce disease in axilla 2","title":"Fox-Fordyce disease","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Fox-Fordyce disease</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/105576_Fox_Frdyc_dss_axll_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple follicular papules in the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105576 Version 1.0</div></div></div>"},"105577":{"type":"graphic_picture","displayName":"Fox-Fordyce disease in axilla 3","title":"Fox-Fordyce disease","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Fox-Fordyce disease</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/105577_Fx_Frdyc_dss_axll_3.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple follicular papules in the axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105577 Version 1.0</div></div></div>"},"105578":{"type":"graphic_picture","displayName":"Fox-Fordyce disease on areola","title":"Fox-Fordyce disease","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Fox-Fordyce disease</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/105578_Fox_Frdyc_dss_arl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple follicular papules on the areola.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105578 Version 1.0</div></div></div>"},"105580":{"type":"graphic_picture","displayName":"MPCM in adults","title":"Maculopapular cutaneous mastocytosis in adults","html":"<div class=\"graphic\"><div style=\"width: 818px\" class=\"figure\"><div class=\"ttl\">Maculopapular cutaneous mastocytosis in adults</div><div class=\"cntnt\"><img style=\"width:798px; height:429px;\" src=\"images/ALLRG/105580_MPCM_adult.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MPCM in patients with adulthood-onset mastocytosis.<br />(A) Characteristic small brown monomorphic lesions often start to develop on the thigh.<br />(B-E) Lesions spread over several years to the trunk and extremities.<br />(F) Confluence of lesions might be associated with advanced SM categories.</div><div class=\"graphic_footnotes\">MPCM: maculopapular cutaneous mastocytosis; SM: systemic mastocytosis.</div><div class=\"graphic_reference\">Reproduced from: Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma &amp; Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 2015. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105580 Version 1.0</div></div></div>"},"105581":{"type":"graphic_picture","displayName":"Maculopapular cutaneous mastocytosis in children","title":"Maculopapular cutaneous mastocytosis in children","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Maculopapular cutaneous mastocytosis in children</div><div class=\"cntnt\"><img style=\"width:333px; height:808px;\" src=\"images/ALLRG/105581_MPCM_chldrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">MPCM in patients with childhood-onset mastocytosis. (A-G) Most children have characteristic large brown lesions of different sizes (polymorphic). Lesion margins can be sharp (A and E) or indistinct (B and G) and elevated (C and E) or flat (B and F). Nodular lesions present during infancy (C and E) may develop into plaques or macules at the age of 5 to 10 years (D and F) before they regress by adolescence. (G) Lesions on the forehead are characteristic for polymorphic MPCM. (H and I) Few pediatric patients show small monomorphic lesions like the ones observed in adults. (J) Atypical variants can also occur in children, such as one with yellow firm lesions, which was previously also termed xanthelasmoid CM.</div><div class=\"graphic_footnotes\">MPCM: maculopapular cutaneous mastocytosis; SM: systemic mastocytosis; CM: cutaneous mastocytosis.</div><div class=\"graphic_reference\">Reproduced from: Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma &amp; Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 2015. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105581 Version 2.0</div></div></div>"},"105583":{"type":"graphic_picture","displayName":"Fox-Fordyce disease in pubic area","title":"Fox-Fordyce","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Fox-Fordyce</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/105583_Fox_Frdyc_dss_pbc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple follicular papules in the pubic area.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105583 Version 1.0</div></div></div>"},"105584":{"type":"graphic_picture","displayName":"Diffuse cutaneous mastocytosis - Multiple images","title":"Diffuse cutaneous mastocytosis","html":"<div class=\"graphic\"><div style=\"width: 818px\" class=\"figure\"><div class=\"ttl\">Diffuse cutaneous mastocytosis</div><div class=\"cntnt\"><img style=\"width:798px; height:429px;\" src=\"images/ALLRG/105584_DCM.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) DCM is characterized by erythema and generalized thickened skin.<br />(B and C) Papules can be associated with DCM.<br />(D) Pronounced dermographism is characteristic for DCM.<br />(E and F) Infants with DCM often present initially with large blisters.<br />(C and F) Courtesy of the National Institutes of Health/National Institute of Allergy and Infectious Diseases.</div><div class=\"graphic_footnotes\">DCM: diffuse cutaneous mastocytosis.</div><div class=\"graphic_reference\">Reproduced from: Hartmann K, Escribano L, Grattan C, et al. Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma &amp; Immunology; and the European Academy of Allergology and Clinical Immunology. J Allergy Clin Immunol 2015. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105584 Version 2.0</div></div></div>"},"105586":{"type":"graphic_table","displayName":"Diagnoses and findings in children with joint pain or swelling","title":"Serious diagnoses and associated findings in children with joint pain and/or swelling","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Serious diagnoses and associated findings in children with joint pain and/or swelling</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Emergency diagnoses</td> <td class=\"subtitle1\">Typical clinical features</td> <td class=\"subtitle1\">Investigations</td> </tr> <tr> <td>Septic arthritis or osteomyelitis</td> <td>Hectic, spiking&nbsp;fever; ill appearance; rash; rapid-onset monoarthritis; pseudo-paralysis; pinpoint bony tenderness</td> <td>Blood cultures, arthrocentesis for microscopy and culture, blood count, imaging of affected bone/joint (plain radiograph, CT scan)</td> </tr> <tr> <td>Kawasaki disease</td> <td>Hectic fever, irritable infant, sentinel cervical lymph node, conjunctivitis, oral mucositis, peripheral arthralgia/edema, rash, carditis, peeling fingertips</td> <td>Echocardiography, exclude sepsis, blood count and acute phase proteins</td> </tr> <tr> <td>Neoplasia</td> <td>Irritability, pallor, unexplained bruising, bone pain (especially nocturnal)</td> <td>Blood count, bone marrow examination, abdominal ultrasound, imaging of affected area</td> </tr> <tr> <td>Nonaccidental injury</td> <td>Disparities between history given and features on examination, irritability, pallor, unexplained bruising and other injuries, bone pain</td> <td>Blood count, bleeding and clotting studies, skeletal survey, refer to child protection procedures for your hospital</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Courtesy of Taunton R Southwood, MD, FRACP, FRCPA, FRCP, FRCPCH and Yukiko Kimura, MD.</div><div id=\"graphicVersion\">Graphic 105586 Version 1.0</div></div></div>"},"105588":{"type":"graphic_table","displayName":"STEPW subm fibroid classific","title":"STEPW submucosal fibroid classification system","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">STEPW submucosal fibroid classification system</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Size (cm)</td> <td class=\"subtitle1\">Topography</td> <td class=\"subtitle1\">Extension of the base</td> <td class=\"subtitle1\">Penetration</td> <td class=\"subtitle1\">Lateral wall</td> <td class=\"subtitle1\">Total</td> </tr> <tr> <td>0</td> <td>&#60;2</td> <td>Low</td> <td>&#60;1/3</td> <td>0</td> <td class=\"divider_bottom centered\" style=\"vertical-align: middle;\" rowspan=\"3\">+1</td> <td class=\"highlight_gray_text divider_bottom\" rowspan=\"3\">&nbsp;</td> </tr> <tr> <td>1</td> <td>&#62;2 to 5</td> <td>Middle</td> <td>&#62;1/3 to 2/3</td> <td>&#60;50%</td> </tr> <tr class=\"divider_bottom\"> <td>2</td> <td>&#62;5</td> <td>Upper</td> <td>&#62;2/3</td> <td>&#62;50%</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Score</strong></td> <td style=\"text-align: right;\"><strong>+</strong></td> <td style=\"text-align: right;\"><strong>+</strong></td> <td style=\"text-align: right;\"><strong>+</strong></td> <td style=\"text-align: right;\"><strong>+</strong></td> <td style=\"text-align: right;\"><strong>+</strong></td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1 highlight_green_text\" colspan=\"7\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1\">Score</td> <td class=\"subtitle1\">Group</td> <td class=\"subtitle1\" colspan=\"5\">Complexity and therapeutic options</td> </tr> <tr> <td>0 to 4</td> <td>I</td> <td colspan=\"5\">Low-complexity hysteroscopic myomectomy.</td> </tr> <tr> <td>5 to 6</td> <td>II</td> <td colspan=\"5\">High-complexity hysteroscopic myomectomy. Consider GnRH use? Consider two-step hysteroscopic myomectomy.</td> </tr> <tr> <td>7 to 9</td> <td>III</td> <td colspan=\"5\">Consider alternatives to the hysteroscopic technique.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">STEPW: size, topography, extension, penetration, wall; GnRH: gonadotropin-releasing hormone.</div><div class=\"graphic_reference\">Reproduced from: Lasmar RB, Xinmei Z, Indman PD, et al. Feasibility of a new system of classification of submucous myomas: a multicenter study. Fertil Steril 2011; 95:2073. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105588 Version 1.0</div></div></div>"},"105589":{"type":"graphic_picture","displayName":"Pancreatoscopy MD-IPMN","title":"Pancreatoscopy of a main-duct intraductal papillary mucinous tumor (IPMN)","html":"<div class=\"graphic\"><div style=\"width: 568px\" class=\"figure\"><div class=\"ttl\">Pancreatoscopy of a main-duct intraductal papillary mucinous tumor (IPMN)</div><div class=\"cntnt\"><img style=\"width:548px; height:546px;\" src=\"images/GAST/105589_Pncrtscpy_MD_IPMN.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Digital pancreatoscopy of a main-duct IPMN in the pancreatic head. This lesion was not seen on magnetic resonance cholangiopancreatography or endoscopic ultrasound. A noninvasive adenocarcinoma was detected when the lesion was surgically resected.</div><div id=\"graphicVersion\">Graphic 105589 Version 1.0</div></div></div>"},"105592":{"type":"graphic_picture","displayName":"Neutropenia-associated periodontitis","title":"Neutropenia-associated periodontitis","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">Neutropenia-associated periodontitis</div><div class=\"cntnt\"><img style=\"width:784px; height:396px;\" src=\"images/PEDS/105592_Ntrpnasscprdntt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Periodontitis in a four-year-old girl with autoimmune neutropenia. Note the severe erythematous gingivitis and gingival recession revealing the cervical portion of the roots of the central incisors (arrows), indicative of alveolar bone loss.</div><div id=\"graphicVersion\">Graphic 105592 Version 2.0</div></div></div>"},"105594":{"type":"graphic_figure","displayName":"Sickle pain schema","title":"Sickle pain schema","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Sickle pain schema</div><div class=\"cntnt\"><img style=\"width:534px; height:586px;\" src=\"images/HEME/105594_Sickle_pain_schema.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is a general approach for a patient with SCD who presents to the emergency department with a painful episode. Individual care plans and local institutional protocols should also be consulted. We do not use nonsteroidal anti-inflammatory drugs (NSAIDs) for acute pain in hospitalized patients due to lack of demonstrated efficacy and clear evidence that they may cause serious complications, especially ketorolac. Refer to UpToDate content on SCD for additional information.</div><div class=\"graphic_footnotes\">PCA: patient controlled analgesia; HELLP: hemolysis, elevated liver function tests, low platelets; SCD: sickle cell disease; IV: intravenous.</div><div id=\"graphicVersion\">Graphic 105594 Version 2.0</div></div></div>"},"105596":{"type":"graphic_algorithm","displayName":"Genetic testing in thoracic aortic aneurysm or dissection","title":"Genetic testing in thoracic aortic aneurysm or dissection","html":"<div class=\"graphic\"><div style=\"width: 872px\" class=\"figure\"><div class=\"ttl\">Genetic testing in thoracic aortic aneurysm or dissection</div><div class=\"cntnt\"><img style=\"width:852px; height:638px;\" src=\"images/SURG/105596_Genetic_thorcic_artc_anrysm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Several issues are still open about genetic testing, in particular in sporadic TAADs. In familial TAADs, existing knowledge on disease genes provides the basis for implementing disease-specific diagnostic work-up and genetic testing. Advanced technologies for DNA sequencing NGS platforms will rapidly modify the current scenario and increase the series of TAADs specifically diagnosed on the basis of the disease genes. In parallel, clinical phenotypes associated with mutations of the different disease genes will be confirmed.</div><div class=\"graphic_footnotes\">TAADs: thoracic aortic aneurysms and dissections; DNA: deoxyribonucleic acid; NGS: next generation sequencing; LDS: Loeys-Dietz syndrome; PDA: patent ductus arteriosus; AOS: aneurysm-osteoarthritis syndrome.</div><div class=\"graphic_reference\">Original figure modified for this publication. Arbustini E, Narula N. Extra-aortic identifiers to guide genetic testing in familial thoracic aortic aneurysms and dissections syndromes: it is all about the company one keeps. J Am Coll Cardiol 2012; 60:404. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105596 Version 1.0</div></div></div>"},"105611":{"type":"graphic_table","displayName":"Risk factors for resistance in patients with acute sinusitis","title":"Risk factors for resistance in patients with acute sinusitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors for resistance in patients with acute sinusitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Living in geographic regions with rates of penicillin-nonsusceptible <em>S. pneumonia</em> exceeding 10%*</td> </tr> <tr> <td>Age &#8805;65 years</td> </tr> <tr> <td>Hospitalization in the last five days</td> </tr> <tr> <td>Antibiotic use in the previous month</td> </tr> <tr> <td>Immunocompromise</td> </tr> <tr> <td>Multiple comorbidities (eg, diabetes or chronic cardiac, hepatic, or renal disease)</td> </tr> <tr> <td>Severe infection (eg, evidence of systemic toxicity with temperature of &#8805;102&#176;F, threat of suppurative complications)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Local and regional histograms of bacterial resistance should be referenced to understand resistance trends in the local community.</div><div id=\"graphicVersion\">Graphic 105611 Version 1.0</div></div></div>"},"105614":{"type":"graphic_table","displayName":"Risk assessment for HIV, HBV, or HCV infection","title":"Risk assessment for HIV, HBV, or HCV infection","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk assessment for HIV, HBV, or HCV infection</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">The following questions should be asked of all living donor candidates:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Have you had sex with a person known or suspected to have HIV, HBV, or HCV infections in the preceding 12 months? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>If male: Have you had sex with another man in the preceding 12 months? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>If female: Have you had sex with a man with a history of MSM behavior in the preceding 12 months? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Have you had sex in exchange for money or drugs in the preceding 12 months? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Have you had sex with a person that has injected drugs (by IV, IM, or subcutaneous route) for nonmedical reasons in the preceding 12 months? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Have you injected drugs (by IV, IM, or subcutaneous route) for nonmedical reasons in the preceding 12 months? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Have you been in lockup, jail, prison, or a juvenile correctional facility for more than 72 hours in the preceding 12 months? </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Have you been newly diagnosed with or have been treated for syphilis, gonorrhea, <em>Chlamydia</em>, or genital ulcers in the preceding 12 months? </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Have you been on hemodialysis in the preceding 12 months?* </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">If using a checklist, include the following criteria and mark \"not applicable\":</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>A child who is &#8804;18 months of age and born to a mother known to be infected with, or at increased risk for, HIV, HBV or HCV infection. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>A child who has been breastfed within the preceding 12 months and the mother is known to be infected with, or at increased risk for, HIV infection. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HIV: human immunodeficiency virus; HBV: hepatitis B virus; HCV: hepatitis C virus; MSM: male sex with male; IV: intravenous; IM: intramuscular.<br />* This criterion identifies donor candidates who are at increased risk for recent HCV infection only.</div><div class=\"graphic_reference\">Reference: Seem DL, Lee I, Umscheid CA, Kuehnert MJ. Excerpt from PHS guideline for reducing HIV, HBV, and HCV transmission through organ transplantation. Am J Transplant 2013; 13:1953.</div><div id=\"graphicVersion\">Graphic 105614 Version 1.0</div></div></div>"},"105636":{"type":"graphic_figure","displayName":"Residual renal function in hemodialysis patients (Kru)","title":"Residual renal function in hemodialysis patients (Kru)","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Residual renal function in hemodialysis patients (Kru)</div><div class=\"cntnt\"><img style=\"width:452px; height:478px;\" src=\"images/NEPH/105636_Resd_rnl_fnctn_hmdlyss_pat.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><ul>&#xD;&#xA;    <li>10,080 is the number of minutes in a week.</li>&#xD;&#xA;    <li>Equation 1 expresses weekly intermittent dialyzer clearance as continuous clearance.</li>&#xD;&#xA;    <li>Equation 2 incorporates S into a variable volume model that accounts for ultrafiltration and for residual kidney function.</li>&#xD;&#xA;</ul></div><div class=\"graphic_footnotes\">S: stdKt/V assuming constant volume; stdKt/V: standard Kt/V; N: number of dialyses per week; U<SUB>f</SUB>: weekly ultrafiltration volume in mL; V: volume of urea distribution in mL; Kru: residual native kidney clearance of urea in mL/min; F: number of sessions per week.</div><div class=\"graphic_reference\">From: National Kidney Foundation. KDOQI Clinical Practice Guideline for hemodialysis adequacy: 2015 update. Am J Kidney Dis 2015; 66:884.</div><div id=\"graphicVersion\">Graphic 105636 Version 1.0</div></div></div>"},"105651":{"type":"graphic_figure","displayName":"Classification of sports","title":"Classification of sports based on peak static and dynamic components during competition","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Classification of sports based on peak static and dynamic components during competition</div><div class=\"cntnt\"><img style=\"width:558px; height:566px;\" src=\"images/CARD/105651_Classification_of_sports.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This classification is based on peak static and dynamic components achieved during competition; however, higher values may be reached during training. The increasing dynamic component is defined in terms of the estimated percentage of maximal oxygen uptake (VO<sub>2max</sub>) achieved and results in an increasing cardiac output. The increasing static component is related to the estimated percentage of maximal voluntary contraction reached and results in an increasing blood pressure load. The lowest total cardiovascular demands (cardiac output and blood pressure) are shown in the palest color, with increasing dynamic load depicted by increasing blue intensity and increasing static load by increasing red intensity. Note the graded transition between categories, which should be individualized on the basis of player position and style of play.</div><div class=\"graphic_footnotes\">* Danger of bodily collision (see related&nbsp;table on sports according to risk of impact and educational&nbsp;background)<br />¶ Increased risk if syncope occurs.<SUP>[1]</SUP></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Mitchell JH, Haskell W, Snell P, Van Camp SP. Task Force 8: classification of sports. J Am Coll Cardiol 2005; 45:1364.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Levine BD, Baggish AL, Kovacs RJ. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 1: Classification of Sports: Dynamic, Static, and Impact: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol 2015; 66:2350. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105651 Version 2.0</div></div></div>"},"105653":{"type":"graphic_figure","displayName":"Survival nomogram after resection typical bronchial carcinoid","title":"Nomogram to predict five-year survival after resection of a typical bronchial carcinoid tumor","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Nomogram to predict five-year survival after resection of a typical bronchial carcinoid tumor</div><div class=\"cntnt\"><img style=\"width:571px; height:512px;\" src=\"images/ONC/105653_Srvvl_nmgr_aftr_rsct_typ_brnch_crcn.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Nomogram derived from the Cox model.</div><div class=\"graphic_footnotes\">pTNM: pathologic tumor, node, metastasis (TNM) stage according to the American Joint Committee on Cancer; ECOG PS: performance status, according to the scale of the Eastern Cooperative Oncology Group (ECOG).</div><div class=\"graphic_reference\">Reproduced from: Filosso PL, Guerrera F, Evangelista A, et al. Prognostic model of survival for typical bronchial carcinoid tumours: Analysis of 1109 patients on behalf of the European Association of Thoracic Surgeons (ESTS) Neuroendocrine Tumours Working Group. Eur J Cardiothorac Surg 2015; 48(3):441-7, by permission of Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. Copyright © 2017.</div><div id=\"graphicVersion\">Graphic 105653 Version 3.0</div></div></div>"},"105656":{"type":"graphic_algorithm","displayName":"Algorithm for suspected foreign body aspiration in children","title":"Algorithm for suspected foreign body aspiration in children","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">Algorithm for suspected foreign body aspiration in children</div><div class=\"cntnt\"><img style=\"width:534px; height:498px;\" src=\"images/PEDS/105656_Algo_suspctd_forgn_body_asp.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CT: computerized tomography; FBA: foreign body aspiration.<br />* Refer to algorithm for complete airway obstruction in children.<br />&para; A moderate or high suspicion of foreign body aspiration includes all children with a witnessed FBA (regardless of symptoms), and those with suggestive respiratory symptoms or suspicious characteristics on imaging, especially if there is a history of choking.<br />&Delta; For stable patients with a high clinical suspicion of aspiration, it is reasonable to proceed directly to bronchoscopy, even if the plain radiographs are normal or inconclusive. Alternatively, computed tomography (CT) can be performed first to help clarify the diagnosis (dotted line), if the provider judges that negative imaging would be sufficient to preclude bronchoscopy.<br /><span class=\"lozenge\">&loz;</span> Rigid bronchoscopy is the procedure of choice to remove a foreign body. In cases where the diagnosis or location of the foreign body is unclear, it is usually preferable to perform flexible bronchoscopy first, then proceed to rigid bronchoscopy for foreign body removal.</div><div class=\"graphic_reference\">Courtesy of Fadel Ruiz, MD.</div><div id=\"graphicVersion\">Graphic 105656 Version 3.0</div></div></div>"},"105660":{"type":"graphic_figure","displayName":"BMI decline after bariatric surgery in adolescents","title":"Decline in body mass index after bariatric surgery in adolescents","html":"<div class=\"graphic\"><div style=\"width: 578px\" class=\"figure\"><div class=\"ttl\">Decline in body mass index&nbsp;after bariatric surgery in adolescents</div><div class=\"cntnt\"><img style=\"width:558px; height:504px;\" src=\"images/PEDS/105660_Wt_loss_bariatric_surg_adol.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Changes in body mass index (BMI) among 228 adolescents undergoing&nbsp;sleeve gastrectomy (SG&nbsp;= 67) or roux-en-y gastric bypass (RYGB&nbsp;= 161).&nbsp;Mean preoperative BMI for each procedure is compared with mean BMI three years postoperatively (SG = 48; RYGB = 125). </div><div class=\"graphic_reference\">Data from: Inge TH, Courcoulas AP, Jenkins TM, et al. Weight Loss and Health Status 3 Years after Bariatric Surgery in Adolescents. N Engl J Med 2015.</div><div id=\"graphicVersion\">Graphic 105660 Version 3.0</div></div></div>"},"105665":{"type":"graphic_diagnosticimage","displayName":"Aortic dissection noncontrast CT","title":"Aortic dissection noncontrast CT","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Aortic dissection noncontrast CT</div><div class=\"cntnt\"><img style=\"width:756px; height:492px;\" src=\"images/SURG/105665_Aortic_dissection_CT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this noncontrast CT scan, calcification is appreciated in the middle of the aortic lumen. Displacement of calcification may be an indicator of a dissection flap of an aortic dissection.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div id=\"graphicVersion\">Graphic 105665 Version 1.0</div></div></div>"},"105673":{"type":"graphic_table","displayName":"The effects of anesthetic agents on cerebral physiology","title":"The effects of anesthetic agents on cerebral physiology","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The effects of anesthetic agents on cerebral physiology</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Anesthetic agents</td> <td class=\"subtitle1\">CMRO<sub>2</sub></td> <td class=\"subtitle1\">CBF</td> <td class=\"subtitle1\">ICP</td> <td class=\"subtitle1\">Cerebral autoregulation</td> </tr> <tr> <td>Nitrous oxide</td> <td>&#8593;&#8593;</td> <td>&#8593;&#8593;&#8593;</td> <td>&#8593;&#8593;</td> <td>No change</td> </tr> <tr> <td>Sevoflurane</td> <td>&#8595;</td> <td>&#8593;&#8593;</td> <td>&#8593;</td> <td>No change</td> </tr> <tr> <td>Isoflurane</td> <td>&#8595;&#8595;</td> <td>&#8593;</td> <td>&#8593;</td> <td>No change</td> </tr> <tr> <td>Desflurane</td> <td>&#8595;</td> <td>&#8593;&#8593;&#8593;</td> <td>&#8593;&#8593;</td> <td>No change</td> </tr> <tr> <td>Propofol, thiopental, and etomidate</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;&#8595;</td> <td>&#8595;&#8595;</td> <td>No change</td> </tr> <tr> <td>Benzodiazepines</td> <td>&#8595;</td> <td>&#8595;&#8595;</td> <td>&#8595;</td> <td>No change</td> </tr> <tr> <td>Ketamine</td> <td>&#8593;&#8593;</td> <td>Unknown</td> <td>Unknown</td> <td>No change</td> </tr> <tr> <td>Dexmedetomidine</td> <td>&#8595;&#8595;</td> <td>&#8595;</td> <td>No change</td> <td>&#8595;</td> </tr> <tr> <td>Opioids</td> <td>&#8593;</td> <td>&#8595;&#8595;</td> <td>&#8595;</td> <td>No change</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For further details, refer to the UpToDate topic on anesthesia for craniotomy.</div><div class=\"graphic_footnotes\">CMRO<sub>2</sub>: cerebral metabolic rate of oxygen; CBF: cerebral blood flow; ICP: intracranial pressure.</div><div id=\"graphicVersion\">Graphic 105673 Version 3.0</div></div></div>"},"105674":{"type":"graphic_figure","displayName":"OPT of male urethral embryonic development","title":"Optical projection tomography demonstrating male urethral embryonic development","html":"<div class=\"graphic\"><div style=\"width: 790px\" class=\"figure\"><div class=\"ttl\">Optical projection tomography demonstrating male urethral embryonic development</div><div class=\"cntnt\"><img style=\"width:770px; height:520px;\" src=\"images/PEDS/105674_OPT_male_urethral_embry_dev.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Optical projection tomography demonstrating male urethral development from 6.5 to 16.5 weeks of gestation. Note the progression of the urethral meatus from scrotal folds at 6.5 weeks gestation&nbsp;to a terminal position on the glans at 16.5 weeks gestation. Wide open urethral groove is best seen from 9.5 to 13 weeks gestation, with progression of proximal to distal fusion of the edges of the&nbsp;urethral groove to form the tubular urethra. At 13 weeks gestation, the urethral groove is within the glans penis&nbsp;and the&nbsp;tubular urethra is completely formed within the shaft of the penis.</div><div class=\"graphic_reference\">Reproduced from: Li Y, Sinclair A, Cao M, et al. Canalization of the Urethral Plate Precedes Fusion of the Urethral Folds during Male Penile Urethral Development: The Double Zipper Hypothesis. J Urol 2015; 193:1353. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105674 Version 1.0</div></div></div>"},"105677":{"type":"graphic_picture","displayName":"Anatomy of vulvar vestibule","title":"Anatomy of vulvar vestibule","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Anatomy of vulvar vestibule</div><div class=\"cntnt\"><img style=\"width:538px; height:503px;\" src=\"images/OBGYN/105677_Anatomy_of_vulvar_vestibule.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shaded&nbsp;area includes tissue inside of Hart's line</div><div id=\"graphicVersion\">Graphic 105677 Version 3.0</div></div></div>"},"105678":{"type":"graphic_table","displayName":"Common causes of groin and hip pain in the athlete","title":"Common causes of groin and hip pain in the athlete","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common causes of groin and hip pain in the athlete</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition</td> <td class=\"subtitle1\">Common &#38; important examples</td> <td class=\"subtitle1\">History &#38; mechanism</td> <td class=\"subtitle1\">Physical examination</td> <td class=\"subtitle1\">Diagnostic testing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Acute or acute-on-chronic conditions</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Muscle &#38; tendon injuries</td> <td>Adductor strain</td> <td>Often acute strain that occurs w intense, repetitive, side to side movement (eg, skating), sprinting, or sudden forced hip abduction; Causes proximal groin/inguinal pain</td> <td>Focal groin/inguinal tenderness at muscle origin; pain w resisted hip adduction</td> <td>US; MRI (typically unnecessary)</td> </tr> <tr> <td>Quadriceps strain (rectus femoris most common)</td> <td>Often acute strain that occurs w rapid change of direction while sprinting or when landing from jump; Causes proximal anterior thigh pain</td> <td>Focal tenderness at site of injury; Hip flexion activities (eg, climbing stairs) &#38; resisted hip flexion cause pain</td> <td>US; MRI (typically unnecessary)</td> </tr> <tr> <td>Hamstring strain</td> <td>Often acute strain that occurs with sprinting or hill running; Causes proximal posterior thigh pain</td> <td>Focal tenderness at MT junction and/or tendon insertion onto ischial tuberosity; Pain with resisted knee flexion &#38; hip extension</td> <td>US; MRI (typically unnecessary)</td> </tr> <tr class=\"divider_bottom\"> <td>External snapping hip</td> <td>Patient c/o palpable or audible \"snap\" in area of greater trochanter w particular hip movements; may or may not be painful </td> <td>Some combination of hip flexion, abduction, and/or external rotation reproduces symptoms</td> <td>Dynamic US may reveal tendon motion w particular hip movements</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Trochanteric pain syndrome (formerly trochanteric \"bursitis\")</td> <td>&nbsp;</td> <td>Lateral hip pain at &#38; around greater trochanter; pain often increases w running or climbing stairs or inclines; caused by insertional tendinopathy</td> <td>Focal tenderness at greater trochanter; Resisted hip abduction, hip internal rotation, or FABER test may elicit pain</td> <td>US often reveals tendon abnormalities</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Labral tear</td> <td>&nbsp;</td> <td>Groin pain exacerbated by sport, often jumping or sprinting involving aggressive hip flexion, or develops towards end of long runs; Groin pain may occur w sitting, transition to standing, descending stairs, or putting on shoes while seated</td> <td>Pain increases w repeated hip flexion, resisted hip flexion, and FADIR test</td> <td>MRA may be necessary for Dx &#38; to distinguish from femoracetabular impingement</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Stress fracture</td> <td>Femoral neck stress fracture</td> <td>May start w vague groin pain that worsens &#38; localizes over time; acute increase in pain w weight-bearing activity; relatively common w running, dance, and jumping sports; more common in women</td> <td>Pain may increase when hip placed at extremes of motion; Hopping test often positive</td> <td>Plain radiographs diagnostic if reveal fracture but may be normal; MRI preferred study</td> </tr> <tr> <td>Proximal femoral shaft stress fracture</td> <td>Often starts w vague anterior thigh pain that worsens and localizes to proximal thigh over time; acute increase in pain w weight-bearing activity; more common in runners &#38; women</td> <td>Hopping and fulcrum tests often positive</td> <td>Plain radiographs diagnostic if reveal fracture but may be normal; MRI preferred study</td> </tr> <tr> <td>Sacral stress fracture</td> <td>Persistent pain in region of SI joint; more common in women involved in running or jumping sports</td> <td>Tenderness w palpation of bony prominences of sacrum - pain is diffuse and NOT only at the SI joint; NO pain with resisted strength testing of gluteal muscles</td> <td>Plain radiographs often unrevealing; MRI preferred study</td> </tr> <tr class=\"divider_bottom\"> <td>Pubic ramus stress fracture</td> <td>Pain in region of pubic ramus; occurs in distance runners; more common in women</td> <td>Focal tenderness at pubic ramus; pain increases when pelvis is rocked or compressed</td> <td>Plain radiographs may reveal pathologic changes, but MRI preferred study</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Subacute &#38; chronic conditions</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"4\">Neuropathies</td> <td>Piriformis syndrome (sciatic nerve entrapment)</td> <td>Causes gradual onset of buttock pain that increases w sitting; May cause paresthesias but classic sciatica is uncommon; occurs in some runners</td> <td>Standard tests for lumbar radiculopathy are negative; neurologic testing normal; resisted hip abduction &#38; external rotation may increase pain; forced hip adduction, flexion, &#38; internal rotation may increase pain</td> <td>MRI may be performed to rule out alternative diagnoses</td> </tr> <tr> <td>Pudendal nerve entrapment</td> <td>Symptoms include ipsilateral perineal pain, which often increases with sitting, and penile or labial numbness; Relatively common among cyclists</td> <td>Sensory deficits often absent</td> <td>None</td> </tr> <tr> <td>Ilioinguinal nerve entrapment</td> <td>Symptoms consist of groin pain radiating to the genitalia; Can occur in hockey players (often associated w external oblique aponeurosis tear) &#38; bodybuilders</td> <td>Tenderness may be present about 2-3 cm below the anterior superior iliac spine</td> <td>MRI may be performed primarily to assess other possible diagnoses</td> </tr> <tr class=\"divider_bottom\"> <td>Femoral nerve entrapment</td> <td>Causes paresthesias over anterior and anteromedial thigh; Associated w activities involving repeated forceful hip flexion, jumping sports, and gymnastics</td> <td>May cause sensory deficits over anterior or anteromedial thigh; May cause quadriceps weakness</td> <td>US may show entrapment at inguinal region</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Osteitis pubis (symphysis pubis stress injury)</td> <td>&nbsp;</td> <td>Causes gradual onset of unilateral or bilateral groin pain; typically no acute injury; pain may radiate to low abdomen or hip or thigh; more common in males playing sports involving rapid acceleration &#38; deceleration, kicking, &#38; pivoting </td> <td>Tenderness at symphysis pubis; Passive stretch of hip adductors and resisted hip adduction (performed at several positions) increase pain</td> <td>Plain radiographs often reveal suggestive changes; MRI is definitive study</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Femoroacetabular impingement</td> <td>&nbsp;</td> <td>Presentation often insidious &#38; diagnosis difficult; Mild groin pain may be present for months before abruptly worsening; buttock pain may develop but is less common; pain increases w transition from sitting to standing</td> <td>Hip internal rotation often decreased but external rotation is near normal; FADIR test often reproduces pain; extreme hip flexion &#38; FABER test may reproduce pain; EABER test may reproduce pain</td> <td>Plain radiographs (special views needed) demonstrate type of hip deformity</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Athletic pubalgia (\"sports hernia\")</td> <td>&nbsp;</td> <td>Pain in vicinity of common attachment of rectus abdominis &#38; inguinal ligament and origin of adductor longus on superior pubic ramus; Athletes describe groin or low abdominal pain w exertion or when trying to play their sport; Pain often develops insidiously but may be acute; pain is diffuse &#38; may be burning; more common in men involved in hockey or field sports involving rapid change in direction</td> <td>Tenderness at insertion of conjoint tendon, over deep inguinal ring, at external inguinal ring, and/or origin of adductor longus tendon</td> <td>MRI can reveal suggestive findings, but may be misleading; US may reveal suggestive findings but is technically challenging</td> </tr> <tr> <td class=\"indent1\">Osteoarthritis of hip</td> <td>&nbsp;</td> <td>Causes chronic, progressive hip pain punctuated by acute flares; pain increases w activity but diminishes w rest; joint stiffness common; generally occurs in patients over 40 years</td> <td>Hip motion is diminished and mobility testing causes pain</td> <td>Plain radiographs reveal diminished joint space, sclerosis, &#38; other characteristic changes</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 105678 Version 1.0</div></div></div>"},"105685":{"type":"graphic_picture","displayName":"Site for palpation of tarsal navicular bone","title":"Site for palpation of tarsal navicular bone","html":"<div class=\"graphic\"><div style=\"width: 786px\" class=\"figure\"><div class=\"ttl\">Site for palpation of tarsal navicular bone</div><div class=\"cntnt\"><img style=\"width:766px; height:564px;\" src=\"images/SM/105685_Siteplptntrslnvclrbone.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Most, but not all, patients with a tarsal navicular stress fracture experience tenderness at the dorsal navicular somewhere between the tibialis anterior&nbsp;and extensor hallucis longus tendons. In the photograph above, these tendons are outlined and the high point of the dorsal aspect of the navicular bone is marked by an X. This&nbsp;location is sometimes referred to as the \"N spot.\"</div><div class=\"graphic_footnotes\">EHL: Extensor hallucis longus tendon; TIB A: Tibialis anterior tendon</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD.</div><div id=\"graphicVersion\">Graphic 105685 Version 2.0</div></div></div>"},"105687":{"type":"graphic_table","displayName":"Comparison of inhaled glycopyrronium preparations","title":"Comparison of inhaled glycopyrrolate (glycopyrronium) preparations available in various countries*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of inhaled glycopyrrolate (glycopyrronium) preparations available in various countries*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_single centered\">Availability</td> <td class=\"subtitle1_single centered\">Brand (trade) name</td> <td class=\"subtitle1_single centered\">Dose</td> <td class=\"subtitle1_single\">Content per inhalation capsule or MDI puff:<br /> Glycopyrrolate (glycopyrronium) base</td> <td class=\"subtitle1_single\">Content per inhalation capsule or MDI puff:<br /> Glycopyrrolate(glycopyrronium) bromide salt</td> <td class=\"subtitle1_single\">Drug delivered from mouthpiece:<br /> Glycopyrrolate (glycopyrronium) base</td> <td class=\"subtitle1_single\">Drug delivered from mouthpiece:<br /> Glycopyrrolate (glycopyrronium) bromide salt</td> </tr> <tr class=\"divider_top\"> <td class=\"subtitle2_left\" colspan=\"7\">Single agent dry powder inhalers (DPI)</td> </tr> <tr> <td class=\"indent1\">United States</td> <td>Seebri Neohaler</td> <td>1 inhalation twice daily</td> <td>12.5 mcg glycopyrrolate base</td> <td>15.6 mcg glycopyrrolate bromide <span class=\"green\">(labeling within United States)</span></td> <td>10.5 mcg glycopyrrolate base</td> <td>13.1 mcg glycopyrrolate bromide</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Canada and European Union</td> <td>Seebri Breezhaler</td> <td>1 inhalation once daily</td> <td>50 mcg glycopyrronium base <span class=\"green\">(labeling within Canada)</span></td> <td>63 mcg glycopyrronium bromide</td> <td>44 mcg glycopyrronium base <span class=\"green\">(labeling within European Union)</span></td> <td>55 mcg glycopyrronium bromide</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Combination long-acting antimuscarinic (LAMA) and long-acting beta<sub>2</sub> agonist (LABA) DPI</td> </tr> <tr> <td class=\"indent1\">United States</td> <td>Utibron Neohaler</td> <td>1 inhalation twice daily</td> <td>12.5 mcg glycopyrrolate base and 27.5 mcg indacaterol</td> <td>15.6 mcg glycopyrrolate bromide and 27.5 mcg indacaterol <span class=\"green\">(labeling within United States)</span></td> <td>10.2 mcg glycopyrrolate base and 20.8 mcg indacaterol</td> <td>12.8 mcg glycopyrrolate bromide and 20.8 mcg indacaterol</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Canada and European Union</td> <td>Ultibro Breezhaler</td> <td>1 inhalation once daily</td> <td>50 mcg glycopyrronium base and 110 mcg indacaterol <span class=\"green\">(labeling within Canada)</span></td> <td>63 mcg glycopyrronium bromide and 110 mcg indacaterol</td> <td>43 mcg glycopyrronium and 85 mcg indacaterol <span class=\"green\">(labeling within European Union)</span></td> <td>54 mcg glycopyrronium bromide and 85 mcg indacaterol</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"7\">Combination LAMA and LABA metered dose inhaler (MDI)</td> </tr> <tr> <td class=\"indent1\">United States (expected availability in 2016)</td> <td>Bevespi Aerosphere</td> <td>2 puffs twice daily</td> <td>8.3 mcg glycopyrrolate base and 5.5 mcg formoterol per puff released from valve</td> <td>10.4 mcg glycopyrrolate bromide and 5.5 mcg formoterol per puff released from valve</td> <td>7.2 mcg of glycopyrrolate base and 4.8 mcg formoterol per puff delivered from mouthpiece</td> <td>9 mcg glycopyrrolate bromide and 4.8 mcg formoterol per puff delivered from mouthpiece <span class=\"green\">(labeling within United States)</span></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The long-acting antimuscarinic known as glycopyrrolate in the United States is called glycopyrronium in other countries. The dose of glycopyrrolate (glycopyrronium) can be expressed in any one of the four following ways depending upon country. This table provides the equivalence for doses expressed as: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Glycopyrrolate (glycopyrronium) base per inhalation capsule or per puff from MDI valve</LI>&#xD;&#xA;<LI>Glycopyrrolate (glycopyrronium) bromide salt per inhalation capsule or per puff from MDI valve</LI>&#xD;&#xA;<LI>Glycopyrrolate (glycopyrronium) base delivered from the mouthpiece</LI>&#xD;&#xA;<LI>Glycopyrrolate (glycopyrronium) bromide salt delivered from the mouthpiece</LI></UL></div><div class=\"graphic_footnotes\">* Labeling detail shown according to approved product information within the countries of European Union, Canada, and United States. Labeling conventions may vary in other countries. For additional detail, refer to the Lexicomp drug monographs included within UpToDate and locally approved product information.</div><div class=\"graphic_reference\">Source (accessed May 2, 2016): &#xD;&#xA;<OL>&#xD;&#xA;<LI>United States FDA approved prescribing information available at <A href=\"http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm\" target=_blank>http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</A>.</LI>&#xD;&#xA;<LI>European Medicines Agency Summary of Product Characteristics available at <A href=\"http://www.ema.europa.eu/ema/\" target=_blank>http://www.ema.europa.eu/ema/</A>.</LI>&#xD;&#xA;<LI>Health Canada Product Monograph available at http://webprod5.hc-sc.gc.ca/dpd-bdpp/index-eng.jsp.</LI></OL></div><div id=\"graphicVersion\">Graphic 105687 Version 4.0</div></div></div>"},"105688":{"type":"graphic_table","displayName":"SSc-ILD with an increased likelihood of disease progression","title":"Features of systemic sclerosis (scleroderma)-associated interstitial lung disease with an increased likelihood of disease progression","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Features of systemic sclerosis (scleroderma)-associated interstitial lung disease with an increased likelihood of disease progression</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Disease duration &#60;4 years</td> </tr> <tr> <td>Diffuse cutaneous systemic sclerosis</td> </tr> <tr> <td>Pulmonary function tests</td> </tr> <tr> <td class=\"indent1\">FVC &#60;65%</td> </tr> <tr> <td class=\"indent1\">DLCO &#60;55%</td> </tr> <tr> <td>HRCT</td> </tr> <tr> <td class=\"indent1\">Interstitial lung disease&nbsp;affecting &#62;20% of the lung</td> </tr> <tr> <td>Serology</td> </tr> <tr> <td class=\"indent1\">Anti-topoisomerase I (anti-Scl-70) antibodies</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FVC: forced vital capacity; DLCO: diffusing capacity for carbon monoxide; HRCT: high resolution computed tomography.</div><div class=\"graphic_reference\">Data from:<br /><OL>&#xD;&#xA;<LI>Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66:1625. </LI>&#xD;&#xA;<LI>Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013; 52:155.</LI></OL></div><div id=\"graphicVersion\">Graphic 105688 Version 1.0</div></div></div>"},"105689":{"type":"graphic_picture","displayName":"Verruciform xanthoma","title":"Verruciform xanthoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Verruciform xanthoma</div><div class=\"cntnt\"><img style=\"width:367px; height:341px;\" src=\"images/DERM/105689_Verruciform_xanthoma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Solitary papule on the scrotum.</div><div id=\"graphicVersion\">Graphic 105689 Version 1.0</div></div></div>"},"105692":{"type":"graphic_figure","displayName":"Gotch's standard weekly Kt/V","title":"Gotch's standard weekly Kt/V","html":"<div class=\"graphic\"><div style=\"width: 701px\" class=\"figure\"><div class=\"ttl\">Gotch's standard weekly Kt/V</div><div class=\"cntnt\"><img style=\"width:681px; height:514px;\" src=\"images/NEPH/105692_GtchsstndrdwklyKtV.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">spKt/V: single-pool Kt/V.</div><div class=\"graphic_reference\">Modified from: Gotch FA. The current place of urea kinetic modeling with respect to different dialysis modalities. Nephrol Dial Transplant 1998; 13(Suppl 6):10, by permission of Oxford University Press on behalf of European Renal Association–European Dialysis and Transplant Association.</div><div id=\"graphicVersion\">Graphic 105692 Version 5.0</div></div></div>"},"105694":{"type":"graphic_table","displayName":"Surveillance for CCHS","title":"Suggested surveillance for individuals with congenital central hypoventilation syndrome (CCHS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Suggested&nbsp;surveillance for individuals with congenital central hypoventilation syndrome (CCHS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">At diagnosis</td> <td class=\"subtitle1\">Follow-up</td> </tr> <tr> <td><strong>Polysomnography (including endogenous and exogenous gas challenges)</strong></td> <td class=\"centered\">X</td> <td> <p>0 to 3 years: Every 6 months</p> 3 years and older: At least annually</td> </tr> <tr> <td><strong>Echocardiogram</strong></td> <td class=\"centered\">X</td> <td> <p>0 to 3 years: Every 6 months</p> 3 years and older: At least annually</td> </tr> <tr> <td><strong>Hemoglobin, hematocrit, reticulocytes, HCO<sub>3</sub></strong></td> <td class=\"centered\">X</td> <td> <p>0 to 3 years: Every 6 months</p> 3 years and older: At least annually</td> </tr> <tr> <td><strong>Electrocardiography (72-hour continuous monitoring)</strong></td> <td class=\"centered\">X</td> <td> <p>0 to 3 years: Every 6 months</p> 3 years and older: At least annually</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Neurocognitive testing</strong></td> <td class=\"centered\">X</td> <td> <p>0 to 3 years: Every 6 months</p> 3 years and older: Annually</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Neural crest tumor surveillance</td> </tr> <tr> <td class=\"indent1\">NPARM mutations: Chest and abdominal imaging, urine catecholamines (for neuroblastoma)</td> <td class=\"centered\">X</td> <td> <p>0 to 2 years: Every 3 months</p> 2 to 7 years: Every 6 months</td> </tr> <tr> <td class=\"indent1\">Long PARM mutations (20/28 and longer): Chest and abdominal imaging (for ganglioneuromas and ganglioneuroblastomas) </td> <td class=\"centered\">X</td> <td>Annually</td> </tr> <tr> <td class=\"indent1\">Short PARM mutations (20/24, 20/25, 20/26, or 20/27)</td> <td class=\"centered\">Not required</td> <td>Not required</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><SPAN style=\"COLOR: black\">This table outlines the approach to surveillance suggested in the American Thoracic Society (ATS) statement.&nbsp;Evidence for these guidelines is based on the ATS authors' experience rather than randomized trials or cohort studies. Other approaches to monitoring may be appropriate depending on the&nbsp;characteristics and history of the individual patient and&nbsp;practicality within the local&nbsp;health care system.</SPAN> </div><div class=\"graphic_footnotes\">CCHS: congenital central hypoventilation syndrome; HCO<SUB>3</SUB>: bicarbonate; NPARM: non-polyalanine repeat mutations; PARM: polyalanine repeat mutations; ATS: American Thoracic Society.</div><div class=\"graphic_reference\">Source: Based on recommendations in: Weese-Mayer DE, Berry-Kravis EM, Ceccherini I, et al. An official ATS clinical policy statement: Congenital central hypoventilation syndrome: genetic basis, diagnosis, and management. Am J Respir Crit Care Med 2010; 181:626.</div><div id=\"graphicVersion\">Graphic 105694 Version 2.0</div></div></div>"},"105695":{"type":"graphic_picture","displayName":"Jaccoud arthropathy","title":"Jaccoud arthropathy","html":"<div class=\"graphic\"><div style=\"width: 878px\" class=\"figure\"><div class=\"ttl\">Jaccoud arthropathy</div><div class=\"cntnt\"><img style=\"width:858px; height:511px;\" src=\"images/ALLRG/105695_Jaccoud_arthrpthy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Ulnar deviation, metacarpophalangeal subluxation, and swan-neck deformities are present. There is also diffuse soft-tissue swelling.<br />(B) A radiograph shows the deformities, but there is no true joint space narrowing or erosion, which would be expected in a patient with rheumatoid arthritis with similar hand deformities. This type of deformity in systemic lupus erythematosus is reducible and is caused by tendon laxity, rather than bony destruction, and may also be seen in post-rheumatic fever arthritis.</div><div class=\"graphic_reference\">&copy; 2016 American College of Rheumatology. Used with permission.</div><div id=\"graphicVersion\">Graphic 105695 Version 2.0</div></div></div>"},"105710":{"type":"graphic_diagnosticimage","displayName":"Intracranial epidural abscess by MRI","title":"Intracranial epidural abscess by MRI","html":"<div class=\"graphic\"><div style=\"width: 822px\" class=\"figure\"><div class=\"ttl\">Intracranial epidural abscess by MRI</div><div class=\"cntnt\"><img style=\"width:802px; height:459px;\" src=\"images/ID/105710_Intrcrnl_epdrl_abscess_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Intracranial epidural abscess in a 55-year-old patient six weeks after surgical intervention for chronic subdural hematoma. (A) T1-weighted MRI showed a contrast-enhancing (arrows) space-occupying lesion (asterisk) with (B) an increased signal intensity on diffusion-weighted imaging (asterisk).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced with permission from: Pfister HW, Klein M, Tunkel AR, Scheld WM. Epidural abscess. In: Infections of the Central Nervous System, 4th ed, Scheld WM, Whitley RJ, Marra CM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2014. Copyright © 2014 Wolters Kluwer Health. <A href=\"http://www.lww.com/\" target=_blank>www.lww.com</A>.</div><div id=\"graphicVersion\">Graphic 105710 Version 2.0</div></div></div>"},"105713":{"type":"graphic_picture","displayName":"Nevus anemicus","title":"Nevus anemicus​","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Nevus anemicus​</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/105713_Nevus_anmcs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A hypopigmented macule with irregular border is visible on the trunk of this infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105713 Version 1.0</div></div></div>"},"105714":{"type":"graphic_algorithm","displayName":"Evaluation of mechanical valve obstruction","title":"Algorithm for evaluation of mechanical prosthetic heart valve obstruction (thrombus versus pannus)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluation of mechanical prosthetic heart valve obstruction (thrombus versus pannus)</div><div class=\"cntnt\"><img style=\"width:415px; height:1051px;\" src=\"images/CARD/105714_Sspctvlvobstrctthrmbpnns.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">TTE: transthoracic echocardiography; TEE: transesophageal echocardiography; CT: computed tomography.<br />* Evaluation should include assessment of any findings suggestive of prosthetic valve endocarditis. Refer to UpToDate content on the diagnosis and treatment of prosthetic valve endocarditis.<br />¶ Exclude increased stroke volume as a cause of increased transvalvular gradients.<br />Δ The urgency of surgery depends upon the acuity and severity of the patient's symptoms.<br /><FONT class=lozenge>◊</FONT> Since Björk-Shiley and Sorin monoleaflet valves are not well visualized by CT due to severe artifact, fluoroscopy or TEE is preferred for visualization of leaflet motion for these valve types.<br />§ Some experts prefer CT to TEE as the primary test to evaluate prosthetic leaflet motion and appearance (except for monoleaflet valves).<br />¥ Echodensity of a mass can be evaluated using the intensity ratio (defined as the intensity of mass/intensity of prosthesis). Intensity ratio ≤0.45 is low; intensity ratio &gt;0.45 is high.<br />‡ CT imaging is not generally helpful for a monoleaflet mechanical valve; for such valves, fluoroscopy enables assessment of leaflet motion if TEE is indeterminate.<br />† CT characteristics of mass consistent with thrombus include low attenuation, irregular shape, and attachment to leaflets or hinge points.<br />** CT characteristics of mass consistent with pannus include high attenuation (HU ≥145) and extension along the valve ring.<br />¶¶ When imaging is indeterminate for thrombus or pannus, management is generally as for pannus unless clinical features are strongly suggestive of thrombus.</div><div id=\"graphicVersion\">Graphic 105714 Version 6.0</div></div></div>"},"105715":{"type":"graphic_picture","displayName":"Pediatric melanoma histopathology","title":"Histopathologic features of pediatric melanoma ","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Histopathologic&nbsp;features of pediatric melanoma </div><div class=\"cntnt\"><img style=\"width:726px; height:277px;\" src=\"images/DERM/105715_Hstpthpdtrcmlnm1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histopathology of melanoma from an adolescent patient.<br />(A) Polypoid expansile proliferation of severely atypical epithelioid melanocytes in nests extending into the mid-dermis (4x magnification).<br />(B)&nbsp;Hyperchromatic epithelioid melanocytes with irregular nuclear contours and mitotic figures (40x magnification).</div><div class=\"graphic_reference\">Courtesy of Birgitta Schmidt, MD.</div><div id=\"graphicVersion\">Graphic 105715 Version 2.0</div></div></div>"},"105717":{"type":"graphic_figure","displayName":"PHOX2B and genetic mechanisms of CCHS","title":"PHOX2B gene and molecular mechanisms of congenital central hypoventilation syndrome","html":"<div class=\"graphic\"><div style=\"width: 554px\" class=\"figure\"><div class=\"ttl\">PHOX2B gene and molecular&nbsp;mechanisms of congenital central hypoventilation syndrome</div><div class=\"cntnt\"><img style=\"width:534px; height:507px;\" src=\"images/SLEEP/105717_PHOX2B_genetic_mechanisms_CCHS.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Congenital central hypoventilation syndrome (CCHS) is caused by heterozygous mutations in PHOX2B (paired-like homeobox 2B) gene, located on chromosome 4p12. <br />Panel A: Most cases of CCHS are caused by expansions of a 20-polyalanine tract on exon 3 of the PHOX2B gene. Heterozygous expansions to 25, 26 or 27 polyalanines are most frequent. Four different codons (GCA, GCC, GCG, and GCT), as&nbsp;shown by different colors, code for alanine. The blue segments on exons two and three represent the homeodomain. <br />Panel B: When the sequence of codons in the polyalanine tracts from the mother and father are different, it is possible to determine the parental chromosome from which a <EM>de novo</EM> mutation is derived. In the example shown, note that it would only be possible for the duplicated seven codons found in the affected child to have been&nbsp;derived from a paternal chromosome.<SUP>[1]</SUP> Additional upstream and downstream testing for polymorphisms has likewise confirmed that most PARM mutations in the PHOX2B gene are derived from paternal chromosomes.<SUP>[2]</SUP> The mechanism is thought to be unequal sister chromatid exchange during spermatogenesis.</div><div class=\"graphic_footnotes\">CCHS: congenital central hypoventilation syndrome; PARM: polyalanine repeat expansion mutation.</div><div class=\"graphic_reference\">Adapted from the following sources:&nbsp;<br /><OL>&#xD;&#xA;<LI>Arai H, Otagiri T, Sasaki A et al. De novo polyalanine expansion of PHOX2B in congenital central hypoventilation syndrome: unequal sister chromatid exchange during paternal gametogenesis. J Hum Genet 2007; 52:921. </LI>&#xD;&#xA;<LI>Arai H, Otagiri T, Sasaki A et al. Polyalanine expansion of&nbsp;PHOX2B&nbsp;in congenital central hypoventilation syndrome: rs17884724:A&gt;C is associated with 7-alanine expansion. J Hum Genet 2010; 55:4.</LI>&#xD;&#xA;<LI>Weese-Mayer DE, Berry-Kravis EM, Ceccherini I, et al. An official ATS clinical policy statement: Congenital central hypoventilation syndrome: genetic basis, diagnosis, and management. Am J Respir Crit Care Med 2010; 181:626<br /></LI></OL></div><div id=\"graphicVersion\">Graphic 105717 Version 1.0</div></div></div>"},"105718":{"type":"graphic_picture","displayName":"Cystic hygroma","title":"Macrocystic lymphatic malformation (cystic hygroma)","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Macrocystic lymphatic malformation (cystic hygroma)</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/105718_Cystc_hygrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cystic hygroma presenting in a neonate as a large, soft mass at the base of the neck with overlying normal skin.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105718 Version 1.0</div></div></div>"},"105721":{"type":"graphic_algorithm","displayName":"Algorithm molar pregnancy management","title":"Molar pregnancy management algorithm","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Molar pregnancy management algorithm</div><div class=\"cntnt\"><img style=\"width:596px; height:548px;\" src=\"images/ONC/105721_Algo_molar_pregnancy_manag.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Beta-human chorionic gonadotropin.<br />&para; Patients should use contraception until follow-up is complete.<br />&Delta; A decreasing &beta;-hCG is defined as a level that decreases &gt;10 percent compared with the previous result, and continues to meet this criterion across four values during a three-week period.<br /><span class=\"lozenge\">&loz;</span> An increasing &beta;-hCG is defined as a level that increases &gt;10 percent compared with the previous result, and continues to meet this criterion across three values during a two-week period.<br />&sect; An unchanged &beta;-hCG is defined as a level that remains with +/&ndash; 10 percent compared with the previous result, and continues to meet this criterion across four values during a three-week period.<br />&yen; After achieving one undetectable &beta;-hCG value (&lt;5 mIU/mL), the risk of developing gestational trophoblastic neoplasia is &lt;1 percent. American College of Obstetrician and Gynecology guidelines advise that after the &beta;-hCG is undetectable, to continue to measure &beta;-hCG monthly for six months. Based on the extremely low risk of a rise in hCG after it becomes undetectable, in our practice, we continue monthly &beta;-hCG follow-up for three months and then follow-up is complete.</div><div id=\"graphicVersion\">Graphic 105721 Version 1.0</div></div></div>"},"105724":{"type":"graphic_figure","displayName":"Pathogenesis of osteoarthritis","title":"Pathogenesis of osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 755px\" class=\"figure\"><div class=\"ttl\">Pathogenesis of osteoarthritis</div><div class=\"cntnt\"><img style=\"width:735px; height:484px;\" src=\"images/RHEUM/105724_Pthgns_ostrthrts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Osteoarthritis involves all of the joint tissues including the menisci in the knee, ligaments, synovium, articular cartilage, and bone. Damage to the menisci and ligament tears not only alter joint mechanics but, along with the inflamed synovium (synovitis), produce proinflammatory factors (cytokines and chemokines) and matrix-degrading enzymes (eg, matrix metalloproteinases [MMPs]). These factors are also produced by chondrocytes and serve to promote joint tissue destruction.</div><div class=\"graphic_reference\">Courtesy of Richard Loeser, MD.</div><div id=\"graphicVersion\">Graphic 105724 Version 1.0</div></div></div>"},"105727":{"type":"graphic_movie","displayName":"Echo of membranous VSD","title":"Echocardiogram of membranous ventricular septal defect","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of membranous ventricular septal defect</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/105727_EchomembranousVSDvid.mp4\" style=\"width:704px;height:272px\"></div><img style=\"width:656px; height:289px;\" src=\"images/CARD/105727_EchomembranousVSDimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transthoracic echocardiogram with two-dimensional parasternal long-axis view (left) and basal short-axis view (right) with color-flow Doppler demonstrating a membranous ventricular septal defect (VSD). The left-to-right VSD shunt is noted in close proximity to the aortic valve (left) and tricuspid valve (right).</div><div class=\"graphic_footnotes\">LV: left ventricle; LA: left atrium; RV: right ventricle; Ao: aorta.</div><div id=\"graphicVersion\">Graphic 105727 Version 1.0</div></div></div>"},"105728":{"type":"graphic_movie","displayName":"Echo of supracristal VSD","title":"Echocardiogram of supracristal ventricular septal defect","html":"<div class=\"graphic normal\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of supracristal ventricular septal defect</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/105728_EchosupracrystalVSDvid.mp4\" style=\"width:640px;height:288px\"></div><img style=\"width:656px; height:274px;\" src=\"images/CARD/105728_EchosupracrystalVSDimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transthoracic echocardiogram with two-dimensional parasternal long-axis view (left) and basal short-axis view (right) with color-flow Doppler demonstrating a supracristal ventricular septal defect (VSD). The left-to-right VSD shunt is noted in close proximity to the aortic valve (left) and pulmonic valve (right). Prolapse of the right aortic valve cusp into the VSD causes mild eccentric aortic regurgitation.</div><div class=\"graphic_footnotes\">LV: left ventricle; LA: left atrium; RV: right ventricle; Ao: aorta.</div><div id=\"graphicVersion\">Graphic 105728 Version 2.0</div></div></div>"},"105729":{"type":"graphic_movie","displayName":"Echo of DCRV","title":"Echocardiogram of double-chambered right ventricle","html":"<div class=\"graphic normal\"><div style=\"width: 724px\" class=\"figure\"><div class=\"ttl\">Echocardiogram of double-chambered right ventricle</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/105729_EchoDCRVvid.mp4\" style=\"width:704px;height:288px\"></div><img style=\"width:692px; height:270px;\" src=\"images/CARD/105729_EchoDCRVimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transthoracic echocardiogram with two-dimensional parasternal short-axis view (left) and color flow Doppler (right) at the level of the aortic valve demonstrating flow acceleration with systolic obstruction in the right ventricle (arrow) typical of double chambered right ventricle. The muscular ridge divides the right ventricle into two chambers, one proximal to the obstruction and one distal to the obstruction. Mild central aortic regurgitation as well as mild tricuspid regurgitation are also identified by echo-Doppler.</div><div class=\"graphic_footnotes\">RV: right ventricle; RA: right atrium; Ao: aorta.</div><div id=\"graphicVersion\">Graphic 105729 Version 1.0</div></div></div>"},"105731":{"type":"graphic_algorithm","displayName":"Bartholin abscess management","title":"Bartholin abscess management algorithm","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Bartholin abscess management algorithm</div><div class=\"cntnt\"><img style=\"width:412px; height:422px;\" src=\"images/OBGYN/105731_Bartholin_abscess_mngmnt.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shaded box = completed therapy.</div><div class=\"graphic_footnotes\">I&amp;D: incision and drainage.<br />* Biopsy of the Bartholin gland lining should be performed at the time of I&amp;D, marsupialization, or gland excision if there is concern for a Bartholin gland carcinoma (eg, palpable or visible solid mass, unresponsive or worsening despite treatment).<br />&para; I&amp;D alone without placement of a Word catheter may be performed if a Word catheter is not available or if the abscess cavity is too small for a Word catheter.<br />&Delta; If positive for gonorrhea or chlamydia, treat with appropriate antibiotics. If positive for methicillin-resistant <em>Staphylococcus aureus</em>, treat with antibiotics.</div><div id=\"graphicVersion\">Graphic 105731 Version 1.0</div></div></div>"},"105738":{"type":"graphic_picture","displayName":"Palisaded and neutrophilic granulomatous dermatitis on elbow","title":"Palisaded neutrophilic and granulomatous dermatitis","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Palisaded neutrophilic and granulomatous dermatitis</div><div class=\"cntnt\"><img style=\"width:712px; height:531px;\" src=\"images/DERM/105738_Plsd_ntrph_grnlmt_drmt_elbw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Classic presentation of erythematous papules around the elbows, some with slight umbilication and central crusting.</div><div class=\"graphic_reference\">Reproduced from: Rosenbach M, English JC III. Reactive Granulomatous Dermatitis: A Review of Palisaded Neutrophilic and Granulomatous Dermatitis, Interstitial Granulomatous Dermatitis, Interstitial Granulomatous Drug Reaction, and a Proposed Reclassification. Dermatol Clin. 2015 Jul;33(3):373-87. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105738 Version 1.0</div></div></div>"},"105739":{"type":"graphic_table","displayName":"Return to running rehab for navicular stress fracture","title":"Return to running rehabilitation for uncomplicated navicular stress fracture","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Return to running rehabilitation for&nbsp;uncomplicated navicular stress fracture</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Sample rehabilitation program for return to running following uncomplicated tarsal navicular stress fracture limited to dorsal cortex and treated non-surgically</td> </tr> <tr> <td class=\"subtitle2_single\">Phase 1:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Weeks 1 to 6 (may extend to week 8 if more severe injury or complicating factors): Strict non weight bearing in a short leg cast. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Phase 2:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Weeks 7 and 8. Cast is removed and patient placed in a weight-bearing cast-boot. If navicular is non-tender and there is no pain while walking in boot, patient may perform stationary cycling for 30 minutes daily at low resistance, and normal ADLs are permitted while weight-bearing in boot. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Weight-bearing in a boot should be delayed as necessary, up to week 12,&nbsp;if tenderness persists or there is pain with weight bearing. Patient is referred to a surgeon if tenderness or pain is present at week 12. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Phase 3:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Weeks 9 and 10 in uncomplicated cases. Patient begins fast walking in boot on treadmill: 15 minutes daily during week 9; 20 minutes daily during week 10. Patient may perform 30 minutes of stationary cycling in addition to fast walking. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Phase 4:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Weeks 11 and 12 in uncomplicated cases. Patient begins treadmill running out of the boot: 2 minute run alternating with 1 minute walk for a total of 21 minutes. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Most patients require a supportive running shoe and a custom orthotic. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Stationary cycling can be used to supplement aerobic training for a maximum total of 50 minutes of aerobic activity daily, and on non-running days. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>During week 11, run-walk cycles are done for 4 days. During week 12, run-walk cycles are done for 5 days, and the total time permitted is increased to 30 minutes. Total time permitted for all aerobic activity (run-walk cycles plus stationary cycling) is increased to 60 minutes daily during week 12. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_single\">Phase 5*:</td> </tr> <tr> <td class=\"indent1\">This phase averages 4 to 6 weeks and involves the following steps:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>First week: Run 15 minutes, then walk 3 minutes. May perform this cycle twice for a total of 36 minutes up to 5 days per week. Cross training on stationary bicycle permitted, but total aerobic activity is not to exceed 70 minutes daily. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Second week: Run 20 minutes, then walk 5 minutes. May perform this cycle twice for a total of 50 minutes daily, up to 5 days per week. Cross training on stationary bicycle permitted, but total aerobic activity is&nbsp;not to exceed 70 minutes daily. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Third week: Continuous running for 30 minutes. Not to exceed 6 days per week. Limit total aerobic cross training to 70 minutes daily. </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Fourth to sixth weeks: Patient may add 10 minutes per week to total running time, but no more. If successful, patient can return to normal training starting with the seventh week of this phase. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">ADL: Activity of daily living</div><div class=\"graphic_footnotes\">* If at any point the athlete develops pain or soreness, they should move back one level of activity.</div><div id=\"graphicVersion\">Graphic 105739 Version 1.0</div></div></div>"},"105740":{"type":"graphic_algorithm","displayName":"Overview of the evaluation of newly identified CKD","title":"Overview of the evaluation of newly identified chronic kidney disease","html":"<div class=\"graphic\"><div style=\"width: 667px\" class=\"figure\"><div class=\"ttl\">Overview of the evaluation of newly identified chronic kidney disease</div><div class=\"cntnt\"><img style=\"width:647px; height:669px;\" src=\"images/NEPH/105740_Evltn_nw_idntf_CKD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">RBC: red blood cell; SPEP: serum protein electrophoresis; UPEP: urine protein electrophoresis; NSAID: nonsteroidal anti-inflammatory drug.<br />* Among patients at higher risk for multiple myeloma, we obtain SPEP, UPEP with immunofixation, and serum free light chains at the time of initial evaluation. Higher-risk patients are those &gt;40 years who have a documented increase in creatinine over three to six months and have no other obvious cause for kidney dysfunction such as NSAID use or exposure to contrast.<br />&para; Risk factors for renovascular disease include hyperlipidemia, cigarette smoking, age &gt;50 years, coronary artery disease, peripheral arterial disease in other vascular beds.</div><div id=\"graphicVersion\">Graphic 105740 Version 2.0</div></div></div>"},"105741":{"type":"graphic_algorithm","displayName":"Evaluation of subacute kidney injury","title":"Evaluation of subacute kidney injury","html":"<div class=\"graphic\"><div style=\"width: 806px\" class=\"figure\"><div class=\"ttl\">Evaluation of subacute kidney injury</div><div class=\"cntnt\"><img style=\"width:786px; height:1113px;\" src=\"images/NEPH/105741_Evl_sbct_kdny_injry.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">AKI: acute kidney injury; NSAID: nonsteroidal anti-inflammatory drug; ACE: angiotensin-converting enzyme; ARB: angiotensin receptor blocker; RBC: red blood cell; RPGN: rapidly progressive glomerulonephritis; ATN: acute tubular necrosis; SPEP: serum protein electrophoresis; UPEP: urine protein electrophoresis; MGUS: monoclonal gammopathy of undetermined significance; GFR: glomerular filtration rate.<br />* For patients with chronic kidney disease, in whom small fluctuations in creatinine are common, mild injury may be better defined as &lt;50% change in creatinine.<br />&para; For patients at higher risk for multiple myeloma (ie, age &gt;40 years, and no other obvious cause of reduced GFR), SPEP, UPEP, immunofixation, and serum free light chains are obtained at time of initial evaluation. Some clinicians follow this approach for all adult patients.<br />&Delta; Irreversible kidney is suggested by the combination of increased echogenicity and kidney length &lt;10 cm.</div><div id=\"graphicVersion\">Graphic 105741 Version 2.0</div></div></div>"},"105742":{"type":"graphic_algorithm","displayName":"Evaluation and management of pancreatic cysts","title":"Evaluation and management of pancreatic cysts","html":"<div class=\"graphic\"><div style=\"width: 842px\" class=\"figure\"><div class=\"ttl\">Evaluation and management of pancreatic cysts</div><div class=\"cntnt\"><img style=\"width:822px; height:1306px;\" src=\"images/GAST/105742_Eval_manag_pancreatic_cysts.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Published guidelines on the management of pancreatic cystic neoplasms are variable. This algorithm reflects the authors' approach. Refer to UpToDate topic reviews on pancreatic cystic neoplasms for additional details.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; MRCP: magnetic resonance cholangiopancreatography; IPMN: intraductal pancreatic mucinous neoplasm; SPN: solid pseudopapillary neoplasm; MCN: mucinous cystic neoplasm; EUS-FNA: endoscopic ultrasound-guided fine-needle aspiration; CEA: carcinoembryonic antigen.<br />* A pancreatic protocol computed tomography scan is an alternative for patients who cannot undergo MRI.<br />&para; Refer to UpToDate topics on the evaluation of pancreatic cystic neoplasms for details on the specific features needed to make a diagnosis.<br />&Delta; The decision to recommend surgery should take into account factors such as the patient's age and general health, the malignant risk of the specific lesion, and the suspicion for malignancy.<br /><span class=\"lozenge\">&loz;</span> Surveillance should be considered because these cysts, despite being small, may be precancerous. The decision to pursue surveillance should take into account factors such as the patient's age, comorbidities, and willingness to undergo surgery if worrisome features develop.<br />&sect; Cyst fluid should be tested for cytology; CEA level; and the molecular markers KRAS, GNAS, VHL, CTNNB1, TP53, P1K3CA, and PTEN. KRAS and GNAS have been associated with IPMNs and MCNs, and GNAS appears to be highly specific for IPMN. TP53, PIK3CA, and PTEN have been associated with high-grade dysplasia or invasive carcinoma in patients with IPMN. VHL is seen in serous cystic tumors, whereas CTNNB1 is seen in SPNs.<br />&yen; Refer to UpToDate topic on the management of IPMNs for details.<br />&Dagger; Refer to UpToDate content on the management of pancreatic cysts for details.</div><div id=\"graphicVersion\">Graphic 105742 Version 2.0</div></div></div>"},"105743":{"type":"graphic_algorithm","displayName":"Evaluation of AKI among hospitalized patients","title":"Evaluation of acute kidney injury among hospitalized patients","html":"<div class=\"graphic\"><div style=\"width: 700px\" class=\"figure\"><div class=\"ttl\">Evaluation of acute kidney injury among hospitalized patients</div><div class=\"cntnt\"><img style=\"width:680px; height:1009px;\" src=\"images/NEPH/105743_Eval_AKI_amng_hsptl_ptn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ATN: acute tubular necrosis; AKI: acute kidney injury; GFR: glomerular filtration rate; SPEP: serum protein electrophoresis; UPEP: urine protein electrophoresis.<br />* For patients who are at higher risk for multiple myeloma, we also check SPEP, UPEP with immunofixation, and a serum free light chain assay. Higher-risk patients include all patients &gt;40 years who have no other obvious cause for increased creatinine.</div><div id=\"graphicVersion\">Graphic 105743 Version 3.0</div></div></div>"},"105744":{"type":"graphic_table","displayName":"Monogenic hypertension genes","title":"Monogenic hypertension genes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Monogenic hypertension genes</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"22%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup span=\"3\" width=\"22%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gene(s)</td> <td class=\"subtitle1\">Chromosome position</td> <td class=\"subtitle1\">Disease name and MIM identifier</td> <td class=\"subtitle1\">Key features of clinical syndrome</td> <td class=\"subtitle1\">Mode of inheritance and genetic mechanism</td> </tr> <tr> <td> <p>NR3C2</p> (mineralocorticoid receptor gene)</td> <td>4q</td> <td> <p>Early-onset autosomal dominant hypertension with exacerbation in pregnancy</p> MIM 605115</td> <td>Hypertension, severe hypertension in pregnancy</td> <td>AD; GOF</td> </tr> <tr> <td> <p>CYP11B2</p> (aldosterone synthase gene)</td> <td>8p</td> <td> <p>Glucocorticoid-remediable aldosteronism</p> MIM 103900</td> <td>Hypertension, low plasma renin, increased aldosterone, response to dexamethasone; high genetic heterogeneity and potassium level often normal; high prevalence of intracranial aneurysms</td> <td>AD; GOF; gene expressed under ACTH control (fusion of the promoter region of the gene for CYP11B1 and the coding sequences of CYP11B2)</td> </tr> <tr> <td> <p>CYP11B1</p> (11-beta-hydroxylase gene)</td> <td>8q</td> <td> <p>CAH type IV (congenital adrenal hyperplasia, due to 11-beta-hydroxylase deficiency)</p> MIM 202010</td> <td>Hypertension, hypokalemia, virilization (variable); two-thirds of patients have severe, \"classic form\" with hypertension in first years of life; otherwise, hypertension is usually mild to moderate in intensity; accounts for 5 to 8 percent of all CAH cases</td> <td>AR; LOF</td> </tr> <tr> <td> <p>CYP17A1</p> (steroid 17-hydroxylase/17,20 lyase gene)</td> <td>10q</td> <td> <p>Congenital adrenal hyperplasia, due to 17-alpha-hydroxylase deficiency = CAH type V</p> MIM 202110</td> <td>Hypertension, hypokalemia, hypogonadism/androgen deficiency</td> <td>AR; LOF</td> </tr> <tr> <td> <p>KCNJ5</p> (potassium inwardly rectifying channel gene, subfamily J, member 5)</td> <td>11q</td> <td> <p>Familial hyperaldosteronism type III</p> MIM 613677</td> <td>Hypertension, hypokalemia, high aldosterone, high 18-oxocortisol and 18-hydroxycortisol</td> <td>AD; LOF</td> </tr> <tr> <td> <p>WNK1, WNK4</p> <p>(lysine-deficient protein kinase 1 &#38; 4 genes)</p> <p>KLHL3</p> <p>(kelch-like 3 gene)</p> <p>CUL3</p> (cullin 3 gene)</td> <td> <p>12p (WNK)</p> <p>5q (KLHL3)</p> 2q (CUL3)</td> <td> <p>Pseudohypoaldosteronism type 2 (PHA2) = Gordon's syndrome</p> <p>WNK1: PHA2C MIM 614492</p> <p>WNK4: PHA2B MIM 614491</p> <p>KLHL3: PHA2D MIM 614495</p> CUL3: PHA2E MIM 614496</td> <td>Hypertension, hyperkalemia, response to thiazides</td> <td> <p>WNK1: AR; GOF</p> <p>WNK4: AR; LOF; + &ndash; expression of the thiazide-sensitive Na-Cl co-transporter SLC12A3 (NCCT) </p> <p>KLHL3: AD or AR; LOF (inhibition of KLHL3 increases the activity of SLC12A3)</p> CUL3: AD; LOF</td> </tr> <tr> <td> <p>PDE3A</p> (phosphodiesterase 3A gene)</td> <td>12p</td> <td> <p>Autosomal dominant hypertension with brachydactyly</p> MIM 123805</td> <td>Hypertension, brachydactyly</td> <td>AD; GOF</td> </tr> <tr> <td> <p>SCNN1B, SCNN1G</p> (amiloride-sensitive sodium channel, beta &#38; gamma subunit gene encoding two subunits of the ENaC sodium channel)</td> <td>16p</td> <td> <p>Liddle's syndrome = pseudoaldosteronism</p> MIM 177200</td> <td>Hypertension, hypokalemia, metabolic alkalosis, low plasma renin, low aldosterone, respond to amiloride</td> <td>AD; GOF</td> </tr> <tr> <td> <p>HSD11B2</p> (11-beta-hydroxy steroid dehydrogenase 2 gene)</td> <td>16q</td> <td> <p>Cortisol 11-beta-ketoreductase deficiency = syndrome of apparent mineralocorticoid excess</p> MIM 218030</td> <td>Hypertension, hypokalemia, low plasma renin, responsiveness to spironolactone; severe hypertension</td> <td>AR; LOF</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">For each gene in which variants can induce monogenic hypertension syndromes, the gene name (abbreviation and full name), the physical position, the disease name, and key clinical and genetic features are shown.</div><div class=\"graphic_footnotes\">AD: autosomal dominant; GOF: gain of function; ACTH: adrenocorticotropic hormone; CAH: congenital adrenal hyperplasia; AR: autosomal recessive; LOF: loss of function.</div><div class=\"graphic_reference\">Adapted from: Ehret GB, Caulfield MJ. Genes for blood pressure: An opportunity to understand hypertension. Eur Heart J 2013; 34:951.</div><div id=\"graphicVersion\">Graphic 105744 Version 2.0</div></div></div>"},"105746":{"type":"graphic_picture","displayName":"Pediatric melanoma knee ","title":"Pediatric melanoma","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Pediatric melanoma</div><div class=\"cntnt\"><img style=\"width:725px; height:526px;\" src=\"images/DERM/105746_Rghtantrrknlsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Pigmented nodular lesion on the knee of a three-year-old girl.<br />(B) Histologic image of the lesion showing high mitotic activity, poor cellular maturation, and atypical melanocytes (H&amp;E&nbsp;stain, x20 magnification).</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin.</div><div class=\"graphic_reference\">From: Albino FP, Wood BC, Oh A, et al. A case of pediatric melanoma: Treatment considerations in advanced disease. Plast Reconstr Surg Glob Open 2015; 3:e402. DOI: <a href=\"http://journals.lww.com/prsgo/pages/articleviewer.aspx?year=2015&amp;issue=05000&amp;article=00013&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/GOX.0000000000000370</a>. Copyright &copy; 2015 American Society of Plastic Surgeons. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105746 Version 2.0</div></div></div>"},"105748":{"type":"graphic_figure","displayName":"Pathways affected in monogenic hypertension","title":"Pathways affected in monogenic hypertension","html":"<div class=\"graphic\"><div style=\"width: 1260px\" class=\"figure\"><div class=\"ttl\">Pathways affected in monogenic hypertension</div><div class=\"cntnt\"><img style=\"width:1240px; height:614px;\" src=\"images/NEPH/105748_Pthwy_affctd_mngnc_hyprtnsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The location of the gene products mutated in monogenic hypertensive syndromes are shown in the context of their pathway. Proteins mutated in monogenic hypertension syndromes are marked with a star. The PDE3A gene product is not shown because the location of action is yet unknown.</div><div class=\"graphic_footnotes\">TAL: thick ascending limb of the loop of Henle; DCT: distal convoluted tubule; CD: collecting duct; DHEA: dehydroepiandrosterone.</div><div class=\"graphic_reference\">Reproduced from: Ehret GB, Caulfield MJ. Genes for blood pressure: An opportunity to understand hypertension. Eur Heart J 2013; 34(13):951-61, by permission of Oxford University Press on behalf of the European Society of Cardiology. Copyright © 2017.</div><div id=\"graphicVersion\">Graphic 105748 Version 3.0</div></div></div>"},"105749":{"type":"graphic_picture","displayName":"Melanoma child","title":"Melanoma in a child","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Melanoma in a child</div><div class=\"cntnt\"><img style=\"width:715px; height:556px;\" src=\"images/DERM/105749_Lsnptntchk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Photos of lesion on patient's right cheek (A) at 13 months, (B) upon evolution to an erythematous, rubbery papule at 14 months, and (C) after ulceration at 15 months.<br />(D) Nonulcerated region in the right cheek mass showing malignant melanoma, Spitzoid type, with nested and solid growth pattern and absence of pagetoid spread (H&amp;E, 40x).<br />(E) Malignant melanoma, Spitzoid type, showing spindle cells with large pleomorphic nuclei and prominent nucleoli with several mitotic figures (H&amp;E, 200x).</div><div class=\"graphic_footnotes\">H&amp;E: hematoxylin and eosin.</div><div class=\"graphic_reference\">Reproduced from: Tashiro J, Peryln CA, Melnick SJ, et al. Non-pigmented melanoma with nodal metastases masquerading as pyogenic granuloma in a 1-year old. J Pediatr Surg 2014; 49:653. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105749 Version 2.0</div></div></div>"},"105751":{"type":"graphic_picture","displayName":"Amelanotic melanoma in a large congenital melanocytic nevus","title":"Amelanotic melanoma arising in a large congenital melanocytic nevus","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Amelanotic melanoma arising in a large congenital melanocytic nevus</div><div class=\"cntnt\"><img style=\"width:571px; height:392px;\" src=\"images/DERM/105751_Amlntcmlnmlrgcngnmlnnvs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Amelanotic melanoma arising in a large congenital melanocytic nevus in a 17-year-old boy.</div><div class=\"graphic_reference\">Reproduced from: Cordoro KM, Gupta D, Frieden IJ, et al. Pediatric melanoma: Results of a large cohort study and proposal for modified ABCD detection criteria for children. J Am Acad Dermatol 2013; 68:913. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105751 Version 2.0</div></div></div>"},"105752":{"type":"graphic_picture","displayName":"Pediatric melanoma thigh","title":"Pediatric melanoma","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Pediatric melanoma</div><div class=\"cntnt\"><img style=\"width:473px; height:354px;\" src=\"images/DERM/105752_Malignantmelanomartthigh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Melanoma on the right thigh of a 16-month boy. The lesion appears as a dome-shaped, pigmented lesion measuring 17x19 mm, with central ulceration. Histology revealed a severely atypical melanocytic tumor with a&nbsp;Breslow thickness of&nbsp;7.5 mm.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2016 American Journal of Medical Case Reports. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105752 Version 2.0</div></div></div>"},"105753":{"type":"graphic_table","displayName":"HyQvia initial ramp-up schedule","title":"Hyaluronidase-facilitated subcutaneous immune globulin (HyQvia): Initial treatment interval/dose ramp-up schedule","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hyaluronidase-facilitated subcutaneous immune globulin (HyQvia): Initial treatment interval/dose ramp-up schedule</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Week</td> <td class=\"subtitle1\">Infusion number</td> <td class=\"subtitle1\">Dose interval</td> <td class=\"subtitle1\">Example for 30 grams per four weeks</td> </tr> <tr> <td class=\"centered\">1</td> <td>First infusion</td> <td>One-week dose</td> <td>7.5 grams</td> </tr> <tr> <td class=\"centered\">2</td> <td>Second infusion</td> <td>Two-week dose</td> <td>15 grams</td> </tr> <tr> <td class=\"centered\">3</td> <td class=\"centered\" colspan=\"3\">No infusion</td> </tr> <tr> <td class=\"centered\">4</td> <td>Third infusion</td> <td>Three-week dose</td> <td>22.5 grams</td> </tr> <tr> <td class=\"centered\">5</td> <td class=\"centered\" colspan=\"3\">No infusion</td> </tr> <tr> <td class=\"centered\">6</td> <td class=\"centered\" colspan=\"3\">No infusion</td> </tr> <tr> <td class=\"centered\">7</td> <td>Fourth infusion (if required)</td> <td>Four-week dose</td> <td>30 grams</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><EM>For patients switching from intravenous immune globulin (human) (IVIG) treatment:</EM> &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>After the initial dose ramp-up, administer HyQvia at the same dose and frequency as the previous intravenous treatment.</LI></UL><EM>For patients naïve to immune globulin treatment or switching from immune globulin subcutaneous (human) (SCIG):</EM> &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>After initial ramp-up, administer HyQvia at 300 to 600 mg/kg at three- to four-week intervals.</LI></UL></div><div class=\"graphic_reference\">Reproduced from: HYQVIA. US Food &amp; Drug Administration (FDA) approved product information. Revised September, 2014. US National Library of Medicine. Available online at <a href=\"http://www.dailymed.nlm.nih.gov/\" target=\"_blank\">www.dailymed.nlm.nih.gov</a> (Accessed December 3, 2015).</div><div id=\"graphicVersion\">Graphic 105753 Version 2.0</div></div></div>"},"105762":{"type":"graphic_picture","displayName":"Pyogenic granuloma infant","title":"Pyogenic granuloma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Pyogenic granuloma</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/105762_Pygnc_grnlm_infnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pyogenic granuloma presenting as friable, easily bleeding lesion on the nasal bridge of an infant.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105762 Version 1.0</div></div></div>"},"105764":{"type":"graphic_table","displayName":"Hemodynamics of pre-and post-capillary PH","title":"Hemodynamic definitions of pre- and post-capillary pulmonary hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Hemodynamic definitions of pre- and post-capillary pulmonary hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Definition</td> <td class=\"subtitle1\">Characteristics*</td> <td class=\"subtitle1\">Clinical group(s)</td> </tr> <tr class=\"divider_bottom\"> <td>PH</td> <td>mPAP &#8805;25 mmHg</td> <td>All</td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td>Pre-capillary PH</td> <td>mPAP &#8805;25 mmHg<br /> PAWP &#8804;15 mmHg</td> <td> <ol class=\"numbers_to_nine\"> <li>Pulmonary arterial hypertension </li> <li value=\"3\">PH due to lung diseases </li> <li>Chronic thromboembolic PH </li> <li>PH with unclear and/or multifactorial mechanisms </li> </ol> </td> </tr> <tr class=\"divider_bottom\"> <td>Post-capillary PH</td> <td>mPAP &#8805;25 mmHg<br /> PAWP &#62;15 mmHg</td> <td> <ol class=\"numbers_to_nine\"> <li value=\"2\">PH due to left heart disease </li> <li value=\"5\">PH with unclear and/or multifactorial mechanisms </li> </ol> </td> </tr> <tr class=\"divider_bottom highlight_gray_text\"> <td>Isolated post-capillary PH<br /> (Ipc-PH)</td> <td>DPG &#60;7 mmHg and/or<br /> PVR &#8804;3 WU<sup>&#182;</sup></td> <td> <ol class=\"numbers_to_nine\"> <li value=\"2\">PH due to left heart disease </li> <li value=\"5\">PH with unclear and/or multifactorial mechanisms </li> </ol> </td> </tr> <tr> <td>Combined post-capillary and pre-capillary PH<br /> (Cpc-PH)</td> <td>DPG &#8805;7 mmHg and/or<br /> PVR &#62;3 WU<sup>&#182;</sup></td> <td> <ol class=\"numbers_to_nine\"> <li value=\"2\">PH due to left heart disease </li> <li value=\"5\">PH with unclear and/or multifactorial mechanisms </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PH: pulmonary hypertension; mPAP: mean pulmonary arterial pressure; PAWP: pulmonary arterial wedge pressure; DPG: diastolic pressure gradient (diastolic PAP – mean PAWP); PVR: pulmonary vascular resistance; WU: Wood units.<br />* All values measured at rest.<br />¶ Wood units are preferred to dynes.s.cm<SUP>–5</SUP>.</div><div class=\"graphic_reference\">Reproduced from: Galiè N, Humbert M, Vachiery JL, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37(1):67-119, by permission of Oxford University Press on behalf of the European Society of Cardiology. Copyright © 2016 Oxford University Press. Available at: <A spellcheck=true href=\"http://www.escardio.org/\" target=_blank>www.escardio.org</A>.</div><div id=\"graphicVersion\">Graphic 105764 Version 5.0</div></div></div>"},"105765":{"type":"graphic_table","displayName":"PCL-5","title":"PTSD checklist for DSM-5","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">PTSD checklist for DSM-5</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"50%\"></colgroup><colgroup span=\"5\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">In the past month, how much were you bothered by:</td> <td class=\"subtitle1\">Not at all</td> <td class=\"subtitle1\">A little bit</td> <td class=\"subtitle1\">Moderately</td> <td class=\"subtitle1\">Quite a bit</td> <td class=\"subtitle1\">Extremely</td> </tr> <tr> <td>1. Repeated, disturbing, and unwanted memories of the stressful experience?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>2. Repeated, disturbing dreams of the stressful experience?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>3. Suddenly feeling or acting as if the stressful experience were actually happening again (as if you were actually back there reliving it)?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>4. Feeling very upset when something reminded you of the stressful experience?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>5. Having strong physical reactions when something reminded you of the stressful experience (for example, heart pounding, trouble breathing, sweating)?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>6. Avoiding memories, thoughts, or feelings related to the stressful experience?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>7. Avoiding external reminders of the stressful experience (for example, people, places, conversations, activities, objects, or situations)?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>8. Trouble remembering important parts of the stressful experience?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>9. Having strong negative beliefs about yourself, other people, or the world (for example, having thoughts such as: I am bad, there is something seriously wrong with me, no one can be trusted, the world is completely dangerous)?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>10. Blaming yourself or someone else for the stressful experience or what happened after it?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>11. Having strong negative feelings such as fear, horror, anger, guilt, or shame?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>12. Loss of interest in activities that you used to enjoy?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>13. Feeling distant or cut off from other people?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>14. Trouble experiencing positive feelings (for example, being unable to feel happiness or have loving feelings for people close to you)?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>15. Irritable behavior, angry outbursts, or acting aggressively?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>16. Taking too many risks or doing things that could cause you harm?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>17. Being \"superalert\" or watchful or on guard?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>18. Feeling jumpy or easily startled?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>19. Having difficulty concentrating?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> <tr> <td>20. Trouble falling or staying asleep?</td> <td class=\"centered\">0</td> <td class=\"centered\">1</td> <td class=\"centered\">2</td> <td class=\"centered\">3</td> <td class=\"centered\">4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PTSD: Posttraumatic stress disorder; DSM-5: Diagnostic and Statistical Manual of Mental Disorders, 5th edition.</div><div class=\"graphic_reference\">Reproduced from: Weathers FW, Litz BT, Keane TM, et al (2013). The PTSD Checklist for DSM-5 (PCL-5). Scale available from the National Center for PTSD at <a href=\"http://www.ptsd.va.gov/\" spellcheck=\"true\" target=\"_blank\">www.ptsd.va.gov</a>.</div><div id=\"graphicVersion\">Graphic 105765 Version 1.0</div></div></div>"},"105766":{"type":"graphic_table","displayName":"Onset, peak and duration of opioid withdrawal syndrome: ","title":"Opioid withdrawal syndrome","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Opioid withdrawal syndrome</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Drug</td> <td class=\"subtitle1\" colspan=\"3\">Time course of opioid withdrawal symptoms following last dose</td> </tr> <tr> <td class=\"subtitle2\">Onset</td> <td class=\"subtitle2\">Peak</td> <td class=\"subtitle2\">Nearly complete</td> </tr> <tr> <td>Fentanyl (IV)</td> <td>3 to 5 hours</td> <td>8 to 12 hours</td> <td>4 to 5 days</td> </tr> <tr> <td>Heroin (diamorphine) (IV or inhaled)</td> <td>8 to 12 hours</td> <td>36 to 72 hours</td> <td>7 to 10 days</td> </tr> <tr> <td>Methadone</td> <td>24 to 72 hours</td> <td>4 to 6 days</td> <td>14 to 21 days</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Heroin (diamorphine) time course of abstinence symptoms approximates those for oxycodone, hydrocodone, codeine, and morphine.</div><div class=\"graphic_footnotes\">IV: Intravenous.<br /></div><div id=\"graphicVersion\">Graphic 105766 Version 1.0</div></div></div>"},"105768":{"type":"graphic_picture","displayName":"Lymphangioma circumscriptum","title":"Microcystic lymphatic malformation (lymphangioma circumscriptum)","html":"<div class=\"graphic\"><div style=\"width: 545px\" class=\"figure\"><div class=\"ttl\">Microcystic lymphatic malformation (lymphangioma circumscriptum)</div><div class=\"cntnt\"><img style=\"width:525px; height:700px;\" src=\"images/DERM/105768_Lymphngm_crcmscrptm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple tense vesicles, some of which hemorrhagic, in the perianal area of an infant with microcystic lymphatic malformation.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105768 Version 1.0</div></div></div>"},"105803":{"type":"graphic_table","displayName":"Sports according to risk of impact and educational background","title":"Sports according to risk of impact and educational background","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Sports according to risk of impact and educational background</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Junior high school</td> <td class=\"subtitle1\">High school/college</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Impact expected</strong></td> <td> <p>American football</p> <p>Ice hockey</p> <p>Lacrosse</p> <p>Wrestling</p> <p>Karate/judo</p> <p>Fencing</p> Boxing</td> <td> <p>American football</p> <p>Soccer</p> <p>Ice hockey</p> <p>Lacrosse</p> <p>Basketball</p> <p>Wrestling</p> <p>Karate/judo</p> <p>Downhill skiing</p> <p>Squash</p> <p>Fencing</p> Boxing</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Impact may occur</strong></td> <td> <p>Soccer</p> <p>Basketball</p> <p>Field hockey</p> <p>Downhill skiing</p> <p>Equestrian</p> <p>Squash</p> Cycling</td> <td> <p>Field hockey</p> <p>Equestrian</p> <p>Cycling</p> <p>Baseball/softball</p> <p>Gymnastics</p> Figure skating</td> </tr> <tr> <td><strong>Impact not expected</strong></td> <td> <p>Baseball/softball</p> <p>Cricket</p> <p>Golf</p> <p>Riflery</p> <p>Gymnastics</p> <p>Volleyball</p> <p>Swimming</p> <p>Track and field</p> <p>Tennis</p> <p>Figure skating</p> <p>Cross-country skiing</p> <p>Rowing</p> <p>Sailing</p> <p>Archery</p> <p>Weightlifting</p> Badminton</td> <td> <p>Cricket</p> <p>Golf</p> <p>Riflery</p> <p>Volleyball</p> <p>Swimming</p> <p>Track and field</p> <p>Tennis</p> <p>Cross-country skiing</p> <p>Rowing</p> <p>Sailing</p> <p>Archery</p> <p>Weightlifting</p> Badminton</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced from: Levine BD, Baggish AL, Kovacs RJ, et al. Eligibility and Disqualification Recommendations for Competitive Athletes With Cardiovascular Abnormalities: Task Force 1: Classification of Sports: Dynamic, Static, and Impact: A Scientific Statement From the American Heart Association and American College of Cardiology. J Am Coll Cardiol 2015; 66:2350. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 105803 Version 1.0</div></div></div>"},"105804":{"type":"graphic_table","displayName":"Phakomatosis pigmentovascularis","title":"Classification of phakomatosis pigmentovascularis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of phakomatosis pigmentovascularis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Type</td> <td class=\"subtitle1\">Clinical features</td> </tr> <tr> <td>I</td> <td>Capillary malformation, epidermal nevus</td> </tr> <tr> <td>II (Cesioflammea)</td> <td>Capillary malformation, dermal melanosis (Mongolian spots, nevus of Ota)</td> </tr> <tr> <td>III (Spilorosea)</td> <td>Capillary malformation, nevus spilus, nevus anemicus</td> </tr> <tr> <td>IV (Unclassified)</td> <td>Capillary malformation, dermal melanosis (Mongolian spots, nevus of Ota), nevus spilus, nevus anemicus</td> </tr> <tr> <td>V (Cesiomarmorata)</td> <td>Cutis marmorata telangiectatica congenita, dermal melanosis</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Hasegawa Y, Yasuhara M. Phakomatosis pigmentovascularis type IVa. Arch Dermatol 1985;121:651.</li>&#xD;&#xA;    <li>Happle R. Phacomatosis pigmentovascularis revisited and reclassified. Arch Dermatol 2005;141:385.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 105804 Version 2.0</div></div></div>"},"105805":{"type":"graphic_diagnosticimage","displayName":"CT PVOD","title":"Computed tomography of pulmonary venous occlusive disease","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Computed tomography of pulmonary venous occlusive disease</div><div class=\"cntnt\"><img style=\"width:726px; height:254px;\" src=\"images/PULM/105805_CT_PVOD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">High resolution CT of the chest in PVOD.<br />(A) High resolution CT of the chest showing marked ground-glass opacities with centrilobular pattern, poorly defined nodular opacities, septal lines, and minimal right pleural effusion.<br />(B) High resolution CT of the chest showing mediastinal lymph node enlargement.</div><div class=\"graphic_footnotes\">CT: computed tomography; PVOD: pulmonary venous occlusive disease.</div><div class=\"graphic_reference\">Reproduced with permission from: Montani D, Achouh L, Dorfm&uuml;ller P, et al. Pulmonary veno-occlusive disease: clinical, functional, radiologic, and hemodynamic characteristics and outcome of 24 cases confirmed by histology. Medicine (Baltimore) 2008; 87:220. DOI: <a href=\"http://journals.lww.com/md-journal/pages/articleviewer.aspx?year=2008&amp;issue=07000&amp;article=00005&amp;type=abstract\" target=\"_blank\">10.1097/MD.0b013e31818193bb</a>. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105805 Version 1.0</div></div></div>"},"105806":{"type":"graphic_table","displayName":"Clinical features of PVOD","title":"Clinical features of pulmonary veno-occlusive disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of pulmonary veno-occlusive disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Signs and symptoms</strong></td> <td> <p>Clinical signs and symptoms of pulmonary hypertension (eg, dyspnea on exertion, lethargy, lower extremity swelling)</p> <p>Onset following respiratory tract infection*</p> Risk factors specific for PVOD (eg, chemotherapy, stem cell transplantation, family history of PVOD)*</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Genetic</strong></td> <td>EIF2AK4 gene mutations*</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Computed tomographic</strong></td> <td> <p>Signs of pulmonary hypertension (eg, enlarged central pulmonary arteries, right ventricular, hypertrophy, dilation, intraventricular septal bowing)</p> <p>Signs of venous congestion, eg, pulmonary edema, centrilobular ground glass opacities, septal thickening*</p> <p>Mediastinal lymphadenopathy*</p> <p>Pleural effusion</p> Normal-sized left atrium and central pulmonary veins</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pulmonary function tests</strong></td> <td> <p>Severe reduction in single breath diffusion of carbon monoxide (&#60;55% predicted)*</p> Normal or minimal abnormalities in spirometry and lung volumes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Arterial blood gas and six-minute walk test</strong></td> <td>Severe hypoxemia (partial pressure of oxygen &#60;65 mmHg [8.7 kPa]); low nadir on six-minute walk testing (&#60;85%)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Echocardiography</strong></td> <td> <p>Signs of right ventricular (RV) strain (eg, RV hypertrophy, RV dilatation, septal bowing)</p> Normal left-sided cardiac function*</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Right heart catheterization</strong></td> <td> <p>Mean pulmonary artery pressure &#8805;25 mmHg*</p> Pulmonary artery occlusion pressure &#60;15 mmHg*</td> </tr> <tr> <td><strong>Bronchoscopy</strong></td> <td>Hemosiderin-laden macrophages on bronchoalveolar lavage<sup>&#182;</sup></td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PVOD: pulmonary veno-occlusive disease; PAH: pulmonary arterial hypertension; mPAP: mean pulmonary artery pressure.<br />* Patients with PVOD typically have hemodynamic findings of PAH (an elevated mPAP &ge;25 mmHg and a normal pulmonary artery occlusion pressure &lt;15 mmHg). Suspicion for PVOD is increased when PAH is severe (mPAP &gt;45 mmHg). Patients with PVOD also have signs of venous congestion in the absence of having left-sided heart disease. The constellation of such clinical, computed tomographic, physiologic, and hemodynamic findings as indicated by the * are highly suggestive of PVOD and may obviate the need for biopsy.<br />&para; Bronchoscopy is only performed by some, not all, experts. Hemosiderin-laden macrophages may indicate occult hemorrhage that may be more common in patients with PVOD than in patients with PAH.</div><div id=\"graphicVersion\">Graphic 105806 Version 1.0</div></div></div>"},"105808":{"type":"graphic_figure","displayName":"Sample polysomnogram data interpretation summary","title":"Sample polysomnogram data interpretation summary","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Sample polysomnogram data interpretation summary</div><div class=\"cntnt\"><img style=\"width:582px; height:912px;\" src=\"images/SLEEP/105808_Sample_PSG_data_interpret.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">REM: rapid eye movement; NREM: non-rapid eye movement; PLM: periodic limb movement; RERAs: respiratory effort-related arousals; AHI: apnea hypopnea index; RDI: respiratory disturbance index; ODI: oxygen desaturation index.</div><div id=\"graphicVersion\">Graphic 105808 Version 2.0</div></div></div>"},"105809":{"type":"graphic_picture","displayName":"Dyschromatosis symmetric ahereditaria hands-foot","title":"Dyschromatosis symmetrica hereditaria","html":"<div class=\"graphic\"><div style=\"width: 601px\" class=\"figure\"><div class=\"ttl\">Dyschromatosis symmetrica hereditaria</div><div class=\"cntnt\"><img style=\"width:581px; height:756px;\" src=\"images/DERM/105809_Dschrmt_smmtrc_ahrdtr_hnd_ft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A mixture of hypopigmented and hyperpigmented macules approximately 5 mm in diameter on the dorsum of the hands and feet in a patient with dyschromatosis symmetrica hereditaria.</div><div class=\"graphic_reference\">Courtesy of Michihiro Kono, MD, PhD.</div><div id=\"graphicVersion\">Graphic 105809 Version 1.0</div></div></div>"},"105810":{"type":"graphic_picture","displayName":"Dyschromatosis symmetrica hereditaria knees","title":"Dyschromatosis symmetrica hereditaria","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Dyschromatosis symmetrica hereditaria</div><div class=\"cntnt\"><img style=\"width:513px; height:781px;\" src=\"images/DERM/105810_Dschrmts_smmtrc_hrdtr_kne.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A&nbsp;mixture of hypopigmented and hyperpigmented macules approximately 5 mm in diameter on the knees of a child with dyschromatosis symmetrica hereditaria.</div><div class=\"graphic_reference\">Courtesy of Michihiro Kono, MD, PhD.</div><div id=\"graphicVersion\">Graphic 105810 Version 1.0</div></div></div>"},"105811":{"type":"graphic_picture","displayName":"Dyschromatosis symmetrica hereditaria face","title":"Dyschromatosis symmetrica hereditaria","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Dyschromatosis symmetrica hereditaria</div><div class=\"cntnt\"><img style=\"width:716px; height:305px;\" src=\"images/DERM/105811_Dschrmts_smmtrc_hrdtr_fc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Freckle-like lesions on the face of a child with dyschromatosis symmetrica hereditaria.</div><div class=\"graphic_reference\">Courtesy of Michihiro Kono, MD, PhD.</div><div id=\"graphicVersion\">Graphic 105811 Version 1.0</div></div></div>"},"105812":{"type":"graphic_picture","displayName":"Reticulate acropigmentation of Kitamura","title":"Reticulate acropigmentation of Kitamura","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Reticulate acropigmentation of Kitamura</div><div class=\"cntnt\"><img style=\"width:712px; height:714px;\" src=\"images/DERM/105812_Rtclt_acrpgmntt_ktmr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pigmented macules on the dorsum of the hands of a patient with reticulate acropigmentation of Kitamura. </div><div class=\"graphic_reference\">Courtesy of Michihiro Kono, MD, PhD.</div><div id=\"graphicVersion\">Graphic 105812 Version 1.0</div></div></div>"},"105815":{"type":"graphic_figure","displayName":"Joints affected in OA","title":"Joints affected in osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 486px\" class=\"figure\"><div class=\"ttl\">Joints affected in osteoarthritis</div><div class=\"cntnt\"><img style=\"width:466px; height:529px;\" src=\"images/RHEUM/105815_Joints_affct_OA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Target symptomatic joints for OA.</div><div class=\"graphic_footnotes\">OA: osteoarthritis.</div><div class=\"graphic_reference\">Reproduced with permission from: OARSI Online Primer. Edited by Henrotin Y, Hunter D, Kawaguchi H. 2012. Osteoarthritis Research Society International. (http://primer.oarsi.org).</div><div id=\"graphicVersion\">Graphic 105815 Version 1.0</div></div></div>"},"105816":{"type":"graphic_picture","displayName":"Heberden's nodes","title":"Heberden's nodes","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\">Heberden's nodes</div><div class=\"cntnt\"><img style=\"width:716px; height:571px;\" src=\"images/RHEUM/105816_Heberden_node.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Heberden's nodes, appearing as discrete postero-lateral swellings (index finger) or as a dorsal bar (middle finger) over the DIP joints.</div><div class=\"graphic_footnotes\">DIP: distal interphalangeal.</div><div class=\"graphic_reference\">Reproduced with permission from: OARSI Online Primer. Edited by Henrotin Y, Hunter D, Kawaguchi H. 2012. Osteoarthritis Research Society International. (http://primer.oarsi.org).</div><div id=\"graphicVersion\">Graphic 105816 Version 1.0</div></div></div>"},"105817":{"type":"graphic_picture","displayName":"Hand OA","title":"Patient with hand osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 478px\" class=\"figure\"><div class=\"ttl\">Patient with hand osteoarthritis</div><div class=\"cntnt\"><img style=\"width:458px; height:712px;\" src=\"images/RHEUM/105817_Hand_OA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Heberden's nodes (thumb, middle, ring, and little finger DIP joints), Bouchard's nodes (index finger PIP joint), and lateral radial/ulnar deviation (index PIP joint, ring DIP joint) in the left hand of a person with nodal OA.</div><div class=\"graphic_footnotes\">DIP: distal interphalangeal; PIP: proximal interphalangeal; OA: osteoarthritis.</div><div class=\"graphic_reference\">Reproduced with permission from: OARSI Online Primer. Edited by Henrotin Y, Hunter D, Kawaguchi H. 2012. Osteoarthritis Research Society International. (http://primer.oarsi.org).</div><div id=\"graphicVersion\">Graphic 105817 Version 2.0</div></div></div>"},"105818":{"type":"graphic_picture","displayName":"Thumb-base OA","title":"Thumb-base osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Thumb-base osteoarthritis</div><div class=\"cntnt\"><img style=\"width:720px; height:540px;\" src=\"images/RHEUM/105818_Thumb_base_OA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thumb-base OA: prominence and \"squaring\" of the thumb base, due to osteophyte formation and subluxation at the first CMC joint.</div><div class=\"graphic_footnotes\">OA: osteoarthritis; CMC: carpometacarpal.</div><div class=\"graphic_reference\">Reproduced with permission from: OARSI Online Primer. Edited by Henrotin Y, Hunter D, Kawaguchi H. 2012. Osteoarthritis Research Society International. (http://primer.oarsi.org).</div><div id=\"graphicVersion\">Graphic 105818 Version 1.0</div></div></div>"},"105819":{"type":"graphic_picture","displayName":"Erosive OA of the hand","title":"Erosive osteoarthritis of the hand","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Erosive osteoarthritis of the hand</div><div class=\"cntnt\"><img style=\"width:343px; height:530px;\" src=\"images/RHEUM/105819_Erosive_OA_hand.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erosive hand&nbsp;OA with marked radial deviation and fixed flexion deformity in the left middle PIP joint, radial deviation with restriction in the index PIP joint, and bony swelling of both fingers. Note the&nbsp;absence of Heberden's nodes.</div><div class=\"graphic_footnotes\">OA: osteoarthritis; PIP: proximal interphalangeal.</div><div class=\"graphic_reference\">Reproduced with permission from: OARSI Online Primer. Edited by Henrotin Y, Hunter D, Kawaguchi H. 2012. Osteoarthritis Research Society International. (http://primer.oarsi.org).</div><div id=\"graphicVersion\">Graphic 105819 Version 1.0</div></div></div>"},"105821":{"type":"graphic_picture","displayName":"Unilateral knee OA","title":"Patient with unilateral knee osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 727px\" class=\"figure\"><div class=\"ttl\">Patient with unilateral knee osteoarthritis</div><div class=\"cntnt\"><img style=\"width:707px; height:562px;\" src=\"images/RHEUM/105821_UnilateralkneeOA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Unilateral knee OA: swollen left knee with varus and fixed flexion deformity in a 63-year-old man with a prior history of knee trauma. On palpation, there was marked crepitus, restricted flexion, bony swelling, and a small effusion. The cruciates were intact, but there was minor varus/valgus instability on stress testing.</div><div class=\"graphic_footnotes\">OA: osteoarthritis.</div><div class=\"graphic_reference\">Reproduced with permission from: OARSI Online Primer. Edited by Henrotin Y, Hunter D, Kawaguchi H. 2012. Osteoarthritis Research Society International. (http://primer.oarsi.org).</div><div id=\"graphicVersion\">Graphic 105821 Version 2.0</div></div></div>"},"105823":{"type":"graphic_picture","displayName":"Rotation deformity in hip OA","title":"Findings in patient with right hip osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Findings in patient with right hip osteoarthritis</div><div class=\"cntnt\"><img style=\"width:420px; height:448px;\" src=\"images/RHEUM/105823_Rttn_dfrmty_hip_OA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with right hip OA, showing fixed flexion and external rotation deformity.</div><div class=\"graphic_footnotes\">OA: osteoarthritis.</div><div class=\"graphic_reference\">Reproduced with permission from: OARSI Online Primer. Edited by Henrotin Y, Hunter D, Kawaguchi H. 2012. Osteoarthritis Research Society International. (http://primer.oarsi.org).</div><div id=\"graphicVersion\">Graphic 105823 Version 1.0</div></div></div>"},"105824":{"type":"graphic_picture","displayName":"Right hip OA exam findings","title":"Findings on hip examination in patient with osteoarthritis","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Findings on hip examination in patient with osteoarthritis</div><div class=\"cntnt\"><img style=\"width:528px; height:710px;\" src=\"images/RHEUM/105824_Right_hip_OA_exam_find.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Patient with right hip OA, showing painful restriction with internal rotation in flexion. This is the \"tight-pack\" position for the hip (when the capsule is at its tightest) and is&nbsp;the first movement to be affected.</div><div class=\"graphic_footnotes\">OA: osteoarthritis.</div><div class=\"graphic_reference\">Reproduced with permission from: OARSI Online Primer. Edited by Henrotin Y, Hunter D, Kawaguchi H. 2012. Osteoarthritis Research Society International. (http://primer.oarsi.org).</div><div id=\"graphicVersion\">Graphic 105824 Version 2.0</div></div></div>"},"105825":{"type":"graphic_picture","displayName":"Knee effusion","title":"Knee effusion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Knee effusion</div><div class=\"cntnt\"><img style=\"width:369px; height:275px;\" src=\"images/RHEUM/105825_Knee_effusion.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Knee effusions are usually not marked in OA. This person had a large effusion expanding the suprapatellar pouch, with positive balloon sign (fluctuance) and patellar tap, and OA with CPPD.</div><div class=\"graphic_footnotes\">OA: osteoarthritis; CPPD: calcium pyrophosphate crystal deposition.</div><div class=\"graphic_reference\">Reproduced with permission from: OARSI Online Primer. Edited by Henrotin Y, Hunter D, Kawaguchi H. 2012. Osteoarthritis Research Society International. (http://primer.oarsi.org).</div><div id=\"graphicVersion\">Graphic 105825 Version 2.0</div></div></div>"},"105826":{"type":"graphic_table","displayName":"Clinical indicators of LV dysfunction","title":"Clinical indicators of asymptomatic left ventricular systolic and/or diastolic dysfunction","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical indicators of asymptomatic left ventricular systolic and/or diastolic dysfunction</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">History of:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Alcohol or cocaine abuse </li> <li>Prior myocardial infarction </li> <li>Previous cardiotoxic chemotherapy </li> <li>Longstanding hypertension </li> <li>Family history of heart failure </li> <li>Diabetes mellitus </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Physical signs:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Resting tachycardia </li> <li>Displaced apical impulse </li> <li>Third and/or fourth heart sound </li> <li>Mitral regurgitant murmur </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Electrocardiographic findings:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Evidence of extensive ischemic myocardial injury </li> <li>T-wave abnormalities and/or left bundle branch block </li> <li>New onset atrial fibrillation or other arrhythmias </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Chest radiograph:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Increased cardiothoracic ratio </li> <li>Apical redistribution of pulmonary blood flow </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 105826 Version 2.0</div></div></div>"},"105827":{"type":"graphic_algorithm","displayName":"HF syndrome and urgent surgery","title":"Algorithm for patients with a heart failure syndrome with an indication for urgent noncardiac surgery","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Algorithm for patients with a heart failure syndrome with an indication for urgent noncardiac surgery</div><div class=\"cntnt\"><img style=\"width:510px; height:644px;\" src=\"images/CARD/105827_HF_syndrome_urgent_surg.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACS: acute coronary syndrome; HF: heart failure; MACE: made adverse cardiac events.<br />* Refer to UpToDate content on management of ACS.<br />¶ Stable HF syndromes include stable HF as well as asymptomatic left ventricular dysfunction.<br />Δ Refer to UpToDate content on management of heart failure with reduced ejection fraction, heart failure with preserved ejection fraction, and refractory heart failure.</div><div id=\"graphicVersion\">Graphic 105827 Version 1.0</div></div></div>"},"105828":{"type":"graphic_algorithm","displayName":"HF syndrome and elective surgery","title":"Algorithm for patients with a heart failure syndrome with an indication for elective noncardiac surgery","html":"<div class=\"graphic\"><div style=\"width: 552px\" class=\"figure\"><div class=\"ttl\">Algorithm for patients with a heart failure syndrome with an indication for elective noncardiac surgery</div><div class=\"cntnt\"><img style=\"width:532px; height:706px;\" src=\"images/CARD/105828_HF_syndrome_elective_surg.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ACS: acute coronary syndrome; HF: heart failure; MACE: major adverse cardiac events.<br />* Refer to UpToDate content on management of ACS.<br />&#182; Stable HF syndromes include stable HF as well as asymptomatic left ventricular dysfunction.<br />&#916; Refer to UpToDate content on management of refractory heart failure.</div><div id=\"graphicVersion\">Graphic 105828 Version 1.0</div></div></div>"},"105829":{"type":"graphic_algorithm","displayName":"Treatment of mercury toxicity","title":"Treatment of mercury toxicity","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Treatment of mercury toxicity</div><div class=\"cntnt\"><img style=\"width:378px; height:320px;\" src=\"images/NEPH/105829_Trtmnt_mrcry_txcy.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* For supportive care, refer to UpToDate topics on mercury toxicity.</div><div id=\"graphicVersion\">Graphic 105829 Version 1.0</div></div></div>"},"105841":{"type":"graphic_algorithm","displayName":"Evaluation of puncture injuries for infectious complications","title":"Evaluation of puncture injuries for infectious complications","html":"<div class=\"graphic\"><div style=\"width: 867px\" class=\"figure\"><div class=\"ttl\">Evaluation of puncture injuries for infectious complications</div><div class=\"cntnt\"><img style=\"width:847px; height:863px;\" src=\"images/ID/105841_Evl_pnctr_injr_infct_cmplc.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Refer to the topic on Tetanus immunization for indications on tetanus prophylaxis.<br />¶ Deep infection includes deep space abscess, septic arthritis, necrotizing soft tissue infection, tenosynovitis, and osteomyelitis.<br />Δ Risk factors include increased age, diabetes mellitus, deeply penetrating wounds, injuries to the forefoot or through shoes, grossly contaminated or organic/vegetative penetrating object.<br /><FONT class=lozenge>◊</FONT> For patients with known or suspected deep infection, magnetic resonance imaging (MRI) or computed tomography (CT) is preferred. Otherwise, plain radiographs or ultrasonography can identify foreign bodies.<br />§ There are no prospective, randomized trials that have examined the role of antibiotic administration in the prevention of infection following puncture wounds. We suggest not routinely administering prophylactic antibiotics. It is reasonable to use them in patients at high risk for infection, such as those who have contaminated puncture wounds (especially with organic matter), diabetes mellitus, immunodeficiency, a retained organic foreign body, and an injury through an intact shoe.<br />¥ Inert foreign bodies that are not causing pain or infection that cannot easily be removed may be left in place.<br />‡ Broader empiric coverage may be warranted depending on the exposure (eg, to dirt or water). Refer to the topic on Infectious complications of puncture wounds for more details on empiric antibiotic regimens.</div><div id=\"graphicVersion\">Graphic 105841 Version 3.0</div></div></div>"},"105859":{"type":"graphic_picture","displayName":"Segmental vitiligo child","title":"Segmental vitiligo","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Segmental vitiligo</div><div class=\"cntnt\"><img style=\"width:710px; height:545px;\" src=\"images/DERM/105859_Sgmntlvtlgchld.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Segmental vitiligo in a child. Note the typical involvement of&nbsp;only one side of the face.</div><div class=\"graphic_reference\">Courtesy of Pearl E Grimes, MD.</div><div id=\"graphicVersion\">Graphic 105859 Version 3.0</div></div></div>"},"105860":{"type":"graphic_picture","displayName":"Vitiligo before after face","title":"Vitiligo","html":"<div class=\"graphic\"><div style=\"width: 743px\" class=\"figure\"><div class=\"ttl\">Vitiligo</div><div class=\"cntnt\"><img style=\"width:723px; height:306px;\" src=\"images/DERM/105860_Vtlg_bfr_aftr_fc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Nonsegmental facial vitiligo before treatment.<br />(B) Complete repigmentation after treatment with topical tacrolimus for three months.</div><div class=\"graphic_reference\">Courtesy of Pearl E Grimes, MD.</div><div id=\"graphicVersion\">Graphic 105860 Version 1.0</div></div></div>"},"105862":{"type":"graphic_picture","displayName":"Venous malformation","title":"Venous malformation","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Venous malformation</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/105862_Venous_mlfrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Venous malformation presenting in an infant as a bluish compressible lesion.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 105862 Version 1.0</div></div></div>"},"105865":{"type":"graphic_table","displayName":"Risk factors in intra-abdominal infections","title":"Risk factors that warrant broad empiric antimicrobial coverage for intra-abdominal infections","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk factors that warrant broad empiric antimicrobial coverage for intra-abdominal infections</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Factors associated with mortality</td> </tr> <tr> <td class=\"indent1\">Age &#62;70 years</td> </tr> <tr> <td class=\"indent1\">Medical comorbidity (eg, renal or liver disease, presence of malignancy, chronic malnutrition)</td> </tr> <tr> <td class=\"indent1\">Immunocompromising condition (eg, poorly controlled diabetes mellitus, chronic high-dose corticosteroid use, use of other immunosuppressive agents, neutropenia, advanced HIV infection, B or T leukocyte deficiency)&nbsp;</td> </tr> <tr> <td class=\"indent1\">High severity of illness (ie, sepsis)</td> </tr> <tr> <td class=\"indent1\">Extensive peritoneal involvement or diffuse peritonitis</td> </tr> <tr> <td class=\"indent1\">Delay in initial intervention (source control) &#62;24 hours</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Inability to achieve adequate debridement or drainage control</td> </tr> <tr> <td class=\"subtitle1_single\">Factors associated with infection with antibiotic-resistant bacteria</td> </tr> <tr> <td class=\"indent1\">Healthcare-acquired infection</td> </tr> <tr> <td class=\"indent1\">Travel to areas with higher rates of antibiotic-resistant organisms* within the few weeks prior to infection onset or if antibiotics were received during travel</td> </tr> <tr> <td class=\"indent1\">Known colonization with antibiotic-resistant organisms</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* High rates of antibiotic resistance have been reported from southeast Asia, east Asia, the Middle East, and Africa.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:133.</li>&#xD;&#xA;    <li>Woerther PL, Burdet C, Chachaty E, Andremont A. Trends in human fecal carriage of extended-spectrum &beta;-lactamases in the community: toward the globalization of CTX-M. Clin Microbiol Rev 2013; 26:744.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 105865 Version 2.0</div></div></div>"},"105869":{"type":"graphic_table","displayName":"HEART score for chest pain patients in the emergency room","title":"Composition of the HEART score for chest pain patients in the emergency room","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Composition of the HEART score for chest pain patients in the emergency room</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"2\">HEART score for chest pain patients</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>H</strong>istory</td> <td>Highly suspicious</td> <td>2</td> </tr> <tr> <td>Moderately suspicious</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>Slightly suspicious</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>E</strong>CG</td> <td>Significant ST depression</td> <td>2</td> </tr> <tr> <td>Nonspecific repolarisation disturbance</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>Normal</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>A</strong>ge</td> <td>&#8805;65 year</td> <td>2</td> </tr> <tr> <td>45-65 year</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>&#60;45 year</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>R</strong>isk factors</td> <td>&#8805;3 risk factors or history of atherosclerotic disease</td> <td>2</td> </tr> <tr> <td>1 or 2 risk factors</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>No risk factors known</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\"><strong>T</strong>roponin</td> <td>&#62;2x normal limit</td> <td>2</td> </tr> <tr> <td>1-2x normal limit</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>&#8804;normal limit</td> <td>0</td> </tr> <tr> <td colspan=\"2\">&nbsp;</td> <td><strong>Total _____</strong></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reproduced with permission from: Six AJ, Backus BE, Kelder JC. Chest pain in the emergency room: value of the HEART score. Neth Heart J 2008; 16:191. Copyright &copy; 2008 Bohn Stafleu van Loghum.</div><div id=\"graphicVersion\">Graphic 105869 Version 1.0</div></div></div>"},"105871":{"type":"graphic_table","displayName":"Management of specific arterial injuries","title":"Management of specific arterial injuries","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of specific arterial injuries</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Nonoperative management</td> <td class=\"subtitle1\">Endovascular repair</td> <td class=\"subtitle1\">Initial open surgery</td> <td class=\"subtitle1\">Definitive open vascular repair at initial operation</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Head/neck, n (%)</td> </tr> <tr> <td class=\"indent1\">Common carotid artery</td> <td>10/13 (76.9)</td> <td>1/13 (7.7)</td> <td>5/13 (38.5)</td> <td>2/13 (15.4)</td> </tr> <tr> <td class=\"indent1\">Internal carotid artery</td> <td>58/62 (93.5)</td> <td>2/62 (3.2)</td> <td>2 (3.2)</td> <td>2 (3.2)</td> </tr> <tr> <td class=\"indent1\">External carotid artery</td> <td>1/2 (50.0)</td> <td>1/2 (50.0)</td> <td>0/2 (0)</td> <td>0/2 (0)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Vertebral artery</td> <td>64/68 (94.1)</td> <td>2/68 (2.9)</td> <td>2/68 (2.9)</td> <td>1/68 (1.5)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Thorax, n (%)</td> </tr> <tr> <td class=\"indent1\">Descending thoracic aorta</td> <td>21/39 (53.8)</td> <td>16/39 (41.0)</td> <td>2/39 (5.1)</td> <td>2/39 (5.1)</td> </tr> <tr> <td class=\"indent1\">Innominate artery</td> <td>1/2 (50.0)</td> <td>1/2 (50.0)</td> <td>0/2 (0)</td> <td>0/2 (0)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Subclavian artery</td> <td>5/15 (33.3)</td> <td>1/15 (6.7)</td> <td>4/15 (26.7)</td> <td>3/15 (20.0)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Abdomen/pelvis, n (%)</td> </tr> <tr> <td class=\"indent1\">Abdominal aorta</td> <td>3/5 (60.0)</td> <td>1/5 (20.0)</td> <td>0/5 (0)</td> <td>1/5 (20.0)</td> </tr> <tr> <td class=\"indent1\">Common, external or internal iliac arteries</td> <td>10/20 (50.0)</td> <td>6/20 (30.0)</td> <td>6/20 (30.0)</td> <td>4/20 (20.0)</td> </tr> <tr> <td class=\"indent1\">Celiac artery</td> <td>1/2 (50.0)</td> <td>1/2 (50.0)</td> <td>0/2 (0)</td> <td>0/2 (0)</td> </tr> <tr> <td class=\"indent1\">Common hepatic artery</td> <td>3/4 (75.0)</td> <td>1/4 (25.0)</td> <td>0/4 (0)</td> <td>0/4 (0)</td> </tr> <tr> <td class=\"indent1\">Superior mesenteric artery</td> <td>1/2 (50.0)</td> <td>1/2 (50.0)</td> <td>0/2 (0)</td> <td>0/2 (0)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Renal artery</td> <td>2/9 (22.2)</td> <td>1/9 (11.1)</td> <td>4/9 (44.4)</td> <td>1/9 (11.1)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Upper extremity, n (%)</td> </tr> <tr> <td class=\"indent1\">Axillary artery</td> <td>4/8 (50.0)</td> <td>1/8 (12.5)</td> <td>3/8 (37.5)</td> <td>3/8 (37.5)</td> </tr> <tr> <td class=\"indent1\">Brachial artery</td> <td>10/42 (23.8)</td> <td>1/42 (2.4)</td> <td>31/42 (73.8)</td> <td>29/42 (69.0)</td> </tr> <tr> <td class=\"indent1\">Radial artery</td> <td>8/25 (32.0)</td> <td>0/25 (0)</td> <td>17/25 (68.0)</td> <td>10/25 (40.0)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ulnar artery</td> <td>8/25 (32.0)</td> <td>0/25 (0)</td> <td>17/25 (68.0)</td> <td>12/25 (48.0)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Lower extremity, n (%)</td> </tr> <tr> <td class=\"indent1\">Common, superficial or deep femoral artery</td> <td>24/57 (42.1)</td> <td>2/57 (3.5)</td> <td>31/57 (54.4)</td> <td>27/57 (47.4)</td> </tr> <tr> <td class=\"indent1\">Popliteal artery</td> <td>13/36 (36.1)</td> <td>1/36 (2.8)</td> <td>22/36 (61.1)</td> <td>21/36 (58.3)</td> </tr> <tr> <td class=\"indent1\">Anterior tibial artery</td> <td>14/22 (63.6)</td> <td>0/22 (0)</td> <td>8/22 (36.4)</td> <td>4/22 (18.2)</td> </tr> <tr> <td class=\"indent1\">Posterior tibial artery</td> <td>9/19 (47.4)</td> <td>0/19 (0)</td> <td>10/19 (52.6)</td> <td>3/19 (15.8)</td> </tr> <tr> <td class=\"indent1\">Peroneal artery</td> <td>6/7 (85.7)</td> <td>0/7 (0)</td> <td>1/7 (14.3)</td> <td>1/7 (14.3)</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">A total of 542 vascular&nbsp;injuries at 14 centers were treated. The distribution of these injuries and treatment are shown in the table. Hard signs of vascular injury, including hypotension, were noted in 29 percent of patients. A prehospital tourniquet was used for extremity injuries in 20 percent&nbsp;(47 of 233). Nonoperative management was undertaken in 51 percent, with failure in 4.0 percent. Definitive endovascular and open repair were used in 7.4&nbsp;&nbsp;and 23.2 percent of&nbsp;patients, respectively. Damage-control maneuvers were used in 10.5 percent, including vascular ligation in&nbsp;5.7 percent&nbsp;and shunting in 2.6 percent. Reintervention of initial repair was required in 7.7 percent. Amputation was performed in 7.7 percent&nbsp;of extremity vascular injuries, and overall hospital mortality was 12.7 percent.&nbsp;</div><div class=\"graphic_reference\">From: DuBose JJ, Savage SA, Fabian TC, et al. The American Association for the Surgery of Trauma PROspective Observational Vascular Injury Treatment (PROOVIT) registry: Multicenter data on modern vascular injury diagnosis, management, and outcomes. J Trauma Acute Care Surg 2015; 78:215. DOI: <a href=\"http://journals.lww.com/jtrauma/pages/articleviewer.aspx?year=2015&amp;issue=02000&amp;article=00001&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/TA.0000000000000520</a>. Copyright &copy; 2015 American Association for the Surgery of Trauma. Reproduced with permission from Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105871 Version 1.0</div></div></div>"},"105872":{"type":"graphic_table","displayName":"Overall Neuropathy Limitations Scale (ONLS)","title":"Overall Neuropathy Limitations Scale (ONLS)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Overall Neuropathy Limitations Scale (ONLS)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"55%\"></colgroup><colgroup span=\"3\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"highlight_gray_text divider_bottom\" rowspan=\"2\">&nbsp;</td> <td colspan=\"3\">Name:</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\">Date:</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\"><strong>Instructions:</strong> The examiner should question <strong>and</strong> observe the patient in order to determine the answers to the following questions. Note should be made of any other disorder other than peripheral neuropathy which limits function at the foot of the page.</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"4\">ARM SCALE</td> </tr> <tr> <td class=\"indent1 divider_bottom\" rowspan=\"2\" colspan=\"2\"><strong>Does the patient have any symptoms in their hands or arms, eg, tingling, numbness or weakness?</strong></td> <td><span class=\"primarybox_left\">&nbsp;</span><strong>Yes</strong></td> <td><span class=\"primarybox_left\">&nbsp;</span><strong>No</strong></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"2\">(if \"no\", please go to \"legs\" section)</td> </tr> <tr> <td class=\"indent1\"><strong>Is the patient affected in their ability to:</strong></td> <td><strong>Not affected</strong></td> <td><strong>Affected but not prevented</strong></td> <td><strong>Prevented</strong></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Wash and brush their hair </li> </ul> </td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Turn a key in a lock </li> </ul> </td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Use a knife and fork together (or spoon, if knife and fork not used) </li> </ul> </td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Do or undo buttons or zips </li> </ul> </td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Dress the upper part of their body excluding buttons or zips </li> </ul> </td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> <td class=\"indent1\"><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>If all these functions are prevented can the patient make purposeful movements with their hands or arms? </li> </ul> </td> <td>Yes<br /> <span class=\"primarybox_left\">&nbsp;</span></td> <td>No<br /> <span class=\"primarybox_left\">&nbsp;</span></td> <td style=\"white-space: nowrap;\">Not applicable<br /> <span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><strong>Arm grade</strong></td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">0 = Normal</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">1 = Minor symptoms in one or both arms but not affecting any of the functions listed</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">2 = Disability in one or both arms affecting but not preventing any of the functions listed</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">3 = Disability in one or both arms preventing at least one but not all functions listed</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">4 = Disability in both arms preventing all functions listed but purposeful movement still possible</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">5 = Disability in both arms preventing all purposeful movements</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><strong>SCORE = _____</strong></td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"4\">LEG SCALE</td> </tr> <tr> <td class=\"indent1 highlight_gray_text\">&nbsp;</td> <td><strong>Yes</strong></td> <td><strong>No</strong></td> <td><strong>Not applicable</strong></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Does the patient have difficulty running or climbing stairs? </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Does the patient have difficulty with walking? </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Does their gait look abnormal? </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent2\" colspan=\"4\"> <ul> <li>How do they mobilize for about 10 meters (ie, 33 feet)? </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: disc;\"> <li>Without aid </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: disc;\"> <li>With one stick or crutch or holding to someone's arm </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: disc;\"> <li>With two sticks or crutches or one stick or crutch holding onto someone's arm or frame </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: disc;\"> <li>With a wheelchair </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>If they use a wheelchair, can they stand and walk 1 meter with the help of one person? </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr> <td class=\"indent2\"> <ul> <li>If they cannot walk as above are they able to make some purposeful movements of their legs, eg, reposition legs in bed? </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li> <p>Does the patient use <strong>ankle foot orthoses/braces</strong>? (please circle)</p> <strong>If yes:</strong> (please circle) <strong>right/left</strong> </li> </ul> </td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td><span class=\"primarybox_left\">&nbsp;</span></td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><strong>Leg grade</strong></td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">0 = Walking/climbing stairs/running not affected</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">1 = Walking/climbing stairs/running is affected, but gait does not look abnormal</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">2 = Walks independently but gait looks abnormal</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">3 = Requires unilateral support to walk 10 meters (stick, single crutch, one arm)</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">4 = Requires bilateral support to walk 10 meters (sticks, crutches, crutch and arm, frame)</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">5 = Requires wheelchair to travel 10 meters but able to stand and walk 1 meter with the help of one person</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">6 = Restricted to wheelchair, unable to stand and walk 1 meter with the help of one person, but able to make some purposeful leg movements</td> </tr> <tr> <td class=\"indent2\" colspan=\"4\">7 = Restricted to wheelchair or bed most of the day, unable to make any purposeful movements of the legs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\" colspan=\"4\"><strong>SCORE = _____</strong></td> </tr> <tr class=\"highlight_blue_text\"> <td class=\"sublist1 divider_bottom\" colspan=\"4\">&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"3\">Overall Neuropathy Limitation Scale = arm scale (range 0 to 5) + leg scale (range 0 to 7); (range: 0 (no disability) to 12 (maximum disability))</td> <td><strong>TOTAL SCORE = _____</strong></td> </tr> <tr> <td colspan=\"2\"><strong>Is there any disorder, other than peripheral neuropathy, which affects the above functions?</strong></td> <td><span class=\"primarybox_left\">&nbsp;</span><strong>Yes</strong></td> <td><span class=\"primarybox_left\">&nbsp;</span><strong>No</strong></td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <p>If <strong>yes</strong> please describe:</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> <p>&nbsp;</p> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">From: Graham RC, Hughes RA. A modified peripheral neuropathy scale: the Overall Neuropathy Limitations Scale. J Neurol Neurosurg Psychiatry 2006; 77:973. Reproduced with permission from BMJ Publishing Group Ltd. Copyright &copy; 2006.</div><div id=\"graphicVersion\">Graphic 105872 Version 2.0</div></div></div>"},"105873":{"type":"graphic_algorithm","displayName":"Evaluation of an infant/young child with possible mastocytosis","title":"Evaluation of an infant or prepubertal child with skin lesions suggestive of mastocytosis","html":"<div class=\"graphic\"><div style=\"width: 694px\" class=\"figure\"><div class=\"ttl\">Evaluation of an infant or prepubertal child with skin lesions suggestive of mastocytosis</div><div class=\"cntnt\"><img style=\"width:674px; height:666px;\" src=\"images/ALLRG/105873_Skin_lesions_mastocytosis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Persistently elevated serum tryptase, in isolation, does not always require bone marrow evaluation. For example, children with DCM may have persistently elevated tryptase due to high mast cell burden in the skin, but this does not necessitate further evaluation for systemic mastocytosis in the absence of other signs and symptoms of systemic disease. For other exceptions, refer to the UpToDate topic on evaluation and diagnosis of mastocytosis in children.</div><div id=\"graphicVersion\">Graphic 105873 Version 3.0</div></div></div>"},"105874":{"type":"graphic_table","displayName":"Management of exercise-induced bronchoconstriction (EIB)","title":"Management of exercise-induced bronchoconstriction (EIB)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of exercise-induced bronchoconstriction (EIB)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical problem</td> <td class=\"subtitle1\">Intervention</td> <td class=\"subtitle1\">Comments</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">All patients with EIB</td> <td>Educate about features of exercise that are likely to provoke EIB (eg, effect of temperature, dry air, intensity of exertion, allergens, pollution) and measures for mitigation</td> <td>&nbsp;</td> </tr> <tr> <td>Educate about use of SABA to treat EIB symptoms (eg, albuterol two puffs)</td> <td>&nbsp;</td> </tr> <tr> <td>Educate about use of SABA or other agent to prevent EIB</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Advise caution about vigorous exercise when asthma is poorly-controlled </td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"7\">Patients intolerant of SABA</td> <td>Try one puff of albuterol instead of two</td> <td>May not provide adequate prevention of EIB symptoms.</td> </tr> <tr> <td>Review inhaler technique and consider use of spacer/chamber</td> <td>&nbsp;</td> </tr> <tr> <td>Improve general control of asthma (eg, with inhaled glucocorticoid) to reduce need for prophylaxis</td> <td>If asthma not well-controlled (based on frequency/severity of symptoms or need for rescue inhaler, low peak flow or FEV<sub>1</sub>), add inhaled glucocorticoid. If asthma is otherwise well-controlled, try alternate preventive agents.</td> </tr> <tr> <td>Try alternate SABA (eg, levalbuterol)*</td> <td>Try levalbuterol if above interventions are unsuccessful and levalbuterol is available. Levalbuterol can also be used for breakthrough symptoms. May not completely eliminate adverse effects of SABA.</td> </tr> <tr> <td>Try regular use of LTRA*<sup>&#182;</sup><sup>&#916;</sup></td> <td>LTRA may be more effective in children than adults.</td> </tr> <tr> <td>Try ipratropium two puffs, 20 to 30 minutes prior to exercise*<sup>&#916;</sup></td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Substitute cromolyn or nedocromil (where available) for SABA for prophylaxis*<sup>&#916;</sup></td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">EIB refractory to SABA</td> <td>Add regular use of LTRA</td> <td>&nbsp;</td> </tr> <tr> <td>Improve general control of asthma (eg, with inhaled glucocorticoid)</td> <td>&nbsp;</td> </tr> <tr> <td>Use cromoglycate with SABA as prophylaxis (where available)</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td>Reassess diagnosis</td> <td>&nbsp;</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Patients who exercise for more than three hours or more than once&nbsp;per day</td> <td>Avoid LABA monotherapy or daily use of SABA</td> <td>Tachyphylaxis may occur with daily SABA or LABA.</td> </tr> <tr> <td>Try LTRA</td> <td>May be more effective for prevention of EIB in children than adults.</td> </tr> <tr class=\"divider_bottom\"> <td>Improve general control of asthma (eg, with inhaled glucocorticoid)</td> <td>&nbsp;</td> </tr> <tr> <td rowspan=\"2\">Patients who exercise in extreme conditions (eg, high intensity or in dry cold air)</td> <td>Try methods for mitigation (eg, warm-up, scarf or face mask), depending on setting</td> <td>&nbsp;</td> </tr> <tr> <td>Empiric trial of combination albuterol-ipratropium 20 to 30 minutes prior to exercise</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SABA: short-acting beta-agonist; FEV<SUB>1</SUB>: forced expiratory volume in one second; LTRA: leukotriene-receptor antagonist; LABA: long-acting beta-agonist.<br />​* Choice between levalbuterol, LTRA, ipratropium, and cromoglycate is based on drug availability and patient/clinician preference.<br />¶ LTRA must be taken at least two hours prior to exercise if used episodically.<br />Δ Patient will still need to have a SABA inhaler available for treatment of breakthrough symptoms.</div><div id=\"graphicVersion\">Graphic 105874 Version 2.0</div></div></div>"},"105875":{"type":"graphic_algorithm","displayName":"Antithrombotic rx acute ischemic stroke (not on anticoagulation)","title":"General approach to antithrombotic therapy for acute ischemic stroke in patient not on anticoagulation prior to stroke onset","html":"<div class=\"graphic\"><div style=\"width: 1042px\" class=\"figure\"><div class=\"ttl\">General approach to antithrombotic therapy for acute ischemic stroke in patient not on anticoagulation prior to stroke onset</div><div class=\"cntnt\"><img style=\"width:1022px; height:600px;\" src=\"images/NEURO/105875_Anti_ischmc_strk_not_anticg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended to provide basic guidance regarding the use of antithrombotic therapy for patients with acute ischemic stroke. The steps outlined here may not apply to all patients. The selection, timing, and sequencing of specific antithrombotic drugs should be based upon clinical judgment, individual patient characteristics, and the efficacy, safety, and cost profile of the drugs. For further details, including suggested dosing regimens of antiplatelet and anticoagulant agents, refer to the relevant UpToDate topic reviews.</div><div class=\"graphic_footnotes\">CAS: carotid artery stenting; CEA: carotid endarterectomy; DAPT: dual antiplatelet therapy; OA: oral anticoagulation.<br />* \"Large\" infarcts are defined as those that involve more than one-third of the middle cerebral artery territory or more than one-half of the posterior cerebral artery territory based upon neuroimaging with CT or MRI. Though less reliable, large infarct size can also be defined clinically (eg, NIHSS score &gt;15).<br />&para; Refer to relevant UpToDate topics for management.<br />&Delta; Long-term aspirin therapy is alternative (though less effective) if OA contraindicated or refused.<br /><span class=\"lozenge\">&loz;</span> Non-vitamin K antagonist oral anticoagulant (NOAC) agents have a more rapid anticoagulant effect than warfarin, a factor that may influence the choice of agent and timing of OA initiation.<br />&sect; Long-term antiplatelet therapy for secondary stroke prevention should be continued with aspirin monotherapy, clopidogrel monotherapy, or the combination of aspirin-extended-release dipyridamole.</div><div id=\"graphicVersion\">Graphic 105875 Version 3.0</div></div></div>"},"105877":{"type":"graphic_algorithm","displayName":"Antithrombotic rx TIA","title":"General approach to antithrombotic therapy for acute transient ischemic attack (TIA)","html":"<div class=\"graphic\"><div style=\"width: 788px\" class=\"figure\"><div class=\"ttl\">General approach to antithrombotic therapy for acute transient ischemic attack (TIA)</div><div class=\"cntnt\"><img style=\"width:768px; height:546px;\" src=\"images/NEURO/105877_Antithrombotic_rx_TIA.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended to provide basic guidance regarding the use of antithrombotic therapy for patients with a TIA. The steps outlined here may not apply to all patients. The selection, timing, and sequencing of specific antithrombotic drugs should be based upon clinical judgment, individual patient characteristics, and the efficacy, safety, and cost profile of the drugs. For further details, including suggested dosing regimens of antiplatelet and anticoagulant agents, refer to the relevant UpToDate topic reviews.</div><div class=\"graphic_footnotes\">TIA: transient ischemic attack; CAS: carotid artery stenting; CEA: carotid endarterectomy; DAPT: dual antiplatelet therapy.<br />* Brain and neurovascular imaging, cardiac evaluation, and (for select patients) other laboratory tests.<br />&para; Long-term aspirin therapy is alternative (though less effective) if oral anticoagulation contraindicated or refused.<br />&Delta; Long-term antiplatelet therapy for secondary stroke prevention should be continued with aspirin monotherapy, clopidogrel monotherapy, or the combination of aspirin-extended-release dipyridamole.<br /><span class=\"lozenge\">&loz;</span> Refer to relevant UpToDate topics for management.</div><div id=\"graphicVersion\">Graphic 105877 Version 4.0</div></div></div>"},"105878":{"type":"graphic_algorithm","displayName":"Antithrombotic rx acute ischemic stroke (intracardiac thrombus)","title":"General approach to antithrombotic therapy for acute cardioembolic ischemic stroke in patient with intracardiac thrombus","html":"<div class=\"graphic\"><div style=\"width: 490px\" class=\"figure\"><div class=\"ttl\">General approach to antithrombotic therapy for acute cardioembolic ischemic stroke in patient with intracardiac thrombus</div><div class=\"cntnt\"><img style=\"width:470px; height:436px;\" src=\"images/NEURO/105878_Antithromb_acut_ischmc_strk.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended to provide basic guidance regarding the use of antithrombotic therapy for patients with acute ischemic stroke. The steps outlined here may not apply to all patients. The selection, timing, and sequencing of specific antithrombotic drugs should be based upon clinical judgment, individual patient characteristics, and the efficacy, safety, and cost profile of the drugs. For further details, including suggested dosing regimens of antiplatelet and anticoagulant agents, refer to the relevant UpToDate topic reviews.</div><div class=\"graphic_footnotes\">LMWH: low molecular weight heparin; OA: oral anticoagulation.<br />* Early aspirin rather than anticoagulation favored by other experts.<br />&para; Long-term antiplatelet therapy for secondary stroke prevention should be continued with aspirin monotherapy, clopidogrel monotherapy, or the combination of aspirin-extended-release dipyridamole.</div><div id=\"graphicVersion\">Graphic 105878 Version 1.0</div></div></div>"},"105879":{"type":"graphic_algorithm","displayName":"Antithrombotic rx acute ischemic stroke (on anticoagulation)","title":"General approach to antithrombotic therapy for acute ischemic stroke in patient on long-term anticoagulation (appropriately) prior to stroke onset","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">General approach to antithrombotic therapy for acute ischemic stroke in patient on long-term anticoagulation (appropriately) prior to stroke onset</div><div class=\"cntnt\"><img style=\"width:450px; height:516px;\" src=\"images/NEURO/105879_Antithr_ischmc_strk_anticg.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This algorithm is intended to provide basic guidance regarding the use of antithrombotic therapy for patients with acute ischemic stroke. The steps outlined here may not apply to all patients. The selection, timing, and sequencing of specific antithrombotic drugs should be based upon clinical judgment, individual patient characteristics, and the efficacy, safety, and cost profile of the drugs. For further details, including suggested dosing regimens of antiplatelet and anticoagulant agents, refer to the relevant UpToDate topic reviews.</div><div class=\"graphic_footnotes\">INR: international normalized ratio; NIHSS: National Institutes of Health Stroke Scale; OA: oral anticoagulation; PT: prothrombin time; NOAC: non-vitamin K antagonist oral anticoagulant.<br />* Evaluation to determine stroke mechanism includes brain and neurovascular imaging, cardiac evaluation, and (for select patients) other laboratory tests.<br />&para; Exclusion criteria for intravenous thrombolysis include current anticoagulant use with an INR &gt;1.7 or PT &gt;15 seconds, or current use of a direct oral anticoagulant with evidence of anticoagulant effect by other laboratory tests. Thus, many patients on OA will not be eligible for intravenous thrombolysis.<br />&Delta; Large infarcts are defined as those that involve more than one-third of the middle cerebral artery territory or more than one-half of the posterior cerebral artery territory based upon neuroimaging with CT or MRI. Though less reliable, large infarct size can also be defined clinically (eg, NIHSS score &gt;15).<br /><span class=\"lozenge\">&loz;</span> NOAC agents have a more rapid anticoagulant effect than warfarin, which may affect the choice of agent and timing of OA initiation.</div><div id=\"graphicVersion\">Graphic 105879 Version 1.0</div></div></div>"},"105881":{"type":"graphic_movie","displayName":"TEE view of MR vena contracta","title":"TEE view of mitral regurgitation vena contracta","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">TEE view of mitral regurgitation vena contracta</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/105881_MRvenacontractavid.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:624px; height:445px;\" src=\"images/ANEST/105881_MRvenacontractaimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Four-chamber mid-esophageal color-flow assessment of the mitral valve reveals severe mitral regurgitation. The vena contracta (narrowest neck of the jet) is measured at 0.8 cm in systole, indicating the presence of severe MR.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; MR: mitral regurgitation.</div><div id=\"graphicVersion\">Graphic 105881 Version 1.0</div></div></div>"},"105882":{"type":"graphic_movie","displayName":"TEE (ME 4CV view) of right ventricular failure","title":"TEE (midesophageal 4-chamber view) of right ventricular failure","html":"<div class=\"graphic normal\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">TEE (midesophageal 4-chamber view) of right ventricular failure</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/ANEST/105882_Rightventricularfailvid.mp4\" style=\"width:512px;height:400px\"></div><img style=\"width:630px; height:440px;\" src=\"images/ANEST/105882_Rightventricularfailimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This video of the mid-esophageal four-chamber view demonstrates the following classic findings of right ventricular failure: basal hypokinesis, reduced or absent tricuspid annular excursion, chamber enlargement, and paradoxical septal motion.</div><div class=\"graphic_footnotes\">TEE: transesophageal echocardiography; ME: midesophageal; 4CV: 4-chamber view.</div><div id=\"graphicVersion\">Graphic 105882 Version 2.0</div></div></div>"},"105893":{"type":"graphic_waveform","displayName":"Sample polysomnography montage","title":"Sample polysomnography montage","html":"<div class=\"graphic\"><div style=\"width: 1013px\" class=\"figure\"><div class=\"ttl\">Sample polysomnography montage</div><div class=\"cntnt\"><img style=\"width:993px; height:958px;\" src=\"images/SLEEP/105893_Sample_polysomnography_mntg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The screen shows a 30-second sample of data collection during a sleep study, summarized in a way that makes rapid interpretation more practical for the reviewing provider. Across the top, the sleep stage is noted (N2). From top to bottom, the additional displayed channels are six electroencephalographic leads, two electrooculographic leads, chin electromyography, snore microphone, electrocardiography, right and left leg electromyography, nasal pressure transducer, oronasal thermistry, thoracic and abdominal effort leads, and pulse oximetry.</div><div class=\"graphic_footnotes\">EEG: electroencephalography; EOG: electrooculography; EKG: electrocardiography.</div><div id=\"graphicVersion\">Graphic 105893 Version 1.0</div></div></div>"},"105894":{"type":"graphic_waveform","displayName":"Obstructive apnea","title":"Obstructive apnea","html":"<div class=\"graphic\"><div style=\"width: 1020px\" class=\"figure\"><div class=\"ttl\">Obstructive apnea</div><div class=\"cntnt\"><img style=\"width:1000px; height:390px;\" src=\"images/SLEEP/105894_Obstructive_apnea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The absence of signal in the nasal pressure transducer and near absence of signal in the thermistor identifies the event as an apnea. The continuing effort in the thoracic and abdominal leads indicates that it is an obstructive apnea. Note that ongoing effort in either of these leads would be sufficient to label this as an obstructive event.</div><div id=\"graphicVersion\">Graphic 105894 Version 1.0</div></div></div>"},"105895":{"type":"graphic_waveform","displayName":"Central apnea","title":"Central apnea","html":"<div class=\"graphic\"><div style=\"width: 920px\" class=\"figure\"><div class=\"ttl\">Central apnea</div><div class=\"cntnt\"><img style=\"width:900px; height:310px;\" src=\"images/SLEEP/105895_Central_apnea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The absence of signal in either of the airflow leads indicates that this is an apnea; the absence of respiratory effort in either the thoracic or abdominal effort leads identifies this as a central apnea.</div><div id=\"graphicVersion\">Graphic 105895 Version 2.0</div></div></div>"},"105896":{"type":"graphic_waveform","displayName":"Mixed apnea","title":"Mixed apnea","html":"<div class=\"graphic\"><div style=\"width: 1147px\" class=\"figure\"><div class=\"ttl\">Mixed apnea</div><div class=\"cntnt\"><img style=\"width:1127px; height:320px;\" src=\"images/SLEEP/105896_Mixed_apnea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lack of signal in either the pressure transducer or the thermistor confirms the shaded event as an apnea. The thoracic and abdominal effort leads show no effort during the first part of the event, with a subsequent resumption of effort during the latter part of the event, defining this as a mixed apnea.</div><div id=\"graphicVersion\">Graphic 105896 Version 1.0</div></div></div>"},"105897":{"type":"graphic_waveform","displayName":"Hypopnea","title":"Hypopnea","html":"<div class=\"graphic\"><div style=\"width: 1069px\" class=\"figure\"><div class=\"ttl\">Hypopnea</div><div class=\"cntnt\"><img style=\"width:1049px; height:270px;\" src=\"images/SLEEP/105897_Hypopnea.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The absence of airflow in the nasal pressure channel is insufficient to call this event an apnea; the thermistor, which is a more sensitive method for detecting low levels of flow, continues to record flow, albeit with a reduced amplitude. This, in combination with the desaturation that occurs subsequent to the event, identifies this as a hypopnea.</div><div id=\"graphicVersion\">Graphic 105897 Version 1.0</div></div></div>"},"105898":{"type":"graphic_waveform","displayName":"Respiratory effort-related arousal","title":"Respiratory effort-related arousal","html":"<div class=\"graphic\"><div style=\"width: 947px\" class=\"figure\"><div class=\"ttl\">Respiratory effort-related arousal</div><div class=\"cntnt\"><img style=\"width:927px; height:422px;\" src=\"images/SLEEP/105898_Resp_effort_related_arousal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This event shows a significant decrease in airflow as measured by the nasal pressure transducer, with significant persistent flow. The end of the event (the right side of the blue bracket) is associated with an abrupt increase in electroencephalography (EEG) frequency (the six leads above the respiratory traces), suggesting an arousal. Because the arousal occurs at the end of the subtle decrease in airflow, this event is a respiratory effort-related arousal (RERA). Note that no subsequent change in oxyhemoglobin saturation levels occurs, confirming this to be a significantly more mild decrease in airflow than is seen with a hypopnea.</div><div id=\"graphicVersion\">Graphic 105898 Version 1.0</div></div></div>"},"105899":{"type":"graphic_waveform","displayName":"Cheyne-Stokes respiration","title":"Cheyne-Stokes respiration","html":"<div class=\"graphic\"><div style=\"width: 860px\" class=\"figure\"><div class=\"ttl\">Cheyne-Stokes respiration</div><div class=\"cntnt\"><img style=\"width:840px; height:550px;\" src=\"images/SLEEP/105899_Cheyne_Stokes_respiration.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This compressed figure shows four cycles of crescendo-decrescendo respiratory flow and effort, which defines Cheyne-Stokes respiration. Note that each cycle is associated with significant oxyhemoglobin desaturation, though this is not strictly required to diagnose Cheyne-Stokes respiration.</div><div id=\"graphicVersion\">Graphic 105899 Version 1.0</div></div></div>"},"105900":{"type":"graphic_figure","displayName":"Visual summary of polysomnographic data","title":"Visual summary of polysomnographic data","html":"<div class=\"graphic\"><div style=\"width: 647px\" class=\"figure\"><div class=\"ttl\">Visual summary of polysomnographic data</div><div class=\"cntnt\"><img style=\"width:627px; height:773px;\" src=\"images/SLEEP/105900_Visual_summary_PG_data.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Graphical representation of&nbsp;an entire polysomnogram, with the beginning of data collection at left and the end of the study at right. The top line shows the variation in sleep stages through the night; directly below is a notation of body position through the night, followed by oxyhemoglobin saturation, transcutaneous carbon dioxide levels (not measured in this particular study), and maximum/minimum heart rate. At the bottom are summary signals for respiratory events, including respiratory mechanics instability (RMI; a measurement of thoracoabdominal dyssynchrony), and&nbsp;events that&nbsp;have been scored as apneas or hypopneas.</div><div class=\"graphic_footnotes\">BPM: beats per minute; RMI: respiratory mechanics instability.</div><div id=\"graphicVersion\">Graphic 105900 Version 1.0</div></div></div>"},"105902":{"type":"graphic_figure","displayName":"Drug-induced immune hemolysis","title":"Drug-induced immune hemolysis","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Drug-induced immune hemolysis</div><div class=\"cntnt\"><img style=\"width:538px; height:504px;\" src=\"images/HEME/105902_Drug-induced_immune_hemolysis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Various mechanisms of drug-induced hemolysis are illustrated, including drug-independent and drug-dependent mechanisms, with typical examples. Refer to UpToDate content on red blood cell antibodies and hemolytic anemia for further information about the clinical implications and management.</div><div class=\"graphic_footnotes\">RBC: red blood cell.</div><div class=\"graphic_reference\">Courtesy of Lynne Uhl, MD</div><div id=\"graphicVersion\">Graphic 105902 Version 1.0</div></div></div>"},"105904":{"type":"graphic_algorithm","displayName":"Diagnostic evaluation pediatric metabolic acidosis","title":"Diagnostic evaluation for pediatric metabolic acidosis","html":"<div class=\"graphic\"><div style=\"width: 1116px\" class=\"figure\"><div class=\"ttl\">Diagnostic evaluation for pediatric metabolic acidosis</div><div class=\"cntnt\"><img style=\"width:1096px; height:760px;\" src=\"images/PEDS/105904_Diag_eval_ped_metab_acidsis.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HCO<SUB>3</SUB>–: bicarbonate; TPN: total parenteral nutrition.<br />* Anion gap (AG) is calculated as the difference in the concentration of sodium (Na+) and the major anions chloride (Cl–) and HCO<SUB>3</SUB>–: (Na+) – (Cl– + HCO<SUB>3</SUB>–). In patients with low serum albumin levels, the AG will need to be corrected. See text for further details.<br />¶ Elevated anion gap in children &gt;14 mEq/L and in infants &gt;16 mEq/L.<br />Δ Elevated serum osmolal gap ≥10; serum osmolal gap is the difference between the measured and calculated serum osmolality. Serum osmolality is calculated by the following calculated Sosm = (2 x serum [Na]) + [glucose (mg/dL)] / 18 + [blood urea nitrogen (mg/dL)] / 2.8.<br /><FONT class=lozenge>◊</FONT> Urine anion gap is calculated using measurements of urinary sodium (Na), potassium (K) and chloride (Cl) as follows: UAG (mEq/L) = Urine (Na + K – Cl). A positive urine gap is &lt;–10.</div><div id=\"graphicVersion\">Graphic 105904 Version 2.0</div></div></div>"},"105906":{"type":"graphic_table","displayName":"Classification of vulvar pain caused by a specific disorder","title":"Classification of vulvar pain caused by a specific disorder​","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of vulvar pain caused by a specific disorder​</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Example 1</td> <td class=\"subtitle1\">Example 2</td> <td class=\"subtitle1\">Example 3</td> </tr> <tr> <td><strong>Infectious</strong></td> <td>Recurrent candidiasis</td> <td>Herpes</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Inflammatory</strong></td> <td>Lichen sclerosus</td> <td>Lichen planus</td> <td>Immunobullous disorders</td> </tr> <tr> <td><strong>Neoplastic</strong></td> <td>Paget disease</td> <td>Squamous cell carcinoma</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Neurologic</strong></td> <td>Post-herpetic neuralgia</td> <td>Nerve compression or injury</td> <td>Neuroma</td> </tr> <tr> <td><strong>Trauma</strong></td> <td>Female genital cutting</td> <td>Obstetric injury</td> <td>&nbsp;</td> </tr> <tr> <td><strong>Iatrogenic</strong></td> <td>Postoperative</td> <td>Chemotherapy</td> <td>Radiation</td> </tr> <tr> <td><strong>Hormonal deficiency</strong></td> <td>Genito-urinary syndrome of menopause</td> <td>Lactational amenorrhea</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Representative examples are presented for each category. These examples are not an exhaustive list.</div><div class=\"graphic_reference\">Reproduced with permission from: Bornstein J, Goldstein A, Coady D. 2015 Consensus terminology and classification of persistent vulvar pain. Copyright &copy; 2015 ISSVD.</div><div id=\"graphicVersion\">Graphic 105906 Version 1.0</div></div></div>"},"105908":{"type":"graphic_picture","displayName":"Histopathology of autosomal dominant polycystic kidney disease","title":"Histopathology of autosomal dominant polycystic kidney disease (ADPKD)","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Histopathology of autosomal dominant polycystic kidney disease (ADPKD)</div><div class=\"cntnt\"><img style=\"width:648px; height:425px;\" src=\"images/PEDS/105908_Histo_auto_dom_plycyst_kdny.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Renal histopathologic findings of patient with autosomal dominant polycystic disease (ADPKD) include the characteristic cortical and medullary cysts of varying sizes that are lined with cuboidal or flattened epithelium, tubular atrophy, interstitial fibrosis, and lymphocytic infiltrates.</div><div id=\"graphicVersion\">Graphic 105908 Version 1.0</div></div></div>"},"105909":{"type":"graphic_picture","displayName":"Cross-section ADPKD kidney","title":"Cross-section of kidney from a patient with autosomal dominant polycystic kidney disease (ADPKD)","html":"<div class=\"graphic\"><div style=\"width: 571px\" class=\"figure\"><div class=\"ttl\">Cross-section of kidney from a patient with autosomal dominant polycystic kidney disease (ADPKD)</div><div class=\"cntnt\"><img style=\"width:551px; height:351px;\" src=\"images/PEDS/105909_Cross_section_ADPKD_kidney.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Picture of a cross-sectional view of a kidney from a patient with autosomal dominant polycystic disease (ADPKD) that shows numerous medullary and cortical cysts, which replace most of the renal parenchyma.</div><div id=\"graphicVersion\">Graphic 105909 Version 1.0</div></div></div>"},"105910":{"type":"graphic_figure","displayName":"Cotton swab testing in localized vulvar vestibular pain syndrome","title":"Cotton swab testing in localized vulvar vestibular pain syndrome","html":"<div class=\"graphic\"><div style=\"width: 645px\" class=\"figure\"><div class=\"ttl\">Cotton swab testing in localized vulvar vestibular pain syndrome</div><div class=\"cntnt\"><img style=\"width:625px; height:606px;\" src=\"images/OBGYN/105910_Cttn_swb_lcl_vlvr_vstbl_pn_snd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cotton swab testing for localized vulvar vestibular pain syndrome. The vestibule is tested at different locations (examiner simulates the arms of a clock) between the hymen and Hart's line.</div><div class=\"graphic_reference\">Reproduced with permission from: Haefner HK. Critique of new gynecologic surgical procedures: surgery for vulvar vestibulitis. Clin Obstet Gynecol 2000; 43:689. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 105910 Version 1.0</div></div></div>"}};